(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 November 2024 (21.11.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/238404 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/028982

(22) International Filing Date:
10 May 2024 (10.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/501,924 12 May 2023 (12.05.2023) US

(71) Applicant: **PMV PHARMACEUTICALS, INC.** [US/US]; One Research Way, Princeton, New Jersey 08540 (US).

(72) Inventors: **DUMBLE, Melissa**; One Research Way, Princeton, New Jersey 08540 (US). **PUZIO-KUTER, Anna**; One Research Way, Princeton, New Jersey 08540 (US). **VU, Binh**; One Research Way, Princeton, New Jersey 08540 (US). **AHMED, Tamer**; One Research Way, Princeton, New Jersey 08540 (US).

(74) Agent: **SCHWAMB, Charles B.** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: COMBINATION THERAPY FOR TREATMENT OF CANCER




FIG. 1

(57) **Abstract:** Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes methods of recovering wild-type function to p53 mutants by treating a tumor with a compound and a second agent. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used in combination with an MDM2, PI3K, or AKT inhibitor to reduce the progression of cancers that contain a p53 mutation.

[Continued on next page]

WO 2024/238404 A2

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

COMBINATION THERAPY FOR TREATMENT OF CANCER

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63/501,924, filed May 12, 2023, which is incorporated herein by reference in its entirety.

BACKGROUND

[0002] Cancer, an uncontrolled proliferation of cells, is a multifactorial disease characterized by tumor formation, growth, and in some instances, metastasis. Cells carrying an activated oncogene, damaged genome, or other cancer-promoting alterations can be prevented from replicating through an elaborate tumor suppression network. A central component of this tumor suppression network is p53, one of the most potent tumor suppressors in the cell. Both the wild type and mutant conformations of p53 are implicated in the progression of cancer.

INCORPORATION BY REFERENCE

[0003] Each patent, publication, and non-patent literature cited in the application is hereby incorporated by reference in its entirety as if each was incorporated by reference individually.

SUMMARY OF THE INVENTION

[0004] Provided herein is a method of treating a solid tumor in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound, wherein the compound binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-tumor activity; and (ii) administering to the subject a therapeutically-effective amount of an MDM2 inhibitor.

[0005] Also provided herein is a method of treating a solid tumor in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-cancer activity of a mutant p53 protein in the subject; and (ii) administering to the subject a therapeutically-effective amount of an MDM2 inhibitor.

[0006] Further provided herein is a method of treating a solid tumor, the method comprising: (i) administering to a subject in need thereof a therapeutically-effective amount of a compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of an MDM2 inhibitor, wherein if in a controlled study of treatment of the cancer in a first patient population and a second patient population: (a) a first median survival time of the first patient population is determined, wherein the first patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity;

and (b) a second median survival time of the second patient population is determined, wherein the second patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-tumor activity and the therapeutically-effective amount of the MDM2 inhibitor; then the second median survival time is at least about 50% greater than is the first median survival time.

[0007] Provided herein is a method of treating a solid tumor in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound, wherein the compound binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-tumor activity; and (ii) administering to the subject a therapeutically-effective amount of a PI3K inhibitor.

[0008] Also provided herein is a method of treating a solid tumor in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-cancer activity of a mutant p53 protein in the subject; and (ii) administering to the subject a therapeutically-effective amount of a PI3K inhibitor.

[0009] Further provided herein is a method of treating a solid tumor, the method comprising: (i) administering to a subject in need thereof a therapeutically-effective amount of a compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of a PI3K inhibitor, wherein if in a controlled study of treatment of the cancer in a first patient population and a second patient population: (a) a first median survival time of the first patient population is determined, wherein the first patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (b) a second median survival time of the second patient population is determined, wherein the second patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-tumor activity and the therapeutically-effective amount of the PI3K inhibitor; then the second median survival time is at least about 50% greater than is the first median survival time.

[0010] Provided herein is a method of treating a solid tumor in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound, wherein the compound binds to a mutant p53 protein and reconforms the mutant p53

protein to a conformation of p53 that exhibits anti-tumor activity; and (ii) administering to the subject a therapeutically-effective amount of an AKT inhibitor.

[0011] Also provided herein is a method of treating a solid tumor in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-cancer activity of a mutant p53 protein in the subject; and (ii) administering to the subject a therapeutically-effective amount of an AKT inhibitor.

[0012] Further provided herein is a method of treating a solid tumor, the method comprising: (i) administering to a subject in need thereof a therapeutically-effective amount of a compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of an AKT inhibitor, wherein if in a controlled study of treatment of the cancer in a first patient population and a second patient population: (a) a first median survival time of the first patient population is determined, wherein the first patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (b) a second median survival time of the second patient population is determined, wherein the second patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-tumor activity and the therapeutically-effective amount of the AKT inhibitor; then the second median survival time is at least about 50% greater than is the first median survival time.

BRIEF DESCRIPTION OF THE FIGURES

[0013] FIG. 1 shows changes in % survival in a mouse xenograft model of gastric cancer (NUGC3) over 90 days upon receiving treatment with vehicle (QD); Compound 1, 50 mg/kg (QD); MDM2 inhibitor RG7388 20 mg/kg (QD); Compound 1, 100 mg/kg (QD); Compound 1, 50 mg/kg (QD) simultaneously with MDM2 inhibitor RG7388, 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) simultaneously with MDM2 inhibitor RG7388, 20 mg/kg (QD).

[0014] FIG. 2 shows changes in tumor volume (mm^3) in a mouse xenograft model of gastric cancer (NUGC3-71) over 15 days upon receiving treatment with vehicle (QD); MDM2 inhibitor AMG232 20 mg/kg (QD); Compound 1, 50 mg/kg (QD); Compound 1, 100 mg/kg (QD); Compound 1, 50 mg/kg (QD) + MDM2 inhibitor AMG232 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) + MDM2 inhibitor AMG232 20 mg/kg (QD); Compound 1, 50 mg/kg (QD) 6

hours apart from treatment with MDM2 inhibitor AMG232, 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor AMG232, 20 mg/kg (QD).

[0015] FIG. 3A shows changes in tumor volume (mm^3) in a mouse xenograft model of gastric cancer (NUGC3-71) over 15 days upon receiving treatment with vehicle (QD); MDM2 inhibitor RAIN-32 (milademetan) 20 mg/kg (QD); Compound 1, 50 mg/kg (QD); Compound 1, 100 mg/kg (QD); Compound 1, 50 mg/kg (QD) + MDM2 inhibitor RAIN-32 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) + MDM2 inhibitor RAIN-32 20 mg/kg (QD); Compound 1, 50 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor RAIN-32, 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor RAIN-32, 20 mg/kg (QD).

[0016] FIG. 3B shows the changes in percent body weight change in mice implanted with NUGC3-71 mouse syngeneic gastric cancer tumors upon receiving treatment with vehicle (QD); MDM2 inhibitor RAIN-32 20 mg/kg (QD); Compound 1, 50 mg/kg (QD); Compound 1, 100 mg/kg (QD); Compound 1, 50 mg/kg (QD) + MDM2 inhibitor RAIN-32 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) + MDM2 inhibitor RAIN-32 20 mg/kg (QD); Compound 1, 50 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor RAIN-32, 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor RAIN-32, 20 mg/kg (QD).

[0017] FIG. 4A shows the changes in tumor volume (mm^3) in eight individual mice implanted with NUGC3-70 cancer tumors upon receiving treatment with Compound 1, 100 mg/kg (QD).

[0018] FIG. 4B shows the changes in tumor volume (mm^3) in eight individual mice implanted with NUGC3-70 cancer tumors upon receiving treatment with Compound 1, 100 mg/kg (QD) dosed simultaneous with MDM2 inhibitor AMG232 20 mg/kg (QD).

[0019] FIG. 4C shows the changes in tumor volume (mm^3) in eight individual mice implanted with NUGC3-70 cancer tumors upon receiving treatment with Compound 1, 100 mg/kg (QD) dosed 6 hours apart from treatment with MDM2 inhibitor AMG232, 20 mg/kg (QD).

[0020] FIG. 5A shows changes in tumor volume (mm^3) in a mouse xenograft model of gastric cancer (NUGC3-71) over 80 days upon receiving treatment with vehicle (QD); MDM2 inhibitor AMG232 20 mg/kg (QD); Compound 1, 50 mg/kg (QD); Compound 1, 100 mg/kg (QD); Compound 1, 50 mg/kg (QD) + MDM2 inhibitor AMG232 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) + MDM2 inhibitor AMG232 20 mg/kg (QD); Compound 1, 50 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor AMG232, 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor AMG232, 20 mg/kg (QD).

[0021] FIG. 5B shows changes in % survival in a mouse xenograft model of gastric cancer (NUGC3-70) over 80 days upon receiving treatment with vehicle (QD); MDM2 inhibitor AMG232 20 mg/kg (QD); Compound 1, 50 mg/kg (QD); Compound 1, 100 mg/kg (QD); Compound 1, 50 mg/kg (QD) + MDM2 inhibitor AMG232 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) + MDM2 inhibitor AMG232 20 mg/kg (QD); Compound 1, 50 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor AMG232, 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor AMG232, 20 mg/kg (QD).

[0022] FIG. 5C shows the changes in percent body weight change in mice implanted with NUGC3-71 mouse syngeneic gastric cancer tumors upon receiving treatment with vehicle (QD); MDM2 inhibitor AMG232 20 mg/kg (QD); Compound 1, 50 mg/kg (QD); Compound 1, 100 mg/kg (QD); Compound 1, 50 mg/kg (QD) + MDM2 inhibitor AMG232 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) + MDM2 inhibitor AMG232 20 mg/kg (QD); Compound 1, 50 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor AMG232, 20 mg/kg (QD); or Compound 1, 100 mg/kg (QD) 6 hours apart from treatment with MDM2 inhibitor AMG232, 20 mg/kg (QD).

[0023] FIG. 6A shows changes in percent viability (mm^3) in an MTT cell model of gastric cancer (NUGC3) upon receiving treatment with vehicle; MDM2 inhibitor nutlin-3a 0-10 mM together with Compound 1 0.01-10 mM.

[0024] FIG. 6B shows changes in percent viability (mm^3) in an MTT cell model of gastric cancer (NUGC3) upon receiving treatment with vehicle; MDM2 inhibitor RG7112 0-1 mM together with Compound 1 0-10 mM.

[0025] FIG. 6C shows changes in percent viability (mm^3) in an MTT cell model of gastric cancer (NUGC3) upon receiving treatment with vehicle; MDM2 inhibitor RG7338 0-10 mM together with Compound 1 0.01-10 mM.

[0026] FIG. 7A shows changes in percent viability (mm^3) in an MTT cell model of pancreatic cancer (T3M4) upon receiving treatment with vehicle; MDM2 inhibitor nutlin-3a 0-10 mM together with Compound 1 0.01-10 mM.

[0027] FIG. 7B shows changes in percent viability (mm^3) in an MTT cell model of pancreatic cancer (T3M4) upon receiving treatment with vehicle; MDM2 inhibitor RG7112 0-1 mM together with Compound 1 0-10 mM.

[0028] FIG. 7C shows changes in percent viability (mm^3) in an MTT cell model of pancreatic cancer (T3M4) upon receiving treatment with vehicle; MDM2 inhibitor RG7338 0-10 mM together with Compound 1 0.01-10 mM.

[0029] FIGS. 8A-8L show highest single agent (HSA) synergy scores between PI3K inhibitor alpelisib (0.078-10 mM) and Compound 1 (0.039-10 mM) as calculated by Combenefit software in p53 Y220C cell models of cancer.

[0030] FIGS. 9A-9B show changes in percent viability (**FIG. 9A**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9B**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor alpelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0031] FIGS. 9C-9D show changes in percent viability (**FIG. 9C**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9D**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor inavolisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0032] FIGS. 9E-9F show changes in percent viability (**FIG. 9E**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9F**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor serabelisib (0.07810 mM) together with Compound 1 (0.039-10 mM).

[0033] FIGS. 9G-9H show changes in percent viability (**FIG. 9G**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9H**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor GSK2636771 (GSK263) (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0034] FIGS. 9I-9J show changes in percent viability (**FIG. 9I**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9J**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor eganelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0035] FIGS. 9K-9L show changes in percent viability (**FIG. 9K**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9L**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor idelalisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0036] FIGS. 9M-9N show changes in percent viability (**FIG. 9M**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9N**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor duvelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0037] FIGS. 9O-9P show changes in percent viability (**FIG. 9O**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9P**) in a CTG cell model of lung cancer (HCC2935)

treated with vehicle, or AKT inhibitor MK2206 (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0038] FIGS. 9Q-9R show changes in percent viability (**FIG. 9Q**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9R**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or AKT inhibitor ipataserib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0039] FIGS. 9S-9T show changes in percent viability (**FIG. 9S**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9T**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or AKT inhibitor capivasertib (0.03-10 mM) together with Compound 1 (0.039-10 mM).

[0040] FIGS. 9U-AC show percent viability in HCC2935 cells treated with Compound 1 (0.04-10 mM) in combination with alpelisib (**FIG. 9U**), inavolisib (**FIG. 9V**), serabelisib (**FIG. 9W**), GSK2636771 (GSK263) (**FIG. 9X**), eganelisib (**FIG. 9Y**), idelalisib (**FIG. 9Z**), duvelisib (**FIG. 9AA**), MK2206 (**FIG. 9AB**), and ipatasertib (**FIG. 9AC**).

[0041] FIGS. 10A-10B show changes in percent viability (**FIG. 10A**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10B**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor alpelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0042] FIGS. 10C-10D show changes in percent viability (**FIG. 10C**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10D**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor inavolisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0043] FIGS. 10E-10F show changes in percent viability (**FIG. 10E**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10F**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor serabelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0044] FIGS. 10G-10H show changes in percent viability (**FIG. 10G**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10H**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor GSK2636771 (GSK263) (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0045] FIGS. 10I-10J show changes in percent viability (**FIG. 10I**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10J**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor eganelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0046] FIGS. 10K-10L show changes in percent viability (**FIG. 10K**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10L**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor idelalisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0047] FIGS. 10M-10N show changes in percent viability (**FIG. 10M**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10N**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor duvelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0048] FIGS. 10O-10P show changes in percent viability (**FIG. 10O**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10P**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or AKT inhibitor MK2206 (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0049] FIGS. 10Q-10R show changes in percent viability (**FIG. 10Q**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10R**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or AKT inhibitor ipataserib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0050] FIGS. 10S-10T show changes in percent viability (**FIG. 10S**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10T**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or AKT inhibitor capivasertib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0051] FIGS. 10U-10Z show percent viability in SNUNCC19 cells treated with Compound 1 (0.04-10 mM) in combination with GSK2636771 (GSK263) (**FIG. 10U**), eganelisib (**FIG. 10V**), idelalisib (**FIG. 10W**), duvelisib (**FIG. 10X**), MK2206 (**FIG. 10Y**), and ipatasertib (**FIG. 10Z**).

[0052] FIGS. 11A-11B show changes in percent viability (**FIG. 11A**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 11B**) in a CTG cell model of pancreatic cancer (T3M4) treated with vehicle, or AKT inhibitor capivasertib (0.03-10 mM) together with Compound 1 (0.039-10 mM).

[0053] FIG. 12 provides a list of PI3K and AKT inhibitors.

[0054] FIG. 13 shows the changes in tumor volume (mm^3) in mice implanted with NUGC3-74 cancer tumors upon receiving treatment with Compound 1, 50 or 100 mg/kg (QD) dosed 6 hours apart from treatment with PI3K inhibitor alpelisib, 20 mg/kg (QDx21).

[0055] FIG. 14 shows the changes in tumor volume (mm^3) in eight individual mice implanted with T3M4-19 cancer tumors upon receiving treatment with Compound 1, 100 mg/kg (QD) dosed 6 hours apart from treatment with PI3K inhibitor alpelisib, 20 mg/kg (QDx13).

DETAILED DESCRIPTION

[0056] The present invention provides compounds and methods for restoring wild-type function to mutant p53. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA. The restoration of activity of the p53 mutant can allow for the activation of downstream effectors of p53 leading to inhibition of cancer progression. The invention further provides methods of treatment of a cancerous lesion or a tumor harboring a p53 mutation with combinations of p53 activating compounds provided herein with agents that modulate additional targets, including, for example, MDM2, PI3K, and AKT.

[0057] In some embodiments, the present disclosure provides a method comprising treating cancer by administering a combination comprising a p53 activating compound provided herein and an MDM2 inhibitor. MDM2, also known as mouse double minute 2 homolog, is a negative regulator of p53, and functions as an E3 ubiquitin ligase that targets p53 for degradation by the proteosome. MDM2 can additionally inhibit the function of p53 by binding and blocking the p53 transcriptional activation domain and facilitating the transport of p53 from the nucleus to the cytoplasm. Inhibition of the MDM2-p53 interaction can suppress each of the aforementioned mechanisms by which MDM2 negatively regulates p53.

[0058] The present disclosure also contemplates methods of treating cancer comprising administration of a p53 activating compound provided herein and a PI3K inhibitor. PI3K kinases are members of a conserved family of intracellular lipid kinases that phosphorylate the 3′-OH group on phosphatidylinositols or phosphoinositides. PI3K kinases are signaling enzymes that can relay signals from cell surface receptors to downstream effectors. The PI3K family comprises at least 15 kinases with distinct substrate specificities, expression patterns, and modes of regulation. The class I PI3K kinases (p110α, p110β, p110δ, and p110γ) can be activated by tyrosine kinases or G-protein coupled receptors to generate PIP3, which engages downstream effectors such as those in the Akt/PDK1 pathway, mTOR, the Tec family kinases, and the Rho family GTPases. The PI3K signaling pathway is known to be one of the most highly mutated in human cancers.

[0059] In some embodiments, the present disclosure provides a method comprising treating cancer by administering a combination comprising a p53 activating compound provided herein and an AKT inhibitor. AKT, also known as protein kinase B (PKB), is a growth regulator in PI3K signaling. Isoform Akt1 is a member of the PI3K/AKT/mTOR signaling pathway, and can serve to inhibit apoptotic processes and promote cell survival.

[0060] Cancer is a collection of related diseases characterized by uncontrolled proliferation of cells with the potential to metastasize throughout the body. Cancer can be classified into five broad categories including, for example: carcinomas, which can arise from cells that cover internal and external parts of the body such as the lung, breast, and colon; sarcomas, which can arise from cells that are located in bone, cartilage, fat, connective tissue, muscle, and other supportive tissues; lymphomas, which can arise in the lymph nodes and immune system tissues; leukemia, which can arise in the bone marrow and accumulate in the bloodstream; and adenomas, which can arise in the thyroid, the pituitary gland, the adrenal gland, and other glandular tissues.

[0061] Although different cancers can develop in virtually any of the body's tissues, and contain unique features, the basic processes that cause cancer can be similar in all forms of the disease. Cancer begins when a cell breaks free from the normal restraints on cell division and begins to grow and divide out of control. Genetic mutations in the cell can preclude the ability of the cell to repair damaged DNA or initiate apoptosis, and can result in uncontrolled growth and division of cells.

[0062] The ability of tumor cell populations to multiply is determined not only by the rate of cell proliferation but also by the rate of cell attrition. Programmed cell death, or apoptosis, represents a major mechanism of cellular attrition. Cancer cells can evade apoptosis through a variety of strategies, for example, through the suppression of p53 function, thereby suppressing expression of pro-apoptotic proteins.

[0063] Oncogenes and tumor suppressor genes can regulate the proliferation of cells. Genetic mutations can affect oncogenes and tumor suppressors, potentially activating or suppressing activity abnormally, further facilitating uncontrolled cell division. Whereas oncogenes assist in cellular growth, tumor suppressor genes slow cell division by repairing damaged DNA and activating apoptosis. Cellular oncogenes that can be mutated in cancer include, for example, Cdk1, Cdk2, Cdk3, Cdk4, Cdk6, EGFR, PDGFR, VEGF, HER2, Raf kinase, K-Ras, and myc. Tumor suppressor genes that can be mutated in cancer include, for example, BRCA1, BRCA2, cyclin-dependent kinase inhibitor 1C, Retinoblastoma protein (pRb), PTEN, p16, p27, p53, and p73.

Tumor suppressor p53.

[0064] The tumor suppressor protein p53 is a 393 amino acid transcription factor that can regulate cell growth in response to cellular stresses including, for example, UV radiation, hypoxia, oncogene activation, and DNA damage. p53 has various mechanisms for inhibiting the progression of cancer including, for example, initiation of apoptosis, maintenance of genomic

stability, cell cycle arrest, induction of senescence, and inhibition of angiogenesis. Due to the critical role of p53 in tumor suppression, p53 is inactivated in almost all cancers either by direct mutation or through perturbation of associated signaling pathways involved in tumor suppression. Homozygous loss of the p53 gene occurs in almost all types of cancer, including carcinomas of the breast, colon, and lung. The presence of certain p53 mutations in several types of human cancer can correlate with less favorable patient prognosis.

[0065] In the absence of stress signals, p53 levels are maintained at low levels via the interaction of p53 with Mdm2, an E3 ubiquitin ligase. In an unstressed cell, Mdm2 can target p53 for degradation by the proteasome. Under stress conditions, the interaction between Mdm2 and p53 is disrupted, and p53 accumulates. The critical event leading to the activation of p53 is phosphorylation of the N-terminal domain of p53 by protein kinases, thereby transducing upstream stress signals. The phosphorylation of p53 leads to a conformational change, which can promote DNA binding by p53 and allow transcription of downstream effectors. The activation of p53 can induce, for example, the intrinsic apoptotic pathway, the extrinsic apoptotic pathway, cell cycle arrest, senescence, and DNA repair. p53 can activate proteins involved in the above pathways including, for example, Fas/Apo1, KILLER/DR5, Bax, Puma, Noxa, Bid, caspase-3, caspase-6, caspase-7, caspase-8, caspase-9, and p21 (WAF1). Additionally, p53 can repress the transcription of a variety of genes including, for example, c-MYC, Cyclin B, VEGF, RAD51, and hTERT.

[0066] Each chain of the p53 tetramer is composed of several functional domains including the transactivation domain (amino acids 1-100), the DNA-binding domain (amino acids 101-306), and the tetramerization domain (amino acids 307-355), which are highly mobile and largely unstructured. Most p53 cancer mutations are located in the DNA-binding core domain of the protein, which contains a central β-sandwich of anti-parallel β-sheets that serves as a basic scaffold for the DNA-binding surface. The DNA-binding surface is composed of two β-turn loops, L2 and L3, which are stabilized by a zinc ion, for example, at Arg175 and Arg248, and a loop-sheet-helix motif. Altogether, these structural elements form an extended DNA-binding surface that is rich in positively-charged amino acids, and makes specific contact with various p53 response elements.

[0067] Due to the prevalence of p53 mutations in virtually every type of cancer, the reactivation of wild type p53 function in a cancerous cell can be an effective therapy. Mutations in p53 located in the DNA-binding domain of the protein or periphery of the DNA-binding surface result in aberrant protein folding required for DNA recognition and binding. Mutations in p53 can occur, for example, at amino acids Val143, His168, Arg175, Tyr220, Gly245, Arg248,

Arg249, Phe270, Arg273, and Arg282. p53 mutations that can abrogate the activity of p53 include, for example, R175H, Y220C, G245S, R248Q, R248W, R273H, and R282H. These p53 mutations can either distort the structure of the DNA-binding site or thermodynamically destabilize the folded protein at body temperature. Wild-type function of p53 mutants can be recovered by binding of the p53 mutant to a compound that can shift the folding-unfolding equilibrium towards the folded state, thereby reducing the rate of unfolding and destabilization.

[0068] Non-limiting examples of amino acids include: alanine (A,Ala); arginine (R, Arg); asparagine (N, Asn); aspartic acid (D, Asp); cysteine (C, Cys); glutamic acid (E, Glu); glutamine (Q, Gln); glycine (G, Gly); histidine (H, His); isoleucine (I, Ile); leucine (L, Leu); lysine (K, Lys); methionine (M, Met); phenylalanine (F, Phe); proline (P, Pro); serine (S, Ser); threonine (T, Thr); tryptophan (W, Trp); tyrosine (Y, Tyr); and valine (V, Val).

Mechanism of compounds of the invention.

[0069] The compounds of the present invention can selectively bind to a p53 mutant and can recover wild-type activity of the p53 mutant including, for example, DNA binding function and activation of downstream targets involved in tumor suppression. In some embodiments, a compound of the invention selectively binds to the p53 Y220C mutant. The Y220C mutant is a temperature sensitive mutant, which binds to DNA at lower temperature and is denatured at body temperature. A compound of the invention can stabilize the Y220C mutant to reduce the likelihood of denaturation of the protein at body temperature.

[0070] In some embodiments, the compounds of the disclosure stabilize a mutant p53 and allows the mutant p53 to bind to DNA, thereby shifting the equilibrium of wild type and mutant p53 proteins to wild type p53. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to provide wild type p53 activity. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to provide pro-apoptotic p53 activity. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to block angiogenesis. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to induce cellular senescence. In some embodiments, the compounds of the disclosure reactivate the mutant p53 protein to induce cell cycle arrest.

[0071] In some embodiments, the compounds of the disclosure can reconform mutant p53 to a conformation of p53 that exhibits anti-cancer activity. In some embodiments, the mutant p53 is reconformed to a wild type conformation p53. In some embodiments, the mutant p53 is reconformed to a pro-apoptotic conformation of p53. In some embodiments, the mutant p53 is reconformed to a conformation of p53 that blocks angiogenesis. In some embodiments, the mutant p53 is reconformed to a conformation of p53 that induces cellular senescence. In some

embodiments, the mutant p53 is reconformed to a conformation of p53 that induces cell-cycle arrest.

[0072] Located in the periphery of the p53 β-sandwich connecting β-strands S7 and S8, the aromatic ring of Y220 is an integral part of the hydrophobic core of the β-sandwich. The Y220C mutation can be highly destabilizing, due to the formation of an internal surface cavity. A compound of the invention can bind to and occupy this surface crevice to stabilize the β-sandwich, thereby restoring wild-type p53 DNA-binding activity.

[0073] To determine the ability of a compound of the invention to bind and stabilize mutant p53, assays can be employed to detect, for example, a conformational change in the p53 mutant or activation of wild-type p53 targets. Conformational changes in p53 can be measured by, for example, differential scanning fluorimetry (DSF), isothermal titration calorimetry (ITC), nuclear magnetic resonance spectrometry (NMR), or X-ray crystallography. Additionally, antibodies specific for the wild type of mutant conformation of p53 can be used to detect a conformational change via, for example, immunoprecipitation (IP), immunofluorescence (IF), or immunoblotting.

[0074] Methods used to detect the ability of the p53 mutant to bind DNA can include, for example, DNA affinity immunoblotting, modified enzyme-linked immunosorbent assay (ELISA), electrophoretic mobility shift assay (EMSA), fluorescence resonance energy transfer (FRET), homogeneous time-resolved fluorescence (HTRF), and a chromatin immunoprecipitation (ChIP) assay.

[0075] To determine whether a compound described herein is able to reactivate the transcriptional activity of p53, the activation of downstream targets in the p53 signaling cascade can be measured. Activation of p53 effector proteins can be detected by, for example, immunohistochemistry (IHC-P), reverse transcription polymerase chain reaction (RT-PCR), and western blotting. The activation of p53 can also be measured by the induction of apoptosis via the caspase cascade and using methods including, for example, Annexin V staining, TUNEL assays, pro-caspase and caspase levels, and cytochrome c levels. Another consequence of p53 activation is senescence, which can be measured using methods such as β-galactosidase staining.

[0076] A p53 mutant that can be used to determine the effectiveness of a compound of the invention to increase the DNA binding ability of a p53 mutant is a p53 truncation mutant, which contains only amino acids 94-312, encompassing the DNA-binding domain of p53. For example, the sequence of the p53 Y220C mutant used for testing compound efficacy can be:

SSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL
NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT

EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN
TFRHSVVVPC EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP
ILTIITLEDS SGNLLGRNSF EVHVCACPGR DRRTEEENLR
KKGEPHHELP PGSTKRALSN NT (**SEQ ID NO. 1**)

[0077] A compound of the invention can increase the ability of a p53 mutant to bind DNA by at least or up to about 0.1%, at least or up to about 0.2%, at least or up to about 0.3%, at least or up to about 0.4%, at least or up to about 0.5%, at least or up to about 0.6%, at least or up to about 0.7%, at least or up to about 0.8%, at least or up to about 0.9%, at least or up to about 1%, at least or up to about 2%, at least or up to about 3%, at least or up to about 4%, at least or up to about 5%, at least or up to about 6%, at least or up to about 7%, at least or up to about 8%, at least or up to about 9%, at least or up to about 10%, at least or up to about 11%, at least or up to about 12%, at least or up to about 13%, at least or up to about 14%, at least or up to about 15%, at least or up to about 16%, at least or up to about 17%, at least or up to about 18%, at least or up to about 19%, at least or up to about 20%, at least or up to about 21%, at least or up to about 22%, at least or up to about 23%, at least or up to about 24%, at least or up to about 25%, at least or up to about 26%, at least or up to about 27%, at least or up to about 28%, at least or up to about 29%, at least or up to about 30%, at least or up to about 31%, at least or up to about 32%, at least or up to about 33%, at least or up to about 34%, at least or up to about 35%, at least or up to about 36%, at least or up to about 37%, at least or up to about 38%, at least or up to about 39%, at least or up to about 40%, at least or up to about 41%, at least or up to about 42%, at least or up to about 43%, at least or up to about 44%, at least or up to about 45%, at least or up to about 46%, at least or up to about 47%, at least or up to about 48%, at least or up to about 49%, at least or up to about 50%, at least or up to about 51%, at least or up to about 52%, at least or up to about 53%, at least or up to about 54%, at least or up to about 55%, at least or up to about 56%, at least or up to about 57%, at least or up to about 58%, at least or up to about 59%, at least or up to about 60%, at least or up to about 61%, at least or up to about 62%, at least or up to about 63%, at least or up to about 64%, at least or up to about 65%, at least or up to about 66%, at least or up to about 67%, at least or up to about 68%, at least or up to about 69%, at least or up to about 70%, at least or up to about 71%, at least or up to about 72%, at least or up to about 73%, at least or up to about 74%, at least or up to about 75%, at least or up to about 76%, at least or up to about 77%, at least or up to about 78%, at least or up to about 79%, at least or up to about 80%, at least or up to about 81%, at least or up to about 82%, at least or up to about 83%, at least or up to about 84%, at least or up to about 85%, at least or up to about 86%, at least or up to about 87%, at least or up to about 88%, at least or up to about 89%, at least or up to about

90%, at least or up to about 91%, at least or up to about 92%, at least or up to about 93%, at least or up to about 94%, at least or up to about 95%, at least or up to about 96%, at least or up to about 97%, at least or up to about 98%, at least or up to about 99%, at least or up to about 100%, at least or up to about 125%, at least or up to about 150%, at least or up to about 175%, at least or up to about 200%, at least or up to about 225%, or at least or up to about 250% as compared to the ability of the p53 mutant to bind DNA in the absence of a compound of the invention.

[0078] A compound described herein can increase the activity of the p53 mutant that is, for example, at least or up to about 2-fold, at least or up to about 3-fold, at least or up to about 4-fold, at least or up to about 5-fold, at least or up to about 6-fold, at least or up to about 7-fold, at least or up to about 8-fold, at least or up to about 9-fold, at least or up to about 10-fold, at least or up to about 11-fold, at least or up to about 12-fold, at least or up to about 13-fold, at least or up to about 14-fold, at least or up to about 15-fold, at least or up to about 16-fold, at least or up to about 17-fold, at least or up to about 18-fold, at least or up to about 19-fold, at least or up to about 20-fold, at least or up to about 25-fold, at least or up to about 30-fold, at least or up to about 35-fold, at least or up to about 40-fold, at least or up to about 45-fold, at least or up to about 50-fold, at least or up to about 55-fold, at least or up to about 60-fold, at least or up to about 65-fold, at least or up to about 70-fold, at least or up to about 75-fold, at least or up to about 80-fold, at least or up to about 85-fold, at least or up to about 90-fold, at least or up to about 95-fold, at least or up to about 100-fold, at least or up to about 110-fold, at least or up to about 120-fold, at least or up to about 130-fold, at least or up to about 140-fold, at least or up to about 150-fold, at least or up to about 160-fold, at least or up to about 170-fold, at least or up to about 180-fold, at least or up to about 190-fold, at least or up to about 200-fold, at least or up to about 250-fold, at least or up to about 300-fold, at least or up to about 350-fold, at least or up to about 400-fold, at least or up to about 450-fold, at least or up to about 500-fold, at least or up to about 550-fold, at least or up to about 600-fold, at least or up to about 650-fold, at least or up to about 700-fold, at least or up to about 750-fold, at least or up to about 800-fold, at least or up to about 850-fold, at least or up to about 900-fold, at least or up to about 950-fold, at least or up to about 1,000-fold, at least or up to about 1,500-fold, at least or up to about 2,000-fold, at least or up to about 3,000-fold, at least or up to about 4,000-fold, at least or up to about 5,000-fold, at least or up to about 6,000-fold, at least or up to about 7,000-fold, at least or up to about 8,000-fold, at least or up to about 9,000-fold, or at least or up to about 10,000-fold greater than the activity of the p53 mutant in the absence of the compound.

[0079] A compound of the invention can be used, for example, to induce apoptosis, cell cycle arrest, or senescence in a cell. In some embodiments, the cell is a cancer cell. In some embodiments, the cell carries a mutation in p53.

Compounds of the invention.

[0080] In some embodiments, a compound of the disclosure comprises a substituted heterocyclyl group, wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant protein. In some embodiments, a compound of the disclosure comprises a heterocyclyl group comprising a halo substituent, wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant protein. In some embodiments, the compound further comprises a 5,6-fused bicyclic ring. In some embodiments, the 5,6-fused bicyclic ring is an indole group. In some embodiments, the 5,6-fused bicyclic ring is a benzothiophene group. In some embodiments, the 5,6-fused bicyclic ring is an indazole group. In some embodiments, the 5,6-fused bicyclic ring is an imidazopyridine group. In some embodiments, the 5,6-fused bicyclic ring is an imidazo[1,2-a]pyridine group. In some embodiments, the 5,6-fused bicyclic ring is an indolizine group. In some embodiments, the 5,6-fused bicyclic ring is a pyrazolopyridine group. In some embodiments, the 5,6-fused bicyclic ring is an pyrazolo[1,5-a]pyridine.

[0081] In some embodiments, the indole group has a 2,2,2,-trifluoroethyl substituent at a 1-position of the indole group. In some embodiments, the indole group has a 2,2,2,-trifluoroethyl substituent at a 1-position of the benzothiophene group. In some embodiments, the indole group has a 2,2,2,-trifluoroethyl substituent at a 3-position of the imidazo[1,2-a]pyridine group. In some embodiments, the indole group has a 2,2,2,-trifluoroethyl substituent at a 3-position of the indolizine group. In some embodiments, the indole group has a 2,2,2,-trifluoroethyl substituent at a 3-position of the pyrazolo[1,5-a]pyridine group.


[0082] In some embodiments, the indole group has a trifluoromethylthio substituent at a 1-position of the indole group. In some embodiments, the indole group has a trifluoromethylthio substituent at a 1-position of the benzothiophene group. In some embodiments, the indole group has a trifluoromethylthio substituent at a 3-position of the imidazo[1,2-a]pyridine group. In some embodiments, the indole group has a trifluoromethylthio substituent at a 3-position of the indolizine group. In some embodiments, the indole group has a trifluoromethylthio substituent at a 3-position of the pyrazolo[1,5-a]pyridine group.

[0083] In some embodiments, the indole group has a propargyl substituent at a 2-position of the indole group. In some embodiments, the indole group has a propargyl substituent at a 2-position of the benzothiophene group. In some embodiments, the indole group has a propargyl

substituent at a 2-position of the imidazo[1,2-a]pyridine group. In some embodiments, the indole group has a propargyl substituent at a 2-position of the indolizine group. In some embodiments, the indole group has a propargyl substituent at a 2-position of the pyrazolo[1,5-a]pyridine group.

[0084] In some embodiments, the propargyl substituent is attached to the indole group via an sp carbon atom of the propargyl substituent. In some embodiments, the propargyl substituent is attached to a nitrogen atom of an aniline group via a methylene group of the propargyl substituent. In some embodiments, the indole group comprises an amino substituent at a 4-position of the indole group. In some embodiments, the amino substituent is attached to the heterocyclyl group. In some embodiments, the heterocyclyl group is a piperidine group. In some embodiments, the halo substituent is a fluoro group. In some embodiments, the halo substituent is a chloro group. In some embodiments, the compound has oral bioavailability that is at least about 50% greater than that of an analogous compound that lacks the halo substituent on the heterocyclyl group.

[0085] In some embodiments, the compound is of the formula:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each W is independently $-Q^1-N(R^3)R^4$, $-Q^1-OR^4$, or $-Q^1-R^4$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- A is a linking group;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of

which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, halogen, or hydrogen;

- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{23}$, -$C(O)OR^{23}$, -$C(O)NR^{23}R^{24}$, -OR^{23}, -SR^{23}, -$NR^{23}R^{24}$, -$NR^{23}C(O)R^{24}$, -$OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,


or a pharmaceutically-acceptable salt thereof.

[0086] In some embodiments, A is alkylene, alkenylene, or alkynylene, each of which is substituted or unsubstituted. In some embodiments, A is alkylene. In some embodiments, A is alkenylene. In some embodiments, A is alkynylene.

[0087] In some embodiments, A is arylene, heteroarylene, or heterocyclylene, each of which is substituted or unsubstituted. In some embodiments, A is arylene. In some embodiments, A is heteroarylene. In some embodiments, A is heterocyclylene. In some embodiments, A is substituted arylene. In some embodiments, A is substituted heteroarylene. In some embodiments, A is substituted heterocyclylene.

[0088] In some embodiments, R^1 is alkyl, alkenyl, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$, each of which is unsubstituted or substituted. In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$.

[0089] In some embodiments, the compound of the formula is:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- X^6 is CR^2, NR^2, O, or S;
- X^7 is C or N;
- X^8 is C or N;
- each Z is independently $-Q^1-N(R^3)J$, $-Q^1-O-J$, or $-Q^1-J$;


wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- A is a linking group;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- each J is independently a cyclic group;
- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, C=O, C=S, -CN, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and J together with the nitrogen atom to which R^3 and J are bound form a ring, wherein the ring is substituted or unsubstituted;

- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0090] In some embodiments, the compound of the formula is:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each Z is independently $-Q^1-N(R^3)J$, $-Q^1-O-J$, or $-Q^1-J$;


wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- A is a linking group;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- each J is independently a cyclic group;

- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R^{16}, -C(O)OR^{16}, -C(O)N$R^{16}R^{17}$, -OR^{16}, -SR^{16}, -N$R^{16}R^{17}$, -NR^{16}C(O)R^{16}, -OC(O)R^{16}, C=O, C=S, -CN, -Si$R^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R^{19}, -C(O)OR^{19}, -C(O)N$R^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen, or R^3 and J together with the nitrogen atom to which R^3 and J are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R^{21}, -C(O)OR^{21}, -C(O)N$R^{21}R^{22}$, -OR^{21}, -SR^{21}, -N$R^{21}R^{22}$, -NR^{21}C(O)R^{22}, -OC(O)R^{21}, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or C(O)R^{23}, -C(O)OR^{23}, -C(O)N$R^{23}R^{24}$, -OR^{23}, -SR^{23}, -N$R^{23}R^{24}$, -NR^{23}C(O)R^{24}, -OC(O)R^{23}, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0091] In some embodiments, a compound of the invention is a compound of the formula



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;


- X^5 is CR^{13}, N, or NR^{13};
- each W is independently $-Q^1-N(R^3)R^4$, $-Q^1-OR^4$, or $-Q^1-R^4$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, C=O, C=S, -CN, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0092] In some embodiments, the compound is of the formula:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each Z is independently $-Q^1-N(R^3)J$, $-Q^1-O-J$, or $-Q^1-J$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- each J is independently a cyclic group;
- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, C=O, C=S, -CN, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 is independently alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and J together with the nitrogen atom to which R^3 and J are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, -

$OC(O)R^{23}$, hydrogen, or halogen;

- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0093] In some embodiments, the pattern of dashed bonds is chosen to provide an aromatic system, for example, an indole, a benzothiophene, a indolizine, a pyrrolopyridine, a pyrrolopyrimidine, or a pyrrolopyrazine.

[0094] In some embodiments, X^1 is CR^5, CR^5R^6, or a carbon atom connected to Q^1. In some embodiments, X^2 is CR^7, CR^7R^8, or a carbon atom connected to Q^1. In some embodiments, X^3 is CR^9, CR^9R^{10}, or a carbon atom connected to Q^1. In some embodiments, X^4 is CR^{11}, $CR^{11}R^{12}$, or a carbon atom connected to Q^1. In some embodiments, X^5 is CR^{13}, N, or NR^{13}. In some embodiments, X^1 is a carbon atom connected to Q^1. In some embodiments, X^2 is a carbon atom connected to Q^1. In some embodiments, X^3 is a carbon atom connected to Q^1. In some embodiments, X^4 is a carbon atom connected to Q^1. In some embodiments, X^5 is N.

[0095] In some embodiments, Q^1 is a bond. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.

[0096] In some embodiments, R^1 is alkyl, alkenyl, each of which is unsubstituted or substituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$.


[0097] In some embodiments, J is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted. In some embodiments, J is substituted aryl. In some embodiments, J is aryl substituted with fluoro-. In some embodiments, J is aryl substituted with chloro-. In some embodiments, J is substituted heteroaryl, In some embodiments, J is heteroaryl substituted with fluoro-. In some embodiments, J is heteroaryl substituted with chloro-. In some embodiments, J is substituted heterocyclyl. In some embodiments, J is heterocyclyl substituted with fluoro-. In some embodiments, J is heterocyclyl substituted with chloro-.

[0098] In some embodiments, J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted. In some embodiments, J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted with at least halo-. In some embodiments, J is piperidinyl substituted

with halo-. In some embodiments, J is methylpiperidinyl substituted with halo-. In some embodiments, J is 3-fluoro-1-methylpiperidinyl. In some embodiments, J is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidinyl. In some embodiments, J is tetrahydropyranyl substituted with at least halo-.

[0099] In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{16} is hydrogen or alkyl. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^{17} is substituted aryl. In some embodiments, R^{17} is substituted phenyl. In some embodiments, R^{17} is phenyl substituted with a sulfoxide group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^{17} is phenyl substituted with at least methoxy. In some embodiments, R^{17} is phenyl substituted with a substituted sulfoxide group. In some embodiments, R^{17} is phenyl substituted with a carboxyl group. In some embodiments, R^{17} is phenyl substituted with a substituted amide group.

[0100] In some embodiments, the compound is of the formula:



[0101] In some embodiments, Q^1 is C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some

embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-alkylene or a bond. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, Q^1 is a bond.

[0102] In some embodiments, W is $-Q^1-N(R^3)R^4$. In some embodiments, W is $-Q^1-OR^4$. In some embodiments, W is $-Q^1-R^4$.


[0103] In some embodiments, Z is $-Q^1-N(R^3)J$. In some embodiments, Z is $-Q^1-O-J$. In some embodiments, Z is $-Q^1-J$.

[0104] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^2 is alkyl. In some embodiments, R^2 is substituted C_1-C_5-alkyl. In some embodiments, R^2 is trifluoroethyl. In some embodiments, R^2 is cycloalkyl. In some embodiments, R^2 is cyclopropyl.


[0105] In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^{13} is hydrogen.

[0106] In some embodiments, R^2 is C_1-C_5-alkyl, and R^{13} is C_1-C_5-alkyl. In some embodiments, R^2 is C_1-C_5-alkyl, and R^{13} is hydrogen. In some embodiments, R^2 is substituted C_1-C_5-alkylene. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl, each of which is substituted or unsubstituted. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.

[0107] In some embodiments, the compound is of the formula:




[0108] In some embodiments, the compound is of the formula:



[0109] In some embodiments, R^3 is H, and R^4 is $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, each R^3 and R^4 is independently substituted or unsubstituted C_1-C_6-alkylene. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted C_1-C_4 alkylene. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted heterocyclyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted piperidinyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted cycloalkyl. In some embodiments, R^3 is H, and R^4 is cycloalkyl substituted with an amino group. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted cyclobutyl. In some embodiments, R^3 is H, and R^4 is cyclobutyl substituted with an amino group. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted cyclohexyl. In some embodiments, R^3 is H, and R^4 is cyclohexyl substituted with an amino group.

[0110] In some embodiments, the compound is of the formula:



wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each Z is independently $-Q^1-N(R^3)J$, $-Q^1-O-J$, or $-Q^1-J$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- A is C_{3-9}cycloalkylene, C_{6-10}arylene, C_{1-9}heterocyclylene, C_{1-6}alkylene, C_{2-6}alkenylene, or C_{2-6}alkynylene each of which is independently unsubstituted or substituted with 1 to 7 R^A; ;
- each Q^1 is independently C=O, C=S, C=$CR^{14}R^{15}$, C=NR^{14}, or a bond; or C_{1-6}alkylene, C_{2-6}alkenylene, or C_{2-6}alkynylene, each of which is independently unsubstituted or substituted with 1 to 7 R^B; ;
- m is 1, 2, 3, or 4;
- each J is independently C_{3-9}cycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^C;
- R^1 is C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^D, or -$(CH_2)_wC(O)R^{16}$, -$(CH_2)_wC(O)OR^{16}$, -$(CH_2)_wC(O)NR^{16}R^{17}$, -$(CH_2)_wOR^{16}$, -$(CH_2)_wSR^{16}$, -$(CH_2)_wNR^{16}R^{17}$, -$(CH_2)_wNR^{16}C(O)R^{17}$, -$(CH_2)_wOC(O)R^{16}$, -$(CH_2)_wP(O)R^{16}R^{17}$, or -$(CH_2)_wSiR^{16}R^{17}R^{19}$, wherein w is 0, 1, 2, or 3;
- each R^3 is independently C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^E, or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen, or R^3 and J together with the nitrogen atom to which R^3 and J are bound form a ring, wherein the ring is unsubstituted or substituted with 1 to 7 R^E;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^F, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^G, or C(O)R^{23}, -$C(O)OR^{23}$, -$C(O)NR^{23}R^{24}$, -OR^{23}, -SR^{23}, -$NR^{23}R^{24}$, -$NR^{23}C(O)R^{24}$, -$OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^H;
- each R^A, R^B, R^C, R^D, R^E, R^F, R^G, and R^H is independently selected from -CN, halogen, -$C(O)R^{23}$, -$C(O)OR^{23}$, -$NR^{23}R^{24}$, -OR^{23}, -$C(O)NR^{23}R^{24}$, -SR^{23}, -$S(O)R^{23}$, -SO_2R^{23}, -

$NR^{23}C(O)R^{23}$, and $-OC(O)R^{23}$; or C_{1-6}alkyl, C_{1-6}heteroalkyl, C_{6-10}aryl, and C_{1-9}heterocyclyl, C_{1-6}alkylene-C_{6-10}aryl, and C_{1-6}alkylene-C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with -CN, halogen, methyl, ethyl, propyl, butyl, $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-S(O)R^{23}$, $-S(O)_2R^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, or $-OC(O)R^{23}$; and

- each R^{23} and R^{24} is independently hydrogen, or C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with -CN, halogen, C_{1-6}alkyl, or C_{1-6}haloalkyl,

or a pharmaceutically-acceptable salt thereof.

[0111] In some embodiments, each Z is $-Q^1-N(R^3)J$.

[0112] In some embodiments, A is C_{6-10}arylene, C_{1-9}heterocyclylene, or C_{2-6}alkynylene, each of which is independently unsubstituted or substituted with 1 to 7 R^A. In some embodiments, A is C_{6-10}arylene. In some embodiments, A is phenylene that is unsubstituted or substituted with 1 to 4 R^A. In some embodiments, A is pyrid-diyl that is unsubstituted or substituted with 1 to 3 R^A. In some embodiments, A is pyrid-2,6-diyl that is unsubstituted or substituted with 1 to 3 R^A. In some embodiments, A is pyrid-2,5-diyl that is unsubstituted or substituted with 1 to 3 R^A. In some embodiments, A is pyrid-2,4-diyl that is unsubstituted or substituted with 1 to 3 R^A. In some embodiments, A is pyrid-2,3-diyl that is unsubstituted or substituted with 1 to 3 R^A. In some embodiments, A is pyrid-3,5-diyl that is unsubstituted or substituted with 1 to 3 R^A. In some embodiments, A is pyrid-3,4-diyl that is unsubstituted or substituted with 1 to 3 R^A.

[0113] In some embodiments, A is C_{1-9}heterocyclylene. In some embodiments, A is 5-membered heteroaryl with 1, 2, or 3 heteroatoms selected from N, O, or S. In some embodiments, A is 1H-imidazoldiyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is 1H-imidazol-2,5-diyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is 1H-pyrazoldiyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is 1H-pyrazol-3,5-diyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is 1H-pyrazol-1,4-diyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is thiophendiyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is thiophen-2,5-diyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is thiazoldiyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is thiazol-2,5-diyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is thiazol-4,5-diyl that is unsubstituted or substituted with 1 or 2 R^A. In some embodiments, A is 1,3,5-thiadiazoldiyl that is unsubstituted or substituted with 1 or 2 R^A.





In some embodiments, A is 1,3,5-thiadiazol-2,5-diyl that is unsubstituted or substituted with 1 or 2 R^A.

[0114] In some embodiments, A is C_{2-6}alkynylene. In some embodiments, A is ethyndiyl.



[0115] In some embodiments, each Q^1 is independently a bond, or C_{1-6}alkylene that is independently unsubstituted or substituted with 1 to 7 R^B. In some embodiments, m is 1. In some embodiments, Q^1 is a bond.

[0116] In some embodiments, R^1 is $-(CH_2)_wNR^{16}R^{17}$ or $-(CH_2)_wNR^{16}C(O)R^{17}$, wherein w is 0 or 1. In some embodiments, R^1 is $-CH_2NR^{16}R^{17}$.

[0117] In some embodiments, the compound is of the formula:


,

,

, or

.

[0118] In some embodiments, the compound is of the formula:


or

.

[0119] R^1 can be a group substituted with one or more substituents selected from a hydroxyl group, sulfhydryl group, halogens, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group. In some embodiments, R^1 is alkyl, alkenyl, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$.

[0120] In some embodiments, R^1 is substituted or unsubstituted C_1-C_3 alkyl. In some embodiments, R^1 is C_1-C_3-alkyl substituted with an amine group. In some embodiments, R^1 is C_1-alkyl substituted with $NR^{16}R^{17}$. In some embodiments, each R^{16} and R^{17} is independently aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{16} is H, and R^{17} is substituted aryl. In some embodiments, R^{16} is H, and R^{17} is substituted phenyl. In some embodiments, R^{16} is H, and R^{17} is phenyl substituted with alkyl, alkoxy, halo, sulfonamide, a sulfone, or a carboxy group. In some embodiments, R^{16} is H, and R^{17} is phenyl substituted with alkyl, alkoxy, halo, sulfonamide, a sulfone, or a carbamoyl group. In some embodiments, R^{16} is H, and R^{17} is phenyl substituted with 1, 2, 3 groups independently selected from methoxy, methanesulfonyl, and methylcarbamoyl. In some embodiments, R^{16} is H, and R^{17} is substituted heteroaryl. In some embodiments, R^{16} is H, and R^{17} is substituted heterocyclyl.

[0121] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is C_1-alkylene, R^{16} is aryl, and R^{17} is alkyl. In some embodiments, Q^1 is C_1-alkylene, R^{16} is aryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C_1-alkylene, R^{16} is heteroaryl, and R^{17} is alkyl. In some embodiments, Q^1 is C_1-alkylene, R^{16} is heteroaryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C_1-alkylene, R^{16} is substituted heteroaryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C_1-alkylene, R^{16} is substituted alkyl, and R^{17} is hydrogen. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with halogen, alkyl, or hydroxyl. In some embodiments, R^{16} is hydrogen, and R^{17} is aryl or heteroaryl, substituted or unsubstituted with halogen or alkyl. In some embodiments, R^{16} is alkyl, and R^{17} is heteroaryl substituted with halogen or alkyl. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with alkyl. In some embodiments, R^{17} is aryl or heteroaryl, each of which is independently substituted with alkyl, wherein the alkyl is optionally substituted with fluorine, chlorine, bromine, iodine, or cyano.

[0122] In some embodiments, R^2 is alkyl, and R^{13} is alkyl, each of which is substituted or substituted. In some embodiments, R^2 is hydrogen, and R^{13} is unsubstituted or substituted alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl, each of which is substituted or unsubstituted. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen. In some

embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.

[0123] In some embodiments, R^3 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen. In some embodiments, R^3 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^3 is substituted alkyl. In some embodiments, R^3 is H.

[0124] In some embodiments, R^3 is H, and R^4 is unsubstituted or substituted alkyl. In some embodiments, R^3 is H, and R^4 is unsubstituted or substituted cycloalkyl. In some embodiments, R^3 is H, and R^4 is substituted cyclohexyl. In some embodiments, R^3 is H, and R^4 is substituted cyclobutyl.

[0125] In some embodiments, at least one of R^3 and R^4 is alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is substituted at least with halo-. In some embodiments, R^4 or J is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^4 or J is substituted or unsubstituted aryl. In some embodiments, R^4 or J is substituted or unsubstituted phenyl. In some embodiments, R^4 or J is substituted or unsubstituted cycloalkyl. In some embodiments, R^4 or J is substituted or unsubstituted cyclopropyl. In some embodiments, R^4 or J is substituted cyclopropyl. In some embodiments, R^4 or J is substituted cyclohexyl. In some embodiments, R^4 or J is cyclohexyl substituted with an amino group.

[0126] In some embodiments, R^3 is H, and R^4 or J is unsubstituted or substituted heterocyclyl. In some embodiments, R^4 or J is heterocyclyl. In some embodiments, R^4 or J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 or J is substituted piperidinyl. In some embodiments, R^3 is H, and R^4 or J is piperidine substituted with alkyl, carboxy, heterocyclyl, or an amide group. In some embodiments, R^3 is H, and R^4 or J is unsubstituted or substituted methyl piperidinyl. In some embodiments, R^3 is H, and R^4 or J is 3-fluoro-1-methylpiperidinyl. In some embodiments, R^3 is H, and R^4 or J is piperidinyl substituted with methoxypropanol. In some embodiments, R^3 is H, and R^4 or J is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidinyl. In some embodiments, R^3 is H, and R^4 or J is unsubstituted or substituted tetrahydropyranyl. In some embodiments, R^3 is H, and R^4 or J is unsubstituted

tetrahydropyranyl. In some embodiments, R^3 is H, and R^4 or J is tetrahydropyranyl substituted with alkyl. In some embodiments, R^3 is H, and R^4 or J is tetrahydrothiopyran-1,1-diooxide.

[0127] In some embodiments, R^3 is H, and J is unsubstituted or substituted heterocyclyl. In some embodiments, J is heterocyclyl. In some embodiments, J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted. In some embodiments, R^3 is H, and J is substituted piperidinyl. In some embodiments, R^3 is H, and J is piperidine substituted with alkyl, carboxy, heterocyclyl, or an amide group. In some embodiments, R^3 is H, and J is unsubstituted or substituted methyl piperidinyl. In some embodiments, R^3 is H, and J is 3-fluoro-1-methylpiperidinyl. In some embodiments, R^3 is H, and J is piperidinyl substituted with methoxypropanol. In some embodiments, R^3 is H, and J is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidinyl. In some embodiments, R^3 is H, and J is unsubstituted or substituted tetrahydropyranyl. In some embodiments, R^3 is H, and J is unsubstituted tetrahydropyranyl. In some embodiments, R^3 is H, and J is tetrahydropyranyl substituted with alkyl. In some embodiments, R^3 is H, and J is tetrahydrothiopyran-1,1-diooxide.

[0128] In some embodiments, R^3 is H, and R^4 is unsubstituted or substituted heterocyclyl. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is substituted piperidinyl. In some embodiments, R^3 is H, and R^4 is piperidine substituted with alkyl, carboxy, heterocyclyl, or an amide group. In some embodiments, R^3 is H, and R^4 is unsubstituted or substituted methyl piperidinyl. In some embodiments, R^3 is H, and R^4 is 3-fluoro-1-methylpiperidinyl. In some embodiments, R^3 is H, and R^4 is piperidinyl substituted with methoxypropanol. In some embodiments, R^3 is H, and R^4 is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidinyl. In some embodiments, R^3 is H, and R^4 is unsubstituted or substituted tetrahydropyranyl. In some embodiments, R^3 is H, and R^4 is unsubstituted tetrahydropyranyl. In some embodiments, R^3 is H, and R^4 is tetrahydropyranyl substituted with alkyl. In some embodiments, R^3 is H, and R^4 is tetrahydrothiopyran-1,1-diooxide.

[0129] In some embodiments, R^4 or J is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is substituted at least with halo-. In some embodiments, R^4 or J is C_4-C_6-cycloalkyl substituted with at least halo-. In some embodiments, R^4 or J is cyclohexyl substituted with at least halo-. In some embodiments, R^4 or J is aryl substituted with at least halo-. In some embodiments, R^4 or J is phenyl substituted with at least halo-. In some embodiments, R^4 or J is aryl substituted with fluoro-. In some embodiments, R^4 or J is phenyl substituted with fluoro-. In

some embodiments, R^4 or J is aryl substituted with chloro-. In some embodiments, R^4 or J is phenyl substituted with chloro-. In some embodiments, R^4 or J is heteroaryl substituted with at least halo-. In some embodiments, R^4 or J is heteroaryl substituted with fluoro-. In some embodiments, R^4 or J is heteroaryl substituted with chloro-. In some embodiments, R^4 or J is C_4-C_6-heterocyclyl substituted with at least halo-. In some embodiments, R^4 or J is heterocyclyl substituted with fluoro-. In some embodiments, R^4 or J is heterocyclyl substituted with chloro-. In some embodiments, J is a cyclic group that is substituted or unsubstituted; R^1 is alkyl, or alkenyl, each of which is unsubstituted or substituted, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$; R^2 is substituted or unsubstituted alkyl; and R^3 is H.

[0130] In some embodiments, R^4 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is substituted at least with halo-. In some embodiments, R^4 is C_4-C_6-cycloalkyl substituted with at least halo-. In some embodiments, R^4 is cyclohexyl substituted with at least halo-. In some embodiments, R^4 is aryl substituted with at least halo-. In some embodiments, R^4 is phenyl substituted with at least halo-. In some embodiments, R^4 is aryl substituted with fluoro-. In some embodiments, R^4 is phenyl substituted with fluoro-. In some embodiments, R^4 is aryl substituted with chloro-. In some embodiments, R^4 is phenyl substituted with chloro-. In some embodiments, R^4 heteroaryl substituted with at least halo-. In some embodiments, R^4 is heteroaryl substituted with fluoro-. In some embodiments, R^4 is heteroaryl substituted with chloro-. In some embodiments, R^4 is C_4-C_6-heterocyclyl substituted with at least halo-. In some embodiments, R^4 is heterocyclyl substituted with fluoro-. In some embodiments, R^4 is heterocyclyl substituted with fluoro- and methyl. In some embodiments, R^4 is 6-membered heterocyclyl substituted with fluoro- and methyl. In some embodiments, R^4 is heterocyclyl substituted with chloro-. In some embodiments, R^4 is a cyclic group that is substituted or unsubstituted; R^1 is alkyl, or alkenyl, each of which is unsubstituted or substituted, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$; R^2 is substituted or unsubstituted alkyl; and R^3 is H.

[0131] In some embodiments, J is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is substituted at least with halo-. In some embodiments, J is C_4-C_6-cycloalkyl substituted with at least halo-. In some embodiments, J is cyclohexyl substituted with at least halo-. In some embodiments, J is aryl substituted with at least halo-. In some embodiments, J is phenyl substituted with at least halo-. In some embodiments, J is aryl substituted with fluoro-. In some embodiments, J is phenyl substituted with fluoro-. In some embodiments, J is aryl substituted with chloro-. In some embodiments, J is phenyl substituted with chloro-. In some embodiments, J heteroaryl substituted with at least halo-. In some embodiments, J is heteroaryl substituted with fluoro-. In some embodiments, J is heteroaryl substituted with chloro-. In some embodiments, J

is C_4-C_6-heterocyclyl substituted with at least halo-. In some embodiments, J is heterocyclyl substituted with fluoro-. In some embodiments, J is heterocyclyl substituted with fluoro- and methyl. In some embodiments, J is 6-membered heterocyclyl substituted with fluoro- and methyl. In some embodiments, J is heterocyclyl substituted with chloro-. In some embodiments, J is a cyclic group that is substituted or unsubstituted; R^1 is alkyl, or alkenyl, each of which is unsubstituted or substituted, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$; R^2 is substituted or unsubstituted alkyl; and R^3 is H.







[0132] In some embodiments, J is C_{3-9}cycloalkyl or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^C. In some embodiments, J is 6-membered cycloalkyl or 6-membered heterocycloalkyl, each of which is independently unsubstituted or substituted with 1 to 7 R^C. In some embodiments, J is cyclohexyl or piperdinyl, each of which is independently unsubstituted or substituted with 1 to 7 R^C; and R^3 is H.





[0133] In some embodiments, R^4 or J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted with at least halo-. In some embodiments, R^4 or J is piperidinyl substituted with halo-. In some embodiments, R^4 or J is methylpiperidinyl substituted with halo-. In some embodiments, R^4 or J is 3-fluoro-1-methylpiperidinyl. In some embodiments, R^4 or J is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidinyl. In some embodiments, R^4 or J is tetrahydropyranyl substituted with at least halo-.

[0134] In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted with at least halo-. In some embodiments, R^4 is piperidinyl substituted with halo-. In some embodiments, R^4 is methylpiperidinyl substituted with halo-. In some embodiments, R^4 is 3-fluoro-1-methylpiperidinyl. In some embodiments, R^4 is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidinyl. In some embodiments, R^4 is tetrahydropyranyl substituted with at least halo-.

[0135] In some embodiments, J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted with at least halo-. In some embodiments, J is piperidinyl substituted with halo-. In some embodiments, J is methylpiperidinyl substituted with halo-. In some embodiments, J is 3-fluoro-1-methylpiperidinyl. In some embodiments, J is 3-fluoro-1-(2-hydroxy-3-methoxypropyl)piperidinyl. In some embodiments, J is tetrahydropyranyl substituted with at least halo-.




[0136] In some embodiments, R^4 or J is a ring that is:






, or

,


wherein the ring is substituted or unsubstituted. In some embodiments, the ring is substituted with halo-. In some embodiments, the ring is substituted with fluoro. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, the ring is substituted with halo-. In some embodiments, the ring is substituted with fluoro. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, the ring is substituted with halo. In some embodiments, the ring is substituted with fluoro. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, the ring is substituted with halo. In some embodiments, the ring is substituted with fluoro. In some embodiments, R^3 is H, and R^4 is a ring that is .

[0137] In some embodiments, the R^4 or J is substituted with one or more substituents selected from a hydroxyl group, sulfhydryl group, halogens, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamoyl group, carbamate group, amide group, urethane group, and ester group.

[0138] In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a substituted heterocycle. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a heterocycle substituted with a hydroxyl group, halogen, amino group, or alkyl group. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a heterocycle, wherein the heterocycle is substituted by a substituted or unsubstituted heterocycle.

[0139] In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring of a following formula: , , or .


[0140] In some embodiments, the compound is of the formula:



, or a pharmaceutically-acceptable salt thereof,

wherein J is a cyclic group that is substituted or unsubstituted; R^1 is alkyl, or alkenyl, each of which is unsubstituted or substituted, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$; R^2 is substituted or unsubstituted alkyl; and R^3 is H.

[0141] In some embodiments, the compound is of the formula:



, or a pharmaceutically-acceptable salt thereof,

wherein:

- J is a cyclic group that is substituted or unsubstituted;
- R^1 is alkyl, or alkenyl, each of which is unsubstituted or substituted, $-C(O)R^{16}$, $-C(O)OR^{16}$, or $-C(O)NR^{16}R^{17}$;
- R^{16} and R^{17} are each independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or

heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen;

- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- R^2 is substituted or unsubstituted alkyl; and
- R^3 is H.


[0142] In some embodiments, R^2 is substituted ethyl. In some embodiments, R^2 is trifluoroethyl. In some embodiments, R^2 is 2,2,2-trifluoroethyl.

[0143] In some embodiments, J is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted. In some embodiments, J is substituted heterocyclyl.

[0144] In some embodiments, R^3 is H, J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.


[0145] In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$; and each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.

[0146] In some embodiments, the compound is of the formula:



[0147] In some embodiments, R^{16} is hydrogen or alkyl. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^{17} is substituted aryl. In some embodiments, R^{17} is phenyl substituted with a sulfoxide group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, or heterocyclyl, each of which is independently substituted or unsubstituted, or halo or cyano.

[0148] In some embodiments, the compound is of the formula:



, or a pharmaceutically-acceptable salt thereof, wherein:

- J is C_{3-9}cycloalkyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^C;
- R^1 is C_{1-6}alkyl, C_{2-6}alkenyl, each of which is independently unsubstituted or substituted with 1 to 7 R^D, or $-(CH_2)_wC(O)R^{16}$, $-(CH_2)_wC(O)OR^{16}$, $-(CH_2)_wNR^{16}R^{17}$, or $-(CH_2)_wC(O)NR^{16}R^{17}$, wherein w is 0, 1, 2, or 3;
- R^2 is C_{1-6}alkyl that is independently unsubstituted or substituted with 1 to 7 R^F;
- each R^{16} and R^{17} is independently C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^F, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^H;
- each R^C, R^D, R^F, and R^H is independently selected from -CN, halogen, $-C(O)R^{23}$, $-C(O)OR^{23}$, $-NR^{23}R^{24}$, $-OR^{23}$, $-C(O)NR^{23}R^{24}$, $-SR^{23}$, $-S(O)R^{23}$, $-SO_2R^{23}$, $-NR^{23}C(O)R^{23}$, and $-OC(O)R^{23}$; or C_{1-6}alkyl, C_{1-6}heteroalkyl C_{6-10}aryl, and C_{1-9}heterocyclyl, C_{1-6}alkylene-C_{6-10}aryl, and C_{1-6}alkylene-C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with -CN, halogen, methyl, ethyl, propyl, butyl, $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-S(O)R^{23}$, $-SO_2R^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, or $-OC(O)R^{23}$;
- each R^{23} and R^{24} is independently hydrogen, or C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with -CN, halogen, C_{1-6}alkyl, or C_{1-6}haloalkyl.

[0149] In some embodiments, R^2 is ethyl substituted with 1 to 3 R^F. In some embodiments, R^2 is trifluoroethyl. In some embodiments, R^2 is 2,2,2-trifluoroethyl.


[0150] In some embodiments, J is C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^C. In some embodiments, C_{1-}

$_9$heterocyclyl that is unsubstituted or substituted with 1 to 7 R^C. In some embodiments, 6-membered heterocyclyl that is unsubstituted or substituted with 1 to 7 R^C.

[0151] In some embodiments, R^3 is H, and J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently unsubstituted or substituted with 1 to 7 R^C.


[0152] In some embodiments, R^1 is C_{1-6}alkyl substituted with $NR^{16}R^{17}$; and each R^{16} and R^{17} is independently C_{1-6}alkyl, C_{2-6}alkynyl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^D ; or hydrogen. In some embodiments, R^1 is $-(CH_2)_wNR^{16}R^{17}$, wherein w is 0, 1, 2, or 3. In some embodiments, R^1 is $-CH_2NR^{16}R^{17}$.

[0153] In some embodiments, the compound is of the formula:




[0154] In some embodiments, R^{16} is hydrogen or C_{1-6}alkyl that is unsubstituted or substituted with 1 to 7 R^F. In some embodiments, R^{17} is C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl each of which is independently unsubstituted or substituted with 1 to 7 R^F. In some embodiments, R^{17} is C_{6-10}aryl that is substituted with 1 to 7 R^F. In some embodiments, R^{17} is phenyl substituted with 1 to 5 R^F. In some embodiments, R^{17} is phenyl substituted 1 to 5 groups independently selected from halogen, cyano, $-S(O)R^{23}$, $-SO_2R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-NR^{23}R^{24}$, or $-OR^{23}$; or C_{1-6}alkyl or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with -CN, halogen, methyl, ethyl, propyl, butyl, $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-S(O)R^{23}$, $-SO_2R^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, or $-OC(O)R^{23}$. In some embodiments, R^{17} is phenyl substituted 1 to 5 groups independently selected from halogen, cyano, $-S(O)R^{23}$, $-S(O)_2R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-NR^{23}R^{24}$, or $-OR^{23}$.


[0155] In some embodiments, the compound is of the formula:



,



,



wherein:

- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, C=O, C=S, -CN, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^Q is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- y is 0, 1, 2, 3, or 4;
- each R^{16}, R^{17}, and R^{18} is independently $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;

and

- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,









or a pharmaceutically-acceptable salt thereof.

[0156] In some embodiments, R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, or aryl, each of which is independently substituted or unsubstituted; or -$NR^{21}R^{22}$, halo or hydrogen.

[0157] In some embodiments, R^1 is substituted C_1-C_3-alkyl. In some embodiments, R^1 is C_1-C_3-alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is a substituted carboxyl group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted aryl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted phenyl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is phenyl substituted with a sulfoxide group, a sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^{17} is phenyl substituted with methoxy. In some embodiments, R^{17} is phenyl substituted with a substituted sulfoxide group. In some embodiments, R^{17} is phenyl substituted with a carboxyl group. In some embodiments, R^{17} is a substituted amide group. In some embodiments, R^{17} is phenyl substituted with an amide group. In some embodiments, R^{17} is phenyl substituted with at least a methoxy group. In some embodiments, R^{17} is substituted with methoxy and sulfonamide. In some embodiments, R^{17} is substituted with methoxy and an amide group. In some embodiments, R^{17} is substituted with methoxy and sulfonyl. In some embodiments, R^{17} is phenyl substituted with -$C(O)NH(C_1$-C_6alkyl), -$S(O)_2(C_1$-C_6alkyl), or C_1-C_6alkoxy. In some embodiments, R^{17} is phenyl substituted with -$C(O)NH(C_1$-C_6alkyl) and C_1-C_6alkoxy. In some embodiments, R^{17} is phenyl substituted with -$S(O)_2(C_1$-C_6alkyl) and C_1-C_6alkoxy. In some embodiments, R^{17} is phenyl substituted with -$C(O)NH(C_1$-C_6hydroxyalkyl) and C_1-C_6alkoxy. In some embodiments, R^{17} is phenyl substituted with -$C(O)NH(C_1$-C_6alkoxy) and C_1-C_6alkoxy.

[0158] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^2 is substituted C_1-C_5-alkylene. In some embodiments, R^2 is trifluoroethyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^2 is alkyl, and R^{13} is alkyl. In some embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen.

[0159] In some embodiments, the compound is of the formula:


,

,

,

,

,

,

, or

,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0160] In some embodiments, each R^Q is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen. In some embodiments, each R^Q is -$NR^{21}R^{22}$ or halogen. In some embodiments, each R^Q is NH_2 or halogen.


[0161] In some embodiments, y is 1. In some embodiments, y is 2. In some embodiments, y is 3. In some embodiments, y is 4.

[0162] In some embodiments, R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, -$NR^{21}R^{22}$, or aryl, each of which is independently substituted or unsubstituted; halo or hydrogen.


[0163] In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is substituted C_1-C_3-alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is C_1-C_3-alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.

[0164] In some embodiments, R^{16} is alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen, and R^{17} is aryl, heteroaryl, or heterocyclyl. In some embodiments, R^{16} is hydrogen, and R^{17} is phenyl, indolyl, piperidinyl, imidazolyl, thiazolyl, morpholinyl, pyrrolyl, or pyridinyl, each of which is substituted or unsubstituted.

[0165] In some embodiments, the compound is of the formula:





or




.

[0166] In some embodiments, the compound is of the formula:


or


[0167] In some embodiments, the compound is of the formula:



[0168] In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, R^{16} is aryl, and R^{17} is alkyl. In some embodiments, R^{16} is aryl, and R^{17} is hydrogen. In some embodiments, R^{16} is heteroaryl, and R^{17} is alkyl. In some embodiments, R^{16} is heteroaryl, and R^{17} is hydrogen. In some embodiments, R^{16} is substituted heteroaryl, and R^{17} is hydrogen. In some embodiments, R^{16} is substituted alkyl, and R^{17} is hydrogen. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with halogen, alkyl, or hydroxyl. In some embodiments, R^{16} is hydrogen, and R^{17} is aryl or heteroaryl, substituted or unsubstituted with halogen or alkyl. In some embodiments, R^{16} is alkyl, and R^{17} is heteroaryl substituted with halogen or alkyl. In some embodiments, R^{16} is hydrogen. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with alkyl. In some embodiments, R^{17} is aryl or heteroaryl, each of which is independently substituted with alkyl, wherein the alkyl is optionally substituted with fluorine, chlorine, bromine, iodine, or cyano. In some embodiments, R^{16} is alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen, and R^{17} is aryl, heteroaryl, or heterocyclyl. In some embodiments, R^{16} is hydrogen, and R^{17} is phenyl, indolyl, piperidinyl, imidazolyl, thiazolyl, morpholinyl, pyrrolyl, or pyridinyl, each of which is substituted or unsubstituted. In some embodiments, R^{16} is hydrogen, and R^{17} is

substituted phenyl. In some embodiments, R^{16} is hydrogen, and R^{17} is phenyl substituted with a sulfoxide group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, halo, cyano, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^{17} is phenyl substituted with methoxy. In some embodiments, R^{17} is phenyl substituted with a substituted sulfoxide group. In some embodiments, R^{17} is phenyl substituted with a carboxyl group. In some embodiments, R^{17} is a substituted amide group. In some embodiments, R^{17} is substituted with methoxy and sulfonamide.

[0169] In some embodiments, R^{17} is phenyl substituted with 1, 2, 3, or 4 R^Z, wherein each R^Z is independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, halo, -CN, -$NR^{21}R^{22}$, -OR^{21}, -$C(O)R^{22}$, -$P(O)R^{21}R^{22}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -$S(O)R^{21}$, -SO_2R^{22}, -$NS(O)R^{21}$, -$NS(O)_2R^{21}$, -$S(O)NR^{21}R^{22}$, and -$S(O)_2NR^{21}R^{22}$.

[0170] In some embodiments, R^{17} is phenyl substituted with 1, 2, 3, or 4 R^Z, wherein each R^Z is independently selected from $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkenyl, $C_{2\text{-}6}$alkynyl, $C_{6\text{-}10}$aryl, $C_{1\text{-}9}$heteroaryl, $C_{1\text{-}9}$heterocyclyl, halo, -CN, -$NR^{21}R^{22}$, -OR^{21}, -$C(O)R^{21}$, -$P(O)R^{21}R^{22}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -$S(O)R^{21}$, -SO_2R^{21}, -$NS(O)R^{21}$, -$NS(O)_2R^{21}$, -$S(O)NR^{21}R^{22}$, and -$S(O)_2NR^{21}R^{22}$.

[0171] In some embodiments, each R^3 and R^4 is independently unsubstituted or substituted alkyl. In some embodiments, R^3 is hydrogen and R^4 is -$C(O)R^{19}$, -$C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^3 is hydrogen, and R^4 is alkyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is substituted heterocyclyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted C_4-C_6-heterocyclyl. In some embodiments, R^3 is H, and R^4 is substituted alkyl. In some embodiments, R^3 is H, and R^4 is substituted C_1-C_6-alkyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted cycloalkyl. In some embodiments, R^3 is H, and R^4 is substituted or unsubstituted C_4-C_6-cycloalkyl. In some embodiments, R^3 is H, and R^4 is C_4-C_6-cycloalkyl substituted with an amino group.

[0172] In some embodiments, each R^3 and R^4 is independently:

- $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$heteroalkyl, $C_{2\text{-}6}$alkenyl, $C_{2\text{-}6}$alkynyl, $C_{3\text{-}9}$cycloalkyl, $C_{6\text{-}10}$aryl, $C_{1\text{-}9}$heteroaryl, or $C_{1\text{-}9}$heterocyclyl, each of which is independently unsubstituted or substituted with 1 to 7 R^X; or
- H, -$C(O)R^{24}$, -$C(O)OR^{24}$, -$C(O)NR^{24}R^{25}$, -SOR^{24}, or -SO_2R^{24}, or
- R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form $C_{1\text{-}9}$heterocyclyl, that is unsubstituted or substituted with 1 to 7 R^X;


wherein

- each R^X is independently selected from -CN, halogen, -C(O)R^{24}, -C(O)OR^{24}, -N$R^{24}R^{25}$, -OR^{24}, -C(O)N$R^{24}R^{25}$, -SR^{24}, -S(O)R^{24}, -SO_2R^{24}, -NR^{24}C(O)R^{25}, and-OC(O)R^{24}; or C_{1-6}alkyl, C_{1-6}heteroalkyl C_{6-10}aryl, and C_{1-9}heterocyclyl, C_{1-6}alkylene-C_{6-10}aryl, and C_{1-6}alkylene-C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with -CN, halogen, methyl, ethyl, propyl, butyl, -C(O)R^{28}, -C(O)OR^{28}, -C(O)N$R^{28}R^{29}$, -OR^{28}, -SR^{28}, -S(O)R^{28}, -SO_2R^{28}, -N$R^{28}R^{29}$, -NR^{28}C(O)R^{29}, or -OC(O)R^{28};
- each R^{24} and R^{25} is independently C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is unsubstituted or substituted with halogen, methyl or ethyl; or H, -C(O)R^{28}, -C(O)OR^{28}, -C(O)N$R^{28}R^{29}$, -OR^{28}, -SR^{28}, -N$R^{28}R^{29}$, -NR^{28}C(O)R^{29}, or -OC(O)R^{28}; or R^{24} and R^{25} together with the nitrogen atom to which R^{24} and R^{25} are bound form a 5- or 6-membered ring, wherein the ring is unsubstituted or substituted with halogen, methyl, or ethyl; and
- each R^{26}, R^{27}, R^{28}, and R^{29} is independently C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{6-10}aryl, C_{1-9}heteroaryl, or C_{1-9}heterocyclyl, each of which is independently unsubstituted or substituted with halogen, cyano, hydroxy, amino, methyl, ethyl, propyl, or butyl; or hydrogen.

[0173] In some embodiments, R^3 is C_{3-9}cycloalkyl, C_{1-9}heterocyclylalkyl, or C_{1-6}heteroalkyl, each of which is independently unsubstituted or substituted with 1 to 7 R^X. In some embodiments, R^3 is C_{1-9}heterocyclylalkyl that is unsubstituted or substituted with 1 to 7 R^X. In some embodiments, R^3 is a 6-membered heterocyclylalkyl that is unsubstituted or substituted with 1 to 7 R^X.


[0174] In some embodiments, each R^X is independently selected from -CN, halogen, -N$R^{24}R^{25}$, -C(O)R^{25}, -NR^{25}C(O)R^{26}, and -OR^{24}; or C_{1-6}alkyl, C_{1-9}heterocyclyl, and C_{1-6}heteroalkyl, each of which is independently unsubstituted or substituted with halogen, -CN, -C(O)N$R^{28}R^{29}$, -C(O)OR^{28}, -SO_2R^{28}, methyl, ethyl, or propyl.

[0175] In some embodiments, the compound is of the formula:



[0176] In some embodiments, each R^3 and J is independently unsubstituted or substituted alkyl. In some embodiments, R^3 is hydrogen and J is $-C(O)R^{19}$, $-C(O)OR^{19}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^3 is hydrogen, and J is alkyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted. In some embodiments, R^3 is H, and J is substituted heterocyclyl. In some embodiments, R^3 is H, and J is substituted or unsubstituted C_4-C_6-heterocyclyl. In some embodiments, R^3 is H, and J is substituted alkyl. In some embodiments, R^3 is H, and J is substituted C_1-C_6-alkyl. In some embodiments, R^3 is H, and J is substituted or unsubstituted cycloalkyl. In some embodiments, R^3 is H, and J is substituted or unsubstituted C_4-C_6-cycloalkyl. In some embodiments, R^3 is H, and J is C_4-C_6-cycloalkyl substituted with an amino group.

[0177] In some embodiments, the compound is of the formula:



,


wherein:

- Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, C=O, C=S, -CN, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each Z^1 and Z^2 is independently CR^{28}, CR^{29}, or N;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of

which is independently substituted or unsubstituted, or -$C(O)R^{23}$, -$C(O)OR^{23}$, -$C(O)NR^{23}R^{24}$, -OR^{23}, -SR^{23}, -$NR^{23}R^{24}$, -$NR^{23}C(O)R^{24}$, -$OC(O)R^{23}$, hydrogen, or halogen;


- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{25}, R^{26}, R^{27}, R^{28}, and R^{29} is independently hydrogen or a substituent selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and ester group.


or a pharmaceutically-acceptable salt thereof.


[0178] In some embodiments, Z^1 is N. In some embodiments, Z^1 and Z^2 are N. In some embodiments, each R^{25} and R^{26} is independently a halogen. In some embodiments, R^{25} is 

. In some embodiments, R^{25} is a substituted sulfone group. In some embodiments, R^{25} is a sulfone group substituted with alkyl. In some embodiments, R^{25} is a methanesulfonyl group. In some embodiments, R^{25} is a sulfone group substituted with an amino group. In some embodiments, R^{25} is a sulfonamide. In some embodiments, R^{25} is a carboxy group. In some embodiments, R^{25} is a methoxycarbonyl group.




















[0179] In some embodiments, the compound is of the formula:



,


,

















,
















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,






,



,



,



,

, or

,

wherein:

- R^2 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^Q is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, cyano, or halogen;
- y is 0, 1, 2, 3, or 4;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{25}, R^{26}, R^{27}, R^{28}, and R^{29} is independently hydrogen or a substituent selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and ester group.

or a pharmaceutically-acceptable salt thereof.

[0180] In some embodiments, the compound is of the formula:




wherein:


- R^2 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^Q is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, cyano, or halogen;
- y is 0, 1, 2, 3, or 4;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{25}, R^{26}, R^{27}, R^{28}, and R^{29} is independently hydrogen or a substituent selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso


group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and ester group.


or a pharmaceutically-acceptable salt thereof.


[0181] In some embodiments, the compound is of the formula:



,



,



,


,


,


,



, or


,


[0182] In some embodiments, R^{25} is a substituted sulfone group. In some embodiments, R^{25} is a sulfone group substituted with alkyl. In some embodiments, R^{25} is a methanesulfonyl group. In some embodiments, R^{25} is a sulfone group substituted with an amino group. In some

embodiments, R^{25} is a sulfonamide. In some embodiments, R^{25} is a carboxy group. In some embodiments, R^{25} is a methoxycarbonyl group.


[0183] In some embodiments, the compound is of the formula:




,




,




,




,




,



,



, or



,


wherein:

- each R^Q is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, cyano, or halogen;
- y is 0, 1, 2, 3, or 4;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- each R^{26}, R^{27}, R^{28}, and R^{29} is independently hydrogen or a substituent selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and ester group; and
- R^{30} is alkyl or an amino group, each of which is substituted or unsubstituted,

or a pharmaceutically-acceptable salt thereof.

[0184] In some embodiments, R^{30} is methyl. In some embodiments, R^{30} is NH_2. In some embodiments, R^{30} is NHMe. In some embodiments, R^{30} is NMe_2.


[0185] In some embodiments, the compound is of the formula:



,


wherein R^{30} is alkyl or an amino group, each of which is unsubstituted or substituted. In some embodiments, R^{30} is methyl.

[0186] In some embodiments, the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.


[0187] Non-limiting examples of compounds of the current disclosure include the following:




,




,




,




,



,




,




and ,

or a pharmaceutically-acceptable salt thereof.


[0188] Non-limiting examples of compounds of the current disclosure include the following:




,




,




,




,




,




,




,




,




,



,




, and




,

or a pharmaceutically-acceptable salt thereof.


[0189] Non-limiting examples of compounds of the current disclosure include the following:




,




,




,



,




, and




,

or a pharmaceutically-acceptable salt thereof.


[0190] Non-limiting examples of compounds of the current disclosure include the following:




,




,




,




,



,









, and



,


or a pharmaceutically-acceptable salt thereof.

[0191] Non-limiting examples of compounds of the current disclosure include the following:



,

,

,

,

, and

,

or a pharmaceutically-acceptable salt thereof.


[0192] Non-limiting examples of compounds of the current disclosure include the following:




,




,




,




,




,




,




,




,



,




, and




,

or a pharmaceutically-acceptable salt thereof.

[0193] Non-limiting examples of compounds of the current disclosure include the following:







and ,

or a pharmaceutically-acceptable salt thereof.


[0194] Non-limiting examples of compounds of the current disclosure include the following:




;




;




;




;













;
























;





;



;

;

;

;

;

;

;

;

;

;



;

;

;

;

;

;

;

;



;

;

;

;

;

;

;

;

;

;

;

;

;



;



;



;



;



;






;


;


;



;



;



;


;



;



;



;



;



;



;



;


;


;










;



; and



,


or a pharmaceutically-acceptable salt of any of the foregoing.


[0195] Non-limiting examples of compounds of the current disclosure include the following:



;

;

;

;

;

;

;

;



;



;



;



;



;



;



;


















;


;


;




;




;




;

;

;

;

;

;

;

;

;

;

;

;

;

;

;

;



;



;




;

;



;

;


;

;


;

;


;

;



;

;











;

;


;



;















;

;


;

;

;

;

;

;

;

; and

,

or a pharmaceutically-acceptable salt of any of the foregoing.













[0196] Non-limiting examples of compounds of the current disclosure include the following:



;

;












;

;

;

;

;

;

;

;

;

;

;

;

;

;











;

;


;

;

;

;

;

;

;

;

;

;

;

;


;

;



;

;

;

;

;

;

;

;

;

;



;

;

;

;

;

;

;

;

;

;

;


;



;



; and



, or a pharmaceutically-acceptable salt of any of the forgoing.

[0197] Non-limiting examples of compounds of the current disclosure include the following:



,


,



,




,



,




,




and ,

or a pharmaceutically-acceptable salt thereof.


[0198] Non-limiting examples of compounds of the current disclosure include the following:




,




,




,




,




,




,




,




,




,



,




, and




,

or a pharmaceutically-acceptable salt thereof.


[0199] Non-limiting examples of compounds of the current disclosure include the following:




,




,




,



,




, and




,

or a pharmaceutically-acceptable salt thereof.


[0200] Non-limiting examples of compounds of the current disclosure include the following:




,




,




,




,



,









, and



,


or a pharmaceutically-acceptable salt thereof.

[0201] Non-limiting examples of compounds of the current disclosure include the following:



,

,

,

,

, and

,

or a pharmaceutically-acceptable salt thereof.


[0202] Non-limiting examples of compounds of the current disclosure include the following:




,




,




,




,




,




,




,







,




,




,



,




, and




,

or a pharmaceutically-acceptable salt thereof.

[0203] Non-limiting examples of compounds of the current disclosure include the following:





and ,

or a pharmaceutically-acceptable salt thereof.

[0204] In some embodiments, the disclosure provides a compound comprising: an indole group, wherein the indole group comprises: a) a haloalkyl group at a 1-position of the indole group; b) a first substituent at a 2-position of the indole group, wherein the first substituent is a cyclic group;

and c) a second substituent, wherein the second substituent is substituted with at least halo-; or a pharmaceutically-acceptable salt thereof.

[0205] In some embodiments, the cyclic group is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted. In some embodiments, the cyclic group is unsubstituted aryl. In some embodiments, the cyclic group is substituted aryl. In some embodiments, the cyclic group is substituted phenyl. In some embodiments, the cyclic group is substituted or unsubstituted heteroaryl. In some embodiments, the heteroaryl is an aromatic 5-membered or 6-membered monocyclic ring. In some embodiments, the heteroaryl is thiazolyl, thiadiazolyl, pyrazolyl, thiophenyl, or oxadiazolyl. In some embodiments, the heteroaryl is pyridinyl or pyrimidinyl.

[0206] In some embodiments, the second substituent is at a 4-position of the indole group. In some embodiments, the second substituent is a second cyclic group that is substituted or unsubstituted. In some embodiments, the second cyclic group is heterocyclyl. In some embodiments, the heterocyclyl is piperidinyl. In some embodiments, the heterocyclyl is tetrahydropyranyl. In some embodiments, the heterocyclyl is substituted with fluoro-. In some embodiments, the heterocyclyl is substituted with chloro-. In some embodiments, the haloalkyl group is trifluoroethyl.

[0207] In some embodiments, the disclosure provides a compound, the compound comprising an indole group, wherein the indole group comprises: a) a substituted or unsubstituted non-cyclic group at a 3-postion of the indole group; and b) a substituted or unsubstituted cyclic group at a 2-position of the indole group, wherein the compound increases a stability of a biologically-active conformation of a p53 mutant relative to a stability of a biologically-active conformation of the p53 mutant in an absence of the compound, or a pharmaceutically-acceptable salt thereof.


[0208] In some embodiments, the non-cyclic group is hydrogen. In some embodiments, the non-cyclic group is halo-. In some embodiments, the cyclic group is aryl, heteroaryl, heterocyclyl, or cycloalkylene, each of which is substituted or unsubstituted. In some embodiments, the cyclic group is aryl or heteroaryl, each of which is substituted or unsubstituted. In some embodiments, the cyclic group is substituted aryl. In some embodiments, the cyclic group is substituted phenyl. In some embodiments, the cyclic group is phenyl substituted with alkyl, cycloalkyl, alkoxy, an amine group, a carboxyl group, a carboxylic acid group, a carbamide group, or an amide group, each of which is substituted or unsubstituted; cyano, halo-, or hydrogen.


[0209] In some embodiments, the cyclic group is substituted heteroaryl. In some embodiments, the cyclic group is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms as ring members, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, the cyclic group is

pyridinyl, pyrimidinyl, thiadiazolyl, thiazolyl, pyrazolyl, thiophenyl, or oxadiazolyl, In some embodiments, the cyclic group is 1,3,5-thiadiazol-2-yl. In some embodiments, the cyclic group is 1,3,4-oxadiazol-2-yl or 1,2,4-oxadiazol-2-yl. In some embodiments, the cyclic group is pyridinyl.


[0210] In some embodiments, the indole group further comprises a substituent at a 4-position of the indole group. In some embodiments, the substituent is an amino group that is substituted or unsubstituted. In some embodiments, the amino group is substituted with a second cyclic group. In some embodiments, the second cyclic group is a heterocyclyl group substituted with at least halo-. In some embodiments, the heterocyclyl group is substituted with at least fluoro-. In some embodiments, the heterocyclyl group is substituted with at least chloro-. In some embodiments, the heterocyclyl group is piperidinyl. In some embodiments, the heterocyclyl group is tetrahydropyranyl.

[0211] Non-limiting examples of compounds of the disclosure include compounds of any of the following formulae:







,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




, and



,

or a pharmaceutically-acceptable salt thereof.

[0212] In some embodiments, the disclosure provides a compound of the formula:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each W is independently $-Q^1-N(R^3)R^4$, $-Q^1-OR^4$, or $-Q^1-R^4$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- J is a substituted or unsubstituted ring;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, or hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each

of which is independently substituted or unsubstituted, or -$C(O)R^{23}$, -$C(O)OR^{23}$, -$C(O)NR^{23}R^{24}$, -OR^{23}, -SR^{23}, -$NR^{23}R^{24}$, -$NR^{23}C(O)R^{24}$, -$OC(O)R^{23}$, hydrogen, or halogen;

- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0213] In some embodiments, J is substituted or unsubstituted arylene, heteroarylene, heterocyclylene, cycloalkylene. In some embodiments, J is a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are optionally substituted. In some embodiments, A is naphthyl. In some embodiments, J is indazolyl.

[0214] In some embodiments, J is substituted arylene. In some embodiments, J is substituted phenylene. In some embodiments, J is phenylene substituted with alkyl, cycloalkyl, alkoxy, an amine group, a carboxyl group, a carboxylic acid group, a carbamide group, or an amide group, each of which is substituted or unsubstituted; cyano, halogen, or hydrogen. In some embodiments, J is phenyl substituted with alkyl, wherein alkyl is substituted. In some embodiments, J is phenylene substituted with alkyl, wherein alkyl is substituted with an amino group that is substituted or unsubstituted. In some embodiments, J is phenylene substituted with an amine group that is substituted or unsubstituted. In some embodiments, J is phenylene substituted with a carboxyl group that is substituted or unsubstituted. In some embodiments, J is phenylene substituted with cyano. In some embodiments, J is phenylene substituted with halo-.

[0215] In some embodiments, J is substituted or unsubstituted heterocyclylene. In some embodiments, J is substituted heterocyclylene.

[0216] In some embodiments, J is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms as ring members, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, J is an aromatic 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system comprising 1, 2, 3, 4, 5, or 6 heteroatoms, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, J is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms, and the aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system is

substituted. In some embodiments, J is an 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system having 1, 2, 3, 4, 5, or 6 heteroatoms, and the 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system is substituted.

[0217] In some embodiments, J is pyridinyl, pyrimidinyl, thiadiazolyl, thiazolyl, pyrazolyl, thiophenyl, or oxadiazolyl, each of which is independently substituted or unsubstituted. In some embodiments, J is 1,3,5-thiadiazol-2-yl. In some embodiments, J is 1,3,4-oxadiazol-2-yl or 1,2,4-oxadiazol-2-yl. In some embodiments, J is 1,3,4-oxadiazol-2-yl.

[0218] In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, W is $-Q^1-N(R^3)R^4$. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond. In some embodiments, Q^1 is a bond.


[0219] In some embodiments, R^2 is hydrogen. In some embodiments, R^2 is substituted or unsubstituted alkyl. In some embodiments, R^2 is trifluoroethyl. In some embodiments, R^2 is cycloalkyl.

[0220] In some embodiments, R^1 is alkyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, cyano, halo, or halogen. In some embodiments, R^1 is $-NR^{16}R^{17}$. In some embodiments, R^1 is substituted alkyl.

[0221] In some embodiments, each R^3 and R^4 is independently aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen. In some embodiments, R^3 is hydrogen, and R^4 is heterocyclyl substituted at least with halo-. In some embodiments, R^4 is heterocyclyl substituted with fluoro. In some embodiments, R^4 is heterocyclyl substituted with chloro.

[0222] In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^{13} is hydrogen.


[0223] In some embodiments, the compound has the formula:



,


or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0224] In some embodiments, the compound has the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0225] In some embodiments, the compound has the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0226] In some embodiments, the compound has the formula:




or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0227] In some embodiments, the disclosure provides a compound of the formula:



, or













,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0228] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In

some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0229] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0230] In some embodiments, R^4 is a ring that is: , , , , , or , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0231] In some embodiments, each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an

amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.


[0232] In some embodiments, the compound is of the formula:



,

wherein R^{25} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)NR^{16}R^{17}$, or hydrogen. In some embodiments, R^{25} is aryl that is substituted or unsubstituted. In some embodiments, R^{25} is substituted phenyl. In some embodiments, R^{25} is $-C(O)R^{16}$, wherein R^{16} is alkyl, aryl, heteroaryl, or heterocyclyl. In some embodiments, R^{25} is $-C(O)R^{16}$, wherein R^{16} is substituted phenyl.

[0233] In some embodiments, the disclosure provides a compound of the formula:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each W is independently $-Q^1-N(R^3)R^4$, $-Q^1-OR^4$, or $-Q^1-R^4$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- Ar is unsubstituted or substituted arylene;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;

- n is 0, 1, 2, 3, or 4;
- each R^x and R^1 is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, cyano, halo, or hydrogen; or R^1 and R^x together with Ar form a fused ring;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{23}$, -$C(O)OR^{23}$, -$C(O)NR^{23}R^{24}$, -OR^{23}, -SR^{23}, -$NR^{23}R^{24}$, -$NR^{23}C(O)R^{24}$, -$OC(O)R^{23}$, hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0234] The pattern of dashed bonds can be chosen to provide an aromatic system, for example, an indole, a pyrrolopyridine, a pyrrolopyrimidine, or a pyrrolopyrazine. In some embodiments, X^1 is CR^5, CR^5R^6, or a carbon atom connected to Q^1. In some embodiments, X^2 is CR^7, CR^7R^8, or a carbon atom connected to Q^1. In some embodiments, X^3 is CR^9, CR^9R^{10}, or a carbon atom connected to Q^1. In some embodiments, X^4 is CR^{11}, $CR^{11}R^{12}$, or a carbon atom connected to Q^1. In some embodiments, X^5 is CR^{13}, N, or NR^{13}. In some embodiments, X^1 is a carbon atom connected to Q^1. In some embodiments, X^2 is a carbon atom connected to Q^1. In some

embodiments, X^3 is a carbon atom connected to Q^1. In some embodiments, X^4 is a carbon atom connected to Q^1. In some embodiments, X^5 is N.

[0235] In some embodiments, Ar is a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are optionally substituted. In some embodiments, Ar is phenylene. In some embodiments, Ar is naphthylene. In some embodiments, Ar is indazolylene.

[0236] R^1 can be alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, or aryl, each of which is independently substituted or unsubstituted; or $-NR^{21}R^{22}$, halo, or hydrogen. In some embodiments, R^1 is methyl, cyclohexyl, methylene, methoxy, or benzyl. In some embodiments, R^1 is fluoro or chloro. In some embodiments, R^1 is phenyl. In some embodiments, R^1 is hydrogen.

[0237] In some embodiments, R^1 is a substituted alkyl. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.

[0238] In some embodiments, R^1 is alkyl substituted with an amine group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is alkyl substituted with $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is alkyl substituted with $-C(O)OR^{16}$. In some embodiments, R^1 is methyl substituted with COOH.

[0239] In some embodiments, m is 1, 2, 3, or 4. In some embodiments, m is 1. In some embodiments, X^3 is carbon atom connected to Q^1, and m is 1. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 0.











[0240] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is a bond. In some embodiments, Q^1 is C_1-alkylene.


[0241] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^2 is alkyl, and R^{13} is alkyl. In some


embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.

[0242] In some embodiments, R^3 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen.

[0243] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.


[0244] In some embodiments, R^4 is a ring that is: , , , , , , or , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is



.


[0245] In some embodiments, the disclosure provides a compound of the formula:




,

wherein the variables are as defined above.

[0246] In some embodiments, the disclosure provides a compound of the formula:



or



,


wherein:

- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;

- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- Ar is unsubstituted or substituted aryl;
- Q^1 is C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
- n is 0, 1, 2, 3, or 4;
- each R^x and R^1 is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, cyano, halo, or hydrogen; or R^1 and R^x together with Ar form a fused ring;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{23}$, -$C(O)OR^{23}$, -$C(O)NR^{23}R^{24}$, -OR^{23}, -SR^{23}, -$NR^{23}R^{24}$, -$NR^{23}C(O)R^{24}$, -$OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0247] In some embodiments, the compound is of the formula:



,

wherein the variables are as defined above.

[0248] In some embodiments, Ar is a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are optionally substituted. In some embodiments, Ar is phenylene. In some embodiments, Ar is naphthylene. In some embodiments, Ar is indazolylene.

[0249] In some embodiments, R^1 is a substituted alkyl. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.












[0250] In some embodiments, R^1 is alkyl substituted with an amine group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is alkyl substituted with $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is alkyl substituted with $-C(O)OR^{16}$. In some embodiments, R^1 is methyl substituted with COOH.

[0251] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is a bond. In some embodiments, Q^1 is C_1-alkylene.


[0252] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^2 is alkyl, and R^{13} is alkyl. In some embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.

[0253] In some embodiments, R^3 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen.

[0254] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.


[0255] In some embodiments, R^4 is a ring that is: , , , , , , or , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is

substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is




.


[0256] In some embodiments, the disclosure provides a compound of the formula:




,



,




, or




,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.


[0257] In some embodiments, the disclosure provides a compound of the formula:




,




,




,




,




,



,



, or



,

wherein:

- Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- each R^1, R^x, R^{x1}, R^{x2}, R^{x3}, and R^{x4} is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, cyano, halo, or hydrogen; or R^1 and R^x together with Ar form a fused ring;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, or $-SO_2R^{19}$; or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- n is 0, 1, 2, 3, or 4;

  each R^2, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or

hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0258] In some embodiments, R^1 is a substituted alkyl. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.

[0259] In some embodiments, R^1 is alkyl substituted with an amine group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is alkyl, aryl, heteroaryl, an amino group, a carboxyl group, or an ester group, any of which is substituted or unsubstituted. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted alkyl, aryl, or heteroaryl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted phenyl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted pyridinyl.

[0260] In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} and R^{17} are hydrogen. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} alkyl. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} methyl. In some embodiments, R^1 is $-C(O)OR^{16}$. In some embodiments, R^1 is -C(O)OH. In some embodiments, R^1 is methyl. In some embodiments, R^1 is halogen. In some embodiments, R^1 is chloro or fluoro.

[0261] In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 0.











[0262] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is a bond. In some embodiments, Q^1 is C_1-alkylene.


[0263] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^2 is alkyl, and R^{13} is alkyl. In some embodiments, R^2 is hydrogen, and R^{13} is alkyl. In some embodiments, R^2 is methyl, ethyl, propyl, iso-propyl, butyl, or tert-butyl. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-


propyl, butyl or tert-butyl. In some embodiments, R^2 is hydrogen, and R^{13} is hydrogen. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.

[0264] In some embodiments, R^3 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen.


[0265] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0266] In some embodiments, R^4 is a ring that is: , , , , , , or , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is



[0267] In some embodiments, the disclosure provides a compound of the formula:



or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0268] In some embodiments, R^1 is a substituted alkyl. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.









[0269] In some embodiments, R^1 is alkyl substituted with an amine group. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is alkyl, aryl, heteroaryl, an amino group, a carboxyl group, or an ester group, any of which is substituted or unsubstituted. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted alkyl, aryl, or heteroaryl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted phenyl. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is substituted or unsubstituted pyridinyl.

[0270] In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} and R^{17} are hydrogen. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} alkyl. In some embodiments, R^1 is $-C(O)NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} methyl. In some embodiments, R^1 is $-C(O)OR^{16}$. In some embodiments, R^1 is $-C(O)OH$. In some embodiments, R^1 is methyl. In some embodiments, R^1 is halogen. In some embodiments, R^1 is chloro or fluoro.









[0271] In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 0.









[0272] In some embodiments, R^3 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen.


[0273] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0274] In some embodiments, R^3 is H, and R^4 is a ring that is: , , , , or . In some embodiments, R^3 is H, and R^4 is a ring that is  or . In some embodiments, R^3 is H, and R^4 is a ring that is .


[0275] Non-limiting examples of compounds of the disclosure include compounds of any of the following formulae:


,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,




,




,



,




,



or ,

or a pharmaceutically-acceptable salt thereof.

[0276] In some embodiments, the disclosure provides a compound of the formula:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each W is independently $-Q^1-N(R^3)R^4$, $-Q^1-OR^4$, or $-Q^1-R^4$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- Het is substituted or unsubstituted heteroarylene;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or

heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and

- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0277] The pattern of dashed bonds can be chosen to provide an aromatic system, for example, an indole, a pyrrolopyridine, a pyrrolopyrimidine, or a pyrrolopyrazine. In some embodiments, X^1 is CR^5, CR^5R^6, or a carbon atom connected to Q^1. In some embodiments, X^2 is CR^7, CR^7R^8, or a carbon atom connected to Q^1. In some embodiments, X^3 is CR^9, CR^9R^{10}, or a carbon atom connected to Q^1. In some embodiments, X^4 is CR^{11}, $CR^{11}R^{12}$, or a carbon atom connected to Q^1. In some embodiments, X^5 is CR^{13}, N, or NR^{13}. In some embodiments, X^1 is a carbon atom connected to Q^1. In some embodiments, X^2 is a carbon atom connected to Q^1. In some embodiments, X^3 is a carbon atom connected to Q^1. In some embodiments, X^4 is a carbon atom connected to Q^1. In some embodiments, X^5 is N.

[0278] In some embodiments, Het is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms as ring members, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, Het is an aromatic 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system comprising 1, 2, 3, 4, 5, or 6 heteroatoms, wherein each heteroatom is independently selected from O, N, or S. In some embodiments, Het is an aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system comprising 1, 2, or 3 heteroatoms, and the aromatic 5-membered, 6-membered, 7-membered, or 8-membered monocyclic ring system is substituted. In some embodiments, Het is an 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system having 1, 2, 3, 4, 5, or 6 heteroatoms, and the 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered bicyclic ring system is substituted.

[0279] In some embodiments, Het is pyridinyl, pyrimidinyl, thiadiazolyl, thiazolyl, pyrazolyl, thiophenyl, or oxadiazolyl, each of which is independently substituted or unsubstituted. In some embodiments, Het is 1,3,5-thiadiazol-2-yl. In some embodiments, Het is 1,3,4-oxadiazol-2-yl or 1,2,4-oxadiazol-2-yl. In some embodiments, Het is 1,3,4-oxadiazol-2-yl.

[0280] In some embodiments, R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -

$SiR^{16}R^{17}R^{18}$, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, $-NR^{21}R^{22}$, or aryl, each of which is independently substituted or unsubstituted; halo or hydrogen. In some embodiments, R^1 is methyl, cyclohexyl, methylene, methoxy, or benzyl. In some embodiments, R^1 is fluoro or chloro. In some embodiments, R^1 is phenyl. In some embodiments, R^1 is hydrogen.

[0281] In some embodiments, R^1 is a substituted alkyl or alkylene. R^1 can be substituted by one or more substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, cyclic alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, urethane group, and ester group.

[0282] In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.

[0283] In some embodiments, m is 1, 2, 3, or 4. In some embodiments, m is 1. In some embodiments, X^1 is carbon atom connected to Q^1, and m is 1. In some embodiments, X^2 is carbon atom connected to Q^1, and m is 1.

[0284] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.









[0285] In some embodiments, Q^1 is C_1-alkylene, R^{16} is aryl, and R^{17} is alkyl. In some embodiments, Q^1 is C_1-alkylene, R^{16} is aryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C_1-alkylene, R^{16} is heteroaryl, and R^{17} is alkyl. In some embodiments, Q^1 is C_1-alkylene, R^{16} is heteroaryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C_1-alkylene, R^{16} is substituted heteroaryl, and R^{17} is hydrogen. In some embodiments, Q^1 is C_1-alkylene, R^{16} is substituted alkyl, and R^{17} is hydrogen. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with halogen, alkyl, or hydroxyl. In some embodiments, R^{16} is hydrogen, and R^{17} is aryl or heteroaryl, substituted or unsubstituted with



halogen or alkyl. In some embodiments, R^{16} is alkyl, and R^{17} is heteroaryl substituted with halogen or alkyl. In some embodiments, R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted with alkyl. In some embodiments, R^{17} is aryl or heteroaryl, each of which is independently substituted with alkyl, wherein the alkyl is optionally substituted with fluorine, chlorine, bromine, iodine, or cyano.

[0286] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^2 is substituted alkyl. In some embodiments, R^2 is trifluoroethyl. In some embodiments, R^{13} is alkyl, alkenyl, hydrogen, or halogen. In some embodiments, R^{13} is methyl, ethyl, propyl, iso-propyl, butyl or tert-butyl. In some embodiments, R^2 is trifluoroethyl, and R^{13} is hydrogen.

[0287] In some embodiments, R^3 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen; and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, or hydrogen.


[0288] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0289] In some embodiments, R^4 is a ring that is: , , , , , or , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is

alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0290] In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a substituted heterocycle. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a heterocycle substituted with a hydroxyl group, halogen, amino group, or alkyl group. In some embodiments, R^3 and R^4 together with the nitrogen atom to which R^3 and $R^4$are bound form a heterocycle, wherein the heterocycle is substituted by a substituted or unsubstituted heterocycle.


[0291] In some embodiments, the disclosure provides a compound of the formula:




,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0292] In some embodiments, the disclosure provides a compound of the formula:




or



,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.


[0293] In some embodiments, the compound is of the formula:




,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.


[0294] In some embodiments, the disclosure provides a compound of the formula:




,



,



, or



,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0295] In some embodiments, R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, or hydrogen. In some embodiments, R^1 is alkyl, alkylene, alkoxy, or aryl, each of which is independently substituted or unsubstituted; or -$NR^{21}R^{22}$, halo, or hydrogen.











[0296] In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^1 is methyl substituted with $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.

[0297] In some embodiments, R^2 is hydrogen or alkyl. In some embodiments, R^2 is substituted alkyl. In some embodiments, R^2 is trifluoroethyl.


[0298] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-

alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0299] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0300] In some embodiments, R^4 is a ring that is: , , , , , or , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0301] In some embodiments, the disclosure provides a compound of the formula:



, or




,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.


[0302] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.

[0303] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.


[0304] In some embodiments, R^4 is a ring that is:




,




,




,




,




, or





, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is



, wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is




, wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring

that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0305] In some embodiments, each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.


[0306] In some embodiments, the compound is of the formula:




,

wherein R^{25} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)NR^{16}R^{17}$, or hydrogen. In some embodiments, R^{25} is aryl that is substituted or unsubstituted. In some embodiments, R^{25} is substituted phenyl. In some embodiments, R^{25} is $-C(O)R^{16}$, wherein R^{16} is alkyl, aryl, heteroaryl, or heterocyclyl. In some embodiments, R^{25} is $-C(O)R^{16}$, wherein R^{16} is substituted phenyl; or a pharmaceutically-acceptable salt thereof,


[0307] In some embodiments, the compound is of the formula:



,



, or



,




wherein:




- Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- o is 1, 2, 3, or 4.

- R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{23}$, -$C(O)OR^{23}$, -$C(O)NR^{23}R^{24}$, -OR^{23}, -SR^{23}, -$NR^{23}R^{24}$, -$NR^{23}C(O)R^{24}$, -$OC(O)R^{23}$, hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.

[0308] In some embodiments, the compound is of the formula:


,

,

,

, , or ,













wherein:

- Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- each R^1, R^{1a}, and R^{1b} is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- o is 0, 1, 2, 3, or 4;
- each R^2, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, or hydrogen or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.


[0309] In some embodiments, each R^{1a} and R^{1b} is independently alkyl, alkoxy, aryl, heteroaryl, heterocyclyl, or $NR^{16}R^{17}$. In some embodiments, R^{1a} is unsubstituted phenyl, and R^{1b} is amino.

[0310] In some embodiments, the compound is of the formula:


,

,

,

,

,

,

,

,

,


,

,

,

,









, or





or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0311] In some embodiments, R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or -$C(O)NR^{16}R^{17}$ or hydrogen. In some embodiments, R^1 is alkyl, alkoxy, aryl, or halo. In some embodiments, R^1 is methoxy, methyl, or phenyl. In some embodiments, each R^{1a} and R^{1b} is independently alkyl, alkoxy, aryl, heteroaryl, heterocyclyl, or $NR^{16}R^{17}$. In some embodiments, R^{1a} is unsubstituted phenyl, and R^{1b} is amino.

[0312] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0313] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or -$C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0314] In some embodiments, R^4 is a ring that is: , , , , , or , wherein the ring is substituted or

unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0315] In some embodiments, each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group.

[0316] In some embodiments, the compound is of the formula:

,

wherein:

- Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- each R^{1c} and R^{1d} is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and R^4


together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;


- each R^2, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, or hydrogen, or halogen;
- each R^{19} and R^{20} is $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,


or a pharmaceutically-acceptable salt thereof.

[0317] In some embodiments, each R^{1c} and R^{1d} is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-OR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, or hydrogen.

[0318] In some embodiments, the compound is of the formula:



,



, or


,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0319] In some embodiments, each R^{1c} and R^{1d} is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or halogen, $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, or hydrogen. In some embodiments, R^{1c} is amino, and R^{1d} is phenyl. In some embodiments, R^{1c} is amino, and R^{1d} is cycloalkenyl.

[0320] In some embodiments, the compound is of the formula:





wherein:

- Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- each R^{1e} and R^{1f} is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,





or a pharmaceutically-acceptable salt thereof.

[0321] In some embodiments, the compound is of the formula:


or

,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.











[0322] In some embodiments, the compound is of the formula:


,

,


, or .

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.



[0323] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.


[0324] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0325] In some embodiments, R^4 is a ring that is:  ,  ,  ,  ,  , or  , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is  , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is  , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is  , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is  , wherein the ring is substituted or unsubstituted.

[0326] In some embodiments, each R^{1e} and R^{1f} is independently alkyl, $NR^{16}R^{17}$, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{1e} is substituted alkyl, and R^{1f} is hydrogen. In some embodiments, R^{1e} is hydrogen, and R^{1f} is $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^{1e} is hydrogen, and R^{1f} is $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is alkyl. In some embodiments, R^{1e} is hydrogen, and R^{1f} is $NR^{16}R^{17}$, wherein R^{16} is hydrogen, and R^{17} is phenyl. In some embodiments, R^{1e} is hydrogen, and R^{1f} is amino.

[0327] In some embodiments, the compound is of the formula:

 ,  , or




,

wherein:


- Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- each R^1, R^{1g}, and R^{1h} is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof.


[0328] In some embodiments, the compound is of the formula:




,



,




,




,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0329] In some embodiments, the compound is of the formula:



or













,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0330] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.

[0331] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen. In some embodiments, R^3





is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0332] In some embodiments, R^4 is a ring that is: , , , , , or , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0333] In some embodiments, R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, or hydrogen. In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group. In some embodiments, R^{16} is hydrogen, and R^{17} is carboxyl substituted with alkyl or aryl. In some

embodiments, R^{16} is hydrogen, and R^{17} is carboxyl substituted with cycloalkyl or phenyl. In some embodiments, R^{16} and R^{17} are hydrogen.



[0334] In some embodiments, the compound is of the formula:


,

,

, or

,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0335] In some embodiments, R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, or hydrogen. In some embodiments, R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is a substituted carboxyl group. In some embodiments, R^{16} is hydrogen, and R^{17} is carboxyl substituted with alkyl or aryl. In some embodiments, R^{16} is hydrogen, and R^{17} is carboxyl substituted with cycloalkyl or phenyl. In some embodiments, R^{16} and R^{17} are hydrogen.











[0336] In some embodiments, the compounds is of the formula:


or

,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.




[0337] In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond. In some embodiments, Q^1 is alkylene, alkenylene, or alkynylene. In some embodiments, Q^1 is C_1-alkylene. In some embodiments, each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, or hydrogen. In some embodiments, Q^1 is a bond.

[0338] In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted; or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen. In some embodiments, R^3 is H, and R^4 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen. In some embodiments, R^4 is heterocyclyl. In some embodiments, R^4 is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted.

[0339] In some embodiments, R^4 is a ring that is: , , , , , or , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^a is alkylene. In some embodiments, R^a is methyl. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted. In some embodiments, R^3 is H, and R^4 is a ring that is , wherein the ring is substituted or unsubstituted.

[0340] In some embodiments, R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, halogen, or hydrogen. In some embodiments R^1 is substituted alkyl. In some embodiments, R^1 is alkyl substituted with $NR^{16}R^{17}$, wherein each R^{16} and R^{17} is independently alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkoxy, carboxyl group, amino group, acyl group, acyloxy group, or an amide group, any of which is unsubstituted or substituted, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is aryl, heteroaryl, carboxyl, or hydrogen. In some embodiments, R^{16} is hydrogen, and R^{17} is carboxyl substituted with aryl, heteroaryl, cycloalkyl, or alkyl. In some embodiments, R^{16} and R^{17} are hydrogen.

[0341] In some embodiments, the compound is of the formula:


,

, or

,




wherein:

- Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- R^1 is alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, heterocyclyl, or halo, each of which is independently substituted or unsubstituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, -$C(O)NR^{16}R^{17}$, -OR^{16}, -SR^{16}, -$NR^{16}R^{17}$, -$NR^{16}C(O)R^{16}$, -$OC(O)R^{16}$, -$SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{19}$, -$C(O)OR^{19}$, -$C(O)NR^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen;

- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{23}$, -$C(O)OR^{23}$, -$C(O)NR^{23}R^{24}$, -OR^{23}, -SR^{23}, -$NR^{23}R^{24}$, -$NR^{23}C(O)R^{24}$, -$OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,







or a pharmaceutically-acceptable salt thereof.

[0342] In some embodiments, the compound is of the formula:


,

, or

,


or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.

[0343] In some embodiments, the compound is of the formula:



,

,

,

,

, or

,

or a pharmaceutically-acceptable salt thereof, wherein the variables are as defined above.


[0344] In some embodiments, the compound is of the formula:



,



, or



,

wherein:







- Q^1 is alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- each R^{1c} and R^{1d} is independently alkyl, alkenyl, alkynyl, alkoxy, aryl, or heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, $-SiR^{16}R^{17}R^{18}$, halogen, or hydrogen;
- each R^3 and R^4 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and R^4 together with the nitrogen atom to which R^3 and R^4 are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and


- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,
- R^{25} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;

or a pharmaceutically-acceptable salt thereof.


[0345] In some embodiments, R^{25} is heterocyclyl, cycloalkyl, aryl, each of which is substituted or unsubstituted. In some embodiments, R^{25} is phenyl or cyclopropyl, each of which is substituted or unsubstituted. In some embodiments, R^{25} is substituted cyclopropyl. In some embodiments, R^{25} is heteroaryl or heterocyclyl, each of which is substituted or unsubstituted. In some embodiments, R^{25} is thiophenyl, indolenyl, or pyrrolyl, each of which is substituted or unsubstituted.

[0346] Non-limiting examples of compounds of the disclosure include compounds of any of the following formulae:



,

,

,

,

,

,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,







,





,




,



,

,

,

or , or a pharmaceutically-acceptable salt thereof.

[0347] Non-limiting examples of compounds of the disclosure include compounds of any of the following formulae:



,

,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




,




,


,




,




,




,




,




,



,



, or




,

or a pharmaceutically-acceptable salt thereof.

[0348] Suitable p53-activating compounds of the present disclosure also can include, for example, p53-activating compounds provided in WO2023025324A1, WO2023165523A1,

WO2023016434A1, WO2022213975A1, CN115960094A, CN116217562A, CN115677722A, and CN115504995A, each of which is incorporated by reference in its entirety. Suitable p53-activating compounds of the present disclosure also can include, for example, p53-activating compounds provided in WO2023147419, WO2024041503, and CN2024117586229A, each of which is incorporated by reference in its entirety.

[0349] In some embodiments, the compound is of the formula:



or a pharmaceutically acceptable salt thereof,

wherein:

each ═══ is independently a single bond or a double bond;

X^1 is CR^5, NR^6, O, S, C=O, C=S or a carbon atom connected to R^2;

X^2 is CR^7, NR^8, O, S,C=O, C=S or a carbon atom connected to R^2;

X^3 is CR^9, NR^{10}, O, S, C=O, C=S or a carbon atom connected to R^2;

X^4 is CR^{11}, NR^{12}, O, S, C=O, C=S or a carbon atom connected to R^2;

X^5 and X^6 are each independently selected from CR^{13} and N;

X^7 is CR^{14} or NR^{14};

wherein at least one of X^1, X^2, X^3 and X^4 is a carbon atom connected to R^2;


at least one of X^5 and X^6 is N;

R^1 is H, alkyl, cycloalkyl, haloalkyl, halogen, hydroxyl, alkoxyl, $-SR^{15}$, $-S(O)R^{15}$, $-S(O)_2R^{15}$, nitro, nitroso, cyano, amino, carboxyl, $-C(O)OR^{15}$, $-NR^{16}R^{17}$, aryl, heteroaryl or heterocyclyl; wherein said alkyl, cycloalkyl, alkoxyl, aryl, heteroaryl or heterocyclyl is optionally substituted with one or more R^{18};

R^2 is alkyl, cycloalkyl, $-NR^{19}R^{20}$, $-C_{1-6}$alky-$NR^{19}R^{20}$, haloalkyl, halogen, hydroxyl, alkoxyl, $-C(O)NR^{19}R^{20}$, aryl, heteroaryl or heterocyclyl; wherein said alkyl, alkoxyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally substituted by one or more R^{21};

R^3 is H, hydroxyl, halogen, nitro, cyano, carboxyl, amino, alkyl, alkoxyl, haloalkyl or cycloalkyl;

R^4 is aryl, heteroaryl, each of which is optionally substituted by one or more R^{22}, or



or

;A is aryl or heteroaryl, each of which is optionally substituted with one or more R^{22};

Z^1, Z^2, and Z^3 are each independently selected from CR'R'', O, S, $S(O)_2$, and NR';

each R' and R'' is independently H, hydroxyl, halogen, nitro, cyano, carboxyl, amino, alkyl, alkoxyl, haloalkyl, or cycloalkyl;

each R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, and R^{13} is independently H, alkyl, halogen, haloalkyl, cycloalkyl, hydroxyl, nitro, amino or alkoxyl;

each R^{14}, R^{16}, R^{17}, R^{19}, R^{20} is independently H, alkyl, cycloalkyl, haloalkyl, halogen, hydroxyl, alkoxyl, $-SR^{15}$, $-S(O)R^{15}$, $-S(O)_2R^{15}$, nitro, nitroso, cyano, amino, carboxyl, $-C(O)OR^{15}$, $-NR^{16}R^{17}$, aryl, heteroaryl and heterocyclyl, wherein each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally substituted by one or more R^{23};

or R^{16} and R^{17}, together with N atom to which R^{16} and R^{17} are bound form a 3-to 6-membered heterocyclyl, said heterocyclyl is optionally substituted by one or more R^{24}, and each R^{14}, R^{19}, and R^{20} is independently H, alkyl, cycloalkyl, haloalkyl, halogen, hydroxyl, alkoxyl, $-SR^{15}$, $-S(O)R^{15}$, $-S(O)_2R^{15}$, nitro, nitroso, cyano, amino, carboxyl, $-C(O)OR^{15}$, $-NR^{16}R^{17}$, aryl, heteroaryl or heterocyclyl, wherein each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally substituted by one or more R^{23};

or R^{19} and R^{20}, together with N atom to which R^{19} and R^{20} are bound form a 3-to 6-membered heterocyclyl, said heterocyclyl is optionally substituted by one or more R^{25}, and each R^{14}, R^{16}, and R^{17}, is independently H, alkyl, cycloalkyl, haloalkyl, halogen, hydroxyl, alkoxyl, $-SR^{15}$, $-S(O)R^{15}$, $-S(O)_2R^{15}$, nitro, nitroso, cyano, amino, carboxyl, $-C(O)OR^{15}$, $-NR^{16}R^{17}$, aryl, heteroaryl or heterocyclyl, wherein each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally substituted by one or more R^{23},Y is $(C(R^{15})_2)_m$;

m is, 0, 1, 2, or 3;

each R^{15} is independently H, hydroxyl, alkyl, cycloalkyl, or halogen;

R^{18} is halogen, cycloalkyl, alkyl, nitro, cyano, alkoxyl or hydroxyl;


R^{23} is $-NR^{26}R^{27}$, alkyl, cycloalkyl, haloalkyl, halogen, hydroxyl, nitro, carboxyl, $-C(O)C_{1-3}alkylNR^{26}R^{27}$, $-C(O)NR^{26}R^{27}$, heterocyclyl, aryl, or heteroaryl, wherein alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl are each optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxyl, hydroxyl, amino and halogen;


each R^{21}, R^{22}, R^{24}, R^{25} is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxyl, hydroxyl, amino, alkylamino-, nitro, carboxyl, cyano, halogen, $-C(O)OR^{28}$, $-C(O)NR^{29}R^{30}$, $-C_{1-3}alkyl-C(O)NR^{29}R^{30}$, $-C(O)C_{1-3}alkyl-NR^{29}R^{30}$, $-S(O)_2R^{28}$, $-S(O)R^{28}$, $-S(O)_2NR^{29}R^{30}$, $-P(O)R^{29}R^{30}$, aryl, heteroaryl and heterocyclyl, wherein aryl, heteroaryl and heterocyclyl are each optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, amino, alkyl and alkoxyl;

each R^{26}, R^{27}, R^{28}, R^{29}, R^{30} is independently selected from H, hydroxyl, alkyl, hydroxylalkyl, alkoxyl, amino, aminoalkyl, cycloalkyl and halogen;


or R^{29} and R^{30}, along with the N or P atom to which R^{29} and R^{30} are attached form a 3-to 6-membered ring which is optionally substituted by one or more substituents independently selected from -C_{1-6} alkyl, and each R^{26}, R^{27}, and R^{28} is independently selected from H, hydroxyl, alkyl, hydroxylalkyl, alkoxyl, amino, aminoalkyl, cycloalkyl and halogen.

[0350] In some embodiments, the compound is of the following:





[0351] In some embodiments, the compound is of the formula:



Y is selected from O, S, NR', -S=O, -S(=O)(=NR') -or $S(=O)_2$;

one of X^1, X^2, X^3 and X^4 is selected from CR^2, and the others of X^1, X^2, X^3 and X^4 are each inde pendently selected from N or CR^4;

X^5 is selected from N or CR^1;

R^1 is independently selected from hydrogen, deuterium, halogen, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, -CN, -OR', -SR', -C(O)R', -C(O)N(R')$_2$, -C(O)OR', -OC O) R', -OC(O)N(R')$_2$, -N(R')$_2$, -NR'C(O)R', -NR'C(O)OR', -NR'C(O)N(R') $_2$, -S(O)R', -S(O)N(R')$_2$, -NR'S(O)R', -NR'S(O)N(R')$_2$, -S(O)$_2$R', -S(O)$_2$N(R')$_2$, -NR'S(O)$_2$R', -NR'S(O)$_2$N(R')$_2$, -PO(R')$_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl and 5-12 membered heteroaryl; said -C $_{1-6}$alkyl, -C $_{2-6}$alkenyl, -C $_{2-6}$alkynyl, -C $_{1-6}$haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, halogen, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-}

$_6$alkynyl, -C_{1-6}haloalkyl, -CN, oxo, -OR', -SR', -C(O)R', -C (O)N(R')$_2$, -C(O)OR', -OC(O)R', -OC(O)N(R')$_2$, -N(R')$_2$, -NR'C(O)R', -NR'C(O)OR', -NR'C(O)N(R')$_2$, -S(O)R', -S(O)N(R')$_2$, -NR'S(O)R', -NR'S(O)N(R')$_2$, -S(O)$_2$R', -S(O)$_2$N(R')$_2$, -NR'S(O)$_2$R', -NR'S(O)$_2$N(R')$_2$, -PO(R')$_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl and 5-12 membered heteroaryl;

R_2 is -$NR_{51}R_{52}$, -OR_{53} or -SR_{54};

R_3 is selected from hydrogen, deuterium, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, -C(O)R', -C(O)N(R')$_2$, -C(O)OR', -S(O)R', -S(O)N(R')$_2$, -S(O)$_2$R', -S(O)$_2$N(R')$_2$, -PO(R')$_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl; said -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) R^{3a};

each R^{3a} is independently selected from deuterium, halogen, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, -CN, oxo, -OR', -SR', -C(O)R', -C(O)N(R')$_2$, -C(O)OR', -OC(O)R', -OC(O)N(R')$_2$, -N(R')$_2$, -NR'C(O)R', -NR'C(O)OR', -NR'C(O)N(R')$_2$, -S(O)R', -S(O)N(R')$_2$, -NR'S(O)R', -NR'S(O)N(R')$_2$, -S(O)$_2$R', -S(O)$_2$N(R')$_2$, -S(=O)(=NR')R', -NR'S(O)$_2$R', -NR'S(O)$_2$N(R')$_2$, -PO(R')$_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl; said -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more substituents R_{3b},

wherein each R^{3b} is independently selected from deuterium, halogen, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, -CN, oxo, -OR', -SR', -C(O)R', -C(O)N(R')$_2$, -C(O)OR', -OC(O)R', -OC(O)N(R')$_2$, -N(R')$_2$, -NR'C(O)R', -NR'C(O)OR', -NR'C(O)N(R')$_2$, -S(O)R', -S(O)N(R')$_2$, -NR'S(O)R', -NR'S(O)N(R')$_2$, -S (O)$_2$R', -S(O)$_2$N(R')$_2$, -S(=O)(=NR')R', -NR'S(O)$_2$R', -NR'S(O)$_2$N(R')$_2$, and -PO(R')$_2$;

R^4 at each occurrence is independently selected from hydrogen, deuterium, halogen, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, -CN, -OR', -SR', -C(O)R', -C(O)N(R')$_2$, -C(O)OR', -

OC(O)R', -OC(O) N(R')$_2$, -N(R')$_2$, -NR'C(O)R', -NR'C(O)OR', -NR'C(O)N (R')$_2$, -S(O)R', -S(O)N(R')$_2$, -NR'S(O)R', -NR'S(O)N (R')$_2$, -S(O)$_2$R', -S(O)$_2$N(R')$_2$, -NR'S(O)$_2$R', -NR'S(O)$_2$N(R')$_2$, -PO(R')$_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl; said -C$_{1-6}$alkyl, -C$_{2-6}$alkenyl, -C$_{2-6}$alkynyl, -C$_{1-6}$haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, halogen, -C$_{1-6}$alkyl, -C$_{2-6}$alkenyl, -C$_{2-6}$alkynyl, -C$_{1-6}$haloalkyl, -CN, oxo, -OR', -SR', -C(O)R', -C(O)N(R')$_2$, -C(O)R', -OC(O)R', -OC(O)N(R')$_2$, -N(R')$_2$, -NR'C(O)R', -NR'C(O)OR', -NR'C(O)N(R')$_2$, -S(O)R', -S(O)N(R')$_2$, -NR'S(O)R', -NR'S(O)N(R')$_2$, -S(O)$_2$R', -S(O)$_2$N(R')$_2$, -S(=O)(=NR')R', -NR'S(O)$_2$R', -NR'S(O)$_2$N(R')$_2$, -PO(R')$_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl;

R^{51}, R^{52}, R^{53} and R^{54} are each independently selected from hydrogen, deuterium, -C$_{1-6}$alkyl, -C$_{2-6}$alkenyl, -C$_{2-6}$alkynyl, -C$_{1-6}$haloalkyl, -C(O)R', -C(O)N(R')$_2$, -C(O)OR', -S(O)R', -S(O)N(R')$_2$, -S(O)$_2$R', -S(O)$_2$N(R')$_2$, -PO(R')$_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl; said -C $_{1-6}$alkyl, -C $_{2-6}$alkenyl, -C $_{2-6}$alkynyl, -C $_{1-6}$haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, halogen, -C$_{1-6}$alkyl, -C$_{2-6}$alkenyl, -C$_{2-6}$alkynyl, -C$_{1-6}$haloalkyl, -CN, oxo, =NR', -C$_{1-6}$alkyl-CH(R')$_2$, -OR', -SR', -C(O)R', -C(O)N(R')$_2$, -C (O)OR', -OC(O)R', -OC(O)N(R')$_2$, -N(R')$_2$, -NR'C(O)R', -NR'C (O)OR', -NR'C(O)N(R')$_2$, -S(O)R', -S (O) N (R')$_2$, -NR'S(O)R', -NR'S(O)N(R')$_2$, -S(O)$_2$R', -S(O)$_2$N(R')$_2$, -S(=O)(=NR')R', -NR'S(O)$_2$R', -NR'S(O)$_2$N(R')$_2$, -PO(R')$_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl;

R^{11} and R^{12} are independently selected from hydrogen, deuterium, -OH, halogen, -CN, oxo, -C $_{1-6}$alkyl, -C$_{1-6}$ haloalkyl, -C $_{1-6}$alkoxy, -NH$_2$, -NHC$_{1-6}$alkyl, -N(C$_{1-6}$alkyl)$_2$, and 3-6 membered cycloalkyl; wherein said -C$_{1-6}$alkyl, -C$_{1-6}$alkoxy and 3-6 membered cycloalkyl are each independently optionally substituted with one or

more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, -OH, halogen, -CN, oxo, -C $_{1-6}$alkoxy, -NH-C_{1-6}alkyl, -N(C_{1-4} alkyl)$_2$, and 3-6 membered cycloalkyl;

R^{13} is selected from hydrogen, deuterium, -C_{1-6}alkyl and 3-6 membered cycloalkyl;

wherein said -C_{1-6}alkyl and 3-6 membered cycloalkyl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, -OH, halogen, -CN, oxo, -C $_{1-6}$alkoxy, -NH_2, -NHC_{1-6}alkyl, and -N(C_{1-4}alkyl)$_2$;

each R' at each occurrence is independently selected from hydrogen, deuterium, halogen, -OH, -CN, oxo, -NH_2, -NHC_{1-6}alkyl, -N (C_{1-6}alkyl)$_2$, -C_{1-6}alkyl, -C_{1-6}alkylOC_{1-6}alkyl, -C_{1-6}alkyl-NHC_{1-6}alkyl, -C_{1-6}alkyl-N (C_{1-6}alkyl)$_2$, -C $_{1-6}$haloalkyl, -OC_{1-6}alkyl, -C_{3-14}cycloalkyl, -C_{3-14}heterocycloalkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, 6-12 membered aryl, and 5-12 membered heteroaryl; wherein said -C_{1-6}alkyl, -OC_{1-6}alkyl, -C_{3-14}cycloalkyl, -C_{3-14}heterocycloalkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents selected from deuterium, halogen, -CN, -C $_{1-3}$alkyl, oxo, -OH, -OC_{1-3}alkyl, -NH_2, -NHC_{1-3}alkyl, -N(C_{1-3}alkyl)$_2$, -C(=O)NH_2, -C(=O)NH(C_{1-3}alkyl), -C(=O)N(C_{1-3}alkyl)$_2$, -S(=O)$_2NH_2$, -S(=O)$_2$NH(C_{1-3}alkyl), -S(=O)$_2C_{1-3}$alkyl, -S(=O)$_2$N(C_{1-3}alkyl)$_2$, -S(=O)(=NH)C_{1-3}alkyl, -S(=O)(=NC_{1-3}alkyl)C_{1-3}alkyl, and 3-6 membered cycloalkyl; said heterocycloalkyl, heterocycloalkenyl, and heteroaryl each independently contains 1, 2 or 3 heteroatoms selected from N, O, P and S;

m is selected from 1, 2, 3, 4, 5 and 6.

[0352] In some embodiments, the compound is of the following:

4-((3-(3-ethyl-7-((1-methylpiperidin-4-yl)amino)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

(Z)-3-fluoro-N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine(racemic)

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide (racemic)

4-((3-(7-(((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide (racemic)

1-((Z)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol (racemic)

N-(2-(3-((5-fluoro-2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

3-methoxy-N-methyl-4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzamide

dimethyl(4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)phosphine oxide

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(fluoromethoxy)phenyl)dimethylphosphine oxide(racemic)

N-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

N-(2-(3-((2-(2,2-difluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

1-methyl-N-(2-(3-((4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine

N-[2-[3-[2-(2-methoxyethoxy)-4-methylsulfonyl-anilino]prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]-1-methyl-piperidin-4-amine

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

N1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-N4,N4-dimethylcyclohexane-1,4-diamine

Trans-N-(4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-amine

cis-N-(4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-amine

Trans-N-(4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-amine

cis-N-(4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-amine

Trans-2,2'-((4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)cyclohexyl)azanediyl)bis(ethan-1-ol)

cis-2,2'-((4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)cyclohexyl)azanediyl)bis(ethan-1-ol)

N-[2-[3-(2-methoxy-4-methylsulfonyl-anilino)prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]-1-(3-methoxypropyl)piperidin-4-amine

3-methoxy-N,N-dimethyl-4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

N-(2-(3-((2-methoxy-4-(morpholinosulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

3-methoxy-4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

N-(2,3-dihydroxypropyl)-3-methoxy-4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-3-methyl-3-azabicyclo[3.2.1]octan-8-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-2-methyl-2-azabicyclo[2.2.1]heptan-5-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-2-azabicyclo[2.2.1]heptan-5-amine

N-(3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-1H-indol-7-amine

N-(3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-3-(piperidin-4-yl)-1H-indol-7-amine

N-(3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)-1H-indol-7-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-3-methyl-3-azabicyclo[3.2.0]heptan-6-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-7-methyl-7-azaspiro[3.5]nonan-2-amine

3-fluoro-N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

diethyl(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)phosphineoxide(racemic)

1-(2-fluoroethyl)-N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-(2,2,2-trifluoroethyl)piperidin-4-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine

Cis-N-(4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

trans-N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide (racemic)

4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide (racemic)

(Z)-3-fluoro-N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-N,1-dimethylpiperidin-4-amine (racemic)

(4-((3-(7-((3,3-difluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(R)-4-((4-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)but-3-yn-2-yl)amino)benzenesulfonamide

(S)-4-((4-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)but-3-yn-2-yl)amino)benzenesulfonamide

4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide(racemic)

4-((3-(7-((3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (racemic)

(1,1-dioxidothiomorpholino)(4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)methanone (racemic)

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)(4-methylpiperazin-1-yl)methanone (racemic)

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)(morpholino)methanone (racemic)

N-(4-fluoro-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

(2-fluoro-4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-5-methoxyphenyl)dimethylphosphineoxide (racemic)

2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-3-(2,2,2-trifluoroethyl)thieno[3,2-b]pyridin-7-amine

(3-methoxy-4-((3-(7-(((tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylazepan-4-amine

2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1-methylpiperidin-4-yl)methyl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-amine

4-((3-(4-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-N-hydroxy-3-methoxybenzamide (racemic)

4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-N-(2-hydroxy-3-methoxypropyl)-3-methoxybenzamide

5-((3-(2,2,2-trifluoroethyl)-7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-4-methoxy-N-methylpicolinamide (racemic)

5-((3-(3-(2,2,2-trifluoroethyl)-7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-4-methoxypicolinamide (racemic)

5-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-6-methoxy-N-methylpicolinamide (racemic)

5-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-6-methoxypicolinamide (racemic)

(3-(difluoromethoxy)-4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide (racemic)

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(trifluoromethoxy)phenyl)dimethylphosphine oxide (racemic)

diethyl(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(fluoromethoxy)phenyl) phosphine oxide

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)(piperidin-1-yl)methanone (racemic)

N-(3-fluoro-1-methylpiperidin-4-yl)-4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide

4-((3-(7-((3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-(2-methyltetrahydro-2H-pyran-4-yl)benzamide

(4-((3-(7-((((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(3-methoxy-4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)thieno[3,2-b]pyridin-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(Z)-(4-((3-(7-((3-fluoro-1'-methyl-[1,4'-bipiperidin]-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(Z)-(4-((3-(7-((3-fluoro-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(4-((3-(7-(((Z)-1-cyclopropyl-3-fluoropiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(4-((3-(7-(((Z)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

4-(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-1-methyl-1,4-azaphosphinane4-oxide (racemic)

5-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-6-methoxy-2,3-dihydrobenzo[d]isothiazole1,1-dioxide (racemic)

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-3,7-diazabicyclo[3.3.1]nonan-9-amine

N-cyclopropyl-4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide

4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(2-methoxyethoxy)-N-methylbenzamide (racemic)

4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(2-(2-methoxyethoxy)ethoxy)-N-methylbenzamide (racemic)

(3-chloro-4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphineoxide (racemic)

(3-fluoro-4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-(2-methoxyethyl)benzamide

(4-((3-(7-(((Z)-3-fluoro-1-isopropylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(Z)-N-[2-[3-(4-dimethylphosphoryl-2-methoxy-anilino)prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]-3-fluoro-1-(trifluoromethyl)piperidin-4-amine

(4-((3-(7-(((Z)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(3-methoxy-4-((3-(7-((5-methyl-5-azaspiro[2.5]octan-8-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

4-((2-(3-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)-1-methylpiperidine-3-carbonitrile

(2,5-difluoro-4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide (racemic)

(5-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-4-methoxypyridin-2-yl)dimethylphosphine oxide

(Z)-N-[2-[3-(4-dimethylphosphoryl-2-methoxy-anilino)prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]-1-(1,1-dioxothian-4-yl)-3-fluoro-piperidin-4-amine

N-(3,3-difluoro-1-methylpiperidin-4-yl)-4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide

3-cyano-4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide (racemic)

4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-(2-(2-methoxyethoxy)ethyl)benzamide (racemic)

1-[(Z)-4-[[2-[3-(4-dimethylphosphoryl-2-methoxy-anilino)prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]amino]-3-fluoro-1-piperidyl]-3-methoxy-propan-2-ol

(Z)-N-[2-[3-(4-dimethylphosphoryl-2-methoxy-anilino)prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]-3-fluoro-1-(trifluoromethyl)piperidin-4-amine

dicyclopropyl(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)phosphine oxide (racemic)

(4-((3-(7-(((Z)-1-ethyl-3-fluoropiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(4-((3-(7-(((Z)-3-fluoro-1-isobutylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(4-((3-(7-(((Z)-1-(cyclopropylmethyl)-3-fluoropiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((Z)-1-cyclobutyl-3-fluoropiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(4-((3-(7-(((Z)-1-cyclopentyl-3-fluoropiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(trifluoromethyl)phenyl)dimethylphosphine oxide

(3-cyclopropoxy-4-((3-(7-(((Z)--3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

2-(2-(3-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)benzo[b]thiophen-3-yl)acetonitrile (racemic)

2-(2-(3-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-7-(((E)-3-fluoro-1-methylpiperidin-4-yl)amino)benzo[b]thiophen-3-yl)acetonitrile (racemic)

2-(2-(3-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)benzo[b]thiophen-3-yl)acrylonitrile (racemic)

2-(2-(3-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-7-(((E)-3-fluoro-1-methylpiperidin-4-yl)amino)benzo[b]thiophen-3-yl)acrylonitrile (racemic)

2-dimethylphosphoryl-5-[3-[7-[((Z)-3-fluoro-1-methyl-4-piperidyl)amino]-3-(2,2,2-trifluoroethyl)benzothiophen-2-yl]prop-2-ynylamino]-4-methoxy-N-methyl-benzamide (racemic)

4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

4-((3-(4-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

(4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(thiazol-5-yl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

((4-((3-(7-(((E)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(thiazol-5-yl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

1-(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)phospholane1- oxide

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)oxy)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(3-methoxy-4-((3-(7-((3-methyl-3-azabicyclo[3.2.1]octan-8-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-1,3-dimethylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((3R,4S)-1,3-dimethylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4S)-1,3-dimethylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((3R,4R)-1,3-dimethylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

1-(tert-butyl)-N-(3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-1H-pyrazole-4-carboxamide (racemic)

1-tert-butyl-N-[3-[7-[(Z)-3-fluoro-1-methyl-4-piperidyl)amino]-3-(2,2,2-trifluoroethyl)benzothiophen-2-yl]prop-2-ynyl]pyrrole-3-carboxamide (racemic)

(3-methoxy-4-((3-(3-(2,2,2-trifluoroethyl)-7-(((Z)-1,3,5-trimethylpiperidin-4-yl)amino)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(3-methoxy-4-((3-(3-(2,2,2-trifluoroethyl)-7-(((E)-1,3,5-trimethylpiperidin-4-yl)amino)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-1-ethyl-3-fluoropiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((3R,4S)-1-ethyl-3-fluoropiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(trifluoromethoxy)phenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(trifluoromethoxy)phenyl)dimethylphosphine oxide

(4-((3-(7-(((E)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(4-fluorophenyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

dicyclopropyl(4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)phosphine oxide

dicyclopropyl(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)phosphine oxide

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(4-fluorophenyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(3-methoxy-4-((3-(3-(2,2,2-trifluoroethyl)-7-((1,2,6-trimethylpiperidin-4-yl)amino)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(3R,4S)-3-chloro-N-[2-[3-(4-dimethylphosphoryl-2-methoxy-anilino)prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]-1-methyl-piperidin-4-amine

(3S,4R)-3-chloro-N-[2-[3-(4-dimethylphosphoryl-2-methoxy-anilino)prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]-1-methyl-piperidin-4-amine

(4-((3-(7-(((3S,4R)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((3R,4S)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

cyclopropyl(4-(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-4-oxido-1,4-azaphosphinan-1-yl)methanone

(3-cyclopropoxy-4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(4-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-2-methoxyphenyl)dimethylphosphine oxide (racemic)

(7-((3-(7-(((Z)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-2,3-dihydrobenzofuran-4-yl)dimethylphosphine oxide

(5-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-6-methoxypyridin-2-yl)dimethylphosphine oxide

(3-methoxy-4-((3-(7-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

diethyl(3-methoxy-4-((3-(7-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)phosphineoxide

diethyl(4-((3-(7-(((3S,4R)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)phosphine oxide

(4-((3-(7-(((3S,4R)-3-fluoro-1-(tetrahydrofuran-3-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

2-dimethylphosphoryl-5-[3-[7-[[(3S,4R)-3-fluoro-1-tetrahydropyran-4-yl-4-piperidyl]amino]-3-(2,2,2-trifluoroethyl)benzothiophen-2-yl]prop-2-ynylamino]-4-methoxy-N-methyl-benzamide

(3-cyclopropoxy-4-((3-(7-(((3S,4R)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(2-fluoro-5-((3-(7-((3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-4-methoxyphenyl)dimethylphosphine oxide

(7-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzo[d][1,3]dioxol-4-yl)dimethylphosphine oxide

(2,2-difluoro-7-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzo[d][1,3]dioxol-4-yl)dimethylphosphine oxide

5-(dimethylphosphoryl)-2-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)oxy)benzamide

(3-methoxy-4-((3-(7-(((Z)-1-methyl-3-(trifluoromethyl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide (racemic)

(3-methoxy-4-((3-(7-(((E)-1-methyl-3-(trifluoromethyl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide (racemic)

(2-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenyl)dimethylphosphine oxide

(3S,4R)-3-fluoro-N-(2-(3-((2-methoxy-4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

(3S,4R)-3-fluoro-N-(2-(3-((4-(5-fluoropyrimidin-2-yl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(methoxy-d_3)phenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(methylsulfonyl)phenyl)dimethylphosphine oxide

(5-((3-(7-(((3S,4R)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-6-methoxypyridin-2-yl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-1-(8-oxabicyclo[3.2.1]octan-3-yl)-3-fluoropiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-3-fluoro-1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

5-((3-(7-((3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-6-methoxy-N-methylpicolinamide

N-(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-N-methylmethanesulfonamide

(4-((3-(7-(((3S,4R)-3-fluoro-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(methoxy-d_3)phenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-3-fluoro-1-(oxepan-3-yl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

N-(4-(dimethylphosphoryl)-2-methoxyphenyl)-3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)propiolamide

(7-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-2,3-dihydrobenzofuran-4-yl)dimethylphosphine oxide

(4-((3-(7-((3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoro-1-hydroxyethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (racemic)

(3-methoxy-4-((3-(7-((2-methyl-2-azaspiro[3.3]heptan-6-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

4-(4-((3-(7-((3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)morpholin-3-one

(8-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)dimethylphosphine oxide

(2-fluoro-4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(4-((3-(7-((3-oxaspiro[5.5]undecan-9-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphineoxide

(3-methoxy-4-((3-(7-(((1S,5R)-7-methyl-3-oxa-7-azabicyclo[3.3.1]nonan-9-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(3-methoxy-4-((3-(7-(((1R,5S)-7-methyl-3-oxa-7-azabicyclo[3.3.1]nonan-9-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(7-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzofuran-4-yl)dimethylphosphine oxide

5-(dimethylphosphoryl)-2-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzamide

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(1H-pyrazol-3-yl)phenyl)dimethylphosphine oxide

2-(2-(3-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)benzo[b]thiophen-3-yl)acrylonitrile

2-(2-(3-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)benzo[b]thiophen-3-yl)acrylonitrile

(5-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-1H-pyrazol-3-yl)dimethylphosphine oxide

(4-((3-(7-((1-(3-fluoropropyl)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphineoxide

(3-fluoro-4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-5-methoxyphenyl)dimethylphosphine oxide

(6-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-5-methoxypyridin-3-yl)dimethylphosphine oxide

(5-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-4-methoxypyrimidin-2-yl)dimethylphosphine oxide

(5-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-6-methoxypyrazin-2-yl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-3-fluoro-1-(methyl-d3)piperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

5-(dimethylphosphoryl)-2-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzonitrile

3-(5-(dimethylphosphoryl)-2-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)-1,2,4-oxadiazol-5(2H)-one

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(1,2,4-oxadiazol-3-yl)phenyl)dimethylphosphine oxide

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(oxazol-5-yl)phenyl)dimethylphosphine oxide

N-cyclopropyl-5-(dimethylphosphoryl)-2-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzamide

5-(dimethylphosphoryl)-2-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-N-(tetrahydro-2H-pyran-4-yl)benzamide

5-(dimethylphosphoryl)-2-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-N-(oxetan-3-yl)benzamide

2-((3-(7-(((3S,4R)-3-chloro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-5-(dimethylphosphoryl)-N,N-dimethylbenzamide

2-((3-(7-(((3S,4R)-3-chloro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-5-(dimethylphosphoryl)-N-(2-methoxyethyl)benzamide

(7-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzo[d]thiazol-4-yl)dimethylphosphine oxide

(2-fluoro-4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(methylthio)phenyl)dimethylphosphine oxide

2-((3S,4R)-4-((2-(3-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)-3-fluoropiperidin-1-yl)-N-methylacetamide

2-((3-(7-(((3S,4R)-3-chloro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-5-(dimethylphosphoryl)-N-(2-methoxyethyl)benzamide


6-(dimethylphosphoryl)-3-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)picolinonitrile

(3-(difluoromethyl)-4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)dimethylphosphine oxide

(S)-(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)(imino)(methyl)-l6-sulfanone

(R)-(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)(imino)(methyl)-l6-sulfanone.

[0353] In some embodiments, the compound is of the formula:



wherein

R_1 is independently selected from hydrogen, deuterium, halogen, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, -CN, -OR', -SR', -C(O)R' , -C(O)N(R')$_2$, -C(O)OR' , -OC(O)R', -OC(O)N(R')$_2$, -N(R')$_2$, -NR'C(O)R', -NR'C(O)OR' , -NR'C(O)N(R')$_2$, -S(O)R', -S(O)N(R')$_2$, -NR'S(O)R' , -NR'S(O)N(R')$_2$, -S(O)$_2$R' , -S(O)$_2$N(R')$_2$, -NR'S(O)$_2$R' , -NR'S(O)$_2$N (R')$_2$, -PO(R')$_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl and 5-12 membered heteroaryl; said -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, halogen, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{1-6}haloalkyl, -CN, oxo, -OR' , -SR' , -C(O)R' , -C(O)N(R')$_2$, -C(O)OR' , -OC(O)R' , -OC(O)N(R')$_2$, -N(R')$_2$, -NR'C(O)R' , -NR'C(O)OR' , -NR'C(O)N(R')$_2$, -S(O)R' , -

$S(O)N(R')_2$, $-NR'S(O)R'$, $-NR'S(O)N(R')_2$, $-S(O)_2R'$, $-S(O)_2N(R')_2$, $-NR'S(O)_2R'$, $-NR'S(O)_2N(R')_2$, $-PO(R')_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl;

R^2 is $-NR^{51}R^{52}$, $-OR^{53}$ or $-SR^{54}$;

R^3 is selected from hydrogen, deuterium, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, $-C(O)R'$, $-C(O)N(R')_2$, $-C(O)OR'$, $-S(O)R'$, $-S(O)N(R')_2$, $-S(O)_2R'$, $-S(O)_2N(R')_2$, $-PO(R')_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl; said $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) R_{3a};

each R^{3a} is independently selected from deuterium, halogen, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, -CN, oxo, $-OR'$, $-SR'$, $-C(O)R'$, $-C(O)N(R')_2$, $-C(O)OR'$, $-OC(O)R'$, $-OC(O)N(R')_2$, $-N(R')_2$, $-NR'C(O)R'$, $-NR'C(O)OR'$, $-NR'C(O)N(R')_2$, $-S(O)R'$, $-S(O)N(R')_2$, $-NR'S(O)R'$, $-NR'S(O)N(R')_2$, $-S(O)_2R'$, $-S(O)_2N(R')_2$, $-S(=O)(=NR')R'$, $-NR'S(O)_2R'$, $-NR'S(O)_2N(R')_2$, $-PO(R')_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl; said $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more R^{3b}, wherein each R^{3b} is independently selected from deuterium, halogen, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, -CN, oxo, $-OR'$, $-SR'$, $-C(O)R'$, $-C(O)N(R')_2$, $-C(O)OR'$, $-OC(O)R'$, $-OC(O)N(R')_2$, $-N(R')_2$, $-NR'C(O)R'$, $-NR'C(O)OR'$, $-NR'C(O)N(R')_2$, $-S(O)R'$, $-S(O)N(R')_2$, $-NR'S(O)R'$, $-NR'S(O)N(R')_2$, $-S(O)_2R'$, $-S(O)_2N(R')_2$, $-S(=O)(=NR')R'$, $-NR'S(O)_2R'$, $-NR'S(O)_2N(R')_2$, and $-PO(R')_2$;

R^4 at each occurrence is independently selected from hydrogen, deuterium, halogen, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, -CN, $-OR'$, $-SR'$, $-C(O)R'$, $-C(O)N(R')_2$, $-C(O)OR'$, $-OC(O)R'$, $-OC(O)N(R')_2$, $-N(R')_2$, $-NR'C(O)R'$, $-NR'C(O)OR'$, $-NR'C(O)N(R')_2$, $-S(O)R'$, $-S(O)N(R')_2$, $-NR'S(O)R'$, $-NR'S(O)N(R')_2$, $-S(O)_2R'$, -

$S(O)_2N(R')_2$, $-NR'S(O)_2R'$, $-NR'S(O)_2N(R')_2$, $-PO(R')_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl; said $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, halogen, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, -CN, oxo, -OR', -SR', -C(O)R', $-C(O)N(R')_2$, -C(O)OR', -OC(O)R', $-OC(O)N(R')_2$, $-N(R')_2$, $-NR'C(O)R'$, $-NR'C(O)OR'$, $-NR'C(O)N(R')_2$, -S(O)R', $-S(O)N(R')_2$, $-NR'S(O)R'$, $-NR'S(O)N(R')_2$, $-S(O)_2R'$, $-S(O)_2N(R')_2$, $-S(=O)(=NR')R'$, $-NR'S(O)_2R'$, $-NR'S(O)_2N(R')_2$, $-PO(R')_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl;

R^{51}, R^{52}, R^{53} and R^{54} are each independently selected from hydrogen, deuterium, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, -C(O)R', $-C(O)N(R')_2$, -C(O)OR', -S(O)R', $-S(O)N(R')_2$, $-S(O)_2R'$, $-S(O)_2N(R')_2$, $-PO(R')_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl; said $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, halogen, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{1-6}$haloalkyl, -CN, oxo, =NR', $-C_{1-6}$alkyl-$CH(R')_2$, -OR', -SR', -C(O)R', $-C(O)N(R')_2$, -C(O)OR', -OC(O)R', $-OC(O)N(R')_2$, $-N(R')_2$, $-NR'C(O)R'$, $-NR'C(O)OR'$, $-NR'C(O)N(R')_2$, -S(O)R', $-S(O)N(R')_2$, $-NR'S(O)R'$, $-NR'S(O)N(R')_2$, $-S(O)_2R'$, $-S(O)_2N(R')_2$, $-S(=O)(=NR')R'$, $-NR'S(O)_2R'$, $-NR'S(O)_2N(R')_2$, $-PO(R')_2$, 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 6-12 membered aryl, and 5-12 membered heteroaryl;

R^{11} and R^{12} are each independently selected from hydrogen, deuterium, -OH, halogen, -CN, oxo, $-C_{1-6}$alkyl, $-C_{1-6}$haloalkyl, $-C_{1-6}$alkoxy, $-NH_2$, $-NHC_{1-6}$alkyl, $-N(C_{1-6}\text{alkyl})_2$ and 3-6 membered cycloalkyl; wherein said $-C_{1-6}$alkyl, $-C_{1-6}$alkoxy and 3-6 membered cycloalkyl are each independently optionally substituted with one or more (such as

1, 2, 3, 4, 5 or 6) substituents selected from deuterium, -OH, halogen, -CN, oxo, -C_{1-6}alkoxy, -NH-C_{1-6}alkyl, -N (C_{1-4} alkyl) $_2$, and 3-6 membered cycloalkyl;

R^{13} is selected from hydrogen, deuterium, -C_{1-6}alkyl and 3-6 membered cycloalkyl; wherein said -C_{1-6}alkyl and 3-6 membered cycloalkyl are each independently optionally substituted with one or more (such as 1, 2, 3, 4, 5 or 6) substituents selected from deuterium, -OH, halogen, -CN, oxo, -C_{1-6}alkoxy, -NH_2, -NHC_{1-6}alkyl, and -N (C_{1-4}alkyl)$_2$;

each R' at each occurrence is independently selected from hydrogen, deuterium, halogen, -OH, -CN, oxo, -NH_2, -NHC_{1-6}alkyl, -N (C_{1-6} alkyl) $_2$, -C_{1-6}alkyl, -C_{1-6}alkylOC_{1-6}alkyl, -C_{1-6}alkyl-NHC_{1-6}alkyl, -C_{1-6}alkyl-N (C_{1-6}alkyl) $_2$, -C_{1-6}haloalkyl, -OC_{1-6}alkyl, -C_{3-14}cycloalkyl, -C_{3-14}heterocycloalkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, 3-12 membered heterocyclyl, 6-12 membered aryl, and 5-12 membered heteroaryl; wherein said -C_{1-6}alkyl, -OC_{1-6}alkyl, -C_{3-14}cycloalkyl, -C_{3-14}heterocycloalkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, 3-12 membered heterocyclyl, 6-12 membered aryl, and 5-12 membered heteroaryl is independently optionally substituted with 1, 2, 3, 4, 5 or 6 substituents selected from deuterium, halogen, -CN, -C_{1-3}alkyl, oxo, -OH, -OC_{1-3}alkyl, -NH_2, -NHC_{1-3}alkyl, -N(C_{1-3}alkyl) $_2$, -C(=O)NH_2, -C(=O)NH(C_{1-3}alkyl) , -C(=O)N(C_{1-3}alkyl)$_2$, -S(=O)$_2NH_2$, -S (=O)$_2$NH(C_{1-3}alkyl) , -S(=O)$_2C_{1-3}$alkyl, -S(=O)$_2$N(C_{1-3}alkyl)$_2$, -S(=O)(=NH)C_{1-3}alkyl, -S(=O)(=NC_{1-3}alkyl)C_{1-3}alkyl, and 3-6 membered cycloalkyl; or

two adjacent R' , together with the atoms to which they are attached respectively, can form 3-12 membered cycloalkyl, 3-12 membered cycloalkenyl, 3-12 membered heterocycloalkyl, 3-12 membered heterocycloalkenyl, 3-12 membered heterocyclyl, 6-12 membered aryl, or 5-12 membered heteroaryl, each of which is independently optionally substituted with one or more substituents selected from deuterium, halogen, -CN, -C_{1-3}alkyl, -C_{1-3}haloalkyl, oxo, -OH, -OC_{1-3}alkyl, -NH_2, -NHC_{1-3}alkyl, -N(C_{1-3}alkyl)$_2$, -C(=O)NH_2, -C(=O)NH(C_{1-3}alkyl), -C(=O)N(C_{1-3}alkyl)$_2$, -S(=O)$_2NH_2$, -S(=O)$_2$NH(C_{1-3}alkyl), -S(=O)$_2C_{1-3}$alkyl, -S(=O)$_2$N(C_{1-3}alkyl)$_2$, -S(=O)(=NH)C_{1-3}alkyl, -S(=O)(=NC_{1-3}alkyl) C_{1-3}alkyl, 3-6 membered heterocyclyl, and 3-6 membered cycloalkyl;

said heterocycloalkyl, heterocycloalkenyl, and heteroaryl each independently contains 1, 2, 3, 4 or 5 heteroatoms selected from N, O, P and S;

m is selected from 1, 2, 3, 4, 5 or 6.

[0354] In some embodiments, the compound is of the following

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide (racemic)

4-((3-(7-(((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide (racemic)(5b)

1-((3S,4R)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol (racemic)

N-(2-(3-((5-fluoro-2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine(7

3-methoxy-N-methyl-4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzamide

dimethyl(4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)phenyl)phosphine oxide.

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-(fluoromethoxy)phenyl)dimethylphosphineoxide (racemic)

N-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

N-(2-(3-((2-(2,2-difluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

1-methyl-N-(2-(3-((4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine

N-[2-[3-[2-(2-methoxyethoxy)-4-methylsulfonyl-anilino]prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]-1-methyl-piperidin-4-amine

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphineoxide (racemic)

N1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-N4,N4-dimethylcyclohexane-1,4-diamine

Trans-N-(4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-amine

cis-N-(4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-amine

Trans-N-(4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-amine

cis-N-(4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-amine

Trans-2,2'-((4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)cyclohexyl)azanediyl)bis(ethan-1-ol)

cis-2,2'-((4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)cyclohexyl)azanediyl)bis(ethan-1-ol)

N-[2-[3-(2-methoxy-4-methylsulfonyl-anilino)prop-1-ynyl]-3-(2,2,2-trifluoroethyl)benzothiophen-7-yl]-1-(3-methoxypropyl)piperidin-4-amine

3-methoxy-N,N-dimethyl-4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide(21

N-(2-(3-((2-methoxy-4-(morpholinosulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

3-methoxy-4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

N-(2,3-dihydroxypropyl)-3-methoxy-4-((3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-3-methyl-3-azabicyclo[3.2.1]octan-8-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-2-methyl-2-azabicyclo[2.2.1]heptan-5-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-2-azabicyclo[2.2.1]heptan-5-amine

N-(3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-1H-indol-7-amine

N-(3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-3-(piperidin-4-yl)-1H-indol-7-amine

N-(3-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)-1H-indol-7-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-3-methyl-3-azabicyclo[3.2.0]heptan-6-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-7-methyl-7-azaspiro[3.5]nonan-2-amine

3-fluoro-N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine

diethyl(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)phosphine oxide (racemic)

1-(2-fluoroethyl)-N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine(36

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-(2,2,2-trifluoroethyl)piperidin-4-amine

N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine

Cis-N-(4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

trans-N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide (racemic)

4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide (racemic)

(3S,4R)-3-fluoro-N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-N,1-dimethylpiperidin-4-amine(racemic)

(4-((3-(7-((3,3-difluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide

(R)-4-((4-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)but-3-yn-2-yl)amino)benzenesulfonamide

(S)-4-((4-(7-((1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)but-3-yn-2-yl)amino)benzenesulfonamide

4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide (racemic)

4-((3-(7-((3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide (racemic)

(1,1-dioxidothiomorpholino)(4-((3-(7-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)methanone (racemic)

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)(4-methylpiperazin-1-yl)methanone (racemic)

(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)(morpholino)methanone (racemic)

N-(4-fluoro-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)-1-methylpiperidin-4-amine


(2-fluoro-4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-5-methoxyphenyl)dimethylphosphineoxide (racemic)

(S)-(5-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-6-methoxypyridin-2-yl)(imino)(methyl)-l6-sulfanone

(R)-(5-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-6-methoxypyridin-2-yl)(imino)(methyl)-l6-sulfanone (S)-(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)(imino)(oxetan-3-yl)-l6-sulfanone

(R)-(4-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)(imino)(oxetan-3-yl)-l6-sulfanone

[0355] In some embodiments, the compound is of the formula:



I

wherein:


- R^1 is selected from aryl, heteroaryl, and heterocyclyl, each of which is independently unsubstituted or substituted with one, two or three substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and an ester group;
- R^2 is selected from hydrogen, $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently unsubstituted or substituted with one, two or three substituents selected from a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and an ester group;
- R^3 is H;
- R^4 is heterocyclyl substituted with one, two or three substituents selected from a halogen group, a hydroxyl group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, amide group, ureido group, epoxy group, and an ester group;

- each R^{21} and R^{22} is independently hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted,; and

  wherein the compound comprises at least one deuterio group;

  or a pharmaceutically-acceptable salt thereof.

[0356] In some embodiments, the compound is of the formula:



wherein:

X^1 is CR^1 or N;

R^1 is hydrogen, halogen, cyano, –OR^4, -NR^4R^5, -$C(=O)R^4$, -$OC(=O)R^4$, –$C(=O)OR^4$, –$C(=O)NR^4R^5$, –SR^4, –$S(=O)R^4$, –$S(O)_2R^4$, -$NR^4C(=O)R^5$, –$R^4C(=O)R^5$, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally substituted 4- 12 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl;


each of X^2, X^3, X^4, and X^5 are CH, N, CR^2 or CR^3, wherein two or more of X^2, X^3, X^4, and X^5 are independently CH, CR^2, or CR^3;

each of Y^1, Y^2, and Y^3 are C or N, wherein one of Y^1, Y^2, and Y^3 is N;

R^A is hydrogen, –OR^6, -NR^6R^7, -$C(=O)R^6$, -$R^6C(=O)R^7$, -$OC(=O)R^6$, -$OC(=O)NR^6R^7$, –$C(=O)OR^6$, –$NR^6C(=O)OR^7$, –$C(=O)NR^6R^7$, –SR^6, –$S(=O)R^6$, –$S(O)_2R^6$, –$S(O)_2NR^6R^7$, –$NR^6S(O)_2R^7$, -$NR^6C(=O)R^7$, -$NR^6C(=O)NR^7R^8$, -$SiR^6R^7R^8$, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally substituted 4-12 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl;

R^B is halogen, cyano, hydroxyl, –NR^8R^9, -OR^8, –$C(=O)NR^8R^9$, –$C(=O)R^8$, -$C(=O)OR^8$, -$NR^8C(=O)OR^9$, –$OC(=O)R^8$, –$OC(=O)NR^8R^9$, –$C(=O)NR^8R^9$, –$NR^8C(=O)R^9$, –$NR^7C(=O)NR^8R^9$, –SR^8, –$S(=O)R^8$, –$S(O)_2R^8$, –$S(O)_2NR^8$, –$NR^8S(O)_2R^9$, -$R^8C(=O)R^9$, -$NR^8C(=O)R^9$, -$NR^7C(=O)NR^8R^9$, optionally substituted C1-C6 alkyl, C1-C6 haloalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally

substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally substituted 3-12 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl;

each R^2 is , , $-Z^1-R^{2A}$, or $-R^{2A}$;

Z^1 is -C(=O)-, $-S(O)_2$-optionally substituted C1-C6 alkylene, optionally substituted C2-C6 alkenylene, optionally substituted C2-C6 alkynylene, or an optionally substituted C3-C4 cycloalkylene;

Z^2 is CR^{2C}, N, or O;

wherein when Z^2 is O, R^{2B} is absent;

R^{2A} and R^{2B} are independently hydrogen, $-C(=O)R^{10}$, $-C(=O)OR^{10}$, $-C(=O)NR^{10}R^{11}$, $-S(=O)R^{10}$, $-S(O)_2R^{10}$, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally substituted 4-12 membered heterocyclyl, optionally substituted 5-10 membered heteroaryl; or R^{2A} and R^{2B} together with the atom to which they are attached together form an optionally substituted 4-10 membered cycloalkyl, an optionally substituted phenyl, an optionally substituted 5-10 membered heteroaryl, or an optionally substituted 4-12 membered heterocyclyl; or Z^2 is O and R^{2B} is absent;

R^{2C} is hydrogen, halogen, or C1-C6 alkyl;

each R^3 is independently halogen, cyano, $-NR^{12}R^{13}$, $-OR^{12}$, $-C(=O)NR^{12}R^{13}$, $-C(=O)R^{12}$, $-C(=O)OR^{12}$, $-OC(=O)R^{12}$, $-NR^{12}(C=O)NR^{13}R^{14}$, $-SR^{12}$, $-S(=O)R^{12}$, $-S(O)_2R^{12}$, $-S(O)_2NR^{12}R^{13}$, $-NR^{12}S(O)_2NR^{13}R^{14}$, $-R^{12}C(=O)R^{13}$, $-NR^{12}C(=O)R^{13}$, optionally substituted C1- C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl, or optionally substituted 5-6 membered heteroaryl;

L is an optionally substituted 4-6 membered heterocyclylene or an optionally substituted 5-6 membered heteroarylene;

m is 0, 1, or 2; and

each R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, and R^{14} are independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally substituted 4-12 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl.

[0357] In some embodiments, the compound is:

N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylpyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3 S,4R)-3 -fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyridin-2 -yl)- 1,2,4- oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylpyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylpyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((5-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)cyclopropanecarboxamide,

N-((5-(8-(((3 S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyridin-2-yl)-1,3,4-thiadiazol-2- yl)methyl)cyclopropanecarboxamide;

N-((5-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3 -vinyl-1-pyrazolo[1,5-a]pyridin-2-yl)- 1,3,4-thiadiazol-2-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H- pyrazole-4-carboxamide;

1 -(tert-butyl)-N-((5 -(7-(((3 S,4R)-3 -fluoro- 1 -methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrrole-3-carboxamide;

1- (tert-butyl)-N-((5-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyridin-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(8-(((3 S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyridin-2 -yl)-1,3,4- thiadiazol-2-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylpyrazolo[1,5-a]pyridin-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3-vinylpyrazolo[1,5-a]pyridin-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(5-amino-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyrazin-2-yl)-1,2,4-oxadiazol-5- yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S,4R)-3 -fluoro-1-methylpiperidin-4-yl)amino)-3-vinylpyrazolo[1,5-a]pyrazin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(5-amino-7-(((3 S,4R)-3-fluoro- 1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1-(tert-butyl)-1H-pyrazole-4-carboxamide;

N-((3-(5-amino-7-(((3 S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H- indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1-(tert-butyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyrazin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8- (((3 S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3 -vinylimidazo[1,2-a]pyrazin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylpyrazolo[1,5-a]pyrazin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylpyrazolo[1,5-a]pyrazin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((5-(5-amino-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)cyclopropanecarboxamide;

N-((5-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyrazin-2-yl)-1,3,4-thiadiazol-2-yl)methyl)cyclopropanecarboxamide;

N-((5-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylpyrazolo[1,5-a]pyrazin-2-yl)-1,3,4-thiadiazol-2-yl)methyl)cyclopropanecarboxamide;

N-((5-(5-amino-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3-vinyl -2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)m ethyl)-1-(tert-butyl)-1H-pyrazole-4-carboxamide;

N-((5-(5-amino-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1-(tert-butyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((5-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyrazin-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(8- (((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylimidazo[1,2-a]pyrazin-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinylpyrazolo[1,5-a]pyrazin-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3-vinylpyrazolo[1,5-a]pyrazin-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(5-fluoro-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

l-(tert-butyl)-N-((3-(5-fluoro-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(5-fluoro-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((5-(5-fluoro-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)cyclopropanecarboxamide;

1- (tert-butyl)-N-((5-(5-fluoro-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(5-fluoro-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-vinyl-2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(prop-1-en-2-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(prop-1-en-2-yl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(prop-1-en-2-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(prop-1-en-2-yl)-2H-indazol-2-yl)- 1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(prop-1-en-2-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(prop-1-en-2-yl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(prop-1-en-2-yl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1 -(tert-butyl)-N-((3 -(7-(((3 S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(prop-1-en-2-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(prop-1-en-2-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(7-(((3S,4R)-3 -fluoro-1-methylpiperidin-4-yl)amino)-3-(1-fluorovinyl)-2H-indazol-2-yl)-1,2,4- oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1-fluorovinyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3-(1-fluorovinyl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1-fluorovinyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3-(1-fluorovinyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3- carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1-fluorovinyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1-fluorovinyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1-fluorovinyl)pyrazolo[1, 5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1-fluorovinyl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((E)-prop-1-en-1-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(8-(((3 S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((E)-prop-1-en-1-yl)imidazo[1,2-a]pyridine-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((E)-prop-1-en-1-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((E)-prop-1-en-1-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((E)-prop-1-en-1-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((E)-prop-1-en-1-yl)imidazo[1,2-a]pyridin-2 -yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((E)-prop-1-en-1-yl)imidazo[1,2-a]pyridin-2 -yl)-1,2,4-oxadiazol- 5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((E)-prop-1-en-1-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((E)-prop-1-en-1-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4- oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(3-(2,2-difluorovinyl)-7-(((3S,4R)-3- fluoro-1-methylpiperidin-4-yl)amino)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(3-(2,2-difluorovinyl)-8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(3-(2,2-difluorovinyl)-7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(3-(2,2-difluorovinyl)-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H- pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(3-(2,2-difluorovinyl)-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(3-(2,2-difluorovinyl)-8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(3-(2,2-difluorovinyl)-8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(3-(2,2-difluorovinyl)-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(3-(2,2-difluorovinyl)-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-lE[-pyrrole-3-carboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1,2,2-trifluorovinyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1 ,2,2-trifluorovinyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1,2,2-trifluorovinyl)pyrazolo[1,5-a]pyridin-2 -yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

2-(5-((((1-(tert-butyl)-1H-pyrazol-4-yl)(12- fluoraneylidene)methyl)amino)methyl)-1,2,4-oxadiazol-3-yl)-N-((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)-3-(1,2,2-trifluorovinyl)-2H-indazol-7-amine;

1-(tert-butyl)-N-((3-(7- (((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1,2,2-trifluorovinyl)-2H-indazol-2-yl)- 1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1,2,2-trifluorovinyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-l-methylpiperidin-4-yl)amino)-3-(1,2,2-trifluorovinyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1,2,2-trifluorovinyl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4- oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(1,2,2-trifluorovinyl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-((R)-oxiran-2-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((S)-oxiran-2-yl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((R)-oxiran-2-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((S)-oxiran-2-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((S)-oxiran-2-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((R)-oxiran-2-yl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4- carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((S)-oxiran-2-yl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3- carboxamide;

1 -(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((R)-oxiran-2-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4- carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((R)-oxiran-2-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3- carboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((S)-oxiran-2-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(8-(((3S,4R)-3- fluoro-1-methylpiperidin-4-yl)amino)-3-((R)-oxiran-2-yl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-((S)-oxiran-2-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((R)-oxiran-2-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)- 1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((R)-oxiran-2-yl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3- carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((S)-oxiran-2-yl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((R)-oxiran-2-yl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3- carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-((S)-oxiran-2-yl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(6-acrylamido-8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1-(tert-butyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-6-methacrylamido-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(6-((E)-4-(dimethylamino)but-2-enamido)-8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2- trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3 -fluoro-1-methylpiperidin-4-yl)amino)-6-((E)-4- (4-methylpiperazin-1-yl)but-2-enamido)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-6-(4-(methylamino)but-2-ynamido)-3 -(2,2,2- trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1 -(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-6-(2-fluoroacrylamido)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-6-propiolamido-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)- 1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3- fluoro-1-methylpiperidin-4-yl)amino)-6-((E)-4-(methylamino)but-2-enamido)-3-(2,2,2- trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4- carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3 -fluoro- 1-methylpiperidin-4-yl)amino)-6-((E)-4-morpholinobut-2-enamido)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol- 5-yl)methyl)-1H-pyrazole-4-carboxamide;

N-((3-(6-(but-2-ynamido)-8-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol- 5-yl)methyl)-1-(tert-butyl)-1H-pyrazole-4-carboxamide;

N-((3-(6-((E)-but-2-enamido)-8- (((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin- 2 -yl)-1, 2, 4-oxadiazol-5-yl)methyl)-1 -(tert-butyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N- ((3-(6-((E)-4-(3,3-difluoroazetidin- 1-yl)but-2-enamido)-8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3 -(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)- 1 ,2,4-oxadiazol-5-yl)methyl)- 1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(6-(4-(dimethylamino)but-2-ynamido)-8-(((3 S,4R)-3-fluoro- 1 -methylpiperidin-4-yl)amino)-3 -(2,2,2-trifluoroethyl)imidazo1,2-a]pyridin- 2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)cyclopropanecarboxamide;

N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5- yl)methyl)cyclopropanecarboxamide;

N-((3-(7-(((3S/lR)-3 -fluoro- 1-methylpiperidin-4- yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)- 1H-pyrrole-3 -carboxamide;

1 -(tert-butyl)-N-((3 -(8-(((3 S,4R)-3-fluoro- 1 - methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1 ,2,4-oxadiazol- 5-yl)methyl)-1H-pyrrole-3-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4- oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro- 1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,2,4- oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((5-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,3,4-thiadiazol-2- yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,3,4-thiadiazol-2- yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,3,4-thiadiazol-2- yl)methyl)-1H-pyrrole-3-carboxamide;

N-((5-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,3,4-thiadiazol-2- yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((5-(8-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(8-(((3S,4R)-3-fluoro- 1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)-1H-pyrrole-3 -carboxamide;

N-((5-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro- 1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)-1H-pyrrole-3 -carboxamide;

N-((3-(5-amino-7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)cyclopropanecarboxamide;

N-((3-(5-amino-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3 -(2, 2,2-trifluoroethyl)-2H-indazol-2-yl)-1, 2, 4-oxadiazol-5-yl)methyl)-1 -(tert-butyl)- 1H-pyrazole-4-carboxamide;

N-((3-(5-amino-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3 -(2, 2, 2-trifluoroethyl)-2H-indazol-2-yl)-1, 2, 4-oxadiazol-5-yl)methyl)-1-(tert-butyl)-1H-pyrrole-3-carboxamide;

N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1 ,2-a]pyrazin-2-yl)- 1,2,4-oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyrazin-2-yl)-1,2,4- oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyrazin-2-yl)-1,2,4- oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrazin-2-yl)-1,2,4- oxadiazol-5-yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrazin-2-yl)-1,2,4- oxadiazol-5-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrazin-2-yl)-1,2,4- oxadiazol-5-yl)methyl)-1H-pyrrole-3-carboxamide;

N-((5-(5-amino-7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,3,4-thiadiazol-2- yl)methyl)cyclopropanecarboxamide;

N-((5-(5-amino-7-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)-1-(tert-butyl)- 1H-pyrrole-3-carboxamide;

N-((5-(8-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2- trifluoroethyl)imidazo[1,2-a]pyrazin-2-yl)-1,3,4-thiadiazol-2- yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((5-(8-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyrazin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(8-(((3S,4R)-3-fluoro- 1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyrazin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)-1H-pyrrole-3 -carboxamide;

N-((5-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrazin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)cyclopropanecarboxamide;

N-((5-(5-amino-7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,3,4-thiadiazol-2- yl)methyl)-1 -(tert-butyl)- 1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrazin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)pyrazolo[1,5-a]pyrazin-2-yl)-1,3,4- thiadiazol-2-yl)methyl)-1H-pyrrole-3 -carboxamide;

N-((3-(5-fluoro-7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(5-fluoro-7-(((3S,4R)-3 -fluoro- 1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((3-(5-fluoro-7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)-1H-pyrrole-3-carboxamide;

N-((5-(5-fluoro-7-(((3S,4R)-3-fluoro-1-methylpiperidin- 4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,3,4-thiadiazol-2- yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((5-(5-fluoro-7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,3,4-thiadiazol-2- yl)methyl)-1H-pyrazole-4-carboxamide;

1-(tert-butyl)-N-((5-(5-fluoro-7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(2,2,2-trifluoroethyl)-2H-indazol-2-yl)-1,3,4-thiadiazol-2- yl)methyl)-1H-pyrrole-3-carboxamide;

N-((3-(7-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-3-(perfluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5- yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-(perfluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)- 1H-pyrazole-4-carboxamide;


1-(tert-butyl)-N-((3-(7-(((3S,4R)-3-fluoro-l-methylpiperidin-4- yl)amino)-3-(perfluoroethyl)-2H-indazol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrrole-3- carboxamide;

N-((5-(7-(((3S,4R)-3-fluoro-l-methylpiperidin-4-yl)amino)-3- (perfluoroethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,3,4-thiadiazol-2- yl)methyl)cyclopropanecarboxamide;

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-l- methylpiperidin-4-yl)amino)-3-(perfluoroethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,3,4-thiadiazol-2- yl)methyl)-1H-pyrazole-4-carboxamide; and

1-(tert-butyl)-N-((5-(7-(((3S,4R)-3-fluoro-l- methylpiperidin-4-yl)amino)-3-(perfluoroethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,3,4-thiadiazol-2- yl)methyl)-1H-pyrrole-3-carboxamide.

[0358] In some embodiments, the compound is of the formula:



wherein:

X^1 is CR^1 or N;

R^1 is hydrogen, halogen, cyano, $–OR^4$, $-NR^4R^5$, $-C(=O)R^4$, $-OC(=O)R^4$, $–C(=O)OR^4$, $–C(=O)NR^4R^5$, $–SR^4$, $–S(=O)R^4$, $–S(O)_2R^4$, $-NR^4C(=O)R^5$, $–R^4C(=O)R^5$, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally substituted 4- 12 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl;

each of X^2, X^3, X^4, and X^5 are CH, N, CR^2 or CR^3, wherein two or more of X^2, X^3, X^4, and X^5 are independently CH, CR^2, or CR^3;



each of Y^1, Y^2, and Y^3 are C or N, wherein one of Y^1, Y^2, and Y^3 is N;

R^A is hydrogen, $–OR^6$, $-NR^6R^7$, $-C(=O)R^6$, $-R^6C(=O)R^7$, $-OC(=O)R^6$, $-OC(=O)NR^6R^7$, $–C(=O)OR^6$, $–NR^6C(=O)OR^7$, $–C(=O)NR^6R^7$, $–SR^6$, $–S(=O)R^6$, $–S(O)_2R^6$, $–S(O)_2NR^6R^7$, $–NR^6S(O)_2R^7$, $-NR^6C(=O)R^7$, $-NR^6C(=O)NR^7R^8$, $-SiR^6R^7R^8$, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally

substituted 4-12 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl;

R^B is halogen, cyano, hydroxyl, $-NR^8R^9$, $-OR^8$, $-C(=O)NR^8R^9$, $-C(=O)R^8$, $-C(=O)OR^8$, $-NR^8C(=O)OR^9$, $-OC(=O)R^8$, $-OC(=O)NR^8R^9$, $-C(=O)NR^8R^9$, $-NR^8C(=O)R^9$, $-NR^7C(=O)NR^8R^9$, $-SR^8$, $-S(=O)R^8$, $-S(O)_2R^8$, $-S(O)_2NR^8R^9$, $-NR^8S(O)_2R^9$, $-R^8C(=O)R^9$, $-NR^8C(=O)R^9$, $-NR^7C(=O)NR^8R^9$, optionally substituted C1-C6 alkyl, C1-C6 haloalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally substituted 3-12 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl;

each R^2 is



, $-Z^1-R^{2A}$, or $-R^{2A}$

Z^1 is $-C(=O)-$, $-S(O)_2-$optionally substituted C1-C6 alkylene, optionally substituted C2-C6 alkenylene, optionally substituted C2-C6 alkynylene, or an optionally substituted C3-C4 cycloalkylene;

Z^2 is CR^{2C}, N, or O; wherein when Z^2 is O, R^{2B} is absent;

R^{2A} and R^{2B} are independently hydrogen, $-C(=O)R^{10}$, $-C(=O)OR^{10}$, $-C(=O)NR^{10}R^{11}$, $-S(=O)R^{10}$, $-S(O)_2R^{10}$, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally substituted 4-12 membered heterocyclyl, optionally substituted 5-10 membered heteroaryl; or R^{2A} and R^{2B} together with the atom to which they are attached together form an optionally substituted 4-10 membered cycloalkyl, an optionally substituted phenyl, an optionally substituted 5-10 membered heteroaryl, or an optionally substituted 4-12 membered heterocyclyl; or Z^2 is O and R^{2B} is absent;

R^{2C} is hydrogen, halogen, or C1-C6 alkyl,

each R^3 is independently halogen, cyano, $-NR^{12}R^{13}$, $-OR^{12}$, $-C(=O)NR^{12}R^{13}$, $-C(=O)R^{12}$, $-C(=O)OR^{12}$, $-OC(=O)R^{12}$, $-NR^{12}(C=O)NR^{13}R^{14}$, $-SR^{12}$, $-S(=O)R^{12}$, $-S(O)_2R^{12}$, $-S(O)_2NR^{12}R^{13}$, $-NR^{12}S(O)_2NR^{13}R^{14}$, $-R^{12}C(=O)R^{13}$, $-NR^{12}C(=O)R^{13}$, optionally substituted C1- C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl, or optionally substituted 5-6 membered heteroaryl;

L is an optionally substituted C2-C6 alkynylene;

m is 0, 1, or 2; and

each R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, and R^{14} are independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C10 cycloalkyl, optionally substituted phenyl, optionally substituted 4-12 membered heterocyclyl, or optionally substituted 5-10 membered heteroaryl.

[0359] In some embodiments, the compound is:

(3S,4R)-3-fluoro-N-(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl)- 1-methylpiperidin-4-amine

N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop- 1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl)-1-methylpiperidin-4-amine

2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1- yn-1-yl}-N-(oxan-4-yl)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-amine

N-(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl)- 1-(2-methoxyethyl)piperidin-4-amine

4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop- 1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl)amino]-1lambda6-thiane-1,1-dione

N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1- yl}-3-(2,2,2-trifluoroethyl) imidazo[1,2-a]pyridin-8-yl)-1-(2-methanesulfonylethyl) piperidin-4-amine

N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn- 1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl)-2-methyl-2-azaspiro[3.3]heptan-6- amine

2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1- yl}-N-{2-oxaspiro[3.3]heptan-6-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-amine

(3R,4S)-3-fluoro-N-(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl) imidazo[1,2-a]pyridin-8-yl)- 1-methylpiperidin-4-amine

methyl 4-[(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8- yl)amino]piperidine-1-carboxylate

1-cyclopropyl-N-(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8- yl)piperidin-4-amine

(3S,4R)-3-fluoro-N-(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8- yl)piperidin-4-amine

4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn- 1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl)amino]-N-methylpiperidine-1- carboxamide

1-isopropyl-N-(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8- yl)piperidin-4-amine

1-{4-[(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8- yl)amino]piperidin-1-yl}ethanone

1-{4-[(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo [1,2-a]pyridin-8- yl)amino]piperidin-1-yl}-2-methylpropan-2-ol

(2S)-1-{4-[(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8- yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol

(2R)-1-{4-[(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8- yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol

(3S,4R)-N-(3-ethyl-2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}imidazo[1,2-a]pyridin-8-yl)-3-fluoro-1- methylpiperidin-4-amine

N-(3-ethyl-2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}imidazo[1,2-a]pyridin-8-yl)-1-methylpiperidin-4- amine

4-{[3-(3-ethoxy-8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N- methylbenzamide

(3S,4R)-3-fluoro-1-methyl-N-[2-(prop-1-yn-1-yl)-3-(2,2,2- trifluoroethyl)imidazo[1,2-a]pyridin-8-yl]piperidin-4-amine

1-methyl-N-[2-(prop-1-yn-1-yl)-3-(2,2,2- trifluoroethyl)imidazo[1,2-a]pyridin-8-yl]piperidin-4-amine

(3S,4R)-3-fluoro-1-methyl-N-[2-(prop-1-yn-1-yl)-3-(2,2,2- trifluoroethyl)pyrazolo[1,5-a]pyridin-7-yl]piperidin-4-amine

N-[3-ethenyl-2-(prop-1-yn-1-yl)imidazo[1,2-a]pyridin-8- yl]-1-methylpiperidin-4-amine

(3S,4R)-N-[3-ethenyl-2-(prop-1-yn-1-yl)imidazo[1,2- a]pyridin-8-yl]-3-fluoro-1-methylpiperidin-4-amine

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(prop-2-enamido)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N- methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2-methylprop-2-enamido) imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino} -3-methoxy- N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro- 1-methylpiperidin-4-yl] amino}-3-(methylamino) imidazo[1,2-a] pyridin-2-yl) prop-2-yn-1- yl]amino}-3-methoxy-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(N-methylprop-2-enamido)imidazo[1,2-a]pyridine-2-yl)prop-2-yn-1-yl]amino}-3- methoxy-N-methylbenzamide

2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1- yn-1-yl}-8-[(1-methylpiperidin-4-yl)amino]-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-6- ol

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}- 3-methoxy-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy- N-methylbenzamide

tert-butyl N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl) amino] prop-1-yn-1-yl}-8-[(1-methylpiperidin-4-yl) amino]-3-(2,2,2-trifluoroethyl) imidazo[1,2-a] pyridin-6-yl) carbamate

2-{3-[(4-methanesulfonyl-2-methoxyphenyl) amino] prop- 1-yn-1-yl}-N8-(1-methylpiperidin-4-yl)-3-(2,2,2-trifluoroethyl) imidazo[1,2-a] pyridine-6,8- diamine

2-{3-[(4-methanesulfonyl-2-methoxyphenyl) amino] prop- 1-yn-1-yl}-N6-methyl-N8-(1-methylpiperidin-4-yl)-3-(2,2,2-trifluoroethyl) imidazo[1,2-a] pyridine-6,8-diamine

N-(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-6-phenyl-3-(2,2,2-trifluoroethyl)imidazo [1,2- a]pyridin-8-yl)-1-methylpiperidin-4-amine

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N- methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N- methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}3-methoxy-N-methylbenzamide

4-{[3-(8-{[(4R)-3,3-difluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3- methoxy-N-methylbenzamide

4-{[3-(8-{[(4S)-3,3-difluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3- methoxy-N-methylbenzamide

tert-butyl N-[2-(3-{[2-methoxy-4-(methylcarbamoyl) phenyl] amino} prop-1-yn-1-yl)-8-[(1-methylpiperidin-4-yl) amino]-3-(2,2,2-trifluoroethyl) imidazo[1,2-a] pyridin-6-yl] carbamate

4-[(3-{6-amino-8-[(1-methylpiperidin-4-yl) amino]-3- (2,2,2-trifluoroethyl) imidazo[1,2-a] pyridin-2-yl} prop-2-yn-1-yl) amino]-3-methoxy-N- methylbenzamide

4-[(3-{6-acetamido-8-[(1-methylpiperidin-4-yl)amino]-3- (2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N- methylbenzamide

3-methoxy-N-methyl-4-[(3-{8-[(1-methylpiperidin-4- yl)amino]-6-(prop-2-enamido)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl}prop-2- yn-1-yl)amino]benzamide

3-methoxy-N-methyl-4-[(3-{8-[(1-methylpiperidin-4- yl)amino]-6-(2-methylprop-2-enamido)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2- yl}prop-2-yn-1-yl)amino]benzamide

4-((3-[6-(2-chloro-2-fluoroacetamido)-8-[(1- methylpiperidin-4-yl)amino]-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl]prop-2-yn- 1-ylamino)-3-methoxy-N-methylbenzamide

3-methoxy-N-methyl-4-[(3-{6-[(methylcarbamoyl)amino]-8- [(1-methylpiperidin-4-yl) amino]-3-(2,2,2-trifluoroethyl) imidazo[1,2-a] pyridin-2-yl} prop- 2-yn-1-yl) amino] benzamide

methyl N-[2-(3-{[2-methoxy-4-(methylcarbamoyl) phenyl] amino} prop-1-yn-1-yl)-8-[(1-methylpiperidin-4-yl) amino]-3-(2,2,2-trifluoroethyl) imidazo[1,2-a] pyridin-6-yl] carbamate

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3- methoxy-N,N-dimethylbenzamide

N-ethyl-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3- methoxybenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N-isopropyl-3-methoxybenzamide

N-cyclopropyl-4-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn- 1-yl]amino}-3-methoxybenzamide

(3S,4R)-3-fluoro-N-[2-(3-{[2-methoxy-4-(pyrrolidine-1- carbonyl)phenyl]amino}prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl]- 1-methylpiperidin-4-amine

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(1,1,2,2,2-pentafluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy- N-methylbenzamide

5-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N- methylpyridine-2-carboxamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl] amino}-3- (2,2,2-trifluoroethyl) imidazo[1,2-a] pyridin-2-yl) prop-2-yn-1-yl] amino}-N-methyl-3- (trifluoromethoxy) benzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N-methyl-3-(trifluoromethyl)benzamide

3-chloro-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N- methylbenzamide

3-cyano-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N- methylbenzamide

3-cyclopropyl-4-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn- 1-yl]amino}-N-methylbenzamide

3-ethyl-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl) prop-2-yn-1-yl]amino}-N- methylbenzamide

3-ethoxy-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl] amino}-3-(2,2,2-trifluoroethyl) imidazo[1,2-a] pyridin-2-yl) prop-2-yn-1-yl] amino}-N- methylbenzamide

3-(difluoromethoxy)-4-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn- 1-yl]amino}-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N-methyl-3-(2,2,2-trifluoroethoxy)benzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-(2- methoxyethoxy)-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzenesulfonamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl] amino}- 3-(2,2,2-trifluoroethyl) imidazo[1,2-a] pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzenesulfonamide

(3S,4R)-N-[2-(3-{[4-(ethanesulfonyl)-2- methoxyphenyl]amino}prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl]- 3-fluoro-1-methylpiperidin-4-amine

(3S,4R)-N-[2-(3-{[4-(cyclopropanesulfonyl)-2- methoxyphenyl]amino}prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl]- 3-fluoro-1-methylpiperidin-4-amine

(3S,4R)-3-fluoro-N-(2-{3-[(2-fluoro-4- methanesulfonylphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo [1,2- a]pyridin-8-yl)-1-methylpiperidin-4-amine

4-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3- (2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-2-methylbut-3-yn-2-ol

(2R)-4-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)but-3-yn-2-ol

(2S)-4-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)but-3-yn-2-ol

(1S)-3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1-phenylprop-2-yn-1-ol

(1R)-3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)-1-phenylprop-2-yn-1-ol

(3S,4R)-N-[2-(4-aminobut-1-yn-1-yl)-3-(2,2,2- trifluoroethyl)imidazo[1,2-a]pyridin-8-yl]-3-fluoro-1-methylpiperidin-4-amine

(3S,4R)-N-[2-(3-aminoprop-1-yn-1-yl)-3-(2,2,2- trifluoroethyl)imidazo[1,2-a]pyridin-8-yl]-3-fluoro-1-methylpiperidin-4-amine

(3S,4R)-3-fluoro-N-(2-{3-[(4- methanesulfonylphenyl)amino]prop-1-yn-1-yl}-3-(2,2,2-trifluoroethyl)imidazo[1,2- a]pyridin-8-yl)-1-methylpiperidin-4-amine

(3S,4R)-3-fluoro-N-[2-(3-{[2-methoxy-4-(propane-2- sulfonyl)phenyl]amino}prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl) imidazo[1,2-a]pyridin-8-yl]- 1-methylpiperidin-4-amine

(3S,4R)-3-fluoro-N-[2-(3-{[2-methoxy-4-(propane-2- sulfonyl)phenyl]amino}prop-1-yn-1-yl)-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin- 8-yl]-1-methylpiperidin-4-amine

(3S,4R)-N-[2-(3-{[4-(ethanesulfonyl)-2- methoxyphenyl]amino}prop-1-yn-1-yl)-3-[(trifluoromethyl)sulfanyl]imidazo [1,2-a]pyridin- 8-yl]-3-fluoro-1-methylpiperidin-4-amine

(3S,4R)-N-[2-(3-{[4-(ethanesulfonyl)-2- methoxyphenyl]amino}prop-1-yn-1-yl)-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin- 8-yl]-3-fluoropiperidin-4-amine

(3S,4R)-N-[2-(3-{[4-(cyclopropanesulfonyl)-2- methoxyphenyl]amino}prop-1-yn-1-yl)-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin- 8-yl]-3-fluoro-1-methylpiperidin-4-amine

(3S,4R)-3-fluoro-N-(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin- 8-yl)-1-methylpiperidin-4-amine

(3S,4R)-3-fluoro-N-(2-{3-[(4-methanesulfonyl-2- methoxyphenyl)amino]prop-1-yn-1-yl}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin- 8-yl)piperidin-4-amine)

(3S,4R)-3-fluoro-N-(2-{3-[(5-methanesulfonyl-2- methoxyphenyl) amino] prop-1-yn-1-yl}-3-[(trifluoromethyl)sulfanyl] imidazo[1,2-a] pyridin-8-yl)-1-methylpiperidin-4-amine

N-ethyl-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}- 3-methoxybenzamide

N-cyclopropyl-4-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl) sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop- 2-yn-1-yl]amino}-3-methoxybenzamide

(3S,4R)-N-[2-(3-{[4-(azetidine-1-carbonyl)-2- methoxyphenyl]amino}prop-1-yn-1-yl)-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin- 8-yl]-3-fluoro-1-methylpiperidin-4-amine

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl] amino}- 3-[(trifluoromethyl)sulfanyl] imidazo[1,2-a] pyridin-2-yl) prop-2-yn-1-yl] amino}-3- methoxy-N, N-dimethylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}- N-isopropyl-3-methoxybenzamide

4-({3-[6-(2-fluoroprop-2-enamido)-8-[(1-methylpiperidin-4- yl)amino]-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl]prop-2-yn-1-yl}amino)-3- methoxy-N-methylbenzamide

4-((3-[6-(2-chloroacetamido)-8-[(1-methylpiperidin-4- yl)amino]-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl]prop-2-yn-1-ylamino)-3- methoxy-N-methylbenzamide

5-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-6-methoxy-N- methylpyridine-2-carboxamide

5-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-6-methoxy- N-methylpyridine-2-carboxamide

5-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N-methylpyridine-2-carboxamide

5-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-6-methoxy-2,3-dihydroisoindol-1-one

5-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-6-methoxy- 2,3-dihydroisoindol-1-one

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-(trifluoromethyl)imidazo [1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N- methylbenzamide

4-{[3-(7-fluoro-8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3- (2,2,2-trifluoroethyl)imidazo [1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

4-{[3-(6-fluoro-8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3- (2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoropiperidin- 4-yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3- methoxy-N-methylbenzamide

4-{[3-(8- {[(3R,4R)-3-fluorooxan-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2- yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

4-{[3-(8-{[(3R,4S)-4-fluoropyrrolidin-3-yl] amino}-3-[(trifluoromethyl)sulfanyl] imidazo[1,2-a] pyridin-2-yl) prop-2-yn-1-yl] amino}-3- methoxy-N-methylbenzamide

4-{[3-(8-{[(3R,4S)-4-fluoro-1-methylpyrrolidin-3-yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn- 1-yl]amino}-3-(2-methoxyethoxy)-N-methylbenzamide

3- (difluoromethoxy)-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl] imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide

4-[(3-{3-[(difluoromethyl)sulfanyl]- 8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}imidazo[1,2-a]pyridin-2-yl}prop-2-yn-1- yl)amino]-3-methoxy-N-methylbenzamide

3-{[3-(8-{[(3S,4R)-3- fluoro-1-methylpiperidin-4-yl] amino}-3-[(trifluoromethyl)sulfanyl] imidazo[1,2-a] pyridin-2-yl) prop-2-yn-1-yl] amino}-4-methoxy-N-methylbenzamide

N-ethyl-3-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl] amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2- yn-1-yl]amino}-4-methoxybenzamide

N-cyclopropyl-3-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl) sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2- yn-1-yl]amino}-4-methoxybenzamide

6-{[3-(8-{[(3S,4R)-3-fluoro- 1-methylpiperidin-4-yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1- yl]amino}-7-methoxy-3,4-dihydro-2H-isoquinolin-1-one

2-chloro-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-(2,2,2-trifluoroethyl) imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-5- methoxy-N-methylbenzamide

(3S,4R)-3-fluoro-1-methyl-N-{2-[3- (phenylamino)prop-1-yn-1-yl]-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-8-yl}piperidin-4- amine

3-{[3-(8- {[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl] amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2- yl)prop-2-yn-1-yl]amino}-4-methoxy-N-methylbenzamide

3-{[3-(8-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-3- [(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-4-methoxy-N-methylbenzamide

4-{[3-(8- {[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2- yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

3-{[3-(8-{[(3S,4R)- 3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1- yl]amino}-4-methoxy-N-methylbenzenesulfonamide

4-[(3-{3- [(difluoromethyl)sulfanyl]-8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}indolizin-2- yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide

4-{[3-(5-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-1-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

3-{[3-(6-fluoro-8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-4-methoxy-N-methylbenzamide

4-{[3-(1-{[(3S,4R)-3-fluoro- 1-methylpiperidin-4-yl] amino}-6-[(trifluoromethyl)sulfanyl] pyrrolo[1,2-a] pyrazin-7-yl) prop-2- yn-1-yl] amino}-3-methoxy-N-methylbenzamide

3-{[3- (1-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-6-[(trifluoromethyl)sulfanyl] pyrrolo[1,2- a]pyrazin-7-yl)prop-2-yn-1-yl]amino}-4-methoxy-N-methylbenzamide

(3S,4R)-N-[7-(3-{[4- (dimethylphosphoryl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-6-[(trifluoromethyl)sulfanyl]pyrrolo[1,2-a]pyrazin-1-yl]-3-fluoro-1-methylpiperidin-4-amine

8-{[3-(1-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-6-[(trifluoromethyl)sulfanyl]pyrrolo[1,2-a]pyrazin-7-yl)prop-2-yn- 1-yl]amino}-N-methylimidazo[1,2-a]pyridine-6-carboxamide

4-[(3-{6-[(difluoromethyl)sulfanyl]-1-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}pyrrolo[1,2-a]pyrazin-7-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyrazin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

4-{[3-(7- {[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]pyrazolo[1,5- c]pyrimidin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

4-{[3- (7-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(1-fluoroethyl)sulfanyl]pyrazolo[1,5- c]pyrimidin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

3-{[3-(7-{[(3S,4R)-3-fluoro- 1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]pyrazolo[1,5-a]pyrimidin-2-yl)prop- 2-yn-1-yl]amino}-4-methoxy-N-methylbenzamide

4-[(3-{3-[(difluoromethyl)sulfanyl]-7-{[(3S,4R)-3-fluoro- 1-methylpiperidin-4-yl]amino}pyrazolo[1,5-a]pyridin-2-yl}prop-2-yn-1-yl)amino]-3-methoxy- N-methylbenzamide

4-{[3-(7-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]pyrazolo[1,5-a]pyridin-2-yl)prop-2- yn-1-yl]amino}-3-methoxy-N-methylbenzamide

rel- 4-{[3-(8-{[(1R,5R,6S,7S)-6-fluoro-3-oxa-9-azabicyclo [3.3.1] nonan-7-yl] amino}-3-[(trifluoromethyl)sulfanyl] imidazo[1,2-a] pyridin-2-yl) prop-2-yn-1-yl] amino}-3-methoxy-N-methylbenzamide

4-{[3-(8-{[(3R,4R)-3-fluorooxan-4-yl]amino}-3- [(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-N-methyl-3-[(1- methylazetidin-3-yl)oxy]benzamide

N-[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl] amino}-3-[(trifluoromethyl) sulfanyl] imidazo[1,2-a] pyridin-2-yl) prop-2-yn-1-yl]-5-methoxy- 2H-indazol-6-amine

4-{[3-(8-{[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]amino}-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

4-{[3-(8-{[(1S,2S,3R,5R)-2-fluoro- 8-azabicyclo[3.2.1]octan-3-yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2- yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide

rel- 4-{[3-(8-{[(1R,5R,6S,7S)-6-fluoro-3-oxa-9-azabicyclo [3.3.1] nonan-7-yl] amino}-3-[(trifluoromethyl)sulfanyl] imidazo[1,2-a] pyridin-2-yl) prop-2-yn-1-yl] amino}-3-methoxy-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N-[(2R)-2-hydroxypropyl]-3-methoxybenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3- [(trifluoromethyl)sulfanyl] indolizin-2-yl)prop-2-yn-1-yl]amino}-N-[(2S)-2-hydroxypropyl]-3- methoxybenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}- N-[(1-hydroxycyclopropyl)methyl]-3-methoxybenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N-(2-methanesulfonylethyl)benzamide

1-(4-{[3-(8-{[(3S,4R)-3- fluoropiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}- 3-methoxybenzoyl)-3-methylazetidin-3-ol

4-{[3-(8-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-3- [(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-(oxetan-3- yl)piperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl] indolizin-2-yl)prop-2-yn-1-yl]amino}-3- methoxy-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}- 3-(fluoromethoxy)-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3- fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1- yl]amino}-3-hydroxy-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3- fluoropiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}- 3-hydroxy-N-methylbenzamide

3-chloro-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-[(trifluoromethyl)sulfanyl] indolizin-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide

4-{[3-(1-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-6- [(trifluoromethyl)sulfanyl] pyrrolo[1,2-a]pyrazin-7-yl)prop-2-yn-1-yl]amino}-3-hydroxy-N- methylbenzamide

3-(difluoromethyl)-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N- methylbenzamide

3-fluoro-4-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}- N-methylbenzamide

3-cyano-4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}- 3-[(trifluoromethyl) sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide

3-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3- [(trifluoromethyl)sulfanyl] indolizin-2-yl)prop-2-yn-1-yl]amino}-N2,N6-dimethylpyridine-2,6- dicarboxamide

5-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}- 6-methoxy-N-methylpyridine-2-carboxamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N1,N3- dimethylbenzene-1,3-dicarboxamide

3-{[3-(8- {[(3S,4R)-3-fluoro-1-(oxetan-3-yl)piperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin- 2-yl)prop-2-yn-1-yl]amino}-4-methoxy-N-methylbenzamide

3-{[3-(8-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-3- [(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-4-hydroxy-N-methylbenzamide

3-{[3-(8-{[(3S,4R)- 3-fluoro-1-[(2S*)-2-hydroxypropyl]piperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl] indolizin-2-yl)prop-2-yn-1-yl]amino}-4-methoxy-N-methylbenzamide

3-{[3-(8-{[(3S,4R)- 3-fluoro-1-[(2S*)-2-hydroxypropyl]piperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl] indolizin-2-yl)prop-2-yn-1-yl]amino}-4-methoxy-N-methylbenzamide

3-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N-(2-hydroxy-2-methylpropyl)- 4-(oxetan-3-yloxy)benzamide

3-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl] indolizin-2-yl)prop-2-yn-1-yl]amino}-N-methyl-4-[(1s,3s)-3-hydroxycyclobutoxy]benzamide

3-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl] indolizin-2-yl)prop-2-yn-1-yl]amino}-N-methyl-4-[(1r,3r)-3-hydroxycyclobutoxy] benzamide

8-{[3-(8-{[(3R,4S)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N- methylimidazo[1,2-a]pyridine-6-carboxamide

2-(3-{[6-(dimethylphosphoryl)-4-methoxypyridin- 3-yl]amino}prop-1-yn-1-yl)-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-3- [(trifluoromethyl)sulfanyl]indolizin-8-amine

2-(3-{[6-(dimethylphosphoryl)pyridin-3-yl]amino}prop-1-yn-1-yl)-N-[(3S,4R)-3-fluoro- 1-methylpiperidin-4-yl]-3-[(trifluoromethyl)sulfanyl]indolizin-8-amine

2-(3- {[5-(dimethylphosphoryl)pyridin-2-yl]amino}prop-1-yn-1-yl)-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-3-[(trifluoromethyl)sulfanyl]indolizin-8-amine

2-(3-{[5-(dimethylphosphoryl)-3-methoxypyridin-2- yl]amino}prop-1-yn-1-yl)-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-3- [(trifluoromethyl)sulfanyl]indolizin-8-amine

2-(3-{[2-(dimethylphosphoryl)-4-methoxypyrimidin-5-yl]amino}prop-1-yn-1-yl)-N- [(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-3-[(trifluoromethyl)sulfanyl]indolizin-8-amine

2-(3-{[6- (dimethylphosphoryl)pyridazin-3-yl]amino}prop-1-yn-1-yl)-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-3-[(trifluoromethyl)sulfanyl] indolizin-8-amine

7-(dimethylphosphoryl)-N-[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]-1,3- benzoxazol-4-amine

7-(dimethylphosphoryl)-N-[3-(8-{[(3R,4S)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]-1,3- benzothiazol-4-amine

8-{[3-(8-{[(3S,4R)-3-fluoro-1- methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}- N-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N-[(2R*)-2-hydroxy(2- ^{2}H)propyl]-3-methoxybenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]indolizin-2-yl)prop-2-yn-1-yl]amino}-N-[(2R*)-2-hydroxy(2-2H)propyl]-3-methoxybenzamide

4-((3-(8-(((3S,4R)-3- fluoro-1-(methyl-d3)piperidin-4-yl)amino)-3-((trifluoromethyl)thio)imidazo[1,2-a]pyridin-2- yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

4-((3-(8-(((3S,4R)-3-fluoro-1- methylpiperidin-4-yl)amino)-3-((trifluoromethyl)thio)indolizin-2-yl)prop-2-yn-1-yl)amino)-3- (methoxy-d3)-N-methylbenzamide

4-{[3-(8-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-3-[(trifluoromethyl)sulfanyl]imidazo[1,2-a]pyridin-2-yl)prop-2-yn-1-yl]amino}-3-(^{2}H3)methoxy-N-methylbenzamide

3-((3-(1-(((3S,4R)-3-fluoro-1-methylpiperidin-4- yl)amino)-6-((trifluoromethyl)thio)pyrrolo[1,2-a]pyrazin-7-yl)prop-2-yn-1-yl)amino)-4- (methoxy-d3)-N-methylbenzamide, or

3-{[3-(7-{[(3S,4R)-3-fluoro-1-methylpiperidin-4- yl]amino}-3-[(trifluoromethyl)sulfanyl]pyrazolo[1,5-a]pyridin-2-yl)prop-2-yn-1- yl]amino}-4-(2H3)methoxy-N-methylbenzamide.

[0360] Compounds herein can include all stereoisomers, enantiomers, diastereomers, mixtures, racemates, atropisomers, and tautomers thereof.

[0361] Non-limiting examples of optional substituents include a hydroxyl group, an oxo group, sulfhydryl group, halogen, amino group, nitro group, nitroso group, cyano group, azido group, sulfoxide group, sulfone group, sulfonamide group, carboxyl group, carboxaldehyde group, imine group, alkyl group, halo-alkyl group, alkenyl group, halo-alkenyl group, alkynyl group, halo-alkynyl group, alkoxy group, aryl group, aryloxy group, aralkyl group, arylalkoxy group, heterocyclyl group, acyl group, acyloxy group, carbamate group, carbamoyl group, amide group, phosphine group, phosphine oxide group, ureido group, epoxy group, and ester group.

[0362] Non-limiting examples of alkyl and alkylene groups include straight, branched, and cyclic alkyl and alkylene groups. An alkyl or alkylene group can be, for example, a C_1, C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}, C_{16}, C_{17}, C_{18}, C_{19}, C_{20}, C_{21}, C_{22}, C_{23}, C_{24}, C_{25}, C_{26}, C_{27}, C_{28}, C_{29}, C_{30}, C_{31}, C_{32}, C_{33}, C_{34}, C_{35}, C_{36}, C_{37}, C_{38}, C_{39}, C_{40}, C_{41}, C_{42}, C_{43}, C_{44}, C_{45}, C_{46}, C_{47}, C_{48}, C_{49}, or C_{50} group that is substituted or unsubstituted.

[0363] Non-limiting examples of straight alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.

[0364] Branched alkyl groups include any straight alkyl group substituted with any number of alkyl groups. Non-limiting examples of branched alkyl groups include isopropyl, isobutyl, sec-butyl, and t-butyl.

[0365] Non-limiting examples of substituted alkyl groups includes hydroxymethyl, chloromethyl, trifluoromethyl, trifluoroethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, and 3-carboxypropyl.

[0366] Non-limiting examples of amide groups include $-C(O)NH_2$, $-C(O)N(H)CH_3$, $-C(O)N(H)CH_2CH_3$, $-C(O)N(CH_2CH_3)_2$, $-C(O)N(CH_3)_2$, $-C(O)N(H)CH(CH_3)_2$, and $-C(O)N(H)C(CH_3)_3$.

[0367] Non-limiting examples of sulfonamide groups include $-S(O)_2NH_2$, $-S(O)_2N(H)CH_3$, $-S(O)_2N(H)CH_2CH_3$, $-S(O)_2N(CH_2CH_3)_2$, $-S(O)_2N(CH_3)_2$, $-S(O)_2N(H)CH(CH_3)_2$, and $-S(O)_2N(H)C(CH_3)_3$.

[0368] Non-limiting examples of sulfone groups include $-S(O)_2CH_3$, $-S(O)_2CH_2CH_3$, $-S(O)_2CH(CH_3)_2$, and $-S(O)_2C(CH_3)_3$.

[0369] Non-limiting examples of cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptlyl, and cyclooctyl groups. Cyclic alkyl groups also include fused-, bridged-, and spiro-bicycles and higher fused-, bridged-, and spiro-systems. A cyclic alkyl group can be substituted with any number of straight, branched, or cyclic alkyl groups. Non-limiting examples of cyclic alkyl groups include cyclopropyl, 2-methyl-cycloprop-1-yl, cycloprop-2-en-1-yl, cyclobutyl, 2,3-dihydroxycyclobut-1-yl, cyclobut-2-en-1-yl, cyclopentyl, cyclopent-2-en-1-yl, cyclopenta-2,4-dien-1-yl, cyclohexyl, cyclohex-2-en-1-yl, cycloheptyl, cyclooctanyl, 2,5-dimethylcyclopent-1-yl, 3,5-dichlorocyclohex-1-yl, 4-hydroxycyclohex-1-yl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1*H*-indenyl, 3a,4,5,6,7,7a-hexahydro-3*H*-inden-4-yl, decahydroazulenyl, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.

[0370] Non-limiting examples of alkenyl and alkenylene groups include straight, branched, and cyclic alkenyl groups. The olefin or olefins of an alkenyl group can be, for example, *E*, *Z*, *cis*, *trans*, terminal, or *exo*-methylene. An alkenyl or alkenylene group can be, for example, a C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}, C_{16}, C_{17}, C_{18}, C_{19}, C_{20}, C_{21}, C_{22}, C_{23}, C_{24}, C_{25}, C_{26}, C_{27}, C_{28}, C_{29}, C_{30}, C_{31}, C_{32}, C_{33}, C_{34}, C_{35}, C_{36}, C_{37}, C_{38}, C_{39}, C_{40}, C_{41}, C_{42}, C_{43}, C_{44}, C_{45}, C_{46}, C_{47}, C_{48}, C_{49}, or C_{50} group that is substituted or unsubstituted. Non-limiting examples of alkenyl and alkenylene groups include ethenyl, prop-1-en-1-yl, isopropenyl, but-1-en-4-yl; 2-chloroethenyl, 4-hydroxybuten-1-yl, 7-hydroxy-7-methyloct-4-en-2-yl, and 7-hydroxy-7-methyloct-3,5-dien-2-yl.

[0371] Non-limiting examples of alkynyl or alkynylene groups include straight, branched, and cyclic alkynyl groups. The triple bond of an alkylnyl or alkynylene group can be internal or terminal. An alkylnyl or alkynylene group can be, for example, a C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}, C_{16}, C_{17}, C_{18}, C_{19}, C_{20}, C_{21}, C_{22}, C_{23}, C_{24}, C_{25}, C_{26}, C_{27}, C_{28}, C_{29}, C_{30}, C_{31}, C_{32}, C_{33}, C_{34}, C_{35}, C_{36}, C_{37}, C_{38}, C_{39}, C_{40}, C_{41}, C_{42}, C_{43}, C_{44}, C_{45}, C_{46}, C_{47}, C_{48}, C_{49}, or C_{50} group that is substituted or unsubstituted. Non-limiting examples of alkynyl or alkynylene groups include ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, and 2-methyl-hex-4-yn-1-yl; 5-hydroxy-

5-methylhex-3-yn-1-yl, 6-hydroxy-6-methylhept-3-yn-2-yl, and 5-hydroxy-5-ethylhept-3-yn-1-yl.

[0372] A halo-alkyl group can be any alkyl group substituted with any number of halogen atoms, for example, fluorine, chlorine, bromine, and iodine atoms. A halo-alkenyl group can be any alkenyl group substituted with any number of halogen atoms. A halo-alkynyl group can be any alkynyl group substituted with any number of halogen atoms.

[0373] An alkoxy group can be, for example, an oxygen atom substituted with any alkyl, alkenyl, or alkynyl group. An ether or an ether group comprises an alkoxy group. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, and isobutoxy.

[0374] An aryl group can be heterocyclic or non-heterocyclic. An aryl group can be monocyclic or polycyclic. An aryl group can be substituted with any number of substituents described herein, for example, hydrocarbyl groups, alkyl groups, alkoxy groups, and halogen atoms. Non-limiting examples of aryl groups include phenyl, toluyl, naphthyl, pyrrolyl, pyridyl, imidazolyl, thiophenyl, and furyl. Non-limiting examples of substituted aryl groups include 3,4-dimethylphenyl, 4-*tert*-butylphenyl, 4-cyclopropylphenyl, 4-diethylaminophenyl, 4-(trifluoromethyl)phenyl, 4-(difluoromethoxy)-phenyl, 4-(trifluoromethoxy)phenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 2-chlorophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-methylphenyl, 3-fluorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-methylphenyl, 4-methoxyphenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trifluorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 2,3,4-trichlorophenyl, 2,3,5-trichlorophenyl, 2,3,6-trichlorophenyl, 2,4,5-trichlorophenyl, 3,4,5-trichlorophenyl, 2,4,6-trichlorophenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 2,3,4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,3,6-trimethylphenyl, 2,4,5-trimethylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 2,3,4-triethylphenyl, 2,3,5-triethylphenyl, 2,3,6-triethylphenyl, 2,4,5-triethylphenyl, 2,4,6-triethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, and 4-isopropylphenyl.

[0375] Non-limiting examples of substituted aryl groups include 2-aminophenyl, 2-(*N*-methylamino)phenyl, 2-(*N*,*N*-dimethylamino)phenyl, 2-(*N*-ethylamino)phenyl, 2-(*N*,*N*-diethylamino)phenyl, 3-aminophenyl, 3-(*N*-methylamino)phenyl, 3-(*N*,*N*-dimethylamino)phenyl, 3-(*N*-ethylamino)phenyl, 3-(*N*,*N*-diethylamino)phenyl, 4-aminophenyl, 4-(*N*-methylamino)phenyl, 4-(*N*,*N*-dimethylamino)phenyl, 4-(*N*-ethylamino)phenyl, 2-methoxy-4-(methylsulfonyl)phenyl, 2-methoxy-4-(ethylsulfonyl)phenyl, 2-methoxy-4-(ethylcarbamoyl)phenyl, 2-methoxy-4-(methylcarbamoyl)phenyl, and 4-(*N*,*N*-diethylamino)phenyl.

[0376] A heterocycle can be any ring containing a ring atom that is not carbon, for example, N, O, S, P, Si, B, or any other heteroatom. A heterocycle can be substituted with any number of substituents, for example, alkyl groups and halogen atoms. A heterocycle can be aromatic (heteroaryl) or non-aromatic. Non-limiting examples of heterocycles include pyrrole, pyrrolidine, pyridine, piperidine, succinimide, maleimide, morpholine, imidazole, thiophene, furan, tetrahydrofuran, pyran, and tetrahydropyran.

[0377] Non-limiting examples of heterocycles include: heterocyclic units having a single ring containing one or more heteroatoms, non-limiting examples of which include, diazirinyl, aziridinyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolinyl, oxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-onyl, 2,3,4,5-tetrahydro-1*H*-azepinyl, 2,3-dihydro-1*H*-indole, and 1,2,3,4-tetrahydroquinoline; and ii) heterocyclic units having 2 or more rings one of which is a heterocyclic ring, non-limiting examples of which include hexahydro-1*H*-pyrrolizinyl, 3a,4,5,6,7,7a-hexahydro-1*H*-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1*H*-indolyl, 1,2,3,4-tetrahydroquinolinyl, and decahydro-1*H*-cycloocta[b]pyrrolyl.

[0378] A heterocyclylalkyl group (e.g. "heterocyclylalkyl") can be a stable 3- to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and sulfur. Unless stated otherwise specifically in the specification, the heterocyclylalkyl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocyclylalkyl is bonded through a non-aromatic ring atom), spirocyclic, or bridged ring systems. The nitrogen, phosphorous, carbon, or sulfur atoms in the heterocyclylalkyl radical may be optionally oxidized. For example, a cyclic phosphane group (e.g., 1-methylphospinane) can be substituted with an oxo group to afford the corresponding phosphine oxide (e.g. 1-methylphospinane 1-oxide), or substituted with a =N-R^N

radical to afford the corresponding phosphinanimine (e.g. 1-methyl-1-phosphinan-1-imine), where R^N is any suitable monovalent radical. The nitrogen atom in the heterocyclylalkyl radical can be optionally quaternized.

[0379] Representative heterocyclylalkyls include, but are not limited to, heterocyclylalkyls having from two to fifteen carbon atoms (C_2-C_{15} heterocyclylalkyl), from two to ten carbon atoms (C_2-C_{10} heterocyclylalkyl), from two to eight carbon atoms (C_2-C_8 heterocyclylalkyl), from two to six carbon atoms (C_2-C_6 heterocyclylalkyl), from two to five carbon atoms (C_2-C_5 heterocyclylalkyl), or two to four carbon atoms (C_2-C_4 heterocyclylalkyl). In some embodiments, the heterocyclylalkyl is a 3- to 6-membered heterocyclylalkyl. In some embodiments, the cycloalkyl is a 5- to 6-membered heterocyclylalkyl. Examples of such heterocyclylalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxol-4-yl, and 2-oxo-1,3-dioxol-4-yl. The term heterocyclylalkyl also includes all ring forms of the carbohydrates, including but not limited to, the monosaccharides, the disaccharides, and the oligosaccharides. It is understood that when referring to the number of carbon atoms in a heterocyclylalkyl, the number of carbon atoms in the heterocyclylalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocyclylalkyl (i.e. skeletal atoms of the heterocyclylalkyl ring). Unless stated otherwise specifically in the specification, a heterocyclylalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, and the like. In some embodiments, a heterocyclylalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, $-CF_3$, -OH, -OMe, $-NH_2$, or $-NO_2$. In some embodiments, a heterocyclylalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, $-CF_3$, -OH, or -OMe. In some embodiments, the heterocyclylalkyl is optionally substituted with halogen.

[0380] Non-limiting examples of heteroaryl include: i) heteroaryl rings containing a single ring, non-limiting examples of which include, 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1*H*-imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, thiophenyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl;

and ii) heteroaryl rings containing 2 or more fused rings one of which is a heteroaryl ring, non-limiting examples of which include: 7*H*-purinyl, 9*H*-purinyl, 6-amino-9*H*-purinyl, 5*H*-pyrrolo[3,2-*d*]pyrimidinyl, 7*H*-pyrrolo[2,3-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, 4,5,6,7-tetrahydro-1-*H*-indolyl, quinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, and isoquinolinyl.

[0381] Any compound herein can be purified. A compound herein can be least 1% pure, at least 2% pure, at least 3% pure, at least 4% pure, at least 5% pure, at least 6% pure, at least 7% pure, at least 8% pure, at least 9% pure, at least 10% pure, at least 11% pure, at least 12% pure, at least 13% pure, at least 14% pure, at least 15% pure, at least 16% pure, at least 17% pure, at least 18% pure, at least 19% pure, at least 20% pure, at least 21% pure, at least 22% pure, at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure, at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure, at least 67% pure, at least 68% pure, at least 69% pure, at least 70% pure, at least 71% pure, at least 72% pure, at least 73% pure, at least 74% pure, at least 75% pure, at least 76% pure, at least 77% pure, at least 78% pure, at least 79% pure, at least 80% pure, at least 81% pure, at least 82% pure, at least 83% pure, at least 84% pure, at least 85% pure, at least 86% pure, at least 87% pure, at least 88% pure, at least 89% pure, at least 90% pure, at least 91% pure, at least 92% pure, at least 93% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.1% pure, at least 99.2% pure, at least 99.3% pure, at least 99.4% pure, at least 99.5% pure, at least 99.6% pure, at least 99.7% pure, at least 99.8% pure, or at least 99.9% pure.

[0382] In some embodiments, compounds of the invention can be used to treat cancer in a subject. A compound of the invention can, for example, slow the proliferation of cancer cell lines, or kill cancer cells. Non-limiting examples of cancer that can be treated by a compound of the invention include: acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, appendix cancer, astrocytomas, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancers, brain tumors,

such as cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic glioma, breast cancer, bronchial adenomas, Burkitt lymphoma, carcinoma of unknown primary origin, central nervous system lymphoma, cerebellar astrocytoma, cervical cancer, childhood cancers, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, germ cell tumors, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gliomas, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, Hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi sarcoma, kidney cancer, laryngeal cancer, lip and oral cavity cancer, liposarcoma, liver cancer, lung cancers, such as non-small cell and small cell lung cancer, lymphomas, leukemias, macroglobulinemia, malignant fibrous histiocytoma of bone/osteosarcoma, medulloblastoma, melanomas, mesothelioma, metastatic squamous neck cancer with occult primary, mouth cancer, multiple endocrine neoplasia syndrome, myelodysplastic syndromes, myeloid leukemia, nasal cavity and paranasal sinus cancer, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma/malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, pancreatic cancer, pancreatic cancer islet cell, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal astrocytoma, pineal germinoma, pituitary adenoma, pleuropulmonary blastoma, plasma cell neoplasia, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, renal pelvis and ureter transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcomas, skin cancers, skin carcinoma merkel cell, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, T-cell lymphoma, throat cancer, thymoma, thymic carcinoma, thyroid cancer, trophoblastic tumor (gestational), cancers of unknown primary site, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenström macroglobulinemia, and Wilms tumor. In some embodiments, the solid tumor is selected from small cell lung cancer, pancreatic cancer, prostate cancer, breast cancer, endometrial cancer, and ovarian cancer.

[0383] In some embodiments, the compounds of the invention show non-lethal toxicity.

Pharmaceutically-acceptable salts.

[0384] The invention provides the use of pharmaceutically-acceptable salts of any therapeutic compound described herein. Pharmaceutically-acceptable salts include, for example, acid-

addition salts and base-addition salts. The acid that is added to the compound to form an acid-addition salt can be an organic acid or an inorganic acid. A base that is added to the compound to form a base-addition salt can be an organic base or an inorganic base. In some embodiments, a pharmaceutically-acceptable salt is a metal salt. In some embodiments, a pharmaceutically-acceptable salt is an ammonium salt.

[0385] Metal salts can arise from the addition of an inorganic base to a compound of the invention. The inorganic base consists of a metal cation paired with a basic counterion, such as, for example, hydroxide, carbonate, bicarbonate, or phosphate. The metal can be an alkali metal, alkaline earth metal, transition metal, or main group metal. In some embodiments, the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.

[0386] In some embodiments, a metal salt is a lithium salt, a sodium salt, a potassium salt, a cesium salt, a cerium salt, a magnesium salt, a manganese salt, an iron salt, a calcium salt, a strontium salt, a cobalt salt, a titanium salt, an aluminum salt, a copper salt, a cadmium salt, or a zinc salt.

[0387] Ammonium salts can arise from the addition of ammonia or an organic amine to a compound of the invention. In some embodiments, the organic amine is triethyl amine, diisopropyl amine, ethanol amine, diethanol amine, triethanol amine, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, dibenzylamine, piperazine, pyridine, pyrazole, imidazole, pyrazine, or pyrimidine.

[0388] In some embodiments, an ammonium salt is a triethyl amine salt, a diisopropyl amine salt, an ethanol amine salt, a diethanol amine salt, a triethanol amine salt, a morpholine salt, an N-methylmorpholine salt, a piperidine salt, an N-methylpiperidine salt, an N-ethylpiperidine salt, a dibenzylamine salt, a piperazine salt, a pyridine salt, a pyrazole salt, an imidazole salt, a pyrazine salt, or a pyrimidine salt.

[0389] Acid addition salts can arise from the addition of an acid to a compound of the invention. In some embodiments, the acid is organic. In some embodiments, the acid is inorganic. In some embodiments, the acid is hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, a phosphoric acid, isonicotinic acid, lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisic acid, gluconic acid, glucuronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, oxalic acid, or maleic acid.

[0390] In some embodiments, the salt is a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a nitrate salt, a nitrite salt, a sulfate salt, a sulfite salt, a phosphate salt, isonicotinate salt, a lactate salt, a salicylate salt, a tartrate salt, an ascorbate salt, a gentisate salt, a gluconate salt, a glucuronate salt, a saccharate salt, a formate salt, a benzoate salt, a glutamate salt, a pantothenate salt, an acetate salt, a propionate salt, a butyrate salt, a fumarate salt, a succinate salt, a methanesulfonate (mesylate) salt, an ethanesulfonate salt, a benzenesulfonate salt, a p-toluenesulfonate salt, a citrate salt, an oxalate salt, or a maleate salt.

Pharmaceutical Compositions of the invention.

[0391] A pharmaceutical composition of the invention can be used, for example, before, during, or after treatment of a subject with, for example, another pharmaceutical agent.

[0392] Subjects can be, for example, elderly adults, adults, adolescents, pre-adolescents, children, toddlers, infants, neonates, and non-human animals. In some embodiments, a subject is a patient.

[0393] A pharmaceutical composition of the invention can be a combination of any pharmaceutical compounds described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of the compound to an organism. Pharmaceutical compositions can be administered in therapeutically-effective amounts as pharmaceutical compositions by various forms and routes including, for example, intravenous, subcutaneous, intramuscular, oral, parenteral, ophthalmic, subcutaneous, transdermal, nasal, vaginal, and topical administration.

[0394] A pharmaceutical composition can be administered in a local manner, for example, via injection of the compound directly into an organ, optionally in a depot or sustained release formulation or implant. Pharmaceutical compositions can be provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. A rapid release form can provide an immediate release. An extended release formulation can provide a controlled release or a sustained delayed release.

[0395] For oral administration, pharmaceutical compositions can be formulated by combining the active compounds with pharmaceutically-acceptable carriers or excipients. Such carriers can be used to formulate liquids, gels, syrups, elixirs, slurries, or suspensions, for oral ingestion by a subject. Non-limiting examples of solvents used in an oral dissolvable formulation can include water, ethanol, isopropanol, saline, physiological saline, DMSO, dimethylformamide, potassium phosphate buffer, phosphate buffer saline (PBS), sodium phosphate buffer, 4-2-hydroxyethyl-1-piperazineethanesulfonic acid buffer (HEPES), 3-(N-morpholino)propanesulfonic acid buffer

(MOPS), piperazine-N,N′-bis(2-ethanesulfonic acid) buffer (PIPES), and saline sodium citrate buffer (SSC). Non-limiting examples of co-solvents used in an oral dissolvable formulation can include sucrose, urea, cremaphor, DMSO, and potassium phosphate buffer.

[0396] Pharmaceutical preparations can be formulated for intravenous administration. The pharmaceutical compositions can be in a form suitable for parenteral injection as a sterile suspension, solution or emulsion in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Suspensions of the active compounds can be prepared as oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. The suspension can also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0397] The active compounds can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments. Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[0398] The compounds of the invention can be applied topically to the skin, or a body cavity, for example, oral, vaginal, bladder, cranial, spinal, thoracic, or pelvic cavity of a subject. The compounds of the invention can be applied to an accessible body cavity.

[0399] The compounds can also be formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, and PEG. In suppository forms of the compositions, a low-melting wax such as a mixture of fatty acid glycerides, optionally in combination with cocoa butter, can be melted.

[0400] In practicing the methods of treatment or use provided herein, therapeutically-effective amounts of the compounds described herein are administered in pharmaceutical compositions to a subject having a disease or condition to be treated. In some embodiments, the subject is a mammal such as a human. A therapeutically-effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors. The compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.

[0401] Pharmaceutical compositions can be formulated using one or more physiologically-acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Formulations can be modified depending upon the route of administration chosen. Pharmaceutical compositions comprising a compound described herein can be manufactured, for example, by mixing, dissolving, emulsifying, encapsulating, entrapping, or compression processes.

[0402] The pharmaceutical compositions can include at least one pharmaceutically-acceptable carrier, diluent, or excipient and compounds described herein as free-base or pharmaceutically-acceptable salt form. Pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.

[0403] Methods for the preparation of compositions comprising the compounds described herein include formulating the compounds with one or more inert, pharmaceutically-acceptable excipients or carriers to form a solid, semi-solid, or liquid composition. Solid compositions include, for example, powders, tablets, dispersible granules, capsules, and cachets. Liquid compositions include, for example, solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein. Semi-solid compositions include, for example, gels, suspensions and creams. The compositions can be in liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically-acceptable additives.

[0404] Non-limiting examples of dosage forms suitable for use in the invention include liquid, powder, gel, nanosuspension, nanoparticle, microgel, aqueous or oily suspensions, emulsion, and any combination thereof.

[0405] Non-limiting examples of pharmaceutically-acceptable excipients suitable for use in the invention include binding agents, disintegrating agents, anti-adherents, anti-static agents, surfactants, anti-oxidants, coating agents, coloring agents, plasticizers, preservatives, suspending agents, emulsifying agents, anti-microbial agents, spheronization agents, and any combination thereof.

[0406] A composition of the invention can be, for example, an immediate release form or a controlled release formulation. An immediate release formulation can be formulated to allow the compounds to act rapidly. Non-limiting examples of immediate release formulations include readily dissolvable formulations. A controlled release formulation can be a pharmaceutical formulation that has been adapted such that release rates and release profiles of the active agent

can be matched to physiological and chronotherapeutic requirements or, alternatively, has been formulated to effect release of an active agent at a programmed rate. Non-limiting examples of controlled release formulations include granules, delayed release granules, hydrogels (e.g., of synthetic or natural origin), other gelling agents (*e.g.*, gel-forming dietary fibers), matrix-based formulations (*e.g.,* formulations comprising a polymeric material having at least one active ingredient dispersed through), granules within a matrix, polymeric mixtures, and granular masses.

[0407] In some, a controlled release formulation is a delayed release form. A delayed release form can be formulated to delay a compound's action for an extended period of time. A delayed release form can be formulated to delay the release of an effective dose of one or more compounds, for example, for about 4, about 8, about 12, about 16, or about 24 hours.

[0408] A controlled release formulation can be a sustained release form. A sustained release form can be formulated to sustain, for example, the compound's action over an extended period of time. A sustained release form can be formulated to provide an effective dose of any compound described herein (e.g., provide a physiologically-effective blood profile) over about 4, about 8, about 12, about 16 or about 24 hours.

[0409] Non-limiting examples of pharmaceutically-acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins1999), each of which is incorporated by reference in its entirety.

[0410] Multiple therapeutic agents can be administered in any order or simultaneously. In some embodiments, a compound of the invention is administered in combination with, before, or after treatment with another therapeutic agent. If simultaneously, the multiple therapeutic agents can be provided in a single, unified form, or in multiple forms, for example, as multiple separate pills. The agents can be packed together or separately, in a single package or in a plurality of packages. One or all of the therapeutic agents can be given in multiple doses. If not simultaneous, the timing between the multiple doses can vary to as much as about a month.

[0411] Therapeutic agents described herein can be administered before, during, or after the occurrence of a disease or condition, and the timing of administering the composition containing a therapeutic agent can vary. For example, the compositions can be used as a prophylactic and can be administered continuously to subjects with a propensity to conditions or diseases in order

to lessen a likelihood of the occurrence of the disease or condition. The compositions can be administered to a subject during or as soon as possible after the onset of the symptoms. The administration of the therapeutic agents can be initiated within the first 48 hours of the onset of the symptoms, within the first 24 hours of the onset of the symptoms, within the first 6 hours of the onset of the symptoms, or within 3 hours of the onset of the symptoms. The initial administration can be via any route practical, such as by any route described herein using any formulation described herein.

[0412] A compound can be administered as soon as is practical after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease, such as, for example, from about 1 month to about 3 months. In some embodiments, the length of time a compound can be administered can be about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 3 months, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 4 months, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 5 months, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months, about 18 months, about 19 months, about 20 months, about 21 months, about 22 months about 23 months, about 2 years, about 2.5 years, about 3 years, about 3.5 years, about 4 years, about 4.5 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, or about 10 years. The length of treatment can vary for each subject.

[0413] Pharmaceutical compositions described herein can be in unit dosage forms suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of one or more compounds. The unit dosage can be in the form of a package containing discrete quantities of the formulation. Non-limiting examples are packaged injectables, vials, or ampoules. Aqueous suspension compositions can be packaged in single-dose non-reclosable containers. Multiple-dose reclosable containers can be used, for example, in combination with or without a preservative. Formulations for injection can be presented in unit dosage form, for example, in ampoules, or in multi-dose containers with a preservative.

[0414] Pharmaceutical compositions provided herein, can be administered in conjunction with other therapies, for example, chemotherapy, radiation, surgery, anti-inflammatory agents, and

selected vitamins. The other agents can be administered prior to, after, or concomitantly with the pharmaceutical compositions.

[0415] Depending on the intended mode of administration, the pharmaceutical compositions can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, lotions, creams, or gels, for example, in unit dosage form suitable for single administration of a precise dosage.

[0416] For solid compositions, nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, and magnesium carbonate.

[0417] Non-limiting examples of pharmaceutically active agents suitable for combination with compositions of the disclosure include anti-infectives, i.e., aminoglycosides, antiviral agents, antimicrobials, anticholinergics/antispasmotics, antidiabetic agents, antihypertensive agents, antineoplastics, cardiovascular agents, central nervous system agents, coagulation modifiers, hormones, immunologic agents, immunosuppressive agents, and ophthalmic preparations.

[0418] Compounds can be delivered via liposomal technology. The use of liposomes as drug carriers can increase the therapeutic index of the compounds. Liposomes are composed of natural phospholipids, and can contain mixed lipid chains with surfactant properties (e.g., egg phosphatidylethanolamine). A liposome design can employ surface ligands for attaching to unhealthy tissue. Non-limiting examples of liposomes include the multilamellar vesicle (MLV), the small unilamellar vesicle (SUV), and the large unilamellar vesicle (LUV). Liposomal physicochemical properties can be modulated to optimize penetration through biological barriers and retention at the site of administration, and to reduce a likelihood of developing premature degradation and toxicity to non-target tissues. Optimal liposomal properties depend on the administration route: large-sized liposomes show good retention upon local injection, small-sized liposomes are better suited to achieve passive targeting. PEGylation reduces the uptake of the liposomes by the liver and spleen, and increases the circulation time, resulting in increased localization at the inflamed site due to the enhanced permeability and retention (EPR) effect. Additionally, liposomal surfaces can be modified to achieve selective delivery of the encapsulated drug to specific target cells. Non-limiting examples of targeting ligands include monoclonal antibodies, vitamins, peptides, and polysaccharides specific for receptors concentrated on the surface of cells associated with the disease.

[0419] Non-limiting examples of dosage forms suitable for use in the disclosure include liquid, elixir, nanosuspension, aqueous or oily suspensions, drops, syrups, and any combination thereof. Non-limiting examples of pharmaceutically-acceptable excipients suitable for use in the

disclosure include granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, glidants, anti-adherents, anti-static agents, surfactants, anti-oxidants, gums, coating agents, coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, plant cellulosic material and spheronization agents, and any combination thereof.

[0420] Compositions of the invention can be packaged as a kit. In some embodiments, a kit includes written instructions on the administration/use of the composition. The written material can be, for example, a label. The written material can suggest conditions methods of administration. The instructions provide the subject and the supervising physician with the best guidance for achieving the optimal clinical outcome from the administration of the therapy. The written material can be a label. In some embodiments, the label can be approved by a regulatory agency, for example the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other regulatory agencies.

Dosing.

[0421] Pharmaceutical compositions described herein can be in unit dosage forms suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of one or more compounds. The unit dosage can be in the form of a package containing discrete quantities of the formulation. Non-limiting examples are liquids in vials or ampoules. Aqueous suspension compositions can be packaged in single-dose non-reclosable containers. Multiple-dose reclosable containers can be used, for example, in combination with a preservative. Formulations for parenteral injection can be presented in unit dosage form, for example, in ampoules, or in multi-dose containers with a preservative.

[0422] A compound described herein (e.g. a compound that binds a mutant p53 protein and increases wild-type p53 activity of the mutant protein) can be present in a composition in a range of from about 1 mg to about 2000 mg; from about 100 mg to about 2000 mg; from about 10 mg to about 2000 mg; from about 5 mg to about 1000 mg, from about 10 mg to about 500 mg, from about 50 mg to about 250 mg, from about 100 mg to about 200 mg, from about 1 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 300 mg, from about 300 mg to about 350 mg, from about 350 mg to about 400 mg, from about 400 mg to about 450 mg, from about 450 mg to about 500 mg, from about 500 mg to about 550 mg, from about 550 mg to about 600 mg, from about 600 mg to about 650 mg, from about 650 mg to about 700 mg, from about 700 mg to about 750 mg, from about 750 mg to

about 800 mg, from about 800 mg to about 850 mg, from about 850 mg to about 900 mg, from about 900 mg to about 950 mg, or from about 950 mg to about 1000 mg.

[0423] A compound described herein (e.g. a compound that binds a mutant p53 protein and increases wild-type p53 activity of the mutant protein) can be present in a composition in a range of from about 1 mg to about 5000 mg; from about 100 mg to about 4000 mg; from about 10 mg to about 3500 mg; from about 5 mg to about 3000 mg, from about 10 mg to about 2500 mg, from about 50 mg to about 2000 mg, from about 100 mg to about 200 mg, from about 1 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 300 mg, from about 300 mg to about 350 mg, from about 350 mg to about 400 mg, from about 400 mg to about 450 mg, from about 450 mg to about 500 mg, from about 500 mg to about 550 mg, from about 550 mg to about 600 mg, from about 600 mg to about 650 mg, from about 650 mg to about 700 mg, from about 700 mg to about 750 mg, from about 750 mg to about 800 mg, from about 800 mg to about 850 mg, from about 850 mg to about 900 mg, from about 900 mg to about 950 mg, or from about 950 mg to about 1000 mg. In some embodiments, the therapeutically-effective amount of the compound is from about 250 mg to about 2500 mg. In some embodiments, the therapeutically-effective amount of the compound is from about 500 mg to about 2000 mg. In some embodiments, the therapeutically-effective amount of the compound is from about 1000 mg to about 3000 mg. In some embodiments, the therapeutically-effective amount of the compound is from about 2000 mg to about 3000 mg. A compound described herein (e.g. a compound that binds a mutant p53 protein and increases wild-type p53 activity of the mutant protein) can be present in a composition in an amount of about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg, about 1200 mg, about 1250 mg, about 1300 mg, about 1350 mg, about 1400 mg, about 1450 mg, about 1500 mg, about 1550 mg, about 1600 mg, about 1650 mg, about 1700 mg, about 1750 mg, about 1800 mg, about 1850 mg, about 1900 mg, about 1950 mg, or about 2000 mg. In some embodiments, the therapeutically-effective amount of the compound is about 2250 mg, about 2500 mg, or about 3000 mg. In some embodiments, the therapeutically-effective amount of the compound is

about 1,200 mg. In some embodiments, the therapeutically-effective amount of the compound is about 1,500 m. In some embodiments, the therapeutically-effective amount of the compound is about 2,000 mg. In some embodiments, the therapeutically-effective amount of the compound is about 2,500 mg. In some embodiments, the therapeutically-effective amount of the compound is about 3,000 mg. In some embodiments, the therapeutically-effective amount of the compound is about 3,500 mg.

[0424] In some embodiments, a dose can be expressed in terms of an amount of the drug divided by the mass of the subject, for example, milligrams of drug per kilograms of subject body mass. In some embodiments, a compound is administered in an amount ranging from about 5 mg/kg to about 50 mg/kg, 250 mg/kg to about 2000 mg/kg, about 10 mg/kg to about 800 mg/kg, about 50 mg/kg to about 400 mg/kg, about 100 mg/kg to about 300 mg/kg, or about 150 mg/kg to about 200 mg/kg.

Combination Treatment

[0425] Combination therapy with a compound of the disclosure (e.g. a compound that binds a mutant p53 protein and increases wild-type p53 activity of the mutant protein) and at least one additional therapeutic agent, for example, a MDM2 inhibitor, can be used to treat a condition. In some embodiments, the combination therapy can produce a significantly better therapeutic result than the additive effects achieved by each individual constituent when administered alone at a therapeutic dose. In some embodiments, the dosage of a MDM2 inhibitor in combination therapy can be reduced as compared to monotherapy with each agent, while still achieving an overall therapeutic effect. In some embodiments, a compound and a MDM2 inhibitor can exhibit a synergistic effect. In some embodiments, the synergistic effect of a compound a MDM2 inhibitor can be used to reduce the total amount drugs administered to a subject, which decrease side effects experienced by the subject.


[0426] Accordingly, in one aspect, the present disclosure provides a method for treating cancer, the method comprising administering to a subject in need thereof (a) an effective amount of a compound of the disclosure and (b) an effective amount of a MDM2 inhibitor to provide a combination therapy. In some embodiments, the combination therapy may have an enhanced therapeutic effect compared to the effect of the compound and the at least one additional pharmaceutically active agent each administered alone. According to certain exemplary embodiments, the combination therapy has a synergistic therapeutic effect. According to this embodiment, the combination therapy produces a significantly better therapeutic result (*e.g.*, anti-cancer, cell growth arrest, apoptosis, induction of differentiation, cell death, etc.) than the

additive effects achieved by each individual constituent when administered alone at a therapeutic dose.


[0427] Combination therapy includes but is not limited to the combination of compounds of the disclosure with chemotherapeutic agents, therapeutic antibodies, or radiation treatment, to provide a synergistic therapeutic effect. In some embodiments, the compounds of the disclosure are used in combination with one or more anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Suitable chemotherapeutic agents for use in the combinations of the present disclosure include, but are not limited to, alkylating agents, antibiotic agents, antimetabolic agents, hormonal agents, plant-derived agents, anti-angiogenic agents, differentiation inducing agents, cell growth arrest inducing agents, apoptosis inducing agents, cytotoxic agents, agents affecting cell bioenergetics, biologic agents, *e.g.*, monoclonal antibodies, kinase inhibitors and inhibitors of growth factors and their receptors, gene therapy agents, cell therapy, or any combination thereof.

a. Combination treatment with MDM2 inhibitors


[0428] Disclosed herein are pharmaceutical compositions comprising a MDM2 inhibitor. Also disclosed herein are methods of treating a condition in a subject in need thereof comprising administering a MDM2 inhibitor. In some embodiments, the MDM2 inhibitor is Nutlin-1, Nutlin-2, Nutlin-3, RG7112 (RO5045337), idasanutlin (RG7388), AMG-232 (KRT-232), APG-115, BI-907828, CGM097, siremadlin (HDM201), SAR405838 (MI-77301), MK-8242 (SCH 900242), RAIN-32, or milademetan (DS-3032b), or a pharmaceutically-acceptable salt of any of the foregoing:




Nutlin-1




Nutlin-2




Nutlin-3




RG7112




Idasanutlin




AMG-232




APG-115




CGM097




siremadlin




SAR405838



MK-8242



milademetan



BI-907828.


[0429] MDM2 inhibitors of the present disclosure also include stereoisomers of MDM2 inhibiting structures disclosed herein, including diastereomers, epimers, and enantiomers thereof. For example, Nutlin-3 includes Nutlin-3a (i.e., ((-)-Nutlin-3), or 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazol-1-yl]-oxomethyl]-2-piperazinone) and Nutlin-3b (i.e., ((+)-Nutlin-3), or 4-[[(4R,5S)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazol-1-yl]-oxomethyl]-2-piperazinone).

b. Combination treatment with PI3K inhibitors

[0430] Disclosed herein are pharmaceutical compositions comprising a PI3K inhibitor. In some embodiments, the PI3K inhibitor is selected from idelalisib, copanlisib, duvelisib, alpelisib, seletalisib, gedatolisib, inavolisib, rigosertib sodium, leniolisib, umbralisib, buparlisib (AN2025), AMG-319, GM -604, acalisib, bimiralisib, GDC-0084, ACP-319, tenalisib,


serabelisib, SF-1126, nemiralisib, fimepinostat, LY-3023414, voxtalisib, dactolisib, eganelisib, parsaclisib, GSK2636771, AZD-8186, and ASN-003. In some embodiments, the PI3K inhibitor is selected from a PI3Kα, PI3Kβ, PI3Kγ, or PI3Kδ inhibitor. Also disclosed herein are methods of treating a condition in a subject in need thereof comprising administering a PI3K110α inhibitor. In some embodiments, the PI3K inhibitor is selected from alpelisib, inavolisib, serabelisib, GSK2636771, eganelisib, idelalisib, or duvelisib.

[0431] In some embodiments, the PI3K inhibitor is:




(inavolisib), or a pharmaceutically-acceptable salt thereof.

[0432] In some embodiments, the PI3K inhibitor is:




(serabelisib), or a pharmaceutically-acceptable salt thereof.

[0433] In some embodiments, the PI3K inhibitor is:




(GSK2636771), or a pharmaceutically-acceptable salt thereof.

[0434] In some embodiments, the PI3K inhibitor is:




(eganelisib), or a pharmaceutically-acceptable salt thereof.

[0435] In some embodiments, the PI3K inhibitor is:




(idelalisib), or a pharmaceutically-acceptable salt thereof.

[0436] In some embodiments, the PI3K inhibitor is:



(duvelisib), or a pharmaceutically-acceptable salt thereof.

[0437] In some embodiments, the PI3K inhibitor is




(alpelisib), or a pharmaceutically-acceptable salt thereof.

c. Combination treatment with AKT inhibitors

[0438] Disclosed herein are pharmaceutical compositions comprising an AKT inhibitor. In some embodiments, the AKT inhibitor is selected from the AKT inhibitor is selected from the group consisting of A6730, B2311, 124018, GSK2110183 (afuresertib), Perifosine (KRX-0401), GDC-0068 (ipatasertib), RX-0201, VQD-002, LY294002, A-443654, A-674563, Akti-1, Akti-2, Akti-1/2, AR-42, API-59CJ-OMe, ATI-13148, AZD-5363, erucylphosphocholine, GSK-2141795 (GSK795), MK2206 (CAS # 1032349-93-1), KP372-1, L-418, NL-71-101, PBI-05204,


PIA5, PX-316, SR13668, triciribine, GSK 690693 (CAS # 937174-76-0), FPA 124 (CAS # 902779-59-3), Miltefosine, capivasertib, PHT-427 (CAS # 1 191951-57-1), 10-DEBC hydrochloride, Akt inhibitor III, Akt inhibitor VIII, MK-2206 dihydrochloride (CAS # 1032350-13-2), SC79, AT7867 (CAS # 857531 -00-1), CCT128930 (CAS # 885499-61-6), A-674563 (CAS # 552325-73-2), AGL 2263, AS-041 164 (5-benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione), BML-257 (CAS # 32387-96-5), XL-418, CAS # 612847-09-3, CAS # 98510-80-6, H-89 (CAS # 127243-85-0), OXY-1 1 1 A, and 3-[1-[[4-(7-phenyl-3H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one. Also disclosed herein are methods of treating a condition in a subject in need thereof comprising administering an AKT inhibitor. In some embodiments, the AKT inhibitor is selected from MK2206, ipatasertib, and capivasertib, or a pharmaceutically-acceptable salt thereof. In some embodiments, the AKT inhibitor is an inhibitor of Akt1.

[0439] In some embodiments, the AKT inhibitor is:




(MK2206), or a pharmaceutically-acceptable salt thereof

[0440] In some embodiments, the AKT inhibitor is:



(ipatasertib), or a pharmaceutically-acceptable salt thereof

[0441] In some embodiments, the AKT inhibitor is:



(capivasertib), or a pharmaceutically-acceptable salt thereof.

Administration of Combination Treatment

[0442] A compound of the disclosure or a pharmaceutical composition comprising a compound of the disclosure and at a MDM2 inhibitor can be administered simultaneously (i.e., simultaneous administration) or sequentially (i.e., sequential administration). A compound of the disclosure or a pharmaceutical composition comprising a compound of the disclosure and a PI3K or AKT inhibitor can be administered simultaneously (i.e., simultaneous administration) or sequentially (i.e., sequential administration).

[0443] In some embodiments, a compound of the disclosure and the MDM2 inhibitor are administered simultaneously, either in the same composition or in separate compositions. When the drugs are administered simultaneously, the compound and the MDM2 inhibitor may be contained in the same composition (*e.g.*, a composition comprising both the compound and MDM2 inhibitor) or in separate compositions (*e.g.*, the compound is contained in one composition and the MDM2 inhibitor is contained in another composition). In some embodiments, a compound of the disclosure and the PI3K or AKT inhibitor are administered simultaneously, either in the same composition or in separate compositions. When the drugs are administered simultaneously, the compound and the PI3K or AKT inhibitor may be contained in the same composition (*e.g.*, a composition comprising both the compound and PI3K or AKT inhibitor) or in separate compositions (*e.g.*, the compound is contained in one composition and the PI3K or AKT inhibitor is contained in another composition).

[0444] In some embodiments, the compound and the MDM2 inhibitor are administered sequentially, *i.e.*, the compound is administered either prior to or after the administration of the additional pharmaceutically-active agent. In some embodiments, the compound is administered before the MDM2 inhibitor. In some embodiments, the MDM2 inhibitor, is administered before the compound. The compound and the MDM2 inhibitor are contained in separate compositions, which may be contained in the same or different packages. In some embodiments, the compound and the PI3K or AKT inhibitor are administered sequentially, *i.e.*, the compound is administered either prior to or after the administration of the additional pharmaceutically-active agent. In some embodiments, the compound is administered before the PI3K or AKT inhibitor. In some embodiments, the PI3K or AKT inhibitor, is administered before the compound. The compound and the PI3K or AKT inhibitor are contained in separate compositions, which may be contained in the same or different packages.

[0445] In some embodiments, the administration of the compounds and the MDM2 inhibitor are concurrent, *i.e.*, the administration period of the compounds and that of the agent overlap with each other. In some embodiments, the administration of the compounds and the MDM2 inhibitor are non-concurrent. For example, in some embodiments, the administration of the compound is

terminated before the MDM2 inhibitor is administered. In some embodiments, the administration of the MDM2 inhibitor is terminated before the compound is administered. The time period between these two non-concurrent administrations can range from being days apart to being weeks apart. In some embodiments, the administration of the compounds and the PI3K or AKT inhibitor are concurrent, *i.e.*, the administration period of the compounds and that of the agent overlap with each other. In some embodiments, the administration of the compounds and the PI3K or AKT inhibitor are non-concurrent. For example, in some embodiments, the administration of the compound is terminated before the PI3K or AKT inhibitor is administered. In some embodiments, the administration of the PI3K or AKT inhibitor is terminated before the compound is administered. The time period between these two non-concurrent administrations can range from being days apart to being weeks apart.

[0446] The dosing frequency of the compound and the MDM2 inhibitor may be adjusted over the course of the treatment, based on the judgment of the administering physician. When administered separately, the compound and the MDM2 inhibitor can be administered at different dosing frequency or intervals. For example, the compound can be administered weekly, while the at least one MDM2 inhibitor can be administered more or less frequently. Or, the compound can be administered twice weekly, while MDM2 inhibitor can be administered more or less frequently. In addition, the compound and the MDM2 inhibitor can be administered using the same route of administration or using different routes of administration. The dosing frequency of the compound and the PI3K or AKT inhibitor may be adjusted over the course of the treatment, based on the judgment of the administering physician. When administered separately, the compound and the PI3K or AKT inhibitor can be administered at different dosing frequency or intervals. For example, the compound can be administered weekly, while the at least one PI3K or AKT inhibitor can be administered more or less frequently. Or, the compound can be administered twice weekly, while PI3K or AKT inhibitor can be administered more or less frequently. In addition, the compound and the PI3K or AKT inhibitor can be administered using the same route of administration or using different routes of administration.

[0447] A therapeutically-effective amount of a compound and/or MDM2 inhibitor for use in therapy can vary with the nature of the condition being treated, the length of treatment time desired, the age and the condition of the patient, and can be determined by the attending physician. A therapeutically-effective amount of a compound and/or PI3K or AKT inhibitor for use in therapy can vary with the nature of the condition being treated, the length of treatment time desired, the age and the condition of the patient, and can be determined by the attending physician.

[0448] In some embodiments, when a compound of the disclosure is administered in combination with the MDM2 inhibitor, the dosage of the compound can be given a lower dosage than when the compound is administered alone. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 5 mg/kg to about 1000 mg/kg; from about 50 mg/kg to about 600 mg/kg; from about 150 mg/kg to about 600 mg/kg; or from about 300 mg/kg to about 600 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 5 mg/kg to about 25 mg/kg; from about 25 mg/kg to about 50 mg/kg; from about 50 mg/kg to about 75 mg/kg; from about 75 mg/kg to about 100 mg/kg; from about 100 mg/kg to about 125 mg/kg; from about 125 mg/kg to about 150 mg/kg; from about 150 mg/kg to about 200 mg/kg; from about 200 mg/kg to about 250 mg/kg; from about 250 mg/kg to about 300 mg/kg; from about 300 mg/kg to about 350 mg/kg; from about 350 mg/kg to about 400 mg/kg; from about 400 mg/kg to about 450 mg/kg; from about 450 mg/kg to about 500 mg/kg; from about 500 mg/kg to about 550 mg/kg; from about 550 mg/kg to about 600 mg/kg; from about 600 mg/kg to about 700 mg/kg; from about 700 mg/kg to about 800 mg/kg; from about 800 mg/kg to about 900 mg/kg; or from about 900 mg/kg to about 1000 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 50 mg/kg to about 75 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 75 mg/kg to about 150 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 150 mg/kg to about 300 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 300 mg/kg to about 600 mg/kg. In some embodiments, when a compound of the disclosure is administered in combination with the PI3K or AKT inhibitor, the dosage of the compound can be given a lower dosage than when the compound is administered alone. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 5 mg/kg to about 1000 mg/kg; from about 50 mg/kg to about 600 mg/kg; from about 150 mg/kg to about 600 mg/kg; or from about 300 mg/kg to about 600 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 5 mg/kg to about 25 mg/kg; from about 25 mg/kg to about 50 mg/kg; from about 50 mg/kg to about 75 mg/kg; from about 75 mg/kg to about 100 mg/kg; from about 100 mg/kg to about 125 mg/kg; from about 125 mg/kg to about 150 mg/kg; from about 150 mg/kg to about 200 mg/kg; from about 200 mg/kg to about 250 mg/kg; from about 250 mg/kg to about 300 mg/kg; from about 300 mg/kg to about 350 mg/kg; from about 350 mg/kg to about 400 mg/kg; from about 400 mg/kg to about 450 mg/kg; from about 450 mg/kg to about 500 mg/kg; from about 500 mg/kg to about 550 mg/kg;

from about 550 mg/kg to about 600 mg/kg; from about 600 mg/kg to about 700 mg/kg; from about 700 mg/kg to about 800 mg/kg; from about 800 mg/kg to about 900 mg/kg; or from about 900 mg/kg to about 1000 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 50 mg/kg to about 75 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 75 mg/kg to about 150 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 150 mg/kg to about 300 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be from about 300 mg/kg to about 600 mg/kg.

[0449] In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 5 mg/kg; about 25 mg/kg; about 50 mg/kg; about 75 mg/kg; about 100 mg/kg; about 125 mg/kg; about 150 mg/kg; about 175 mg/kg; about 200 mg/kg; about 250 mg/kg; about 300 mg/kg; about 350 mg/kg; about 400 mg/kg; about 450 mg/kg; about 500 mg/kg; about 550 mg/kg; about 600 mg/kg; about 700 mg/kg; about 800 mg/kg; about 900 mg/kg; or about 1000 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 50 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 75 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 150 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 300 mg/kg. In some embodiments, the dosage of a compound of the disclosure in combination therapy can be in an amount of about 600 mg/kg.

[0450] In some embodiments, when a compound of the disclosure is administered in combination with an MDM2 inhibitor, the dosage of the MDM2 inhibitor can be given a lower dosage than when the compound is administered alone. In some embodiments, the dosage of the MDM2 inhibitor in combination therapy can be from about 1 mg/kg to about 50 mg/kg; from about 50 mg/kg to about 100 mg/kg; from about 100 mg/kg to about 150 mg/kg; from about 150 mg/kg to about 200 mg/kg; from about 1 mg/kg to about 30 mg/kg; from about 1 mg/kg to about 50 mg/kg; from about 1 mg/kg to about 100 mg/kg; from about 10 mg/kg to about 30 mg/kg; from about 40 mg/kg to about 60 mg/kg; from about 1 mg/kg to about 25 mg/kg; from about 25 mg/kg to about 50 mg/kg; from about 50 mg/kg to about 75 mg/kg; from about 75 mg/kg to about 100 mg/kg; or from about 1 mg/kg to about 200 mg/kg. In some embodiments, the dosage of the MDM2 inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg. In some embodiments, when a compound of the disclosure is administered in combination with

an PI3K or AKT inhibitor, the dosage of the MDM-2 inhibitor can be given a lower dosage than when the compound is administered alone. In some embodiments, the dosage of the PI3K or AKT inhibitor in combination therapy can be from about 1 mg/kg to about 50 mg/kg; from about 50 mg/kg to about 100 mg/kg; from about 100 mg/kg to about 150 mg/kg; from about 150 mg/kg to about 200 mg/kg; from about 1 mg/kg to about 30 mg/kg; from about 1 mg/kg to about 50 mg/kg; from about 1 mg/kg to about 100 mg/kg; from about 10 mg/kg to about 30 mg/kg; from about 40 mg/kg to about 60 mg/kg; from about 1 mg/kg to about 25 mg/kg; from about 25 mg/kg to about 50 mg/kg; from about 50 mg/kg to about 75 mg/kg; from about 75 mg/kg to about 100 mg/kg; or from about 1 mg/kg to about 200 mg/kg. In some embodiments, the dosage of the MDM-2 inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg.

[0451] In some embodiments, the dosage of the MDM2 inhibitor in combination therapy can be in an amount of about 1 mg/kg; about 5 mg/kg; about 10 mg/kg; about 20 mg/kg; about 30 mg/kg; about 40 mg/kg; about 50 mg/kg; about 60 mg/kg; about 70 mg/kg; about 80 mg/kg; about 90 mg/kg; or about 100 mg/kg. In some embodiments, the dosage of the MDM2 inhibitor in combination therapy can be in an amount of about 20 mg/kg. In some embodiments, the dosage of the PI3K or AKT inhibitor in combination therapy can be in an amount of about 1 mg/kg; about 5 mg/kg; about 10 mg/kg; about 20 mg/kg; about 30 mg/kg; about 40 mg/kg; about 50 mg/kg; about 60 mg/kg; about 70 mg/kg; about 80 mg/kg; about 90 mg/kg; or about 100 mg/kg. In some embodiments, the dosage of the PI3K or AKT inhibitor in combination therapy can be in an amount of about 20 mg/kg.

[0452] In some embodiments, the dosage of the MDM2 inhibitor in combination therapy can be from about 1 mg to about 5 mg; from about 5 mg to about 25 mg; from about 25 mg to about 50 mg; from about 50 mg to about 75 mg; from about 75 mg to about 100 mg; from about 100 mg to about 150 mg; from about 150 mg to about 200 mg; from about 200 mg to about 250 mg; from about 250 mg to about 300 mg; from about 300 mg to about 350 mg; from about 350 mg to about 400 mg; from about 400 mg to about 450 mg; from about 450 mg to about 500 mg; from about 500 mg to about 750 mg; from about 750 mg to about 1000 mg; from about 1000 mg to about 1250 mg; from about 750 mg to about 1250 mg; from about 500 mg to about 1500 mg; from about 500 mg to about 2000 mg; or from about 500 mg to about 2500 mg. In some embodiments, the dosage of the PI3K or AKT inhibitor in combination therapy can be from about 1 mg to about 5 mg; from about 5 mg to about 25 mg; from about 25 mg to about 50 mg; from about 50 mg to about 75 mg; from about 75 mg to about 100 mg; from about 100 mg to about 150 mg; from about 150 mg to about 200 mg; from about 200 mg to about 250 mg; from about 250 mg to about 300 mg; from about 300 mg to about 350 mg; from about 350 mg to

about 400 mg; from about 400 mg to about 450 mg; from about 450 mg to about 500 mg; from about 500 mg to about 750 mg; from about 750 mg to about 1000 mg; from about 1000 mg to about 1250 mg; from about 750 mg to about 1250 mg; from about 500 mg to about 1500 mg; from about 500 mg to about 2000 mg; or from about 500 mg to about 2500 mg.

[0453] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 600 mg/kg; and the dosage of the MDM2 inhibitor in combination therapy can be from about 1 mg/kg to about 500 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 150 mg/kg; and the dosage of the MDM2 inhibitor in combination therapy can be from about 1 mg/kg to about 100 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 600 mg/kg; and the dosage of MDM2 inhibitor can be from about 1 mg/kg to about 200 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 600 mg/kg; and the dosage of the PI3K or AKT inhibitor in combination therapy can be from about 1 mg/kg to about 500 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 150 mg/kg; and the dosage of the PI3K or AKT inhibitor in combination therapy can be from about 1 mg/kg to about 100 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 600 mg/kg; and the dosage of PI3K or AKT inhibitor can be from about 1 mg/kg to about 200 mg/kg.

[0454] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 50 mg/kg; and the dosage of MDM2 inhibitor in combination therapy can about 20 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 50 mg/kg; and the dosage of MDM2 inhibitor in combination therapy can about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 100 mg/kg; and the dosage of MDM2 inhibitor in combination therapy can about 20 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 50 mg/kg; and the dosage of MDM2 inhibitor in combination therapy can about 10 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 100 mg/kg; and the dosage of MDM2 inhibitor in combination therapy can about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 50 mg/kg; and

the dosage of PI3K or AKT inhibitor in combination therapy can about 20 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 50 mg/kg; and the dosage of PI3K or AKT inhibitor in combination therapy can about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 100 mg/kg; and the dosage of PI3K or AKT inhibitor in combination therapy can about 20 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 50 mg/kg; and the dosage of PI3K or AKT inhibitor in combination therapy can about 10 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be about 100 mg/kg; and the dosage of PI3K or AKT inhibitor in combination therapy can about 50 mg/kg.

[0455] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 500 mg to about 3000 mg; and the dosage of MDM2 inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 500 mg to about 2000 mg; and the dosage of MDM2 inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 500 mg to about 1500 mg; and the dosage of MDM2 inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 500 mg to about 1000 mg; and the dosage of MDM2 inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 500 mg to about 3000 mg; and the dosage of PI3K or AKT inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 500 mg to about 2000 mg; and the dosage of PI3K or AKT inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 500 mg to about 1500 mg; and the dosage of PI3K or AKT inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 500 mg to about 1000 mg; and the dosage of MDM-2 inhibitor in combination therapy can be from about 10 mg/kg to about 50 mg/kg.

[0456] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 100 mg/kg; and the dosage of an MDM2 inhibitor as an additional pharmaceutically-active agent in combination therapy is about 1000 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 100 mg/kg; and the dosage of an MDM2 inhibitor as an additional pharmaceutically-active agent in combination therapy is about 500 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 50 mg/kg; and the dosage of an MDM2 inhibitor as an additional pharmaceutically-active agent in combination therapy is about 1000 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 50 mg/kg; and the dosage of an MDM2 inhibitor as an additional pharmaceutically-active agent in combination therapy is about 500 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 100 mg/kg; and the dosage of a PI3K or AKT inhibitor as an additional pharmaceutically-active agent in combination therapy is about 1000 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 100 mg/kg; and the dosage of a PI3K or AKT inhibitor as an additional pharmaceutically-active agent in combination therapy is about 500 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 50 mg/kg; and the dosage of a PI3K or AKT inhibitor as an additional pharmaceutically-active agent in combination therapy is about 1000 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy can be from about 10 mg/kg to about 50 mg/kg; and the dosage of a PI3K or AKT inhibitor as an additional pharmaceutically-active agent in combination therapy is about 500 mg.

[0457] In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 50 mg/kg; and the dosage of an MDM2 inhibitor as an additional pharmaceutically-active agent in combination therapy is about 1000 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 100 mg/kg; and the dosage of an MDM2 inhibitor as an additional pharmaceutically-active agent in combination therapy is about 500 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 50 mg/kg; and the dosage of an MDM2 inhibitor as an additional pharmaceutically-active agent in combination therapy is about 500 mg. In some embodiments, the dosage of the compound of the disclosure administered in

combination therapy is about 50 mg/kg; and the dosage of an MDM2 inhibitor as an additional pharmaceutically-active agent in combination therapy is about 200 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 50 mg/kg; and the dosage of an MDM2 inhibitor as an additional pharmaceutically-active agent in combination therapy is about 100 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 50 mg/kg; and the dosage of a PI3K or AKT inhibitor as an additional pharmaceutically-active agent in combination therapy is about 1000 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 100 mg/kg; and the dosage of a PI3K or AKT inhibitor as an additional pharmaceutically-active agent in combination therapy is about 500 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 50 mg/kg; and the dosage of a PI3K or AKT inhibitor as an additional pharmaceutically-active agent in combination therapy is about 500 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 50 mg/kg; and the dosage of a PI3K or AKT inhibitor as an additional pharmaceutically-active agent in combination therapy is about 200 mg. In some embodiments, the dosage of the compound of the disclosure administered in combination therapy is about 50 mg/kg; and the dosage of a PI3K or AKT inhibitor as an additional pharmaceutically-active agent in combination therapy is about 100 mg.

[0458] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject three times a day.

[0459] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day once every 3 days. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day once every 3 days. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 7 days. In some embodiments, a pharmaceutically-acceptable amount of a

compound of the disclosure can be administered to a subject once a day once every 7 days. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day once every 7 days.

[0460] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for 1 to 50 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 5 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 10 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 15 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 20 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 25 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 30 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject 1, 2, 3, 4, or 5 times a day once every 1, 2, 3, 4, 5, 6, or 7 days for about 35 doses.

[0461] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day every 7 days for about 5 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day every 7 days for about 10 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day every 7 days for about 15 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day every 3 days for about 20 doses. In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject once a day every 3 days for about 35 doses.

[0462] In some embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day every 7 days for about 5 doses. In some

embodiments, a pharmaceutically-acceptable amount of a compound of the disclosure can be administered to a subject twice a day every 7 days for about 15 doses.

Pharmaceutical compositions for combination treatment

[0463] According to certain embodiments, the compounds and the additional pharmaceutically-active agent, for example, a MDM2 inhibitor, are administered within a single pharmaceutical composition. In some embodiments, the compounds of the disclosure and the MDM2 inhibitor can be provided in a single unit dosage form for being taken together. According to some embodiments, the pharmaceutical composition further comprises pharmaceutically-acceptable diluents or carrier. According to certain embodiments, the compounds of the disclosure and the MDM2 inhibitor are administered within different pharmaceutical composition. In some embodiments, the compounds of the disclosure and the MDM2 inhibitor can be provided in a single unit dosage as separate entities (e.g., in separate containers) to be administered simultaneously or with a certain time difference.

[0464] In some embodiments, the compounds of the disclosure and the MDM2 inhibitor can be administered via the same route of administration. In some embodiments, the compounds of the disclosure and the MDM2 inhibitor can be administered via the different route of administration. In some embodiments, a compound of the disclosure and MDM2 inhibitor are administered orally. In some embodiments, a compound of the disclosure is administered orally, and the MDM2 inhibitor is not administered orally. In some embodiments, a compound of the disclosure is not administered orally, and the MDM2 inhibitor is administered orally. According to certain embodiments, the compounds and the additional pharmaceutically-active agent, for example, a PI3K or AKT inhibitor, are administered within a single pharmaceutical composition. In some embodiments, the compounds of the disclosure and a PI3K or AKT inhibitor can be provided in a single unit dosage form for being taken together. According to some embodiments, the pharmaceutical composition further comprises pharmaceutically-acceptable diluents or carrier. According to certain embodiments, the compounds of the disclosure and a PI3K or AKT inhibitor are administered within different pharmaceutical composition. In some embodiments, the compounds of the disclosure and a PI3K or AKT inhibitor can be provided in a single unit dosage as separate entities (e.g., in separate containers) to be administered simultaneously or with a certain time difference. In some embodiments, the compounds of the disclosure and a PI3K or AKT inhibitor can be administered via the same route of administration. In some embodiments, the compounds of the disclosure and a PI3K or AKT inhibitor can be administered via the different route of administration. In some embodiments, a compound of the disclosure and a PI3K or AKT inhibitor are administered orally. In some embodiments, a

compound of the disclosure is administered orally, and a PI3K or AKT inhibitor is not administered orally. In some embodiments, a compound of the disclosure is not administered orally, and a PI3K or AKT inhibitor is administered orally.

[0465] Treatment of a condition by administering a compound of the disclosure in combination with an additional anti-cancer agent (e.g., MDM2 inhibitor) can increase a median survival time of a subject compared to subjects who do not receive combination therapy with a compound of the disclosure and the additional anti-cancer agent. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a MDM2 inhibitor can be greater than a median survival time of a second patient population that does not receive any cancer therapy. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a MDM2 inhibitor can be greater than a median survival time of a second patient population that receives therapy with a compound of the disclosure alone. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a MDM2 inhibitor can be greater than a median survival time of a second patient population that receives therapy with the MDM2 inhibitor alone. Treatment of a condition by administering a compound of the disclosure in combination with an additional anti-cancer agent (e.g., a PI3K or AKT inhibitor) can increase a median survival time of a subject compared to subjects who do not receive combination therapy with a compound of the disclosure and the additional anti-cancer agent. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a PI3K or AKT inhibitor can be greater than a median survival time of a second patient population that does not receive any cancer therapy. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a PI3K or AKT inhibitor can be greater than a median survival time of a second patient population that receives therapy with a compound of the disclosure alone. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a PI3K or AKT inhibitor can be greater than a median survival time of a second patient population that receives therapy with a PI3K or AKT inhibitor alone.

[0466] In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a MDM2 inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%,

about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 210%, about 220%, about 230%, about 240%, about 250%, about 260%, about 270%, about 280%, about 290%, about 300%, about 310%, about 320%, about 330%, about 340%, about 350%, about 360%, about 370%, about 380%, about 390%, about 400%, about 410%, about 420%, about 430%, about 440%, about 450%, about 460%, about 470%, about 480%, about 490%, or about 500%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a MDM2 inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 50%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a MDM2 inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 100%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a MDM2 inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 150%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a MDM2 inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 200%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a PI3K or AKT inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 210%, about 220%, about 230%, about 240%, about 250%, about 260%, about 270%, about 280%, about 290%, about 300%, about 310%, about 320%, about 330%, about 340%, about 350%, about 360%, about 370%, about 380%, about 390%, about 400%, about 410%, about 420%, about 430%, about 440%, about 450%, about 460%, about 470%, about 480%, about 490%, or about 500%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a PI3K or AKT inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 50%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a PI3K or AKT inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at

least about 100%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a PI3K or AKT inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 150%. In some embodiments, a median survival time of a first patient population receiving combination therapy with a compound of the disclosure and a PI3K or AKT inhibitor can be greater than a median survival time of a second patient population not receiving combination therapy by at least about 200%.

Methods of treatment

[0467] Provided herein is a method of treating cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound, wherein the compound binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a pathway other than p53-induced apoptosis.

[0468] Also provided herein is a method of treating cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-cancer activity of a mutant p53 protein in the subject; and (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a MDM2 pathway. In some embodiments, the anti-cancer agent that functions through a MDM2 pathway is a MDM2 inhibitor. In some embodiments, the anti-cancer agent that functions through a MDM2 pathway binds a MDM2 protein. Also provided herein is a method of treating cancer in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-cancer activity of a mutant p53 protein in the subject; and (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a PI3K or AKT pathway. In some embodiments, the anti-cancer agent that functions through a MDM-2 pathway is a PI3K or AKT inhibitor. In some embodiments, the anti-cancer agent that functions through a PI3K or AKT pathway binds a PI3K or AKT protein.

[0469] In some embodiments, the compound binds to the mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity.

[0470] Further provided herein is a method of treating cancer, the method comprising: (i) administering to a subject in need thereof a therapeutically-effective amount of a compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (ii) administering to the subject a therapeutically-effective

amount of an additional anti-cancer agent that functions through a pathway other than p53-induced apoptosis (e.g., a MDM2 inhibitor), wherein if in a controlled study of treatment of the cancer in a first patient population and a second patient population: (a) a first median survival time of the first patient population is determined, wherein the first patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity; and (b) a second median survival time of the second patient population is determined, wherein the second patient population is treated with the therapeutically-effective amount of the compound that binds to a mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-cancer activity and the therapeutically-effective amount of the additional therapeutic agent; then the second median survival time is at least about 50% greater than is the first median survival time.


[0471] In some embodiments, the second median survival time is at least about 100% greater than the first median survival time. In some embodiments, the second median survival time is at least about 200% greater than the first median survival time.

[0472] In some embodiments, the compound increases a stability of the mutant p53 protein. In some embodiments, the cancer expresses a mutant p53 protein. In some embodiments, the mutant p53 protein has a mutation at amino acid 220. In some embodiments, the mutant p53 protein is p53 Y220C. In some embodiments, the compound selectively binds the mutant p53 protein as compared to a wild type p53. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is lung cancer. In some embodiments, the subject is human.

[0473] In some embodiments, the administering of the compound is oral. In some embodiments, the administering of the compound is subcutaneous. In some embodiments, the administering of the compound is topical. In some embodiments, the therapeutically-effective amount of the compound is from about 1 mg/kg to about 500 mg/kg. In some embodiments, the therapeutically-effective amount of the compound is from about 100 mg to about 5000 mg. In some embodiments, the therapeutically-effective amount of the compound is from about 500 mg to about 2000 mg. In some embodiments, the therapeutically-effective amount of the compound is about 250 mg, about 500 mg, about 750 mg, about 1000 mg, about 1250 mg, about 1500 mg, about 1750 mg, about 2000 mg, about 2250 mg, or about 2500 mg. In some embodiments, the therapeutically-effective amount of the compound is about 150 mg. In some embodiments, the therapeutically-effective amount of the compound is about 300 mg. In some embodiments, the therapeutically-effective amount of the compound is about 500 mg. In some embodiments, the

therapeutically-effective amount of the compound is about 600 mg. In some embodiments, the therapeutically-effective amount of the compound is about 1200 mg. In some embodiments, the therapeutically-effective amount of the compound is about 1500 mg. In some embodiments, the therapeutically-effective amount of the compound is about 2000 mg.


[0474] In some embodiments, the MDM2 inhibitor is a small molecule. In some embodiments, the MDM2 inhibitor is an antibody. In some embodiments, the MDM2 inhibitor binds MDM2 protein.




[0475] In some embodiments, the MDM2 inhibitor is

(Nutlin-1), or a pharmaceutically-acceptable salt thereof.

[0476] In some embodiments, the MDM2 inhibitor is




(Nutlin-2), or a pharmaceutically-acceptable salt thereof.




[0477] In some embodiments, the MDM2 inhibitor is

(Nutlin-3), or a pharmaceutically-acceptable salt thereof.




[0478] In some embodiments, the MDM2 inhibitor is (Nutlin-3a), or a pharmaceutically-acceptable salt thereof.




[0479] In some embodiments, the MDM2 inhibitor is (Nutlin-3b), or a pharmaceutically-acceptable salt thereof.

[0480] In some embodiments, the MDM2 inhibitor is




(RG7112), or a pharmaceutically-acceptable salt thereof.


[0481] In some embodiments, the MDM2 inhibitor is



(idasanutlin), or a pharmaceutically-acceptable salt thereof.




[0482] In some embodiments, the MDM2 inhibitor is (AMG-232), or a pharmaceutically-acceptable salt thereof.




[0483] In some embodiments, the MDM2 inhibitor is (APG-115), or a pharmaceutically-acceptable salt thereof.

[0484] In some embodiments, the MDM2 inhibitor is




(CGM097), or a pharmaceutically acceptable salt thereof.

[0485] In some embodiments, the MDM2 inhibitor is




(siremadlin), or a pharmaceutically-acceptable salt thereof.

[0486] In some embodiments, the MDM2 inhibitor is




(SAR405838), or a pharmaceutically-acceptable salt thereof.

[0487] In some embodiments, the MDM2 inhibitor is




(MK-8242), or a pharmaceutically-acceptable salt thereof.


[0488] In some embodiments, the MDM2 inhibitor is




(milademetan), or a pharmaceutically-acceptable salt thereof.



[0489] In some embodiments, the MDM2 inhibitor is (BI-907828), or a pharmaceutically-acceptable salt thereof.




[0490] In some embodiments, the MDM2 inhibitor is (Nutlin-1), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.


[0491] In some embodiments, the MDM2 inhibitor is




(Nutlin-2), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.




[0492] In some embodiments, the MDM2 inhibitor is (Nutlin-3), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.




[0493] In some embodiments, the MDM2 inhibitor is (Nutlin-3a), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.




[0494] In some embodiments, the MDM2 inhibitor is (Nutlin-3b), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.

[0495] In some embodiments, the MDM2 inhibitor is




(RG7112), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.


[0496] In some embodiments, the MDM2 inhibitor is




(idasanutlin), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.




[0497] In some embodiments, the MDM2 inhibitor is (AMG-232), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.




[0498] In some embodiments, the MDM2 inhibitor is (APG-115), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.

[0499] In some embodiments, the MDM2 inhibitor is




(CGM097), or a pharmaceutically acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.

[0500] In some embodiments, the MDM2 inhibitor is




(siremadlin), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.


[0501] In some embodiments, the MDM2 inhibitor is




(SAR405838), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.

[0502] In some embodiments, the MDM2 inhibitor is  (MK-8242), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is




(Compound 1), or a pharmaceutically-acceptable salt thereof.


[0503] In some embodiments, the MDM2 inhibitor is




(milademetan), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.



[0504] In some embodiments, the MDM2 inhibitor is (BI-907828), or a pharmaceutically-acceptable salt thereof, and the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.

[0505] In some embodiments, the PI3K inhibitor is alpelisib. In some embodiments, the PI3K inhibitor is inavolisib. In some embodiments, the PI3K inhibitor is serabelisib. In some embodiments, the PI3K inhibitor is GSK263 . In some embodiments, the PI3K inhibitor is eganelisib . In some embodiments, the PI3K inhibitor is idelalisib. In some embodiments, the PI3K inhibitor is duvelisib. In some embodiments, the PI3K inhibitor is ipatasertib. In some embodiments, the PI3K inhibitor is capivasertib.

[0506] In some embodiments, the AKT inhibitor is MK2206. In some embodiments, the AKT inhibitor is ipatasertib.

[0507] In some embodiments, the administering of the anti-cancer agent is oral. In some embodiments, the administering of the anti-cancer agent is subcutaneous. In some embodiments, the administering of the anti-cancer agent is topical. In some embodiments, the therapeutically-effective amount of the anti-cancer agent is from about 5 mg/kg to about 100 mg/kg. In some embodiments, the therapeutically-effective amount of the anti-cancer agent is from about 10 mg to about 1500 mg. In some embodiments, the therapeutically-effective amount of the anti-cancer agent is about 1000 mg.

[0508] Pharmacokinetic and pharmacodynamic data can be obtained by various experimental techniques. Appropriate pharmacokinetic and pharmacodynamic profile components describing a particular composition can vary due to variations in drug metabolism in human subjects. Pharmacokinetic and pharmacodynamic profiles can be based on the determination of the mean parameters of a group of subjects. The group of subjects includes any reasonable number of subjects suitable for determining a representative mean, for example, 5 subjects, 10 subjects, 15 subjects, 20 subjects, 25 subjects, 30 subjects, 35 subjects, or more. The mean is determined, for example, by calculating the average of all subject's measurements for each parameter measured. A dose can be modulated to achieve a desired pharmacokinetic or pharmacodynamics profile, such as a desired or effective blood profile, as described herein.

[0509] The pharmacodynamic parameters can be any parameters suitable for describing compositions of the invention. For example, the pharmacodynamic profile can be obtained at a time after dosing of, for example, about zero minutes, about 1 minute, about 2 minutes, about 3

minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 14 minutes, about 15 minutes, about 16 minutes, about 17 minutes, about 18 minutes, about 19 minutes, about 20 minutes, about 21 minutes, about 22 minutes, about 23 minutes, about 24 minutes, about 25 minutes, about 26 minutes, about 27 minutes, about 28 minutes, about 29 minutes, about 30 minutes, about 31 minutes, about 32 minutes, about 33 minutes, about 34 minutes, about 35 minutes, about 36 minutes, about 37 minutes, about 38 minutes, about 39 minutes, about 40 minutes, about 41 minutes, about 42 minutes, about 43 minutes, about 44 minutes, about 45 minutes, about 46 minutes, about 47 minutes, about 48 minutes, about 49 minutes, about 50 minutes, about 51 minutes, about 52 minutes, about 53 minutes, about 54 minutes, about 55 minutes, about 56 minutes, about 57 minutes, about 58 minutes, about 59 minutes, about 60 minutes, about zero hours, about 0.5 hours, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, about 12 hours, about 12.5 hours, about 13 hours, about 13.5 hours, about 14 hours, about 14.5 hours, about 15 hours, about 15.5 hours, about 16 hours, about 16.5 hours, about 17 hours, about 17.5 hours, about 18 hours, about 18.5 hours, about 19 hours, about 19.5 hours, about 20 hours, about 20.5 hours, about 21 hours, about 21.5 hours, about 22 hours, about 22.5 hours, about 23 hours, about 23.5 hours, or about 24 hours.

[0510] The pharmacokinetic parameters can be any parameters suitable for describing a compound. The C_{max} can be, for example, not less than about 1 ng/mL; not less than about 5 ng/mL; not less than about 10 ng/mL; not less than about 15 ng/mL; not less than about 20 ng/mL; not less than about 25 ng/mL; not less than about 50 ng/mL; not less than about 75 ng/mL; not less than about 100 ng/mL; not less than about 200 ng/mL; not less than about 300 ng/mL; not less than about 400 ng/mL; not less than about 500 ng/mL; not less than about 600 ng/mL; not less than about 700 ng/mL; not less than about 800 ng/mL; not less than about 900 ng/mL; not less than about 1000 ng/mL; not less than about 1250 ng/mL; not less than about 1500 ng/mL; not less than about 1750 ng/mL; not less than about 2000 ng/mL; or any other C_{max} appropriate for describing a pharmacokinetic profile of a compound described herein. The C_{max} can be, for example, about 1 ng/mL to about 5,000 ng/mL; about 1 ng/mL to about 4,500 ng/mL; about 1 ng/mL to about 4,000 ng/mL; about 1 ng/mL to about 3,500 ng/mL; about 1 ng/mL to about 3,000 ng/mL; about 1 ng/mL to about 2,500 ng/mL; about 1 ng/mL to about 2,000 ng/mL; about 1 ng/mL to about 1,500 ng/mL; about 1 ng/mL to about 1,000 ng/mL; about 1 ng/mL to

about 900 ng/mL; about 1 ng/mL to about 800 ng/mL; about 1 ng/mL to about 700 ng/mL; about 1 ng/mL to about 600 ng/mL; about 1 ng/mL to about 500 ng/mL; about 1 ng/mL to about 450 ng/mL; about 1 ng/mL to about 400 ng/mL; about 1 ng/mL to about 350 ng/mL; about 1 ng/mL to about 300 ng/mL; about 1 ng/mL to about 250 ng/mL; about 1 ng/mL to about 200 ng/mL; about 1 ng/mL to about 150 ng/mL; about 1 ng/mL to about 125 ng/mL; about 1 ng/mL to about 100 ng/mL; about 1 ng/mL to about 90 ng/mL; about 1 ng/mL to about 80 ng/mL; about 1 ng/mL to about 70 ng/mL; about 1 ng/mL to about 60 ng/mL; about 1 ng/mL to about 50 ng/mL; about 1 ng/mL to about 40 ng/mL; about 1 ng/mL to about 30 ng/mL; about 1 ng/mL to about 20 ng/mL; about 1 ng/mL to about 10 ng/mL; about 1 ng/mL to about 5 ng/mL; about 10 ng/mL to about 4,000 ng/mL; about 10 ng/mL to about 3,000 ng/mL; about 10 ng/mL to about 2,000 ng/mL; about 10 ng/mL to about 1,500 ng/mL; about 10 ng/mL to about 1,000 ng/mL; about 10 ng/mL to about 900 ng/mL; about 10 ng/mL to about 800 ng/mL; about 10 ng/mL to about 700 ng/mL; about 10 ng/mL to about 600 ng/mL; about 10 ng/mL to about 500 ng/mL; about 10 ng/mL to about 400 ng/mL; about 10 ng/mL to about 300 ng/mL; about 10 ng/mL to about 200 ng/mL; about 10 ng/mL to about 100 ng/mL; about 10 ng/mL to about 50 ng/mL; about 25 ng/mL to about 500 ng/mL; about 25 ng/mL to about 100 ng/mL; about 50 ng/mL to about 500 ng/mL; about 50 ng/mL to about 100 ng/mL; about 100 ng/mL to about 500 ng/mL; about 100 ng/mL to about 400 ng/mL; about 100 ng/mL to about 300 ng/mL; or about 100 ng/mL to about 200 ng/mL.

[0511] The T_{max} of a compound described herein can be, for example, not greater than about 0.5 hours, not greater than about 1 hours, not greater than about 1.5 hours, not greater than about 2 hours, not greater than about 2.5 hours, not greater than about 3 hours, not greater than about 3.5 hours, not greater than about 4 hours, not greater than about 4.5 hours, not greater than about 5 hours, or any other T_{max} appropriate for describing a pharmacokinetic profile of a compound described herein. The T_{max} can be, for example, about 0.1 hours to about 24 hours; about 0.1 hours to about 0.5 hours; about 0.5 hours to about 1 hour; about 1 hour to about 1.5 hours; about 1.5 hours to about 2 hour; about 2 hours to about 2.5 hours; about 2.5 hours to about 3 hours; about 3 hours to about 3.5 hours; about 3.5 hours to about 4 hours; about 4 hours to about 4.5 hours; about 4.5 hours to about 5 hours; about 5 hours to about 5.5 hours; about 5.5 hours to about 6 hours; about 6 hours to about 6.5 hours; about 6.5 hours to about 7 hours; about 7 hours to about 7.5 hours; about 7.5 hours to about 8 hours; about 8 hours to about 8.5 hours; about 8.5 hours to about 9 hours; about 9 hours to about 9.5 hours; about 9.5 hours to about 10 hours; about 10 hours to about 10.5 hours; about 10.5 hours to about 11 hours; about 11 hours to about 11.5 hours; about 11.5 hours to about 12 hours; about 12 hours to about 12.5 hours; about 12.5

hours to about 13 hours; about 13 hours to about 13.5 hours; about 13.5 hours to about 14 hours; about 14 hours to about 14.5 hours; about 14.5 hours to about 15 hours; about 15 hours to about 15.5 hours; about 15.5 hours to about 16 hours; about 16 hours to about 16.5 hours; about 16.5 hours to about 17 hours; about 17 hours to about 17.5 hours; about 17.5 hours to about 18 hours; about 18 hours to about 18.5 hours; about 18.5 hours to about 19 hours; about 19 hours to about 19.5 hours; about 19.5 hours to about 20 hours; about 20 hours to about 20.5 hours; about 20.5 hours to about 21 hours; about 21 hours to about 21.5 hours; about 21.5 hours to about 22 hours; about 22 hours to about 22.5 hours; about 22.5 hours to about 23 hours; about 23 hours to about 23.5 hours; or about 23.5 hours to about 24 hours. In some embodiments, the T_{max} of a compound of the disclosure is about 2 hours. In some embodiments, the T_{max} of a compound of the disclosure is about 4 hours. In some embodiments, the T_{max} of a compound of the disclosure is about 6 hours. In some embodiments, the T_{max} of a compound of the disclosure is about 8 hours.

[0512] The $AUC_{(0\text{-}inf)}$ or $AUC_{(last)}$ of a compound described herein can be, for example, not less than about 1 ng•hr/mL, not less than about 5 ng•hr/mL, not less than about 10 ng•hr/mL, not less than about 20 ng•hr/mL, not less than about 30 ng•hr/mL, not less than about 40 ng•hr/mL, not less than about 50 ng•hr/mL, not less than about 100 ng•hr/mL, not less than about 150 ng•hr/mL, not less than about 200 ng•hr/mL, not less than about 250 ng•hr/mL, not less than about 300 ng•hr/mL, not less than about 350 ng•hr/mL, not less than about 400 ng•hr/mL, not less than about 450 ng•hr/mL, not less than about 500 ng•hr/mL, not less than about 600 ng•hr/mL, not less than about 700 ng•hr/mL, not less than about 800 ng•hr/mL, not less than about 900 ng•hr/mL, not less than about 1000 ng•hr/mL, not less than about 1250 ng•hr/mL, not less than about 1500 ng•hr/mL, not less than about 1750 ng•hr/mL, not less than about 2000 ng•hr/mL, not less than about 2500 ng•hr/mL, not less than about 3000 ng•hr/mL, not less than about 3500 ng•hr/mL, not less than about 4000 ng•hr/mL, not less than about 5000 ng•hr/mL, not less than about 6000 ng•hr/mL, not less than about 7000 ng•hr/mL, not less than about 8000 ng•hr/mL, not less than about 9000 ng•hr/mL, not less than about 10,000 ng•hr/mL, or any other $AUC_{(0\text{-}inf)}$ or $AUC_{(last)}$ appropriate for describing a pharmacokinetic profile of a compound described herein. In some embodiments, the $AUC_{(0\text{-}inf)}$ or $AUC_{(last)}$ of a compound described herein can be, for example, not less than about 10,000 ng•hr/mL, not less than about 11,000 ng•hr/mL, not less than about 12,000 ng•hr/mL, not less than about 13,000 ng•hr/mL, not less than about 14,000 ng•hr/mL, not less than about 15,000 ng•hr/mL, not less than about 16,000 ng•hr/mL, not less than about 17,000 ng•hr/mL, not less than about 18,000 ng•hr/mL, not less than about 19,000 ng•hr/mL, not less than about 20,000 ng•hr/mL, not less than about 21,000

ng•hr/mL, not less than about 22,000 ng•hr/mL, not less than about 23,000 ng•hr/mL, not less than about 24,000 ng•hr/mL, or not less than about 25,000 ng•hr/mL.

[0513] The $AUC_{(0\text{-}inf)}$ or $AUC_{(last)}$ of a compound can be, for example, about 1 ng•hr/mL to about 10,000 ng•hr/mL; about 1 ng•hr/mL to about 10 ng•hr/mL; about 10 ng•hr/mL to about 25 ng•hr/mL; about 25 ng•hr/mL to about 50 ng•hr/mL; about 50 ng•hr/mL to about 100 ng•hr/mL; about 100 ng•hr/mL to about 200 ng•hr/mL; about 200 ng•hr/mL to about 300 ng•hr/mL; about 300 ng•hr/mL to about 400 ng•hr/mL; about 400 ng•hr/mL to about 500 ng•hr/mL; about 500 ng•hr/mL to about 600 ng•hr/mL; about 600 ng•hr/mL to about 700 ng•hr/mL; about 700 ng•hr/mL to about 800 ng•hr/mL; about 800 ng•hr/mL to about 900 ng•hr/mL; about 900 ng•hr/mL to about 1,000 ng•hr/mL; about 1,000 ng•hr/mL to about 1,250 ng•hr/mL; about 1,250 ng•hr/mL to about 1,500 ng•hr/mL; about 1,500 ng•hr/mL to about 1,750 ng•hr/mL; about 1,750 ng•hr/mL to about 2,000 ng•hr/mL; about 2,000 ng•hr/mL to about 2,500 ng•hr/mL; about 2,500 ng•hr/mL to about 3,000 ng•hr/mL; about 3,000 ng•hr/mL to about 3,500 ng•hr/mL; about 3,500 ng•hr/mL to about 4,000 ng•hr/mL; about 4,000 ng•hr/mL to about 4,500 ng•hr/mL; about 4,500 ng•hr/mL to about 5,000 ng•hr/mL; about 5,000 ng•hr/mL to about 5,500 ng•hr/mL; about 5,500 ng•hr/mL to about 6,000 ng•hr/mL; about 6,000 ng•hr/mL to about 6,500 ng•hr/mL; about 6,500 ng•hr/mL to about 7,000 ng•hr/mL; about 7,000 ng•hr/mL to about 7,500 ng•hr/mL; about 7,500 ng•hr/mL to about 8,000 ng•hr/mL; about 8,000 ng•hr/mL to about 8,500 ng•hr/mL; about 8,500 ng•hr/mL to about 9,000 ng•hr/mL; about 9,000 ng•hr/mL to about 9,500 ng•hr/mL; or about 9,500 ng•hr/mL to about 10,000 ng•hr/mL. In some embodiments, the $AUC_{(0\text{-}inf)}$ or $AUC_{(last)}$ of a compound described herein can be, for example, about 10,000 ng•hr/mL, about 11,000 ng•hr/mL, about 12,000 ng•hr/mL, about 13,000 ng•hr/mL, about 14,000 ng•hr/mL, about 15,000 ng•hr/mL, about 16,000 ng•hr/mL, about 17,000 ng•hr/mL, about 18,000 ng•hr/mL, about 19,000 ng•hr/mL, about 20,000 ng•hr/mL, about 21,000 ng•hr/mL, about 22,000 ng•hr/mL, about 23,000 ng•hr/mL, about 24,000 ng•hr/mL, or about 25,000 ng•hr/mL.

[0514] The plasma concentration of a compound described herein can be, for example, not less than about 1 ng/mL, not less than about 5 ng/mL, not less than about 10 ng/mL, not less than about 15 ng/mL, not less than about 20 ng/mL, not less than about 25 ng/mL, not less than about 50 ng/mL, not less than about 75 ng/mL, not less than about 100 ng/mL, not less than about 150 ng/mL, not less than about 200 ng/mL, not less than about 300 ng/mL, not less than about 400 ng/mL, not less than about 500 ng/mL, not less than about 600 ng/mL, not less than about 700 ng/mL, not less than about 800 ng/mL, not less than about 900 ng/mL, not less than about 1000 ng/mL, not less than about 1200 ng/mL, or any other plasma concentration of a compound described herein. The plasma concentration can be, for example, about 1 ng/mL to about 2,000

ng/mL; about 1 ng/mL to about 5 ng/mL; about 5 ng/mL to about 10 ng/mL; about 10 ng/mL to about 25 ng/mL; about 25 ng/mL to about 50 ng/mL; about 50 ng/mL to about 75 ng/mL; about 75 ng/mL to about 100 ng/mL; about 100 ng/mL to about 150 ng/mL; about 150 ng/mL to about 200 ng/mL; about 200 ng/mL to about 250 ng/mL; about 250 ng/mL to about 300 ng/mL; about 300 ng/mL to about 350 ng/mL; about 350 ng/mL to about 400 ng/mL; about 400 ng/mL to about 450 ng/mL; about 450 ng/mL to about 500 ng/mL; about 500 ng/mL to about 600 ng/mL; about 600 ng/mL to about 700 ng/mL; about 700 ng/mL to about 800 ng/mL; about 800 ng/mL to about 900 ng/mL; about 900 ng/mL to about 1,000 ng/mL; about 1,000 ng/mL to about 1,100 ng/mL; about 1,100 ng/mL to about 1,200 ng/mL; about 1,200 ng/mL to about 1,300 ng/mL; about 1,300 ng/mL to about 1,400 ng/mL; about 1,400 ng/mL to about 1,500 ng/mL; about 1,500 ng/mL to about 1,600 ng/mL; about 1,600 ng/mL to about 1,700 ng/mL; about 1,700 ng/mL to about 1,800 ng/mL; about 1,800 ng/mL to about 1,900 ng/mL; or about 1,900 ng/mL to about 2,000 ng/mL.

[0515] In some embodiments, the plasma concentration can be about 2,500 ng/mL, about 3,000 ng/mL, about 3,500 ng/mL, about 4,000 ng/mL, about 4,500 ng/mL, about 5,000 ng/mL, about 5,500 ng/mL, about 6,000 ng/mL, about 6,500 ng/mL, about 7,000 ng/mL, about 7,500 ng/mL, about 8,000 ng/mL, about 8,500 ng/mL, about 9,000 ng/mL, about 9,500 ng/mL, or about 10,000 ng/mL. In some embodiments, the plasma concentration can be about 10,000 ng/mL, about 15,000 ng/mL, about 20,000 ng/mL, about 25,000 ng/mL, about 30,000 ng/mL, about 35,000 ng/mL, about 40,000 ng/mL, about 45,000 ng/mL, about 50,000 ng/mL, about 55,000 ng/mL, about 60,000 ng/mL, about 65,000 ng/mL, about 70,000 ng/mL, or about 75,000 ng/mL.

[0516] The pharmacodynamic parameters can be any parameters suitable for describing compositions of the disclosure. For example, the pharmacodynamic profile can exhibit decreases in viability phenotype for the tumor cells or tumor size reduction in tumor cell lines or xenograft studies, for example, about 24 hours, about 48 hours, about 72 hours, or 1 week.

NUMBERED EMBODIMENTS

[0517] Embodiment 1. A method of treating a solid tumor in a subject in need thereof, the method comprising:

(i) administering to the subject a therapeutically-effective amount of a compound that increases anti-tumor activity of a mutant p53 protein in the subject; and

(ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a MDM2 pathway.

[0518] Embodiment 2. The method of embodiment 1, wherein the compound binds to the mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-tumor activity.

[0519] Embodiment 3. The method of embodiment 1 or embodiment 2, wherein the compound increases a stability of the mutant p53 protein.

[0520] Embodiment 4. The method of any one of embodiments 1-3, wherein the solid tumor expresses the mutant p53 protein.

[0521] Embodiment 5. The method of any one of embodiments 1-4, wherein the mutant p53 protein has a mutation at amino acid 220.

[0522] Embodiment 6. The method of any one of embodiments 1-4, wherein the mutant p53 protein is p53 Y220C.

[0523] Embodiment 7. The method of any one of embodiments 1-5, wherein the compound selectively binds the mutant p53 protein as compared to a wild type p53.

[0524] Embodiment 8. The method of any one of embodiments 1-6, wherein the solid tumor is selected from small cell lung cancer, pancreatic cancer, prostate cancer, breast cancer, endometrial cancer, and ovarian cancer.


[0525] Embodiment 9. The method of any one of embodiments 1-7, wherein the therapeutically-effective amount of the compound is from about 500 mg to about 3000 mg.

[0526] Embodiment 10. The method of any one of embodiments 1-8, wherein the subject is human.

[0527] Embodiment 11. The method of any one of embodiments 1-9, wherein the anti-cancer agent that functions through the MDM2 pathway is an MDM2 inhibitor.


[0528] Embodiment 12. The method of embodiment 11, wherein the MDM2 inhibitor is a small molecule.

[0529] Embodiment 13. The method of embodiment 11 or embodiment 12, wherein the MDM2 inhibitor is a compound, or a pharmaceutically-acceptable salt thereof, wherein the compound is selected from:




(Nutlin-1)

,,




(Nutlin-2)




(Nutlin-3)

,




(RG7112)

,




(Idasanutlin)

,




(AMG-232)


,




(APG-115),




(CGM097),




(siremadlin),




(SAR405838),



(MK-8242),




(milademetan), and



(BI-907828).

[0530] Embodiment 14. The method of any one of embodiments 11-13, wherein the therapeutically-effective amount of the MDM2 inhibitor is from about 5 mg/kg to about 500 mg/kg.

[0531] Embodiment 15. The method of any one of embodiments 1-14, wherein the compound that increases anti-tumor activity of the mutant p53 protein is of the formula:



, or a pharmaceutically-acceptable salt thereof,

wherein:

- J is a cyclic group that is substituted or unsubstituted;
- R^1 is alkyl or alkenyl, each of which is unsubstituted or substituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, or -$C(O)NR^{16}R^{17}$;
- R^{16} and R^{17} are each independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- R^2 is substituted or unsubstituted alkyl; and
- R^3 is H.

[0532] Embodiment 16. The method of embodiment 15, wherein J is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted.


[0533] Embodiment 17. The method of any embodiment 15 or embodiment 16, wherein J is unsubstituted or substituted heterocyclyl.

[0534] Embodiment 18. The method of any one of embodiments 15-17, wherein R^2 is substituted ethyl.

[0535] Embodiment 19. The method of any one of embodiments 15-17, wherein R^2 is trifluoroethyl.

[0536] Embodiment 20. The method of any one of embodiments 15-19, wherein R^1 is alkyl substituted with $NR^{16}R^{17}$; and each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.

[0537] Embodiment 21. The method of any one of embodiments 15-17, wherein the compound that increases anti-tumor activity of the mutant p53 protein is of the formula:



,

or a pharmaceutically-acceptable salt thereof.


[0538] Embodiment 22. The method of any one of embodiments 15-21, wherein R^3 is H; J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted; and each of R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted, or H.

[0539] Embodiment 23. The method of any one of embodiments 15-22, wherein R^{16} is hydrogen or alkyl.

[0540] Embodiment 24. The method of any one of embodiments 15-23, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0541] Embodiment 25. The method of any one of embodiments 15-24, wherein R^{17} is phenyl substituted with a sulfoxide group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, or heterocyclyl, each of which is independently substituted or unsubstituted, or halo or cyano.

[0542] Embodiment 26. The method of any one of embodiments 1-25, wherein the compound that increases anti-tumor activity of the mutant p53 protein is




, or a pharmaceutically-acceptable salt thereof.

[0543] Embodiment 27. A combination of a compound that increases anti-tumor activity of a mutant p53 protein in the subject; and an MDM2 inhibitor.

[0544] Embodiment 28. The combination of embodiment 27, wherein the compound that increases anti-tumor activity of the mutant p53 protein is contained in a first unit dosage form, and the MDM2 inhibitor is contained in a second unit dosage form.

[0545] Embodiment 29. The combination of embodiment 27 or embodiment 28, wherein the mutant p53 protein is p53 Y220C.

[0546] Embodiment 30. The combination of any one of embodiments 27-29, wherein the compound is of the formula:



wherein R^3 is H; J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted; and each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or H.

[0547] Embodiment 31. The combination of embodiment 30, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.


[0548] Embodiment 32. The combination of embodiment 30 or embodiment 31, wherein R^{16} is hydrogen or alkyl.

[0549] Embodiment 33. The combination of any one of embodiments 30-32, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.


[0550] Embodiment 34. The combination of any one of embodiments 30-33, wherein R^{17} is substituted aryl.

[0551] Embodiment 35. The combination of any one of embodiments 30-34, wherein R^{17} is phenyl substituted with a sulfoxide group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, or heterocyclyl, each of which is independently substituted or unsubstituted, or halo or cyano.


[0552] Embodiment 36. The combination of any one of embodiments 27-35, wherein the MDM2 inhibitor is selected from:




(Nutlin-1)




(Nutlin-2)




(Nutlin-3)




(RG7112)




(Idasanutlin)




(AMG-232)




(APG-115),




(CGM097),




(siremadlin),




(SAR405838),



(MK-8242),




(milademetan), and



(BI-907828),

or a pharmaceutically-acceptable salt thereof.


[0553] Embodiment 37. The combination of any one of embodiments 30-36, wherein the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.

[0554] Embodiment 38. A method of treating a solid tumor in a subject in need thereof, the method comprising:

(i) administering to the subject a therapeutically-effective amount of a compound that increases anti-tumor activity of a mutant p53 protein in the subject, wherein the compound is of the formula:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each Z is independently $-Q^1-N(R^3)J$, $-Q^1-O-J$, or $-Q^1-J$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- A is a linking group;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- each J is independently a cyclic group;
- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is

independently substituted or unsubstituted, or -C(O)R^{16}, -C(O)OR^{16}, -C(O)N$R^{16}R^{17}$, -OR^{16}, -SR^{16}, -N$R^{16}R^{17}$, -NR^{16}C(O)R^{16}, -OC(O)R^{16}, C=O, C=S, -CN, -Si$R^{16}R^{17}R^{18}$, or hydrogen;

- each R^3 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R^{19}, -C(O)OR^{19}, -C(O)N$R^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen, or R^3 and J together with the nitrogen atom to which R^3 and J are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R^{21}, -C(O)OR^{21}, -C(O)N$R^{21}R^{22}$, -OR^{21}, -SR^{21}, -N$R^{21}R^{22}$, -NR^{21}C(O)R^{22}, -OC(O)R^{21}, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or C(O)R^{23}, -C(O)OR^{23}, -C(O)N$R^{23}R^{24}$, -OR^{23}, -SR^{23}, -N$R^{23}R^{24}$, -NR^{23}C(O)R^{24}, -OC(O)R^{23}, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof; and

(ii) administering to the subject a therapeutically-effective amount of a PI3K inhibitor.

[0555] Embodiment 39. The method of embodiment 38, wherein the PI3K inhibitor is alpelisib, or a pharmaceutically-acceptable salt thereof.

[0556] Embodiment 40. The method of embodiment 38, wherein the PI3K inhibitor is inavolisib, or a pharmaceutically-acceptable salt thereof.

[0557] Embodiment 41. The method of embodiment 38, wherein the PI3K inhibitor is serabelisib, or a pharmaceutically-acceptable salt thereof.


[0558] Embodiment 42. The method of embodiment 38, wherein the PI3K inhibitor is GSK2636771, or a pharmaceutically-acceptable salt thereof.

[0559] Embodiment 43. The method of embodiment 38, wherein the PI3K inhibitor is eganelisib, or a pharmaceutically-acceptable salt thereof.

[0560] Embodiment 44. The method of embodiment 38, wherein the PI3K inhibitor is idelalisib, or a pharmaceutically-acceptable salt thereof.

[0561] Embodiment 45. The method of embodiment 38, wherein the PI3K inhibitor is duvelisib, or a pharmaceutically-acceptable salt thereof.

[0562] Embodiment 46. The method of any one of embodiments 38-45, wherein the compound that increases anti-tumor activity of a mutant p53 protein is of the formula:



wherein R^3 is H; J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted; and each R^{16} and R^{17} is independently H, or alkyl, alkenyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0563] Embodiment 47. The method of embodiment 46, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.


[0564] Embodiment 48. The method of embodiment 46 or embodiment 47, wherein R^{16} is hydrogen or alkyl.

[0565] Embodiment 49. The method of any one of embodiments 46-48, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0566] Embodiment 50. The method of any one of embodiments 46-49, wherein R^{17} is substituted aryl.

[0567] Embodiment 51. The method of any one of embodiments 46-50, wherein R^{17} is phenyl substituted with a sulfoxide group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, or heterocyclyl, each of which is independently substituted or unsubstituted, or halo or cyano.


[0568] Embodiment 52. The method of any one of embodiments 38-48, wherein the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.

[0569] Embodiment 53. A method of treating a solid tumor in a subject in need thereof, the method comprising:

(i) administering to the subject a therapeutically-effective amount of a compound that increases anti-tumor activity of a mutant p53 protein in the subject, wherein the compound is of the formula:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each Z is independently $-Q^1-N(R^3)J$, $-Q^1-O-J$, or $-Q^1-J$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- A is a linking group;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- each J is independently a cyclic group;
- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, C=O, C=S, -CN, $-SiR^{16}R^{17}R^{18}$, or

hydrogen;

- each R^3 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and J together with the nitrogen atom to which R^3 and J are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof; and


(ii) administering to the subject a therapeutically-effective amount of a AKT inhibitor selected from MK2206, ipatasertib, and capivasertib.

[0570] Embodiment 54. The method of embodiment 53, wherein the AKT inhibitor is MK2206, or a pharmaceutically-acceptable salt thereof.

[0571] Embodiment 55. The method of embodiment 53, wherein the AKT inhibitor is ipatasertib, or a pharmaceutically-acceptable salt thereof.

[0572] Embodiment 56. The method of embodiment 53, wherein the AKT inhibitor is capivasertib, or a pharmaceutically-acceptable salt thereof.

[0573] Embodiment 57. The method of any one of embodiments 53-56, wherein the compound is of the formula:



wherein R^3 is H; J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted; and each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted, or unsubstituted, or H.

[0574] Embodiment 58. The method of embodiment 57, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.


[0575] Embodiment 59. The method of embodiment 57 or embodiment 58, wherein R^{16} is hydrogen or alkyl.

[0576] Embodiment 60. The method of any one of embodiments 57-59, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

[0577] Embodiment 61. The method of any one of embodiments 57-60, wherein R^{17} is substituted aryl.

[0578] Embodiment 62. The method of any one of embodiments 57-61, wherein R^{17} is phenyl substituted 1, 2, 3, or 4 groups each independently selected from a sulfoxide group, carbamoyl group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, and heterocyclyl, each of which is independently substituted or unsubstituted, or halo or cyano.

[0579] Embodiment 63. The method of any one of embodiments 53-62, wherein the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.

EXAMPLES

EXAMPLE 1: *Compounds of the disclosure*

[0580] Indole compounds with alkynyl, aryl, and heteroaryl linkers were prepared. Alkynyl-linked indole compounds are shown in **TABLE 1**. Aryl-linked indole compounds are shown in **TABLE 2**. Heteroaryl-linked indole compounds are shown in **TABLE 3**.

TABLE 1. Alkynyl indole compounds of the disclosure.

Mol #	IUPAC name
1.	1-Anilino-3-{1-ethyl-5-[(1-methyl-4-piperidylamino)methyl]-1H-indol-2-yl}-2-propyne
2.	1-Anilino-3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}-2-propyne
3.	1-Anilino-3-{1-ethyl-5-[(tetrahydro-2H-pyran-4-ylamino)methyl]-1H-indol-2-yl}-2-propyne
4.	1-Anilino-3-[5-(benzylaminomethyl)-1-ethyl-1H-indol-2-yl]-2-propyne
5.	3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}-1-(p-fluorophenylamino)-2-propyne
6.	3-{1-Ethyl-5-[(tetrahydro-2H-pyran-4-ylmino)methyl]-1H-indol-2-yl}-1-(p-fluorophenylamino)-2-propyne
7.	1-(p-Chlorophenylamino)-3-{1-ethyl-5-[(1-methyl-4-piperidylamino)methyl]-1H-indol-2-yl}-2-propyne
8.	3-{1-Ethyl-5-[(tetrahydro-2H-pyran-4-ylamino)methyl]-1H-indol-2-yl}-1-(6-methyl-3-pyridylamino)-2-propyne
9.	3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}-1-(6-methyl-3-pyridylamino)-2-propyne
10.	3-{1-Ethyl-5-[(1-methyl-4-piperidylamino)methyl]-1H-indol-2-yl}-1-(2-methyl-4-pyridylamino)-2-propyne
11.	3-[5-(Benzylaminomethyl)-1-ethyl-1H-indol-2-yl]-1-(2-methyl-4-pyridylamino)-2-propyne
12.	N-(3-{5-[(Diethylamino)methyl]-1-ethyl-1H-indol-2-yl}prop-2-yn-1-yl)aniline
13.	4-Chloro-N-(3-{5-[(diethylamino)methyl]-1-ethyl-1H-indol-2-yl}prop-2-yn-1-yl)aniline
14.	N-({1-Ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-5-yl}methyl)oxetan-3-amine
15.	N-[3-(1-Ethyl-5-{[(2-methylpropyl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]aniline
16.	N-[3-(1-Ethyl-5-{[(2-methoxyethyl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]aniline
17.	N-({1-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-5-yl}methyl)-1-methanesulfonylpiperidin-4-amine
18.	N-(3-{1-Ethyl-5-[(ethylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)aniline
19.	N-{3-[5-({[2-(Dimethylamino)ethyl]amino}methyl)-1-ethyl-1H-indol-2-yl]prop-2-yn-1-yl}aniline
20.	6-*tert*-Butyl-N-[3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine

Mol #	IUPAC name
21.	N-[(2-{3-[(4-Chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]oxan-4-amine
22.	6-*tert*-Butyl-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)pyridin-3-amine
23.	4-[(3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
24.	4-*tert*-Butyl-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)benzamide
25.	4-Chloro-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-3-fluorobenzamide
26.	4-Cyano-N-({1-ethyl-2-[3-(phenylformamido)prop-1-yn-1-yl]-1H-indol-5-yl}methyl)-N-methylbenzamide
27.	3-(3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-1-[4-(trifluoromethyl)phenyl]urea
28.	N-{[1-(2-Chloroethyl)-2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl]methyl}oxan-4-amine
29.	2-(4-{[3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
30.	4-Cyano-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)benzamide
31.	N-(3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-6-methylpyridine-3-carboxamide
32.	3-[3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]-1-phenylurea
33.	N-[(2-{3-[(4-Chloro-3-fluorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]-1-methylpiperidin-4-amine
34.	2-(5-{[3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
35.	N-{[1-(2-Chloroethyl)-2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl]methyl}-1-methylpiperidin-4-amine
36.	6-*tert*-Butyl-N-[3-(1-ethyl-5-{[(1-methanesulfonylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
37.	2-(4-{[3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanoic acid
38.	3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)-N-methylprop-2-ynamide
39.	Ethyl 2-(4-{[3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanoate
40.	2-(5-{[3-(1-Ethyl-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
41.	N-[(1-Ethyl-2-{3-[(4-methylphenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl)methyl]-1-methylpiperidin-4-amine
42.	4-{[3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzonitrile

Mol #	IUPAC name
43.	3-(1-Ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)-N-phenylprop-2-ynamide
44.	N-[(2-{3-[(4-Chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]-1-methanesulfonylpiperidin-4-amine
45.	1-(4-{[(2-{3-[(4-Chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]amino}piperidin-1-yl)ethan-1-one
46.	6-*tert*-Butyl-N-[3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]pyridine-3-carboxamide
47.	N-(3-{1-Ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-4-(trifluoromethyl)aniline
48.	N-[(1-Ethyl-2-{3-[(4-methylphenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl)methyl]oxan-4-amine
49.	N-(3-{1-ethyl-4-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)aniline
50.	N-[3-(1-ethyl-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]aniline
51.	N-({1-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-4-yl}methyl)-1-methylpiperidin-4-amine
52.	1-[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-4-yl)methyl]piperidin-4-ol
53.	4-Chloro-N-[3-(1-ethyl-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]aniline
54.	1-[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-4-yl)methyl]-N,N-dimethylpiperidin-4-amine
55.	4-Chloro-N-(3-{1-ethyl-4-[(4-methylpiperazin-1-yl)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)aniline
56.	1-{1-[(2-{3-[(4-Chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-4-yl)methyl]piperidin-4-yl}piperidin-4-ol
57.	2-(5-{[3-(4-{[4-(4-Aminopiperidin-1-yl)piperidin-1-yl]methyl}-1-ethyl-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
58.	1-[(1-ethyl-2-{3-[(4-fluorophenyl)amino]prop-1-yn-1-yl}-1H-indol-5-yl)methyl]-N,N-dimethylpiperidin-4-amine
59.	4-N-({1-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-5-yl}methyl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
60.	4-chloro-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-3-fluoroaniline
61.	6-*tert*-butyl-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)pyridine-3-carboxamide
62.	N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)benzamide
63.	3-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)-1-(4-methylphenyl)urea
64.	4-chloro-N-(3-{1-ethyl-5-[(methylamino)methyl]-1H-indol-2-yl}prop-2-yn-1-yl)aniline
65.	4-{[3-(1-ethyl-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzonitrile

Mol #	IUPAC name
66.	N-[(2-{3-[(4-chloro-3-fluorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]oxan-4-amine
67.	3-[3-(1-ethyl-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]-1-phenylurea
68.	6-*tert*-butyl-N-[3-(1-ethyl-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
69.	4-{[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]amino}-1λ⁶-thiane-1,1-dione
70.	N-[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]-1-(2-methanesulfonylethyl)piperidin-4-amine
71.	1-(4-{[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
72.	2-(4-{[(2-{3-[(4-chlorophenyl)amino]prop-1-yn-1-yl}-1-ethyl-1H-indol-5-yl)methyl]amino}piperidin-1-yl)-N,N-dimethylacetamide
73.	2-*tert*-butyl-N-[3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]pyrimidin-5-amine
74.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
75.	2-[5-({3-[1-(2-fluoroethyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
76.	3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-ol
77.	2-[5-({3-[1-(2-chloroethyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
78.	2-[5-({3-[1-(2,2-difluoroethyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
79.	6-chloro-N-[3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
80.	*tert*-butyl N-({3-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-6-yl}methyl)-N-(oxan-4-yl)carbamate
81.	6-Chloro-N-[3-(1-ethyl-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
82.	3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl benzoate
83.	2-[5-({3-[1-(2-chloroethyl)-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
84.	N-(6-chloropyridin-3-yl)-3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-ynamide
85.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-ynamide
86.	N-({3-ethyl-2-[3-(phenylamino)prop-1-yn-1-yl]-1H-indol-6-yl}methyl)oxan-4-amine
87.	2-[5-({3-[1-(2-chloroethyl)-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile

Mol #	IUPAC name
88.	2-(5-{[3-(5-{[(1-methanesulfonylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
89.	2-[5-({3-[5-({[1-(2-methanesulfonylethyl)piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
90.	2-(5-{[3-(5-{[(1-acetylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
91.	2-{5-[(3-{5-[({1-[2-(dimethylamino)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
92.	2-methyl-2-(5-{[3-(5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
93.	2-methyl-2-{5-[(3-{5-[(methylamino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
94.	6-Chloro-N-[3-(5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
95.	6-chloro-N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
96.	2-[5-({3-[1-(cyclopropylmethyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
97.	2-(5-{[3-(4-{[4-(diethylamino)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
98.	2-methyl-2-{5-[(3-{4-[(4-methylpiperazin-1-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
99.	2-(5-{[3-(1-ethyl-7-fluoro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
100.	2-methyl-2-(5-{[3-(4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
101.	2-(5-{[3-(4-{[4-(4-hydroxypiperidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
102.	N-(6-cyanopyridin-3-yl)-3-(1-ethyl-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-ynamide
103.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-ynamide
104.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-ynamide
105.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(oxiran-2-ylmethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
106.	2-(5-{[3-(5-{[(2-methoxyethyl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
107.	2-methyl-2-[5-({3-[5-({[2-(morpholin-4-yl)ethyl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile

Mol #	IUPAC name
108.	2-methyl-2-(5-{[3-(4-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
109.	2-methyl-2-(5-{[3-(4-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
110.	2-[5-({3-[5-({[2-(dimethylamino)ethyl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
111.	2-(5-{[3-(7-fluoro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
112.	2-methyl-2-[5-({3-[1-(2,2,2-trifluoroethyl)-5-{[(2,2,2-trifluoroethyl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
113.	2-[5-({3-[5-({[1-(2-hydroxyethyl)piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
114.	2-[5-({3-[5-({[1-(2-methoxyethyl)piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
115.	2-[5-({3-[5-({[4-(dimethylamino)cyclohexyl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
116.	2-methyl-2-{5-[(3-{5-[({1-[2-(morpholin-4-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
117.	2-(5-{[3-(4-{[(2-methoxyethyl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
118.	2-methyl-2-{5-[(3-{4-[(methylamino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
119.	2-{5-[(3-{4-[(4-acetylpiperazin-1-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
120.	2-methyl-2-[5-({3-[4-(morpholin-4-ylmethyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
121.	2-(5-{[3-(4-{[4-(dimethylamino)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
122.	2-[5-({3-[4-(hydroxymethyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
123.	2-methyl-2-[5-({3-[4-({4-[2-(morpholin-4-yl)-2-oxoethyl]piperazin-1-yl}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
124.	2-(5-{[3-(3-ethyl-7-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
125.	methyl 5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxylate
126.	N-methyl-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide

Mol #	IUPAC name
127.	N-(2-hydroxyethyl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
128.	N-(2-methoxyethyl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
129.	2-[(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)formamido]acetic acid
130.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxylic acid
131.	N-(2-methanesulfonylethyl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
132.	2-[5-({3-[1-(cyanomethyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
133.	2-methyl-2-[5-({3-[1-(2-methylpropyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
134.	2-methyl-2-{5-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
135.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carbonitrile
136.	N,N-dimethyl-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
137.	N-(oxan-4-yl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
138.	2-*tert*-butyl-N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]pyrimidin-5-amine
139.	N-(1-methylpiperidin-4-yl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
140.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-[1-(2-fluoroethyl)-5-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-ynamide
141.	2-(5-{[3-(7-chloro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
142.	2-(5-{[3-(6-fluoro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
143.	2-(5-{[3-(1-ethyl-5-{[(oxan-4-yl)amino]methyl}-1H-pyrrolo[2,3-c]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
144.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
145.	2-(5-{[3-(5-{[4-(dimethylamino)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
146.	2-(5-{[3-(7-chloro-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile

Mol #	IUPAC name
147.	2-(5-{[3-(4-{[4-(dimethylamino)-piperidin-1-yl]methyl}-6-fluoro-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
148.	2-(5-{[3-(4-{[4-(diethylamino)piperidin-1-yl]methyl}-6-fluoro-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
149.	2-(5-{[3-(6-fluoro-4-{[4-(4-hydroxypiperidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
150.	2-(5-{[3-(6-fluoro-5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
151.	2-(5-{[3-(5-{[(1-acetylpiperidin-4-yl)amino]methyl}-6-fluoro-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
152.	2-(5-{[3-(6-chloro-4-{[4-(dimethylamino)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
153.	2-(5-{[3-(6-chloro-4-{[4-(diethylamino)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
154.	2-(5-{[3-(6-chloro-4-{[4-(4-hydroxypiperidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
155.	2-(5-{[3-(4-{[4-(2-methanesulfonyl-ethyl)piperazin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
156.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]methyl}piperazin-1-yl)-N,N-dimethylacetamide
157.	2-methyl-2-{5-[(3-{4-[(3-oxopiperazin-1-yl)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
158.	2-methyl-2-[5-({3-[4-({4-[2-(morpholin-4-yl)-2-oxoethyl]piperidin-1-yl}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
159.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]methyl}piperazin-1-yl)acetamide
160.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-ynamide
161.	2-(1-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]methyl}piperidin-4-yl)acetamide
162.	2-(5-{[3-(4-{[4-(2-aminoethyl)-piperazin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
163.	2-(1-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]methyl}piperidin-4-yl)-N,N-dimethylacetamide

Mol #	IUPAC name
164.	2-methyl-2-(5-{[3-(4-{[4-(morpholin-4-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
165.	2-(5-{[3-(4-{[4-(4-aminopiperidin-1-yl)piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
166.	2-methyl-2-[5-({3-[1-(oxiran-2-ylmethyl)-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
167.	2-(5-{[3-(3-ethyl-6-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
168.	2-methyl-2-(5-{[3-(6-{[(oxan-4-yl)amino]methyl}-3-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
169.	2-(5-{[3-(1-acetyl-3-ethyl-6-{[(oxan-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
170.	2-(5-{[3-(3-ethyl-6-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
171.	2-methyl-2-(5-{[3-(6-{[(1-methylpiperidin-4-yl)amino]methyl}-3-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
172.	2-{5-[(3-{6-chloro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
173.	2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-6-fluoro-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indole-4-carboxamide
174.	2-[5-({3-[6-fluoro-4-(4-methylpiperazine-1-carbonyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
175.	6-fluoro-2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
176.	2-{5-[(3-{6-fluoro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
177.	5-[(3-{6-fluoro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(pyridin-3-yl)pyridine-2-carboxamide
178.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
179.	2-methyl-2-{5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
180.	2-(5-{[3-(7-chloro-1-ethyl-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl}-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
181.	2-(5-{[3-(7-chloro-5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
182.	2-(5-{[3-(7-chloro-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
183.	2-{5-[(3-{7-fluoro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
184.	2-(5-{[3-(7-fluoro-5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile

Mol #	IUPAC name
185.	2-(5-{[3-(7-fluoro-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
186.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-1,3-benzodiazol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
187.	N-{[2-(2-phenylethynyl)-1-(2,2,2-trifluoroethyl)-1H-1,3-benzodiazol-5-yl]methyl}oxan-4-amine
188.	2-methyl-2-(5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
189.	2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
190.	4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ^6-thiane-1,1-dione
191.	2-methyl-2-{5-[(3-{5-methyl-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
192.	N-[1-(2-methanesulfonylethyl)piperidin-4-yl]-2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
193.	4-[(3-{5-methyl-4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
194.	2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
195.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-5-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
196.	2-[5-({3-[4-(methoxymethyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
197.	2-[5-({3-[4-(cyanomethyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
198.	2-methyl-2-[5-({3-[5-(morpholine-4-carbonyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
199.	2-methyl-2-[5-({3-[5-(4-methylpiperazine-1-carbonyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
200.	2-{5-[(3-{5-[4-(dimethylamino)piperidine-1-carbonyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
201.	2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-N-{1-[2-(dimethylamino)acetyl]piperidin-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indole-5-carboxamide
202.	2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indole-5-carboxamide
203.	2-methyl-2-(5-{[3-(5-{1-[(oxan-4-yl)amino]ethyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
204.	2-methyl-2-{5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-pyrrolo[3,2-c]pyridin-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
205.	2-methyl-2-[5-({3-[5-(morpholin-4-ylmethyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile

Mol #	IUPAC name
206.	2-[5-({3-[5-({[1-(2-cyanoethyl)-piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
207.	2-methyl-2-(5-{[3-(5-{[(1-methylazetidin-3-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
208.	2-methyl-2-(5-{[3-(5-{[(oxetan-3-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
209.	2-(5-{[3-(5-{[4-(dimethylamino)-piperidin-1-yl]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
210.	2-methyl-2-{5-[(3-{5-[({1-[2-(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
211.	2-(5-{[3-(5-{[(1-methoxypropan-2-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
212.	2-methyl-2-(5-{[3-(5-{[(pyridin-4-ylmethyl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
213.	2-methyl-2-(5-{[3-(5-{[(pyridin-3-ylmethyl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
214.	2-[5-({3-[5-({[1-(dimethylamino)-propan-2-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
215.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N-(oxan-4-yl)acetamide
216.	2-[5-({3-[5-({[1-(2-methoxyacetyl)-piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
217.	2-methyl-2-{5-[(3-{5-[({1-[2-(oxan-4-yl)acetyl]piperidin-4-yl}amino)-methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-pyridin-2-yl}propanenitrile
218.	2-methyl-2-{5-[(3-{5-[({1-[2-(pyridin-3-yl)acetyl]piperidin-4-yl}amino)-methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-pyridin-2-yl}propanenitrile
219.	2-methyl-2-(5-{[3-(5-{[(1-{2-[(oxan-4-yl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-propanenitrile
220.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N-methyl-N-(propan-2-yl)acetamide
221.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N-(2-methoxyethyl)-N-methylacetamide
222.	6-methanesulfonyl-N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine

Mol #	IUPAC name
223.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N,N-dimethylacetamide
224.	2-methyl-2-{5-[(3-{5-[({1-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
225.	4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)-N,N-dimethylpiperidine-1-carboxamide
226.	2-{5-[(3-{5-[({1-[2-(azetidin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-pyridin-2-yl}-2-methylpropanenitrile
227.	2-methyl-2-{5-[(3-{5-[({1-[2-(pyrrolidin-1-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-propanenitrile
228.	2-(5-{[3-(5-{[(1-{2-[4-(dimethylamino)piperidin-1-yl]acetyl}piperidin-4-yl)amino]-methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
229.	2-{5-[(3-{5-[({1-[2-(diethylamino)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
230.	2-methyl-2-(5-{[3-(5-{[(1-{2-[methyl(propan-2-yl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
231.	2-methyl-2-{5-[(3-{5-[({1-[2-(pyridin-4-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
232.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N-(pyridin-4-yl)acetamide
233.	2-methyl-2-{5-[(3-{5-[({1-[2-(morpholin-4-yl)-2-oxoethyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
234.	2-methyl-2-{5-[(3-{5-[({1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
235.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N-(pyridin-3-yl)acetamide
236.	2-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)piperidin-1-yl]-N-(1-methylpiperidin-4-yl)acetamide
237.	2-methyl-2-[5-({3-[5-({[4-(morpholin-4-yl)cyclohexyl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile

Mol #	IUPAC name
238.	2-{5-[(3-{5-[({1-[2-(4-hydroxypiperidin-1-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
239.	2-{5-[(3-{5-[({1-[2-(4-acetylpiperazin-1-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
240.	2-(5-{[3-(5-{[(1,1-dioxo-1λ⁶-thian-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
241.	2-{5-[(3-{5-[({1-[2-(1,1-dioxo-1λ⁶,4-thiomorpholin-4-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
242.	2-[5-({3-[5-({[1-(4-acetylpiperazine-1-carbonyl)piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
243.	2-(5-{[3-(5-{[(1-{2-[bis(2-hydroxyethyl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
244.	2-methyl-2-{5-[(3-{5-[({1-[2-(3-oxopiperazin-1-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
245.	2-methyl-2-[5-({3-[5-({[1-(morpholine-4-carbonyl)piperidin-4-yl]amino}-methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
246.	2-methyl-2-(5-{[3-(5-{[(1-methylpiperidin-3-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
247.	N-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)-cyclohexyl]acetamide
248.	2-{5-[(3-{5-[({1-[2-(1H-imidazol-1-yl)acetyl]piperidin-4-yl}amino)-methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
249.	2-(5-{[3-(5-{[(1-{2-[(2-methoxyethyl)(methyl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
250.	N-[4-({[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}amino)-cyclohexyl]methanesulfonamide
251.	2-methyl-2-(5-{[3-(5-{[(1-methyl-6-oxopiperidin-3-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
252.	2-[5-({3-[5-({[3-(dimethylamino)cyclohexyl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
253.	2-methyl-2-[5-({3-[5-({[1-(4-methylpiperazine-1-carbonyl)piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile

Mol #	IUPAC name
254.	2-{5-[(3-{5-[({1-[4-(dimethylamino)piperidine-1-carbonyl]piperidin-4-yl}amino)-methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
255.	2-{5-[(3-{5-[({1-[2-(3-hydroxypyrrolidin-1-yl)acetyl]-piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
256.	2-{5-[(3-{5-[({1-[2-(3-methoxypyrrolidin-1-yl)acetyl]-piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
257.	2-methyl-2-[5-({3-[5-({[1-(2-{2-oxa-8-azaspiro[4.5]decan-8-yl}acetyl)-piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
258.	2-{5-[(3-{5-[({1-[2-(4-hydroxy-4-methylpiperidin-1-yl)acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
259.	2-(5-{[3-(5-{[(1-{2-[bis(2-methoxyethyl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
260.	2-(5-{[3-(5-{[(1-{2-[methoxy(methyl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
261.	2-(5-{[3-(5-{[(1-{2-[(2,3-dihydroxypropyl)(methyl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
262.	2-methyl-2-(5-{[3-(5-{[(1-methyl-2-oxopiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
263.	2-methyl-2-(5-{[3-(5-{[(1-{2-[methyl(1-methylpiperidin-4-yl)amino]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
264.	2-methyl-2-[5-({3-[5-({[1-(2-{9-methyl-3,9-diazaspiro[5.5]undecan-3-yl}acetyl)piperidin-4-yl]amino}methyl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
265.	2-(5-{[3-(5-{[(1-{2-[3-(dimethyl-amino)pyrrolidin-1-yl]acetyl}piperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
266.	N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-6-(pyrrolidine-1-carbonyl)pyridin-3-amine
267.	6-(morpholine-4-carbonyl)-N-[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]pyridin-3-amine
268.	2-chloro-N-[3-(5-{[(oxan-4-yl)amino]-methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]pyrimidin-5-amine
269.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-phenylpyridine-2-carboxamide
270.	N-methyl-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(propan-2-yl)pyridine-2-carboxamide

Mol #	IUPAC name
271.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(pyridin-4-yl)pyridine-2-carboxamide
272.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(pyridin-3-yl)pyridine-2-carboxamide
273.	N-(1-methylazetidin-3-yl)-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
274.	N,N-diethyl-5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
275.	5-{[3-(5-{[(oxan-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(oxetan-3-yl)pyridine-2-carboxamide
276.	1-(4-{[(2-{3-[(2-*tert*-butylpyrimidin-5-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl]amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
277.	1-(4-{[(2-{3-[(6-chloropyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl]amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
278.	5-[(3-{5-[({1-[2-(dimethylamino)-acetyl]piperidin-4-yl}amino)methyl]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(1-methylpiperidin-4-yl)pyridine-2-carboxamide
279.	1-(4-{[(2-{3-[(4-chloro-3-fluorophenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl]amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
280.	2-(dimethylamino)-1-(4-{[(2-{3-[(6-methylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl]amino}piperidin-1-yl)ethan-1-one
281.	1-(4-{[(2-{3-[(6-*tert*-butylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl)methyl]amino}piperidin-1-yl)-2-(dimethylamino)ethan-1-one
282.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-[1-(2-fluoroethyl)-5-{[(1-methylpiperidin-4-yl)amino]methyl}-1H-indol-2-yl]prop-2-ynamide
283.	2-{5-[(3-{5-[({1-[2-(dimethylamino)acetyl]piperidin-4-yl}amino)methyl]-1-ethyl-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
284.	2-[5-({3-[1-(2,2-difluoroethyl)-5-[({1-[2-(dimethylamino)acetyl]piperidin-4-yl}amino)methyl]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
285.	2-{5-[(3-{5-[({1-[2-(dimethylamino)acetyl]piperidin-4-yl}amino)methyl]-1-(2-fluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
286.	N-(6-chloropyridin-3-yl)-3-(5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-ynamide
287.	2-(5-{[3-(5-{[(1-acetylpiperidin-4-yl)amino]methyl}-1-(oxiran-2-ylmethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
288.	2-methyl-2-{5-[(3-{5-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
289.	2-{5-[(3-{4-[(1-acetylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile

Mol #	IUPAC name
290.	2-methyl-2-{5-[(3-{4-[(propan-2-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
291.	2-methyl-2-{5-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
292.	2-(5-{[3-(4-{[1-(2-methoxyethyl)-piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
293.	2-{5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
294.	3-[2-(3-{[6-(1-cyano-1-methylethyl)-pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-1-(oxan-4-yl)urea
295.	3-[2-(3-{[6-(1-cyano-1-methylethyl)-pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-1-(1-methylpiperidin-4-yl)urea
296.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)-pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-N,N-dimethylacetamide
297.	2-methyl-2-(5-{[3-(4-{[1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
298.	2-methyl-2-(5-{[3-(4-{[1-(1-methylpiperidin-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
299.	4-{[2-(3-{[6-(1-cyano-1-methylethyl)-pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-N,N-dimethylpiperidine-1-carboxamide
300.	N-[2-(3-{[6-(1-cyano-1-methylethyl)-pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-4-methylpiperazine-1-carboxamide
301.	1-[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-3,3-dimethylurea
302.	N-[2-(3-{[6-(1-cyano-1-methylethyl)-pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]morpholine-4-carboxamide
303.	2-{5-[(3-{4-[(4-hydroxycyclohexyl)-amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
304.	2-methyl-2-[5-({3-[4-({1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
305.	2-methyl-2-{5-[(3-{4-[(oxan-4-ylmethyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
306.	2-{5-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
307.	2-(5-{[3-(4-{[1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
308.	2-{5-[(3-{4-[(1-methanesulfonylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
309.	2-(5-{[3-(4-{[1-(2-methanesulfonyl-ethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile

Mol #	IUPAC name
310.	2-methyl-2-(5-{[3-(4-{[(1R,4R)-4-hydroxycyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
311.	2-methyl-2-(5-{[3-(4-{[(1S,4S)-4-hydroxycyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
312.	2-methyl-2-[5-({3-[4-({1-[2-(morpholin-4-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
313.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-N,N-bis(2-methoxyethyl)acetamide
314.	2-methyl-2-{5-[(3-{4-[(pyrrolidin-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
315.	2-methyl-2-{5-[(3-{4-[(1-methylpyrrolidin-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
316.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)acetamide
317.	methyl 2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)acetate
318.	2-[5-({3-[4-({1-[2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
319.	2-methyl-2-{5-[(3-{4-[(2-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
320.	**2-{5-[(3-{4-[(1,1-dioxo-1λ⁶-thiolan-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile**
321.	2-methyl-2-[5-({3-[4-({1-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
322.	2-{5-[(3-{4-[(1-{2-[4-(dimethylamino)piperidin-1-yl]-2-oxoethyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
323.	2-[5-({3-[4-({1-[2-(dimethylamino)acetyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
324.	**2-(5-{[3-(4-{[1-(1,1-dioxo-1λ⁶-thian-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile**
325.	2-(5-{[3-(4-{[1-(cyanomethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
326.	2-methyl-2-[5-({3-[1-(2,2,2-trifluoroethyl)-4-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]amino}-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
327.	2-{5-[(3-{4-[(1-{2-[4-(2-methanesulfonylethyl)piperazin-1-yl]-2-oxoethyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile

Mol #	IUPAC name
328.	2-[5-({3-[4-({1-[2-(1,1-dioxo-1λ⁶,4-thiomorpholin-4-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
329.	2-(5-{[3-(4-{[1-(1-methanesulfonylpiperidin-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
330.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-N-(2,3-dihydroxypropyl)-N-methylacetamide
331.	2-(4-{[2-(3-{[6-(1-cyano-1-methylethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-N-(2,3-dihydroxypropyl)acetamide
332.	2-[5-({3-[4-({1-[2-(4-methanesulfonylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
333.	2-{5-[(3-{4-[(1-{2-[4-(2-hydroxyethyl)piperazin-1-yl]-2-oxoethyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
334.	2-methyl-2-(5-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
335.	2-[5-({3-[4-({1-[1-(2-methanesulfonylethyl)piperidin-4-yl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
336.	2-[5-({3-[4-({1-[1-(2-methoxyethyl)piperidin-4-yl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
337.	2-[5-({3-[4-({1-[1-(2-hydroxyethyl)piperidin-4-yl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
338.	2-[5-({3-[4-({1-[2-(dimethylamino)ethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
339.	2-(5-{[3-(4-{[1-(1-acetylpiperidin-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)-2-methylpropanenitrile
340.	2-methyl-2-[5-({3-[4-({1-[(1R,4R)-4-hydroxycyclohexyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
341.	2-methyl-2-[5-({3-[4-({1-[(1S,4S)-4-hydroxycyclohexyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
342.	N-(1-methylpiperidin-4-yl)-2-{3-[(6-methylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
343.	2-methyl-2-{5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile

Mol #	IUPAC name
344.	5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(pyridin-3-yl)pyridine-2-carboxamide
345.	5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carbonitrile
346.	N-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-ynamide
347.	2-{3-[(2-fluorophenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
348.	2-{3-[(3-fluorophenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
349.	4-amino-N-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)benzene-1-sulfonamide
350.	2-{3-[(6-*tert*-butylpyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
351.	2-{3-[(4-fluorophenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
352.	N,N-dimethyl-5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carboxamide
353.	5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(propan-2-yl)pyridine-2-carboxamide
354.	N-(pyridin-3-yl)-5-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
355.	N-(pyridin-3-yl)-5-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
356.	2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
357.	6-*tert*-butyl-N-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)pyridine-3-carboxamide
358.	2-{3-[(6-chloropyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
359.	2-{4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}propan-2-ol
360.	6-methyl-N-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)pyridine-3-carboxamide
361.	N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-2-(3-{[6-(trifluoromethyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1H-indol-4-amine
362.	3-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)-1-phenylurea
363.	2-{3-[(4-*tert*-butyl-2-fluorophenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
364.	2-{3-fluoro-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}-2-methylpropanenitrile

Mol #	IUPAC name
365.	4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
366.	2-{3-[(2,6-difluoro-4-methane-sulfonylphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
367.	N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
368.	2-{3-[(4-methanesulfonyl-3-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
369.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
370.	2-{3-[(5-methanesulfonylpyridin-2-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
371.	2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
372.	methyl 3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoate
373.	N-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}methanesulfonamide
374.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
375.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoic acid
376.	2-{3-[(2,4-dimethoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
377.	2-{3-[(2-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
378.	2-{3-[(5-fluoro-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
379.	2-{3-[(2-ethoxy-4-methane-sulfonylphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
380.	2-{3-[(3-fluoro-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
381.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
382.	2-{3-[(4-fluoro-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
383.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-benzamide
384.	2-{3-[(2-fluoro-6-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
385.	2-{3-[(4-*tert*-butyl-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
386.	4-methoxy-3-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-benzonitrile

Mol #	IUPAC name
387.	2-{3-[(5-*tert*-butyl-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
388.	N-(1-methylpiperidin-4-yl)-2-[3-(phenylamino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
389.	5-methanesulfonyl-2-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
390.	2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
391.	2-{3-[(3-methoxypyridin-4-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
392.	2-{3-[(2-chloro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
393.	2-{3-[(4-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
394.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
395.	5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carbonitrile
396.	4-{[2-(3-{[6-(morpholine-4-carbonyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
397.	4-{[2-(3-{[6-(4-methylpiperazine-1-carbonyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
398.	4-[(2-{3-[(quinolin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
399.	4-[(2-{3-[(quinoxalin-6-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
400.	4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
401.	5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carboxamide
402.	4-[(2-{3-[(6-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
403.	4-{[2-(3-{[6-(4-hydroxypiperidine-1-carbonyl)pyridin-3-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
404.	4-[(2-{3-[(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
405.	4-[(2-{3-[(2-methoxypyridin-4-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
406.	2-{4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-fluorophenyl}-2-methylpropanenitrile
407.	5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(1-methylpiperidin-4-yl)pyridine-2-carboxamide
408.	4-[(2-{3-[(2-fluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione

Mol #	IUPAC name
409.	4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
410.	4-[(2-{3-[(2-*tert*-butylpyrimidin-5-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
411.	3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-N-(4-methanesulfonyl-phenyl)-prop-2-ynamide
412.	5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(oxan-4-yl)pyridine-2-carboxamide
413.	5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(pyridin-3-yl)pyridine-2-carboxamide
414.	5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-methylpyridine-2-carboxamide
415.	4-[(2-{3-[(3-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
416.	N-(2,3-dihydroxypropyl)-5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carboxamide
417.	5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-hydroxypyridine-2-carboxamide
418.	5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(2-hydroxyethyl)pyridine-2-carboxamide
419.	5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-hydroxy-N-methylpyridine-2-carboxamide
420.	4-amino-N-(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)benzene-1-sulfonamide
421.	4-({2-[3-({pyrido[2,3-b]pyrazin-7-yl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione
422.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-benzamide
423.	4-{[2-(3-{[2-(methylsulfanyl)pyrimidin-5-yl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
424.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
425.	4-{[2-(3-{[4-(2-methylpropane-2-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
426.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N,N-dimethylbenzene-1-sulfonamide
427.	4-{[1-(2,2,2-trifluoroethyl)-2-[2-(trimethylsilyl)ethynyl]-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
428.	4-[(2-{3-[(5-methanesulfonylpyridin-2-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
429.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
430.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-methylbenzene-1-sulfonamide

Mol #	IUPAC name
431.	4-{[2-ethynyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
432.	N-{4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxyphenyl}methanesulfonamide
433.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzoic acid
434.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzonitrile
435.	4-[(2-{3-[(5-fluoro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
436.	4-[(2-{3-[(2-methoxy-6-methylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
437.	4-[(2-{3-[(2-hydroxy-6-methylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
438.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzamide
439.	4-[(2-{3-[(2-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
440.	4-[(2-{3-[(4-fluoro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
441.	4-[(2-{3-[(5-*tert*-butyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
442.	4-[(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
443.	4-[(2-{3-[(3-fluoro-2-methoxyphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
444.	4-({2-[3-(methylamino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione
445.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
446.	4-[(2-{3-[(2-fluoro-6-methoxyphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
447.	3-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-4-methoxybenzonitrile
448.	4-[(2-{3-[(4-*tert*-butyl-2-methoxy-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
449.	4-({2-[3-(phenylamino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione
450.	4-{[2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
451.	2-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-5-methanesulfonylbenzonitrile
452.	4-[(2-{3-[(2-chloro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione

Mol #	IUPAC name
453.	4-[(2-{3-[(4-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
454.	4-{[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
455.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N,N-dimethylacetamide
456.	2-methyl-2-(5-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridin-2-yl)propanenitrile
457.	2-(5-((3-(4-(((1S,4S)-4-(dimethylamino)-cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)pyridin-2-yl)-2-methylpropanenitrile
458.	N-[1-(2-methanesulfonylethyl)piperidin-4-yl]-2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
459.	5-({3-[4-({1-[(dimethylcarbamoyl)methyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridine-2-carboxamide
460.	5-{[3-(4-{[1-(2-methanesulfonylethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
461.	5-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridine-2-carboxamide
462.	5-{[3-(4-{[1-(carbamoylmethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
463.	5-{[3-(4-{[1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
464.	5-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
465.	5-{[3-(4-{[(1R,4R)-4-(dimethylamino)-cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
466.	4-{[3-(4-{[1-(2-methanesulfonyl-ethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
467.	4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
468.	5-{[3-(4-{[(1S,4S)-4-(dimethylamino)-cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}pyridine-2-carboxamide
469.	N,N-dimethyl-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
470.	4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
471.	2-{4-[(2-{3-[(4-sulfamoylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-piperidin-1-yl}acetamide
472.	4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N,N-dimethylbenzene-1-sulfonamide
473.	4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
474.	4-{[3-(4-{[1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
475.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
476.	4-({3-[4-({1-[2-(morpholin-4-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide
477.	methyl 2-{4-[(2-{3-[(4-sulfamoylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoro-ethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetate
478.	4-{[3-(4-{[1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
479.	4-({3-[4-({1-[2-(2-hydroxyethoxy)ethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide
480.	N,N-dimethyl-2-{4-[(2-{3-[(4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
481.	4-({3-[4-({1-[2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide
482.	2-{4-[(2-{3-[(4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetic acid
483.	4-({3-[4-({1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide
484.	N-methyl-2-{4-[(2-{3-[(4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
485.	N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
486.	4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzene-1-sulfonamide
487.	N-methyl-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
488.	2-(dimethylamino)ethyl 2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetate
489.	2-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
490.	2-chloro-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
491.	3-methoxy-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
492.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)-piperidin-4-yl]amino}-1-(2,2,2-trifluoro-ethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
493.	3-methoxy-4-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
494.	3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
495.	3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
496.	3-methoxy-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
497.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)-piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
498.	2-[5-({3-[1-(cyanomethyl)-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
499.	2-[5-({3-[1-(3-methoxypropyl)-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
500.	2-[5-({3-[1-(2-chloroethyl)-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
501.	2-methyl-2-{5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(propan-2-yl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
502.	2-{5-[(3-{1-cyclopentyl-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
503.	2-methyl-2-{5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(3,3,3-trifluoropropyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}propanenitrile
504.	1-(2-chloroethyl)-N-(1-methylpiperidin-4-yl)-2-{3-[(6-methylpyridin-3-yl)amino]-prop-1-yn-1-yl}-1H-indol-4-amine
505.	1-(2-chloroethyl)-N-(1-methylpiperidin-4-yl)-2-{3-[(6-methylpyridin-3-yl)amino]-prop-1-yn-1-yl}-1H-indol-4-amine
506.	1-(2-chloroethyl)-2-{3-[(4-chlorophenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1H-indol-4-amine
507.	2-[5-({3-[1-(1-cyanoethyl)-4-[(1-methylpiperidin-4-yl)amino]-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
508.	**2-[5-({3-[1-(cyanomethyl)-4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1H-indol-2-**yl]prop-2-yn-1-yl}amino)pyridin-2-yl]-2-methylpropanenitrile
509.	4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(oxiran-2-ylmethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
510.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(oxiran-2-ylmethyl)-1H-indol-4-amine
511.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(oxiran-2-ylmethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
512.	2-{3-[(4-methanesulfonyl-2-methoxy-phenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(oxiran-2-ylmethyl)-1H-indol-4-amine
513.	1-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea
514.	1-(6-methanesulfonylpyridin-3-yl)-3-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea
515.	**1-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-3-(3-{4-[(1,1-dioxo-1λ⁶-thian-4-**yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea
516.	**3-(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-**yl}prop-2-yn-1-yl)-1-(6-methanesulfonylpyridin-3-yl)urea
517.	1-(6-cyanopyridin-3-yl)-3-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea
518.	**1-(6-cyanopyridin-3-yl)-3-(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-**trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)urea

Mol #	IUPAC name
519.	3-(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)-1-(quinoxalin-6-yl)urea
520.	N-(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)-4-methylpiperazine-1-carboxamide
521.	N-(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)morpholine-4-carboxamide
522.	4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
523.	2-{4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N,N-dimethylacetamide
524.	N-(1-ethylpiperidin-4-yl)-2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
525.	N-[1-(2-methanesulfonylethyl)piperidin-4-yl]-2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
526.	2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
527.	2-{4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
528.	4-{4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1λ⁶-thiane-1,1-dione
529.	2-{4-[(2-{3-[(6-methanesulfonylpyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(4-methylpiperazin-1-yl)ethan-1-one
530.	2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
531.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
532.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(4-methylpiperazin-1-yl)ethan-1-one
533.	2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
534.	N-(2,3-dihydroxypropyl)-2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N-methylacetamide
535.	4-N-(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
536.	(1S,4S)-4-N-(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
537.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
538.	2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(morpholin-4-yl)ethan-1-one

Mol #	IUPAC name
539.	1-(4-hydroxypiperidin-1-yl)-2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
540.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-(piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
541.	N-{1-[1-(2-methanesulfonylethyl)piperidin-4-yl]piperidin-4-yl}-2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
542.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
543.	3-{4-[(2-{3-[(4-methane-sulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propanenitrile
544.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
545.	2-{4-[(2-{3-[(4-methane-sulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
546.	4-{4-[(2-{3-[(4-methane-sulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1λ⁶-thiane-1,1-dione
547.	2-{4-[(2-{3-[(4-methane-sulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N-methylacetamide
548.	2-(3-{[4-(ethanesulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
549.	2-{4-[(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
550.	2-{3-[(2-fluoro-4-methane-sulfonylphenyl)-amino]prop-1-yn-1-yl}-N-[1-(2-methanesulfonylethyl)-piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
551.	2-{4-[(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
552.	2-{3-[(2-fluoro-4-methane-sulfonylphenyl)-amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
553.	1-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methoxyethan-1-one
554.	2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-(1-methylpyrrolidin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
555.	N-hydroxy-2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
556.	3-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
557.	2-{3-[(2-fluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
558.	2-(3-{[4-(ethanesulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
559.	2-{3-[(2-fluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
560.	2-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)ethan-1-ol
561.	1-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-ol
562.	2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-N-[1-(2-methanesulfonylethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
563.	4-{[1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
564.	2-(4-{[1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)ethan-1-ol
565.	N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-amine
566.	2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpyrrolidin-3-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
567.	2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(3-methanesulfonylpropyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
568.	2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
569.	4-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-1λ⁶-thiane-1,1-dione
570.	2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
571.	N-[1-(2-methanesulfonylethyl)-piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethane-sulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-amine
572.	N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-amine
573.	N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-2-{3-[(4-trifluoromethanesulfonylphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-amine
574.	2-{3-[(2-fluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
575.	2-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetonitrile
576.	2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
577.	2-{3-[(3-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
578.	2-{3-[(2,6-difluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
579.	2-{3-[(3-chloro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
580.	2-{4-[(2-{3-[(3-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
581.	(2S)-3-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol

Mol #	IUPAC name
582.	N-(5-aminopentyl)-2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
583.	2-{3-[(2,6-difluoro-4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
584.	2-(3-{[4-(ethanesulfonyl)phenyl]-amino}prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
585.	2-(4-{[2-(3-{[4-(ethanesulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)acetonitrile
586.	2-(3-{[4-(2-methylpropane-2-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
587.	2-(2-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethoxy)ethan-1-ol
588.	1-{4-[(2-{3-[(2-fluoro-4-methane-sulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-ol
589.	3-{4-[(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
590.	(1S,4S)-4-N-(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
591.	3-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol
592.	2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-N-[1-(3-methanesulfonylpropyl)-piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
593.	1-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-ol
594.	2-[2-(4-{[2-(3-{[4-(ethanesulfonyl)-phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)ethoxy]ethan-1-ol
595.	(1R,4R)-4-N-(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethyl-cyclohexane-1,4-diamine
596.	2-{3-[(2,6-difluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methanesulfonylethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
597.	4-{4-[(2-{3-[(2,6-difluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1λ⁶-thiane-1,1-dione
598.	2-{3-[(4-methanesulfonyl-3-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
599.	2-{3-[(4-methanesulfonyl-3-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
600.	4-N-(2-{3-[(2-fluoro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
601.	2-{4-[(2-{3-[(4-methanesulfonyl-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetic acid
602.	2-hydroxyethyl 2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetate
603.	2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-N-(2-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
604.	2-{4-[(2-{3-[(4-methanesulfonyl-3-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
605.	(2S)-2-(2-{4-[(2-{3-[(4-methane-sulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamido)pentanedioic acid
606.	1,5-dimethyl (2S)-2-(2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamido)pentanedioate
607.	N-(4-carbamimidamidobutyl)-2-{4-[(2-{3-[(4-methanesulfonylphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
608.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
609.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-ol
610.	2-{3-[(5-methanesulfonylpyridin-2-yl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
611.	3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
612.	4-[(2-{3-[(2,4-dimethoxyphenyl)-amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
613.	methyl 4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzoate
614.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methanesulfonylethyl)-piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
615.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxyethyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
616.	(1S,4S)-4-N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
617.	(1R,4R)-4-N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-N,1-N-dimethylcyclohexane-1,4-diamine
618.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
619.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-o
620.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpyrrolidin-3-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
621.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(2-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
622.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
623.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(4-methylpiperazin-1-yl)ethan-1-one

Mol #	IUPAC name
624.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamide
625.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
626.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl}piperidin-4-ol
627.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-1-(morpholin-4-yl)ethan-1-one
628.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N,N-dimethylacetamide
629.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetonitrile
630.	methyl 2-{4-[(2-{3-[(4-methane-sulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetate
631.	1-(4-hydroxypiperidin-1-yl)-2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxy-phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
632.	2-(2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethoxy)ethan-1-ol
633.	-[(1R,4R)-4-[(2-{3-[(4-methane-sulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]piperidin-4-ol
634.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetic acid
635.	(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
636.	(1S,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
637.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
638.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl}-3-methylpyrrolidin-3-ol
639.	(3R,4R)-1-{4-[(2-{3-[(4-methane-sulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl}-pyrrolidine-3,4-diol
640.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidine-1-carboximidamide
641.	1-[(1S,4S)-4-[(2-{3-[(4-methane-sulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]piperidin-4-ol
642.	4-[(2-{3-[(3-methoxypyridin-4-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
643.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
644.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
645.	2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
646.	4-{[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
647.	2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
648.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
649.	3-methoxy-4-{[3-(4-{[1-(1-methylpiperidin-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
650.	3-methoxy-4-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-benzamide
651.	3-methoxy-4-{[3-(4-{[1-(1-methylpiperidin-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
652.	3-(4-{[2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol
653.	3-(4-{[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol
654.	2-(4-{[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)acetamide
655.	2-(4-{[2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one
656.	2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
657.	2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
658.	4-[(2-{3-[(4-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
659.	S-{4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxyphenyl}-2-hydroxyethane-1-sulfonamido
660.	2-hydroxy-S-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}ethane-1-sulfonamido
661.	2-methyl-2-[5-({3-[4-(morpholin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)pyridin-2-yl]propanenitrile
662.	-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-N-[5-(2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetamido)pentyl]acetamide
663.	6-[(2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetyl)oxy]hexyl 2-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}acetate

Mol #	IUPAC name
664.	3-methoxy-4-({3-[4-({1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide
665.	2-{5-methanesulfonyl-2-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenoxy}acetamide
666.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
667.	2-(4-{[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)ethan-1-ol
668.	3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoic acid
669.	2-{2-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-5-methanesulfonylphenoxy}acetamide
670.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidine-1-carboxamide
671.	2-{3-[(4-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
672.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidine-1-carbothioamide
673.	4-[(2-{3-[(6-methanesulfonyl-4-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
674.	3-methoxy-4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
675.	4-{[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
676.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
677.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
678.	methyl 4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
679.	methyl 3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoate
680.	3-methoxy-4-({3-[4-({1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzamide
681.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-N-methylpiperidine-1-carboximidamide
682.	2-{3-[(6-methanesulfonyl-4-methoxypyridin-3-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
683.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(pyridin-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
684.	3-(4-{[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol

Mol #	IUPAC name
685.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
686.	2-hydroxy-S-{3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}ethane-1-sulfonamido
687.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
688.	4-{[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
689.	2-hydroxy-S-(3-methoxy-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)ethane-1-sulfonamido
690.	S-(4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)-2-hydroxyethane-1-sulfonamido
691.	2-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl}-2-methylpropanenitrile
692.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[(3R,4R)-3,4-dihydroxypyrrolidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
693.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(3R,4R)-3,4-dihydroxypyrrolidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
694.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
695.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
696.	2-{4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxyphenyl}-2-methylpropanenitrile
697.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
698.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
699.	(3S,4S)-1-[(1S,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]pyrrolidine-3,4-diol
700.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
701.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
702.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N,N-dimethyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
703.	3-methoxy-4-[(3-{4-[(2-methoxyethyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
704.	2-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]acetamide

Mol #	IUPAC name
705.	4-[(3-{4-[(1,5-dihydroxypentan-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
706.	N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)acetamide
707.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-(1-methylpiperidin-4-yl)urea
708.	3-methoxy-4-{[3-(4-{[(1-methylpiperidin-4-yl)carbamoyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
709.	N-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-4-methylpiperazine-1-carboxamide
710.	N-(2-{3-[(4-carbamoyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-4-methylpiperazine-1-carboxamide
711.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-[(1S,4S)-4-(dimethylamino)cyclohexyl]urea
712.	1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-3-(pyridin-4-yl)urea
713.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-[(1R,4R)-4-(dimethylamino)cyclohexyl]urea
714.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-[1-(2-methoxyethyl)piperidin-4-yl]urea
715.	3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-1-[1-(oxan-4-yl)piperidin-4-yl]urea
716.	1-[1-(2,3-dihydroxypropyl)piperidin-4-yl]-3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)urea
717.	2-(4-{[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)carbamoyl]amino}piperidin-1-yl)acetamide
718.	3-methoxy-4-({3-[4-({2-oxaspiro[3.3]heptan-6-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide
719.	[1-(chloromethyl)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclobutyl]methanol
720.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{2-oxaspiro[3.3]heptan-6-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
721.	4-({3-[4-({2-azaspiro[3.3]heptan-6-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
722.	N-{2-azaspiro[3.3]heptan-6-yl}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
723.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(methylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
724.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-aminocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
725.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-aminocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
726.	rel-(1R,3R)-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,3-diamine
727.	rac-(1R,3S)-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,3-diamine
728.	(1R,2S)-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,2-diamineQ
729.	rac-(1R,2S)-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,2-diamine
730.	rel-(1R,3S)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
731.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-hydroxy-4-methylcyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
732.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-hydroxy-4-methylcyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
733.	4-[(3-{4-[(4-cyanocyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
734.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-cyanocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
735.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-cyanocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
736.	3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexane-1-carboxylic acid
737.	2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
738.	(1R,2R,4S)-2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
739.	2-fluoro-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)- N^4-methylcyclohexane-1,4-diamine
740.	(1R,2R,4S)-2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4-methylcyclohexane-1,4-diamine
741.	2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
742.	(1R,2R,4S)-2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
743.	(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
744.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[bis(2-hydroxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
745.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[bis(2-hydroxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
746.	4-((3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
747.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
748.	3-methoxy-N-(1,2-oxazol-3-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
749.	3-methoxy-N-(oxan-4-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
750.	3-methoxy-N-(1,2-oxazol-3-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
751.	3-methoxy-N-(oxan-4-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
752.	N-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
753.	N-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
754.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
755.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
756.	(1S,4S)- N^4-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1-(2-methoxyethyl)-N^1-methylcyclohexane-1,4-diamine
757.	(1R,4R)- N^4-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1-(2-methoxyethyl)-N^1-methylcyclohexane-1,4-diamine
758.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
759.	4-((3-(4-(((1R,4R)-4-((3R,4R)-3,4-dihydroxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
760.	4-((3-(4-(((1R,4S)-4-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
761.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
762.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
763.	4-({3-[4-({1,4-dioxaspiro[4.5]decan-8-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
764.	N-{1,4-dioxaspiro[4.5]decan-8-yl}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
765.	3-methoxy-4-[(3-{4-[(4-oxocyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
766.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-one
767.	(1R,4R)- N^4-[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
768.	(1S,4S)- N^4-[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
769.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
770.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
771.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
772.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
773.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
774.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
775.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
776.	(1R,4R)- N^4-{2-[3-({2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N^1,N^1-dimethylcyclohexane-1,4-diamine
777.	(1R,4R)- N^4-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-[(oxiran-2-yl)methyl]-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
778.	2-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1H-indol-1-yl)methyl]prop-2-enenitrile
779.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol

Mol #	IUPAC name
780.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
781.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
782.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
783.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
784.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
785.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
786.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
787.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
788.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
789.	(1R,4R)- N^4-[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
790.	N-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
791.	N-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
792.	(1R,4R)- N^4-[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
793.	(1S,4S)- N^4-[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
794.	(1S,4S)- N^4-{2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N^1,N^1-dimethylcyclohexane-1,4-diamine
795.	(1R,4R)- N^4-(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
796.	(1S,4S)- N^4-(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
797.	3-hydroxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
798.	3-hydroxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
799.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
800.	(1R,4R)- N^4-{2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N^1,N^1-dimethylcyclohexane-1,4-diamine
801.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
802.	N-ethyl-3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
803.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
804.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
805.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
806.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
807.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
808.	(1S,4S)- N^4-(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
809.	(1R,4R)- N^4-(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
810.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(methylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
811.	(1S,4S)-N^4-(2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
812.	(1R,4R)-N^4-(2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
813.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
814.	3-(2-cyanoethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
815.	N-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]oxy}phenyl)acetamide

Mol #	IUPAC name
816.	N-(2-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)oxy)-5-(methylsulfonyl)phenyl)acetamide
817.	(1R,4R)-N^1-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
818.	(1S,4S)-N^1-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
819.	(1R,4R)-N^4-[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N1,N1-dimethylcyclohexane-1,4-diamine
820.	(1S,4S)-N^4-[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
821.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
822.	2-(4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
823.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
824.	3-(cyanomethoxy)-4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
825.	3-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
826.	3-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
827.	3-methoxy-N,N-dimethyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzene-1-sulfonamide
828.	(1R,4R)-N^1-(2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
829.	(1S,4S)-N^1-(2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
830.	(1R,4R)-N^4-(2-{3-[(4-chloro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
831.	(1S,4S)-N^1-(2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
832.	4-((3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
833.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide

Mol #	IUPAC name
834.	(1R,4R)-N^4-[2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
835.	(1S,4S)-N^1-(2-(3-((2-methoxy-4-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
836.	2-fluoro-5-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
837.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxy-N-methylbenzamide
838.	(1S,4S)-N^4-[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
839.	(1R,4R)-N^4-[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
840.	(1R,4R)-N^4-(2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
841.	(1S,4S)-N^1,N^1-dimethyl-N^4-(2-(3-((2-methyl-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
842.	(1R,4R)-N^4-[2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
843.	(1S,4S)-N^1,N^1-dimethyl-N^4-(2-(3-((4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
844.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
845.	4-((3-(4-(((1S,4S)-4-(diethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
846.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
847.	4-((3-(4-(((1S,4S)-4-(diethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
848.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
849.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
850.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
851.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
852.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
853.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
854.	N-ethyl-3-methoxy-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
855.	(1R,4R)-N^1-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4-(2-methoxyethyl)-N^4-methylcyclohexane-1,4-diamine
856.	(1S,4S)-N^1-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4-(2-methoxyethyl)-N^4-methylcyclohexane-1,4-diamine
857.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
858.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
859.	3-(fluoromethoxy)-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
860.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
861.	3-methoxy-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
862.	(1R,4R)-N^1,N^1-diethyl-N^4-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
863.	(1S,4S)-N^1,N^1-diethyl-N^4-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
864.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
865.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
866.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
867.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
868.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
869.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
870.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
871.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
872.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
873.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
874.	2-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-1-yl)acetonitrile
875.	4-({3-[1-(2-fluoroethyl)-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
876.	1-(2-fluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
877.	4-({3-[1-(cyanomethyl)-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
878.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-propyl-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
879.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2-methylpropyl)-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
880.	1-(2,2-difluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
881.	3-methoxy-4-((3-(4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
882.	3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
883.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
884.	N-ethyl-3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
885.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
886.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile

Mol #	IUPAC name
887.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
888.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
889.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
890.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
891.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
892.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
893.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
894.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
895.	N-((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
896.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
897.	4-((3-(4-(((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
898.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
899.	4-((3-(4-(((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
900.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(2-azaspiro[3.3]heptan-6-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
901.	4-((3-(4-((2-azaspiro[3.3]heptan-6-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
902.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
903.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
904.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
905.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
906.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
907.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
908.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
909.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
910.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(2-fluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
911.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(2-fluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
912.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
913.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
914.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
915.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
916.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
917.	N-(3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide

Mol #	IUPAC name
918.	N-(2-hydroxy-4-methanesulfonylphenyl)-2-methyl-N-[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]propanamide
919.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
920.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
921.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
922.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
923.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
924.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl 2-methylpropanoate
925.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
926.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
927.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)acetamide
928.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl 2-methylpropanoate
929.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
930.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
931.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
932.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
933.	2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
934.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
935.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
936.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
937.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
938.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
939.	N-ethyl-3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
940.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
941.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
942.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
943.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
944.	2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
945.	2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
946.	2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
947.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(2-amino-4-(methylsulfonyl)phenoxy)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
948.	3-hydroxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
949.	3-methoxy-4-[(3-{4-[(4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
950.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzonitrile
951.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
952.	2-(4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
953.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
954.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(fluoromethoxy)-N-methylbenzamide
955.	3-(2-cyanoethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
956.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(2-cyanoethoxy)-N-methylbenzamide
957.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
958.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
959.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
960.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(cyanomethoxy)benzenesulfonamide
961.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
962.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
963.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide

Mol #	IUPAC name
964.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
965.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
966.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
967.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N,N-dimethylbenzenesulfonamide
968.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N,N-dimethylbenzenesulfonamide
969.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
970.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
971.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
972.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
973.	2-fluoro-5-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
974.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
975.	2-fluoro-5-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
976.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxy-N-methylbenzamide
977.	2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
978.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
979.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid

Mol #	IUPAC name
980.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
981.	2-fluoro-5-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzoic acid
982.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzoic acid
983.	2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
984.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methyl-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
985.	2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
986.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
987.	2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
988.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(methylsulfonyl)-2-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
989.	2-{3-[(2-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
990.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-chloro-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
991.	3-(3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
992.	3-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
993.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
994.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
995.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
996.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
997.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
998.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
999.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1000.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1001.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
1002.	2-(4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
1003.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1004.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1005.	N-((4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)acetamide
1006.	N-((4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)acetamide
1007.	N-((4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)-2-aminoacetamide
1008.	N-((4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)-2-aminoacetamide
1009.	methyl 2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetate

Mol #	IUPAC name
1010.	methyl 2-(2-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetate
1011.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetic acid
1012.	2-(2-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetic acid
1013.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1014.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1015.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1016.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1017.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1018.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1019.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1020.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1021.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1022.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1023.	N-((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1024.	N-((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1025.	N-((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1026.	4-(3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-7-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
1027.	4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1028.	4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1029.	N-((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1030.	N-((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1031.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1032.	4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1033.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1034.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1035.	2-fluoro-5-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1036.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1037.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1038.	3-methoxy-4-((3-(4-(((1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1039.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1040.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1041.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1042.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1043.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1044.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1045.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1046.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-morpholinocyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1047.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-morpholinocyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1048.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1049.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1050.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1051.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1052.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1053.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1054.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1055.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1056.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1057.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1058.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1059.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1060.	3-methoxy-4-((3-(4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1061.	3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1062.	4-[(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ⁶-thiomorpholine-1,1-dione

Mol #	IUPAC name
1063.	4-((1S,4S)-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)cyclohexyl)thiomorpholine 1,1-dioxide
1064.	4-[(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ⁴-thiomorpholin-1-one
1065.	4-[(1S,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ⁴-thiomorpholin-1-one
1066.	4-((3-(4-(((1R,4R)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1067.	4-((3-(4-(((1S,4S)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1068.	4-((1S,4S)-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)cyclohexyl)thiomorpholine 1-oxide
1069.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(1-oxo-1λ⁴-thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1070.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(1-oxo-1λ⁴-thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1071.	3-methoxy-4-((3-(4-(((1S,4S)-4-(1-oxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1072.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1073.	4-((3-(4-(((1S,4S)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1074.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1075.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1076.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1077.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1078.	4-((3-(4-(((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1079.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1080.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1081.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1082.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1083.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1084.	N-((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1085.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1086.	4-((3-(4-(((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1087.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1088.	4-((3-(4-(((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1089.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1090.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1091.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1092.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1093.	N-((1R,4R)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1094.	N-((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1095.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1096.	N-((1R,4R)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1097.	N-((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1098.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1099.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1100.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1101.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1102.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1103.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1104.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1105.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1106.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1107.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile

Mol #	IUPAC name
1108.	2-(2-((3-(4-(((1S,4S)-4-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetonitrile
1109.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1110.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1111.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1112.	4-((3-(4-(((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1113.	4-((3-(4-(((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1114.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1115.	N-((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1116.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1117.	4-((3-(4-(((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1118.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1119.	4-((3-(4-(((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1120.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1121.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1122.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1123.	3-methoxy-4-((3-(4-(((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1124.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1125.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1126.	-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1127.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1128.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1129.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1130.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1131.	3-methoxy-4-((3-(4-(((1S,4S)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1132.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1133.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1134.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1135.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1136.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1137.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-N-((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)-1H-indol-4-amine
1138.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1139.	3-methoxy-N-methyl-4-((3-(1-(2,2,2-trifluoroethyl)-4-(((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)amino)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1140.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1141.	3-methoxy-4-((3-(1-(2,2,2-trifluoroethyl)-4-(((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)amino)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1142.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1143.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1144.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1145.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1146.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1147.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1148.	1-[(1S,3R)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-4,5-dihydro-1H-1,2,3,4-tetrazol-5-one
1149.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-morpholinocyclohexyl)-1-(oxiran-2-ylmethyl)-1H-indol-4-amine
1150.	2-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1H-indol-1-yl)methyl)acrylonitrile
1151.	N-((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-4-amine
1152.	N-((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-4-amine
1153.	4-((3-(4-(((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1154.	4-((3-(4-(((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1155.	1-[1-(2-hydroxyethyl)piperidin-4-yl]-3-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)urea
1156.	3-methoxy-4-({3-[4-({2-oxaspiro[3.3]heptan-6-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide

Mol #	IUPAC name
1157.	[1-(chloromethyl)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclobutyl]methanol
1158.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{2-oxaspiro[3.3]heptan-6-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1159.	4-({3-[4-({2-azaspiro[3.3]heptan-6-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
1160.	N-{2-azaspiro[3.3]heptan-6-yl}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1161.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(methylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1162.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-aminocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1163.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-aminocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1164.	rel-(1R,3R)-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,3-diamine
1165.	rac-(1R,3S)-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,3-diamine
1166.	(1R,2S)-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,2-diamine
1167.	rac-(1R,2S)-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,2-diamine
1168.	rel-(1R,3S)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
1169.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-hydroxy-4-methylcyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1170.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-hydroxy-4-methylcyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1171.	4-[(3-{4-[(4-cyanocyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
1172.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-cyanocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1173.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-cyanocyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1174.	3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexane-1-carboxylic acid
1175.	2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1176.	(1R,2R,4S)-2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1177.	2-fluoro-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)- N^4-methylcyclohexane-1,4-diamine
1178.	(1R,2R,4S)-2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4-methylcyclohexane-1,4-diamine

Mol #	IUPAC name
1179.	2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
1180.	(1R,2R,4S)-2-fluoro-N^1-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
1181.	(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-ol
1182.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[bis(2-hydroxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1183.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[bis(2-hydroxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1184.	4-((3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1185.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1186.	3-methoxy-N-(1,2-oxazol-3-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1187.	3-methoxy-N-(oxan-4-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1188.	3-methoxy-N-(1,2-oxazol-3-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1189.	3-methoxy-N-(oxan-4-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1190.	N-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1191.	N-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1192.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1193.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1194.	(1S,4S)- N^4-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1-(2-methoxyethyl)-N^1-methylcyclohexane-1,4-diamine

Mol #	IUPAC name
1195.	(1R,4R)- N^4-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1-(2-methoxyethyl)-N^1-methylcyclohexane-1,4-diamine
1196.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1197.	4-((3-(4-(((1R,4R)-4-((3R,4R)-3,4-dihydroxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1198.	4-((3-(4-(((1R,4S)-4-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1199.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1200.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1201.	4-({3-[4-({1,4-dioxaspiro[4.5]decan-8-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
1202.	N-{1,4-dioxaspiro[4.5]decan-8-yl}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1203.	3-methoxy-4-[(3-{4-[(4-oxocyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1204.	4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexan-1-one
1205.	(1R,4R)- N^4-[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1206.	(1S,4S)- N^4-[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1207.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1208.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1209.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1210.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1211.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1212.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1213.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1214.	(1R,4R)- N^4-{2-[3-({2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N^1,N^1-dimethylcyclohexane-1,4-diamine
1215.	(1R,4R)- N^4-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-[(oxiran-2-yl)methyl]-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
1216.	2-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1H-indol-1-yl)methyl]prop-2-enenitrile
1217.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
1218.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
1219.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1220.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1221.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
1222.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
1223.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
1224.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
1225.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
1226.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
1227.	(1R,4R)- N^4-[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1228.	N-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
1229.	N-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide

Mol #	IUPAC name
1230.	(1R,4R)- N^4-[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1231.	(1S,4S)- N^4-[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1232.	(1S,4S)- N^4-{2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N^1,N^1-dimethylcyclohexane-1,4-diamine
1233.	(1R,4R)- N^4-(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
1234.	(1S,4S)- N^4-(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
1235.	3-hydroxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1236.	3-hydroxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1237.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1238.	(1R,4R)- N^4-{2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}-N^1,N^1-dimethylcyclohexane-1,4-diamine
1239.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1240.	N-ethyl-3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1241.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1242.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1243.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1244.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1245.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1246.	(1S,4S)- N^4-(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
1247.	(1R,4R)- N^4-(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine

Mol #	IUPAC name
1248.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(methylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1249.	(1S,4S)-N^4-(2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
1250.	(1R,4R)-N^4-(2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
1251.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1252.	3-(2-cyanoethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1253.	N-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]oxy}phenyl)acetamide
1254.	N-(2-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)oxy)-5-(methylsulfonyl)phenyl)acetamide
1255.	(1R,4R)-N^1-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
1256.	(1S,4S)-N^1-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
1257.	(1R,4R)-N^4-[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N1,N1-dimethylcyclohexane-1,4-diamine
1258.	(1S,4S)-N^4-[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1259.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
1260.	2-(4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
1261.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1262.	3-(cyanomethoxy)-4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1263.	3-(3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1264.	3-(3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1265.	3-methoxy-N,N-dimethyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino} benzene-1-sulfonamide

Mol #	IUPAC name
1266.	(1R,4R)-N^1-(2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
1267.	(1S,4S)-N^1-(2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
1268.	(1R,4R)-N^4-(2-{3-[(4-chloro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
1269.	(1S,4S)-N^1-(2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
1270.	4-((3-(4-(((1R,4R)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
1271.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide
1272.	(1R,4R)-N^4-[2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1273.	(1S,4S)-N^1-(2-(3-((2-methoxy-4-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4,N^4-dimethylcyclohexane-1,4-diamine
1274.	2-fluoro-5-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1275.	4-((3-(4-(((1S,4S)-4-(dimethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxy-N-methylbenzamide
1276.	(1S,4S)-N^4-[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1277.	(1R,4R)-N^4-[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1278.	(1R,4R)-N^4-(2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
1279.	(1S,4S)-N^1,N^1-dimethyl-N^4-(2-(3-((2-methyl-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1280.	(1R,4R)-N^4-[2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]-N^1,N^1-dimethylcyclohexane-1,4-diamine
1281.	(1S,4S)-N^1,N^1-dimethyl-N^4-(2-(3-((4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1282.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1283.	4-((3-(4-(((1S,4S)-4-(diethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

Mol #	IUPAC name
1284.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1285.	4-((3-(4-(((1S,4S)-4-(diethylamino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1286.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(diethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1287.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1288.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1289.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1290.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1291.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1292.	N-ethyl-3-methoxy-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1293.	(1R,4R)-N^1-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4-(2-methoxyethyl)-N^4-methylcyclohexane-1,4-diamine
1294.	(1S,4S)-N^1-(2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4-(2-methoxyethyl)-N^4-methylcyclohexane-1,4-diamine
1295.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1296.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1297.	3-(fluoromethoxy)-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1298.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1299.	3-methoxy-4-((3-(4-(((1S,4S)-4-((2-methoxyethyl)(methyl)amino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

Mol #	IUPAC name
1300.	(1R,4R)-N^1,N^1-diethyl-N^4-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1301.	(1S,4S)-N^1,N^1-diethyl-N^4-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
1302.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1303.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1304.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1305.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-[bis(2-methoxyethyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1306.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1307.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1308.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1309.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1310.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1311.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1312.	2-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-1-yl)acetonitrile
1313.	4-({3-[1-(2-fluoroethyl)-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1314.	1-(2-fluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
1315.	4-({3-[1-(cyanomethyl)-4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1316.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-propyl-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
1317.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2-methylpropyl)-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine

Mol #	IUPAC name
1318.	1-(2,2-difluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1H-indol-4-amine
1319.	3-methoxy-4-((3-(4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1320.	3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1321.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1322.	N-ethyl-3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1323.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1324.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1325.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1326.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1327.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1328.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1329.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1330.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methanesulfonylazetidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1331.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(3-(methylsulfonyl)azetidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1332.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1333.	N-((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1334.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1335.	4-((3-(4-(((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1336.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-azaspiro[3.3]heptan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1337.	4-((3-(4-(((1S,4S)-4-(2-azaspiro[3.3]heptan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1338.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(2-azaspiro[3.3]heptan-6-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1339.	4-((3-(4-((2-azaspiro[3.3]heptan-6-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1340.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1341.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1342.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1343.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1344.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
1345.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)propanamide
1346.	N-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
1347.	N-(3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzenesulfonyl)acetamide
1348.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(2-fluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1349.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(2-fluoroethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1350.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1351.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1352.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
1353.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenol
1354.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1355.	N-(3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1356.	N-(2-hydroxy-4-methanesulfonylphenyl)-2-methyl-N-[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]propanamide
1357.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
1358.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1359.	2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1360.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1361.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1362.	5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl 2-methylpropanoate
1363.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
1364.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)ethan-1-ol
1365.	N-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)acetamide

Mol #	IUPAC name
1366.	5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl 2-methylpropanoate
1367.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1368.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1369.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1370.	2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1371.	2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1372.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1373.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1374.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1375.	3-(2-methoxyethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1376.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1377.	N-ethyl-3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1378.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1379.	3-(2-fluoroethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1380.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1381.	3-(cyanomethoxy)-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1382.	2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1383.	2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1384.	2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1385.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(2-amino-4-(methylsulfonyl)phenoxy)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1386.	3-hydroxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1387.	3-methoxy-4-[(3-{4-[(4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzonitrile
1388.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzonitrile
1389.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
1390.	2-(4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
1391.	3-(fluoromethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1392.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(fluoromethoxy)-N-methylbenzamide
1393.	3-(2-cyanoethoxy)-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1394.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(2-cyanoethoxy)-N-methylbenzamide
1395.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1396.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1397.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1398.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-(cyanomethoxy)benzenesulfonamide
1399.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1400.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1401.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1402.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1403.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1404.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-chloro-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1405.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N,N-dimethylbenzenesulfonamide
1406.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N,N-dimethylbenzenesulfonamide
1407.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1408.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1409.	N-((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1410.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1411.	2-fluoro-5-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1412.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzamide

Mol #	IUPAC name
1413.	2-fluoro-5-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1414.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxy-N-methylbenzamide
1415.	2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1416.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methoxy-4-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1417.	4-((3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
1418.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
1419.	2-fluoro-5-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzoic acid
1420.	4-((3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2-fluoro-5-methoxybenzoic acid
1421.	2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1422.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-methyl-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1423.	2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1424.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1425.	2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1426.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((4-(methylsulfonyl)-2-(trifluoromethyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1427.	2-{3-[(2-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-6-azaspiro[3.3]heptan-6-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1428.	N-((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)-2-(3-((2-chloro-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1429.	3-(3-(4-(((1R,4R)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1430.	3-(3-(4-(((1S,4S)-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1431.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1432.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1433.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1434.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1435.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1436.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1437.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1438.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1439.	2-(3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenyl)-2-methylpropanenitrile
1440.	2-(4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)-2-methylpropanenitrile
1441.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1442.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile

Mol #	IUPAC name
1443.	N-((4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)acetamide
1444.	N-((4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)acetamide
1445.	N-((4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)-2-aminoacetamide
1446.	N-((4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)sulfonyl)-2-aminoacetamide
1447.	methyl 2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetate
1448.	methyl 2-(2-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetate
1449.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetic acid
1450.	2-(2-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetic acid
1451.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1452.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1453.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1454.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1455.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1456.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1457.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide

Mol #	IUPAC name
1458.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1459.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1460.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1461.	N-((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1462.	N-((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1463.	N-((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-(fluoromethoxy)-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1464.	4-(3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-7-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
1465.	4-((3-(4-(((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1466.	4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzenesulfonamide
1467.	N-((1R,4R)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1468.	N-((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1469.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1470.	4-((3-(4-(((1S,4S)-4-(7-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1471.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1472.	4-((3-(4-(((1S,4S)-4-(6-oxa-2-azaspiro[3.5]nonan-2-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1473.	2-fluoro-5-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{7-oxa-2-azaspiro[3.5]nonan-2-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1474.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1475.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1476.	3-methoxy-4-((3-(4-(((1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1477.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1478.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1479.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1480.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1481.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1482.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1483.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-(morpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1484.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-morpholinocyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1485.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-morpholinocyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1486.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1487.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1488.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1489.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1490.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1491.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1492.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1493.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1494.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1495.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1496.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methoxypiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1497.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypiperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1498.	3-methoxy-4-((3-(4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1499.	3-methoxy-4-((3-(4-(((1S,4S)-4-morpholinocyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1500.	4-[(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ⁶-thiomorpholine-1,1-dione
1501.	4-((1S,4S)-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)cyclohexyl)thiomorpholine 1,1-dioxide
1502.	4-[(1R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ⁴-thiomorpholin-1-one
1503.	4-[(1S,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-1λ⁴-thiomorpholin-1-one
1504.	4-((3-(4-(((1R,4R)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1505.	4-((3-(4-(((1S,4S)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1506.	4-((1S,4S)-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)cyclohexyl)thiomorpholine 1-oxide
1507.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(1-oxo-1λ⁴-thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1508.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(1-oxo-1λ⁴-thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1509.	3-methoxy-4-((3-(4-(((1S,4S)-4-(1-oxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1510.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(1,1-dioxo-1λ⁶-thiomorpholin-4-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1511.	4-((3-(4-(((1S,4S)-4-(1,1-dioxidothiomorpholino)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide

Mol #	IUPAC name
1512.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1513.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1514.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1515.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1516.	4-((3-(4-(((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1517.	3-(cyanomethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1518.	3-(cyanomethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1519.	3-(fluoromethoxy)-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1520.	3-(fluoromethoxy)-4-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1521.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1522.	N-((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1523.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1524.	4-((3-(4-(((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1525.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{1-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1526.	4-((3-(4-(((1S,4S)-4-(1-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide

Mol #	IUPAC name
1527.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1528.	2-(5-methanesulfonyl-2-{[3-(4-{[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1529.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1530.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[(1S,4S)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1531.	N-((1R,4R)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1532.	N-((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1533.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-7-azaspiro[3.5]nonan-7-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1534.	N-((1R,4R)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1535.	N-((1S,4S)-4-(2-oxa-7-azaspiro[3.5]nonan-7-yl)cyclohexyl)-2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1536.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1537.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1538.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1539.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1540.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1541.	3-methoxy-N-methyl-4-{[3-(4-{[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide

Mol #	IUPAC name
1542.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1543.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(1S,4S)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1544.	N-ethyl-3-methoxy-4-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1545.	2-(5-methanesulfonyl-2-{[3-(4-{[(1R,4R)-4-{6-oxa-3-azabicyclo[3.1.1]heptan-3-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1546.	2-(2-((3-(4-(((1S,4S)-4-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetonitrile
1547.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1548.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1549.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{2-oxa-8-azaspiro[4.5]decan-8-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1550.	4-((3-(4-(((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1551.	4-((3-(4-(((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1552.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1553.	N-((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1554.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1555.	4-((3-(4-(((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1556.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{3-oxa-9-azaspiro[5.5]undecan-9-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide

Mol #	IUPAC name
1557.	4-((3-(4-(((1S,4S)-4-(3-oxa-9-azaspiro[5.5]undecan-9-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1558.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1559.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1560.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1561.	3-methoxy-4-((3-(4-(((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1562.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(pyrrolidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1563.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(pyrrolidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1564.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1565.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1566.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1567.	3-methoxy-4-((3-(4-(((1S,4S)-4-(3-methoxypyrrolidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-methylbenzamide
1568.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1569.	3-methoxy-4-((3-(4-(((1S,4S)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1570.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1571.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1R,4R)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1572.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-{hexahydro-1H-furo[3,4-c]pyrrol-5-yl}cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1573.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide

Mol #	IUPAC name
1574.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1575.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-N-((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)-1H-indol-4-amine
1576.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1577.	3-methoxy-N-methyl-4-((3-(1-(2,2,2-trifluoroethyl)-4-(((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)amino)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1578.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-[4-(trifluoromethyl)piperidin-1-yl]cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1579.	3-methoxy-4-((3-(1-(2,2,2-trifluoroethyl)-4-(((1S,4S)-4-(4-(trifluoromethyl)piperidin-1-yl)cyclohexyl)amino)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1580.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1581.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1582.	3-methoxy-N-methyl-4-{[3-(4-{[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1583.	3-methoxy-N-methyl-4-((3-(4-(((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1584.	3-methoxy-4-{[3-(4-{[(1R,4R)-4-(4-methanesulfonylpiperidin-1-yl)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1585.	3-methoxy-4-((3-(4-(((1S,4S)-4-(4-(methylsulfonyl)piperidin-1-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1586.	1-[(1S,3R)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]cyclohexyl]-4,5-dihydro-1H-1,2,3,4-tetrazol-5-one
1587.	2-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-4-(((1R,4R)-4-morpholinocyclohexyl)amino)-1H-indol-1-yl)methyl)acrylonitrile
1588.	N-((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-4-amine

Mol #	IUPAC name
1589.	N-((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-4-amine
1590.	4-((3-(4-(((1R,4R)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1591.	4-((3-(4-(((1S,4S)-4-(2-oxa-8-azaspiro[4.5]decan-8-yl)cyclohexyl)amino)-1-(2,2,2-trifluoroethyl)-1H-benzo[d]imidazol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1592.	1-{3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]pyrrolidin-1-yl}-3-methoxypropan-2-ol
1593.	N-[3-(4-{[1-(2-hydroxy-3-methoxypropyl)pyrrolidin-3-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]benzamide
1594.	1-{3-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]pyrrolidin-1-yl}-3-methoxypropan-2-ol
1595.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxan-4-yl)pyrrolidin-3-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1596.	2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-(piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1597.	3-methoxy-N,N-dimethyl-4-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1598.	2-{5-methanesulfonyl-2-[(3-{4-[(piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenoxy}acetonitrile
1599.	3-methoxy-4-((3-(4-(piperidin-4-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1600.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(3R)-piperidin-3-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1601.	3-methoxy-4-{[3-(4-{[(2S,4S)-2-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1602.	3-methoxy-4-((3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1603.	2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1604.	N-(1-methylpiperidin-4-yl)-2-(3-((4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1605.	2-{4-methoxy-5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
1606.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(1,2-oxazol-3-yl)benzene-1-sulfonamide
1607.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(oxan-4-yl)benzene-1-sulfonamide
1608.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide

Mol #	IUPAC name
1609.	N-(2-hydroxyethyl)-3-methoxy-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1610.	3-methoxy-N,N-dimethyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1611.	4-[(3-{6-fluoro-4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
1612.	6-fluoro-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1613.	2-(3-((4-methoxy-6-(methylsulfonyl)pyridin-3-yl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1614.	3-methoxy-N-(2-methoxyethyl)-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1615.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)(methyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1616.	1-(4-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzenesulfonyl}piperazin-1-yl)ethan-1-one
1617.	2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1618.	3-methoxy-4-((3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzoic acid
1619.	3-methoxy-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1620.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1621.	3-methoxy-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1622.	2-[3-({2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}amino)prop-1-yn-1-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1623.	5-methanesulfonyl-2-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenol
1624.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-6-methoxy-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1625.	2-{3-[2-(dimethylamino)-4-methanesulfonylphenoxy]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1626.	2-{5-methanesulfonyl-2-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenoxy}acetonitrile
1627.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1628.	2-(3-{[2-methoxy-4-(morpholine-4-carbonyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1629.	1-{3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzoyl}piperidin-4-ol

Mol #	IUPAC name
1630.	3-(3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1631.	2-(3-{[2-methoxy-4-(5-methoxypyridin-3-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1632.	2-{3-[(5-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1633.	N-(2-hydroxyethyl)-3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1634.	3-methoxy-N-(2-methoxyethyl)-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1635.	3-methoxy-N-(1-methylpiperidin-4-yl)-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1636.	2-[3-({4-[4-(dimethylamino)piperidine-1-carbonyl]-2-methoxyphenyl}amino)prop-1-yn-1-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1637.	3-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(oxan-4-yl)benzamide
1638.	2-(3-{[2-methoxy-4-(4-methylpiperazine-1-carbonyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1639.	2-{3-[(2-methoxy-4-{2-oxa-6-azaspiro[3.3]heptane-6-carbonyl}phenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1640.	2-(3-{[2-methoxy-4-(pyridin-3-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1641.	2-(3-{[2-methoxy-4-(pyridin-4-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1642.	N-(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)pyridine-3-carboxamide
1643.	2-(3-{[2-methoxy-4-(1,3-oxazol-2-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1644.	2-{3-[(3-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1645.	N-(1-methylpiperidin-4-yl)-2-[3-({4-[(morpholin-4-yl)methyl]phenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1646.	2-(3-{[2-methoxy-4-(1,3-thiazol-2-yl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1647.	2-[3-({2-methoxy-4-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]phenyl}amino)prop-1-yn-1-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1648.	2-{3-[(2-methoxy-4-{7-oxa-2-azaspiro[3.5]nonane-2-carbonyl}phenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1649.	2-{3-[(4-chloro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1650.	2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1651.	2-fluoro-5-methoxy-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1652.	2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1653.	2-fluoro-5-methoxy-N-methyl-4-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
1654.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-[(oxiran-2-yl)methyl]-1H-indol-4-amine
1655.	2-(3-((2-ethoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1656.	2-{3-[(2-fluoro-4-methanesulfonyl-6-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1657.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-3-methyl-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1658.	2-(3-(((3R,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1659.	2-{3-[(5-fluoro-4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1660.	2-{3-[(5-methanesulfonylthiophen-2-yl)amino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1661.	N-methyl-5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]thiophene-2-carboxamide
1662.	N,N-dimethyl-5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]thiophene-2-carboxamide
1663.	5-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]thiophene-2-carboxylic acid
1664.	2-(3-((4-methoxypyridin-3-yl)amino)prop-1-yn-1-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1665.	2-(2-((3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetamide
1666.	N-(2-hydroxyethyl)-3-methoxy-4-((3-(4-((1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1667.	4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-1-methylpiperidin-2-one
1668.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(3R,4S)-3-methoxy-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1669.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(3S,4R)-3-methoxy-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1670.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(3S,4R)-3-methoxy-1-methylpiperidin-4-yl]- N-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1671.	N-(1-ethylpiperidin-4-yl)-2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1672.	4-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
1673.	2-{2-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-5-methanesulfonylphenoxy}acetonitrile
1674.	N-(1-ethylpiperidin-4-yl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1675.	4-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
1676.	3-methoxy-N-methyl-4-{[3-(4-{[1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1677.	2-(5-methanesulfonyl-2-{[3-(4-{[1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}phenoxy)acetonitrile
1678.	2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-N-[1-(propan-2-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1679.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(propan-2-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1680.	3-methoxy-4-{[3-(4-{[1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1681.	2-[2-(2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethoxy)ethoxy]ethan-1-ol
1682.	4-({4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}methyl)-1,3-dioxolan-2-one
1683.	3-methoxy-4-({3-[4-({1-[(2-oxo-1,3-dioxolan-4-yl)methyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzene-1-sulfonamide
1684.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(1,2-oxazol-3-yl)benzene-1-sulfonamide
1685.	4-((3-(4-((1-(2,3-dihydroxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1686.	4-({3-[4-({1-[(2S)-2,3-dihydroxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
1687.	4-({3-[4-({1-[(2R)-2,3-dihydroxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
1688.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide

Mol #	IUPAC name
1689.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(oxan-4-yl)benzene-1-sulfonamide
1690.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-hydroxyethyl)-3-methoxy-N-methylbenzene-1-sulfonamide
1691.	2-(5-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-4-methoxypyridin-2-yl)-2-methylpropanenitrile
1692.	N-(2-hydroxyethyl)-3-methoxy-N-methyl-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1693.	3-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)propane-1,2-diol
1694.	(2R)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
1695.	(2S)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propane-1,2-diol
1696.	3-[4-({2-[3-({2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)piperidin-1-yl]propane-1,2-diol
1697.	4-((3-(4-((1-(2,3-dihydroxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
1698.	methyl 4-((3-(4-((1-(2,3-dihydroxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoate
1699.	3-methoxy-4-[(3-{4-[(1-{[(4R)-2-oxo-1,3-dioxolan-4-yl]methyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1700.	(4R)-4-({4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}methyl)-1,3-dioxolan-2-one
1701.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
1702.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}EtOAc
1703.	N-(1-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}piperidin-4-yl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1704.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1705.	4-[(3-{4-[(1-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
1706.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol

Mol #	IUPAC name
1707.	1-(4-((2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
1708.	1-ethoxy-3-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)propan-2-ol
1709.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(2-methoxyethyl)-N-methylbenzene-1-sulfonamide
1710.	1-(acetyloxy)-3-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1711.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1712.	3-methoxy-4-{[3-(4-{[1-(2-methoxyacetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1713.	1-(4-(N-(2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)acetamido)piperidin-1-yl)propan-2-yl acetate
1714.	1-[4-(4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)piperazin-1-yl]ethan-1-one
1715.	(4S)-4-({4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}methyl)-1,3-dioxolan-2-one
1716.	1-(acetyloxy)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1717.	N-[1-(2,3-dimethoxypropyl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1718.	4-{[3-(4-{[1-(2,3-dimethoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1719.	3-(4-{[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propane-1,2-diol
1720.	4-({3-[4-({1-[(2R)-2,3-dihydroxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzamide
1721.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethyl 2-methylpropanoate
1722.	2-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethyl propanoate
1723.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-(propanoyloxy)propan-2-yl propanoate
1724.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-(propanoyloxy)propan-2-yl propanoate

Mol #	IUPAC name
1725.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-[(2-methylpropanoyl)oxy]propan-2-yl 2-methylpropanoate
1726.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-[(2-methylpropanoyl)oxy]propan-2-yl 2-methylpropanoate
1727.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl propanoate
1728.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl 2-methylpropanoate
1729.	2-hydroxy-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propyl 2-methylpropanoate
1730.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl acetate
1731.	2-hydroxy-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propyl propanoate
1732.	N,N-bis(2-hydroxyethyl)-4-{[3-(4-{[1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1733.	4-{[3-(4-{[1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1734.	(S)-4-((3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1735.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl 2-methylpropanoate
1736.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1737.	2-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethyl 2-methylpropanoate
1738.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1739.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl propanoate
1740.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl 2-methylpropanoate

Mol #	IUPAC name
1741.	1-methoxy-3-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl 2-methylpropanoate
1742.	1-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl propanoate
1743.	N-(4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)acetamide
1744.	N-(4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)propanamide
1745.	2-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethyl propanoate
1746.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzene-1-sulfonamide
1747.	1-methoxy-3-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl propanoate
1748.	(2R)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1749.	(2S)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1750.	3-methoxy-4-{[3-(4-{[(1S,4S)-4-(dimethylamino)cyclohexyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
1751.	3-methoxy-4-((3-(4-((1-(2-methoxyethyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1752.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-(2-methoxyethyl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1753.	3-methoxy-4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1754.	3-methoxy-4-{[3-(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzene-1-sulfonamide
1755.	2-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}EtOAc
1756.	1-methoxy-3-{4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-yl acetate
1757.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1758.	2-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methanesulfonylphenol

Mol #	IUPAC name
1759.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
1760.	4-({3-[4-({1-[(2R)-3-hydroxy-2-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
1761.	N-(4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)-N-methylpropanamide
1762.	1-(4-{[2-(3-{[2-(2-fluoroethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1763.	1-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)tetradecan-1-one
1764.	1-methoxy-3-(4-{[2-(3-{[2-methoxy-4-(propanamidosulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-yl propanoate
1765.	1-(4-{[2-(3-{[2-methoxy-4-(propanamidosulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-(propanoyloxy)propan-2-yl propanoate
1766.	(2R)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methoxypropan-1-ol
1767.	(2S)-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methoxypropan-1-ol
1768.	1-{4-[(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1769.	4-({3-[4-({1-[(2S)-3-hydroxy-2-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxybenzene-1-sulfonamide
1770.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(propan-2-yl)benzamide
1771.	3-hydroxy-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1772.	(2R)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl 2-methylpropanoate
1773.	N-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(N-propionylsulfamoyl)phenyl)propionamide
1774.	1-(4-{[2-(3-{[4-methanesulfonyl-2-(2-methoxyethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol

Mol #	IUPAC name
1775.	(2S)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl 2-methylpropanoate
1776.	N-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)acetamide
1777.	N-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)propionamide
1778.	N-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-N-(2-hydroxy-4-(methylsulfonyl)phenyl)isobutyramide
1779.	2-(2-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methanesulfonylphenoxy)acetonitrile
1780.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-5-methoxy-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1781.	1-(4-{[2-(3-{[2-(2-hydroxyethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1782.	1-(4-{[2-(3-{[4-methanesulfonyl-2-(2,2,2-trifluoroethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1783.	1-[4-({2-[3-(2-amino-4-methanesulfonylphenoxy)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)piperidin-1-yl]-3-methoxypropan-2-ol
1784.	4-({3-[4-({1-[(2R)-2-hydroxy-3-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1785.	4-({3-[4-({1-[(2S)-2-hydroxy-3-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1786.	4-({3-[4-({1-[(2R)-3-hydroxy-2-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1787.	4-({3-[4-({1-[(2S)-3-hydroxy-2-methoxypropyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)-3-methoxy-N-methylbenzamide
1788.	1-{4-[(2-{3-[4-methanesulfonyl-2-(methylamino)phenoxy]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1789.	3-(2-fluoroethoxy)-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1790.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-(2-methoxyethoxy)-N-methylbenzamide

Mol #	IUPAC name
1791.	3-(cyanomethoxy)-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1792.	N-ethyl-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1793.	1-(4-{[2-(3-{[2-methoxy-4-(methylcarbamoyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-(propanoyloxy)propan-2-yl propanoate
1794.	1-methoxy-3-(4-{[2-(3-{[2-methoxy-4-(methylcarbamoyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-yl propanoate
1795.	4-{[3-(4-{[1-(2,3-dihydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1796.	3-(2-cyanoethoxy)-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1797.	1-ethoxy-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-2-ol
1798.	2-(2-{[3-(4-{[1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methanesulfonylphenoxy)acetonitrile
1799.	1-(4-{[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1800.	3-(fluoromethoxy)-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-methylbenzamide
1801.	1-(4-{[2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1802.	2-(4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)-2-methylpropanenitrile
1803.	(2S)-1-(4-{[2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1804.	(2R)-1-(4-{[2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1805.	1-(4-{[2-(3-{[2-(difluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1806.	3-(2-hydroxy-3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propoxy)propane-1,2-diol
1807.	1-{4-[(2-{3-[(5-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol

Mol #	IUPAC name
1808.	3-(3-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-6-(methylsulfonyl)benzo[d]oxazol-2(3H)-one
1809.	1-{4-[(2-{3-[(4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1810.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-(2,2,2-trifluoroethoxy)propan-2-ol
1811.	4-hydroxy-9-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-2-oxa-6λ⁵-azaspiro[5.5]undecan-6-ylium
1812.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(3-methoxypropyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1813.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-3-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1814.	1-{4-[(2-{3-[(5-fluoro-4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1815.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(oxetan-3-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1816.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1817.	(R)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1818.	(S)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-(tetrahydrofuran-3-yl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1819.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(1-((tetrahydrofuran-2-yl)methyl)piperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1820.	2-fluoro-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methoxybenzamide
1821.	1-methoxy-3-(4-((2-(3-(((3S,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)propan-2-ol
1822.	1-(4-{[2-(3-{[4-(cyclopropanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1823.	3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propanenitrile
1824.	4-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)butanenitrile
1825.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{1-[(oxolan-2-yl)methyl]piperidin-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
1826.	1-methoxy-3-(4-{[2-(3-{[2-methoxy-4-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-ol
1827.	2-fluoro-4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methoxy-N-methylbenzamide
1828.	1-(4-{[2-(3-{[4-(benzenesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1829.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(2-methoxy-2-methylpropyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1830.	2-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)ethan-1-ol
1831.	1-methoxy-3-(4-{[2-(3-{[2-methoxy-4-(propane-2-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-ol
1832.	1-{3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1833.	1-methoxy-3-(4-((2-(3-(((3R,4R)-3-methoxytetrahydro-2H-pyran-4-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)propan-2-ol
1834.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-propyl-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1835.	1-(4-{[1-(2-fluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1836.	2-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-1-yl)acetonitrile
1837.	1-(4-{[1-(2-chloroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1838.	rac-1-[(3R,4S)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-3-methylpiperidin-1-yl]-3-methoxypropan-2-ol
1839.	rac-1-[(3R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-3-methylpiperidin-1-yl]-3-methoxypropan-2-ol
1840.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1841.	1-[4-({1-[(2,2-difluorocyclopropyl)methyl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl}amino)piperidin-1-yl]-3-methoxypropan-2-ol
1842.	4-{[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1843.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(3-methanesulfonylpropyl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1844.	4-{[3-(4-{[1-(3-methanesulfonylpropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid

Mol #	IUPAC name
1845.	1-(4-{[2-(3-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1846.	1-(4-{[1-(2,2-difluoroethyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)ino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1847.	1-(4-{[2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1848.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(3,3,3-trifluoropropyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1849.	1-(4-{[1-(2,2-difluoropropyl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
1850.	1-{4-[(2-{3-[(2-chloro-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1851.	1-{4-[(2-{3-[(2-fluoro-4-methanesulfonyl-6-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1852.	1-(4-((2-(3-((4-((6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)sulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
1853.	(2S)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-yl propanoate
1854.	1-{4-[(2-{3-[(4-chloro-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-methoxypropan-2-ol
1855.	2-(2-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)ethoxy)ethan-1-ol
1856.	4-((3-(4-((1-(2,3-dihydroxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-(2-hydroxyethyl)-3-methoxybenzenesulfonamide
1857.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[1-(4-methyl-1,3-thiazol-2-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1858.	N-(1-cyclopropylpiperidin-4-yl)-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1859.	4-[(3-{4-[(1-cyclopropylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzoic acid
1860.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{1-[(3R)-oxolan-3-yl]piperidin-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1861.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{1-[(3S)-oxolan-3-yl]piperidin-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1862.	3-methoxy-4-{[3-(4-{[1-(oxan-4-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzoic acid

Mol #	IUPAC name
1863.	3-methoxy-4-((3-(4-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1864.	N-(2-hydroxyethyl)-3-methoxy-4-((3-(4-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1865.	3-methoxy-4-((3-(4-((1'-methyl-[1,4'-bipiperidin]-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1866.	3-methoxy-4-((3-(4-((1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
1867.	2-{2-[(3-{4-[(1-acetylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-5-methanesulfonylphenoxy}acetonitrile
1868.	4-{[3-(4-{[1-(2-hydroxyacetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
1869.	2-hydroxy-1-{4-[(2-{3-[(2-hydroxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
1870.	2-hydroxy-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
1871.	N-((3S,4S)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1872.	N-((3R,4R)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1873.	N-((3R,4R)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1874.	N-((3R,4S)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1875.	N-((3S,4R)-1,3-dimethylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1876.	1-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-2-methylpiperidin-1-yl)ethan-1-one
1877.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-2-methylpiperidin-1-yl}ethan-1-one
1878.	4-{[3-(4-{[(2S,4S)-1-acetyl-2-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1879.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methoxyethan-1-one
1880.	2-hydroxy-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-1-one

Mol #	IUPAC name
1881.	2-methoxy-1-(4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)ethan-1-one
1882.	3-methoxy-4-((3-(4-((1-(2-methoxyacetyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1883.	4-{[3-(4-{[1-(2-hydroxypropanoyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1884.	3-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile
1885.	4-{[3-(4-{[1-(2-cyanoacetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1886.	4-{[3-(4-{[1-(2-hydroxyacetyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1887.	4-[(3-{4-[(1-acetylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
1888.	2-(dimethylamino)-1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}ethan-1-one
1889.	4-((3-(4-((1-(dimethylglycyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
1890.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}-2-methylpropan-1-one
1891.	3-methoxy-4-{[3-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
1892.	4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-N,N-dimethylpiperidine-1-carboxamide
1893.	4-[(3-{4-[(1-acetylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
1894.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl}propan-1-one
1895.	3-methoxy-4-[(3-{4-[(1-propanoylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1896.	1-(4-{[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)ethan-1-one
1897.	3-methoxy-4-[(3-{4-[(1-{[(4S)-2-oxo-1,3-dioxolan-4-yl]methyl}piperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
1898.	N-((3-methoxy-4-((3-(4-((1-((2-oxo-1,3-dioxolan-4-yl)methyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)phenyl)sulfonyl)propionamide
1899.	N-[3-methoxy-4-({3-[4-({1-[(2-oxo-1,3-dioxolan-4-yl)methyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzenesulfonyl]acetamide
1900.	3-methoxy-N-methyl-4-({3-[4-({1-[(2-oxo-1,3-dioxolan-4-yl)methyl]piperidin-4-yl}amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]prop-2-yn-1-yl}amino)benzamide

Mol #	IUPAC name
1901.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-(octahydroindolizin-7-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1902.	N-[(7R,8aS)-octahydroindolizin-7-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphfenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1903.	N-[(7R,8aR)-octahydroindolizin-7-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1904.	rac-(3R,4S)-3-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1-methylpiperidin-4-ol
1905.	rac-(3R,4R)-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1-methylpiperidin-3-ol
1906.	3-methoxy-4-((3-(4-((1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
1907.	rac-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1908.	N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1909.	N-[(3S,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1910.	N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1911.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1912.	N-[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1913.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1914.	rac-4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1915.	rac-methyl 4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1916.	rac-methyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1917.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1918.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1919.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1920.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide

Mol #	IUPAC name
1921.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1922.	4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
1923.	rac-4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1924.	2-fluoro-4-((3-(4-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-methoxy-N-methylbenzamide
1925.	2-fluoro-4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-methoxy-N-methylbenzamide
1926.	4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1927.	4-{[3-(4-{[(3S,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1928.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1929.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1930.	methyl 4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1931.	rac-4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1932.	methyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1933.	rac-N-[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1934.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1935.	rac-ethyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1936.	rac-ethyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1937.	(2R)-1-(acetyloxy)-3-[(3RS,4SR)-3-fluoro-4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-yl acetate
1938.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide

Mol #	IUPAC name
1939.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1940.	N-[(3S,4R)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1941.	N-[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1942.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1943.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1944.	rac-2-hydroxypropyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1945.	4-((3-(4-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-isopropyl-3-methoxybenzamide
1946.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(propan-2-yl)benzamide
1947.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1948.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1949.	rac-2-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]acetamide
1950.	N-[(3S,4R)-1-ethyl-3-fluoropiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1951.	N-[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1952.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(2-methoxyethyl)benzamide
1953.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzamide
1954.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-hydroxy-3-methoxypropyl)-3-methoxybenzamide
1955.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(propan-2-yl)benzamide
1956.	rac-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(oxan-4-yl)benzamide

Mol #	IUPAC name
1957.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(oxan-4-yl)benzamide
1958.	rac-N-[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1959.	ethyl 4-{[3-(4-{[(3S,4R)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1960.	ethyl 4-((3-(4-(((3R,4S)-1-ethyl-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoate
1961.	ethyl 4-{[3-(4-{[(3S,4R)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoate
1962.	ethyl 4-{[3-(4-{[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoate
1963.	ethyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-(propan-2-yl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
1964.	2-fluoro-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methoxy-N-methylbenzamide
1965.	2-fluoro-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-5-methoxy-N-methylbenzamide
1966.	4-{[3-(4-{[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoic acid
1967.	4-{[3-(4-{[(3S,4R)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoic acid
1968.	rac-N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1969.	rac-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-methyl-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1970.	rac-4-((3-(4-(((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
1971.	rac-4-{[3-(4-{[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1972.	2-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-5-methanesulfonylphenol
1973.	2-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-5-methanesulfonylphenol
1974.	rac-6-fluoro-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1975.	N-(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzenesulfonyl)acetamide

Mol #	IUPAC name
1976.	N-(4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzenesulfonyl)acetamide
1977.	ethyl 4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoate
1978.	ethyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoate
1979.	N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1980.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(3-{[2-(fluoromethoxy)-4-methanesulfonylphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1981.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1982.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1983.	4-{[3-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1984.	4-{[3-(4-{[(3R,4S)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
1985.	N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1986.	N-((3R,4S)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1987.	4-{[3-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
1988.	4-((3-(4-(((3R,4S)-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamide
1989.	4-{[3-(4-{[(3R,4S)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1990.	4-{[3-(4-{[(3R,4S)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1991.	2-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-ol
1992.	2-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-ol
1993.	2-(dimethylamino)-1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one
1994.	2-(dimethylamino)-1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one

Mol #	IUPAC name
1995.	4-{[3-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methylbenzamide
1996.	4-{[3-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
1997.	N-[(3S,4R)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1998.	N-[(3R,4S)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
1999.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-[(2R)-2-hydroxy-3-methoxypropyl]piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
2000.	1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one
2001.	1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one
2002.	1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-1-one
2003.	1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-1-one
2004.	1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]-2-methoxyethan-1-one
2005.	1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]-2-methoxyethan-1-one
2006.	4-{[3-(4-{[(3R,4S)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2007.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-[(2R)-2-hydroxy-3-methoxypropyl]piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
2008.	N-[(7S,8R)-7-fluoro-1,4-dioxaspiro[4.5]decan-8-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2009.	1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-ol
2010.	1-((3S,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol

Mol #	IUPAC name
2011.	1-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2012.	4-((3-(4-(((3S,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2013.	4-((3-(4-(((3R,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2014.	4-((3-(4-(((3R,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2015.	4-((3-(4-(((3S,4R)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2016.	methyl 4-((3-(4-(((3S,4R)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoate
2017.	methyl 4-((3-(4-(((3R,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoate
2018.	(R)-1-((3R,4S)-3-fluoro-4-((2-(3-((2-fluoro-6-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-propyl-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2019.	(R)-1-((3R,4S)-4-((1-allyl-2-(3-((2-fluoro-6-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-yl)amino)-3-fluoropiperidin-1-yl)-3-methoxypropan-2-ol
2020.	4-{[3-(4-{[(3S,4R)-1-[(2R)-2,3-dihydroxypropyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
2021.	4-{[3-(4-{[(3R,4S)-1-[(2R)-2,3-dihydroxypropyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
2022.	(2R)-1-[(3RS,4SR)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-propyl-1H-indol-4-yl)amino]piperidin-1-yl]-3-methoxypropan-2-ol
2023.	4-((3-(4-(((3S,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2024.	4-((3-(4-(((3S,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid
2025.	4-((3-(4-(((3R,4R)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoic acid

Mol #	IUPAC name
2026.	(2R)-1-(acetyloxy)-3-[(3R,4S)-3-fluoro-4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-yl acetate
2027.	N-[(2R)-2,3-dihydroxypropyl]-4-{[3-(4-{[(3RS,4SR)-3-fluoro-1-[(2R)-2-hydroxy-3-methoxypropyl]piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonamide
2028.	(2R)-1-(acetyloxy)-3-[(3S,4R)-3-fluoro-4-[(2-{3-[(2-methoxy-4-sulfamoylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-yl acetate
2029.	rac-N-(2-{bis[(pyridin-2-yl)methyl]amino}ethyl)-2-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl) amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]acetamide
2030.	2-amino-1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one
2031.	2-amino-1-[(3S,4R)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]ethan-1-one
2032.	1-[(3R,4S)-3-fluoro-4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]piperidin-1-yl]propan-2-ol
2033.	3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-ol
2034.	(4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoyl)glycine
2035.	methyl 4-{[3-(4-{[(3S,4R)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2036.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2037.	methyl 4-{[3-(4-{[(3S,4R)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2038.	methyl 4-{[3-(4-{[(3S,4R)-3-fluoro-1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2039.	methyl 4-{[3-(4-{[(3S,4R)-1-(carbamoylmethyl)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2040.	methyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2041.	methyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2042.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-(2-methoxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2043.	methyl 4-{[3-(4-{[(3R,4S)-3-fluoro-1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate

Mol #	IUPAC name
2044.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(2-methoxy-4-{2-oxa-6-azaspiro[3.3]heptane-6-carbonyl}phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2045.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-{3-[(2-methoxy-4-{7-oxa-2-azaspiro[3.5]nonane-2-carbonyl}phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2046.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2047.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(3-{[2-methoxy-4-(morpholine-4-carbonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2048.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(3-{[2-methoxy-4-(4-methylpiperazine-1-carbonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2049.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2050.	4-{[3-(4-{[(3R,4S)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2051.	methyl 4-{[3-(4-{[(3S,4R)-1-[(dimethylcarbamoyl)methyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2052.	methyl 4-{[3-(4-{[(3R,4S)-1-[(dimethylcarbamoyl)methyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2053.	methyl 4-{[3-(4-{[(3R,4S)-1-(carbamoylmethyl)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoate
2054.	2-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)acetamide
2055.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(1,3-thiazol-2-yl)benzamide
2056.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
2057.	1-(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoyl)piperidin-4-ol
2058.	4-{[3-(4-{[(3S,4R)-1-[(dimethylcarbamoyl)methyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2059.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-(2-hydroxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2060.	tert-butyl (3S,4R)-4-{[2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-3-fluoropiperidine-1-carboxylate
2061.	2-(3-((4-(ethylsulfonyl)-2-methoxyphenyl)amino)prop-1-yn-1-yl)-N-((3S,4R)-3-fluoropiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2062.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-[2-(morpholin-4-yl)ethyl]benzamide
2063.	4-{[3-(4-{[(3R,4S)-1-(carbamoylmethyl)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2064.	4-{[3-(4-{[(3S,4R)-1-(carbamoylmethyl)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2065.	4-{[3-(4-{[(3R,4S)-1-[(dimethylcarbamoyl)methyl]-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2066.	tert-butyl (3S,4R)-4-[(2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-3-fluoropiperidine-1-carboxylate
2067.	(2S)-2-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]pentanedioic acid
2068.	(2S)-4-carbamoyl-2-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]butanoic acid
2069.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzene-1-sulfonic acid
2070.	1,5-dimethyl (2S)-2-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]pentanedioate
2071.	2-[3-({4-[4-(dimethylamino)piperidine-1-carbonyl]-2-methoxyphenyl}amino)prop-1-yn-1-yl]-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2072.	4-{[3-(4-{[(3S,4R)-1-(carboxymethyl)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzoic acid
2073.	2-(3-{[4-(ethanesulfonyl)-2-methoxyphenyl]amino}prop-1-yn-1-yl)-N-[(3S,4R)-3-fluoropiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2074.	(1R,2R,4S)-2-fluoro-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)cyclohexane-1,4-diamine
2075.	(1R,2R,4S)-2-fluoro-N^1-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^4-methylcyclohexane-1,4-diamine
2076.	(1S,3R,4R)-3-fluoro-N^4-(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)-N^1,N^1-dimethylcyclohexane-1,4-diamine
2077.	2-(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzenesulfonyl)ethan-1-ol
2078.	N-ethyl-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide

Mol #	IUPAC name
2079.	2-{3-[(2-ethoxy-4-methanesulfonylphenyl)amino]prop-1-yn-1-yl}-N-[(3S,4R)-3-fluoropiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2080.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N,N-dimethylbenzamide
2081.	N-ethyl-4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide
2082.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-methyl-N-(propan-2-yl)benzamide
2083.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-(2-methoxyethyl)benzamide
2084.	N-[2-(diethylamino)ethyl]-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2085.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-hydroxyethyl)-3-methoxybenzamide
2086.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-[(2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide
2087.	4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-(1-hydroxypropan-2-yl)-3-methoxybenzamide
2088.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-[(2R)-1-hydroxypropan-2-yl]-3-methoxybenzamide
2089.	N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]cyclopropanecarboxamide
2090.	(1R,2R)-N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-2-phenylcyclopropane-1-carboxamide
2091.	N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-1-methyl-1H-pyrrole-3-carboxamide
2092.	1-ethyl-N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-1H-pyrrole-3-carboxamide
2093.	1-tert-butyl-N-[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]-1H-pyrrole-3-carboxamide
2094.	methyl (2S)-4-carbamoyl-2-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]butanoate
2095.	4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-((R)-2-hydroxypropyl)-3-methoxybenzamide

Mol #	IUPAC name
2096.	rac-4-{[3-(4-{[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl] amino}-3-methoxybenzoic acid
2097.	4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-N-((S)-2-hydroxypropyl)-3-methoxybenzamide
2098.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-hydroxy-3-methoxypropyl)-3-methoxybenzamide
2099.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-[(2S)-2-hydroxypropyl]-3-methoxybenzamide
2100.	N-(2,3-dihydroxypropyl)-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2101.	N-[(2R)-2,3-dihydroxypropyl]-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2102.	N-[(2S)-2,3-dihydroxypropyl]-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2103.	N-(1,5-dihydroxypentan-3-yl)-4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxybenzamide
2104.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(3-hydroxy-2-methoxypropyl)-3-methoxybenzamide
2105.	1-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]-3-[(2-methylpropanoyl)oxy]propan-2-yl 2-methylpropanoate
2106.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxy-N-[(2-oxo-1,3-dioxolan-4-yl)methyl]benzamide
2107.	4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-N-(2-methanesulfonylethyl)-3-methoxybenzamide
2108.	1-(acetyloxy)-3-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]propan-2-yl acetate
2109.	1-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]-3-(propanoyloxy)propan-2-yl propanoate

Mol #	IUPAC name
2110.	2-[(4-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}-3-methoxyphenyl)formamido]propyl 2-methylpropanoate
2111.	(S)-5-ethoxy-2-(4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamido)-5-oxopentanoic acid
2112.	(4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzoyl)-L-glutamine
2113.	(S)-2-(4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzamido)-5-methoxy-5-oxopentanoic acid
2114.	(S)-1-((3S,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2115.	(S)-1-((3R,4R)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2116.	(S)-1-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2117.	(S)-1-((3S,4R)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2118.	1-((3S,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2119.	1-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2120.	(R)-1-((3S,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2121.	(R)-1-((3R,4R)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2122.	(R)-1-((3R,4S)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2123.	(R)-1-((3S,4R)-3-fluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2124.	4-((3-(4-(((3R,4S)-3-fluoro-1-((R)-2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide

Mol #	IUPAC name
2125.	1-(3,3-difluoro-4-((2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2126.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(1-methylazepan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2127.	1-{4-[(2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]azepan-1-yl}-3-methoxypropan-2-ol
2128.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-{8-methyl-8-azabicyclo[3.2.1]octan-3-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2129.	2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2130.	3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(1,2-oxazol-3-yl)benzene-1-sulfonamide
2131.	3-methoxy-N-(oxan-4-yl)-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2132.	3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2133.	2-{4-methoxy-5-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]pyridin-2-yl}-2-methylpropanenitrile
2134.	N-(2-hydroxyethyl)-3-methoxy-N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2135.	6-fluoro-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2136.	4-[(3-{6-fluoro-4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
2137.	3-methoxy-N,N-dimethyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2138.	3-methoxy-N-(2-methoxyethyl)-N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2139.	1-(4-{3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzenesulfonyl}piperazin-1-yl)ethan-1-one
2140.	2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2141.	3-methoxy-N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzamide
2142.	3-methoxy-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzoic acid
2143.	methyl 3-methoxy-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzoate
2144.	3-methoxy-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide
2145.	3-methoxy-N-(2-methoxyethyl)-N-methyl-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide

Mol #	IUPAC name
2146.	N,N-bis(2-hydroxyethyl)-3-methoxy-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2147.	3-methoxy-N-methyl-4-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2148.	5-methanesulfonyl-2-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenol
2149.	3-methoxy-4-[(3-{5-methoxy-4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2150.	2-[3-({2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}amino)prop-1-yn-1-yl]-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2151.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-5-methoxy-N-(oxan-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2152.	3-methoxy-4-[(3-{6-methoxy-4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]benzene-1-sulfonamide
2153.	5-methanesulfonyl-2-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]phenyl propanoate
2154.	N-(2-hydroxyethyl)-3-methoxy-4-((3-(4-((tetrahydro-2H-pyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzenesulfonamide
2155.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(2S,4R)-2-methyloxan-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2156.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(2S,4S)-2-methyloxan-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2157.	3-methoxy-4-{[3-(4-{[(2S,4R)-2-methyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
2158.	3-methoxy-4-{[3-(4-{[(2S,4S)-2-methyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
2159.	3-methoxy-4-{[3-(4-{[(2S,4R)-2-methyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
2160.	3-methoxy-4-{[3-(4-{[(2S,4S)-2-methyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
2161.	rac-N-[(3R,4R)-3-fluorooxan-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2162.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((3R,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2163.	2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-N-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2164.	N-[(3S,4S)-3-fluorooxan-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2165.	N-[(3R,4R)-3-fluorooxan-4-yl]-2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2166.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(2R,4R,6S)-2,6-dimethyloxan-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2167.	2-{3-[(4-methanesulfonyl-2-methoxyphenyl)amino]prop-1-yn-1-yl}-N-[(2R,4S,6S)-2,6-dimethyloxan-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2168.	3-methoxy-4-{[3-(4-{[(2R,4R,6S)-2,6-dimethyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
2169.	3-methoxy-4-{[3-(4-{[(2R,4S,6S)-2,6-dimethyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzamide
2170.	3-methoxy-4-{[3-(4-{[(2R,4S,6S)-2,6-dimethyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
2171.	3-methoxy-4-{[3-(4-{[(2R,4R,6S)-2,6-dimethyloxan-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl]amino}benzene-1-sulfonamide
2172.	4-((2-(3-((4-methoxypyridin-3-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2173.	2-{5-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-4-methoxypyridin-2-yl}-2-methylpropanenitrile
2174.	4-{[2-(3-{[4-methanesulfonyl-2-(trifluoromethoxy)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
2175.	4-{[2-(3-{[2-methoxy-4-(morpholine-4-sulfonyl)phenyl]amino}prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
2176.	4-({2-[3-({2-[2-(dimethylamino)ethoxy]-4-methanesulfonylphenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione
2177.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-N-(2-hydroxyethyl)-3-methoxy-N-methylbenzene-1-sulfonamide
2178.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-(1,2-oxazol-3-yl)benzene-1-sulfonamide
2179.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide
2180.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-(oxan-4-yl)benzene-1-sulfonamide
2181.	N-(2,3-dihydroxypropyl)-4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxybenzene-1-sulfonamide
2182.	N-[2-(dimethylamino)ethyl]-4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzene-1-sulfonamide
2183.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N,N-dimethylbenzene-1-sulfonamide
2184.	4-({2-[3-({4-[(4-acetylpiperazin-1-yl)sulfonyl]-2-methoxyphenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione
2185.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-(2-methoxyethyl)-N-methylbenzene-1-sulfonamide
2186.	4-[(2-{3-[(2-methoxy-4-{2-oxa-6-azaspiro[3.3]heptane-6-sulfonyl}phenyl)amino]prop-1-yn-1-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione

Mol #	IUPAC name
2187.	4-({2-[3-({2-methoxy-4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}amino)prop-1-yn-1-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione
2188.	4-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}prop-2-yn-1-yl)amino]-3-methoxy-N-methylbenzamide
2189.	4-((2-(3-((4-methoxy-6-(methylsulfonyl)pyridin-3-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2190.	4-((2-(3-((4-(methylsulfonyl)-2-(2,2,2-trifluoroethoxy)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2191.	2-(2-((3-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetamide
2192.	2-(2-((3-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-5-(methylsulfonyl)phenoxy)acetamide
2193.	N-(2,3-dihydroxypropyl)-4-((3-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxybenzenesulfonamide
2194.	3-methoxy-4-((3-(4-(3-(1-methylpiperidin-4-yl)ureido)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)benzamide

TABLE 2. Aryl-linked indole compounds of the disclosure.

Mol #	Structure IUPAC name
2195.	4-{4- [(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}benzamide
2196.	4- ({2- [4-(aminomethyl)phenyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione
2197.	4-[(2-{4-[(methylamino)methyl]phenyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
2198.	tert-butyl N- [(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]-N-methylcarbamate
2199.	4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-N-methylbenzamide
2200.	tert-butyl N- [(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]carbamate
2201.	2-(5-{[(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]amino}pyridin-2-yl)-2-methylpropanenitrile
2202.	4-{[2-(4-{[(4-methanesulfonylphenyl)amino]methyl}phenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
2203.	4-[(2-{4-[(phenylamino)methyl]phenyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
2204.	3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}benzonitrile
2205.	4-{[2-(2-fluoro-4-methylphenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
2206.	4-{[2-(3-chlorophenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
2207.	-{[2-(3-methoxyphenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
2208.	4-{[2-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
2209.	4-tert-butyl-N-[(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]benzamide
2210.	4-cyano-N- [(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]benzamide
2211.	4-chloro-N-[(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]benzamide
2212.	3-[6-(1-cyano-1-methylethyl)pyridin-3-yl]-1-[(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]urea
2213.	3-[(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]-1-phenylurea
2214.	3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}benzoic acid
2215.	4-({2-[3-(dimethylamino)phenyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione
2216.	3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-N-methylbenzamide

Mol #	Structure IUPAC name
2217.	4-{4-[(11-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}benzoic acid
2218.	4-[(2-{4-[(morpholin-4-yl)methyl]phenyl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
2219.	methyl N-(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)carbamate
2220.	1-(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)cyclopropane-1-carbonitrile
2221.	4-({2-[4-(hydroxymethyl)phenyl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione
2222.	1-[(4-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}phenyl)methyl]-3-(4-methanesulfonylphenyl)urea
2223.	4-{[2-(4-{[(6-methanesulfonylpyridin-3-yl)amino]methyl}phenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
2224.	2-(4-{[(4-methanesulfonylphenyl)amino]methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2225.	2-(4-{[(6-methylpyridin-3-yl)amino]methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2226.	2-(4-{[(4-chlorophenyl)amino]methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2227.	2-(4-{[(4-methoxyphenyl)amino]methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2228.	2-(4-{[(3-chlorophenyl)amino]methyl}phenyl)-N-[1-(oxan-4-yl)piperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2229.	6-methyl-N-{[4-(5-{[(1-methylpiperidin-4-yl)amino]methyl}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)phenyl]methyl}pyridin-3-amine
2230.	N-{[2-(4-{[(4-methanesulfonylphenyl)amino]methyl}phenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-5-yl]methyl}-1-methylpiperidin-4-amine
2231.	2-(5-amino-[1,1'-biphenyl]-3-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2232.	2-{4-[amino(phenyl)methyl]phenyl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2233.	2-(4-(amino(cyclohexyl)methyl)phenyl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2234.	2-{4-[(cyclopentylamino)methyl]phenyl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2235.	2-(4-{1-[(4-methanesulfonylphenyl)amino]ethyl}phenyl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2236.	(+/-)-2-{4-[(cyclopropylamino)methyl]phenyl}-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2237.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(4-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}phenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2238.	N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(4-{[(4-methanesulfonylphenyl)amino]methyl}phenyl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2239.	(+/-)-N-{[4-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)phenyl]methyl}benzamide

Mol #	Structure IUPAC name
2240.	(+/-)-N-{[4-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)phenyl]methyl}cyclopropanecarboxamide
2241.	1-methoxy-3-(4-{[2-(3-methyl-2H-indazol-6-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)propan-2-ol
2242.	1-(4-{[2-(2H-indazol-6-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}piperidin-1-yl)-3-methoxypropan-2-ol
2243.	4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-2',3'-dihydro-1H,1'H-[2,6'-biindol]-2'-one
2244.	4-(4-((1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)isoindolin-1-one
2245.	N-[3-(4-{[1-(2-hydroxy-3-methoxypropyl)piperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)phenyl]acetamide

TABLE 3. Heteroaryl-linked indole compounds of the disclosure.

Mol #	IUPAC name
2246.	4-((2-(6-methoxypyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide -indol-4-amine
2247.	4-((2-(6-methylpyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2248.	4-((2-(6-(dimethylamino)pyridin-3-yl)-1- (2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2249.	4-((2-(quinolin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2250.	4-((2-(2-fluoropyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2251.	1-(4-((2-(5-aminopyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)piperidin-1-yl)-3-methoxypropan-2-ol
2252.	2-(2-amino-6-phenylpyridin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2253.	5-(4-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-N-methylpicolinamide
2254.	2-(2-amino-6-phenylpyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2255.	2-(2-amino-6-(cyclohex-1-en-1-yl)pyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2256.	2-(2-amino-6-cyclohexylpyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2257.	2-(2-(methylamino)pyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2258.	2-(2-aminopyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2259.	4-{[2-(1-methyl-1H-pyrazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl]amino}-1λ⁶-thiane-1,1-dione
2260.	4-({2-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl}amino)-1λ⁶-thiane-1,1-dione

Mol #	IUPAC name
2261.	4-[(2-{1-[(pyridin-3-yl)methyl]-1H-pyrazol-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
2262.	4-((2-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)tetrahydro-2H-thiopyran 1,1-dioxide
2263.	4-[(2-{1-[(pyridin-4-yl)methyl]-1H-pyrazol-4-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino]-1λ⁶-thiane-1,1-dione
2264.	2-(5-amino-1-phenyl-1H-pyrazol-3-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2265.	2-{5-[amino(phenyl)methyl]-1H-pyrazol-3-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2266.	2-(5-amino-1H-pyrazol-3-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2267.	2-(5-{[(4-methanesulfonylphenyl)amino]methyl}-1H-pyrazol-3-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2268.	2-[5-(methylamino)-1H-pyrazol-3-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2269.	2-(5-{[(4-methanesulfonylphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2270.	N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}cyclopropanecarboxamide
2271.	N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}benzamide
2272.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2273.	(+/-)-N-[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2274.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}cyclopentanecarboxamide
2275.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}thiophene-2-carboxamide
2276.	1-fluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2277.	(+/-)-2,2-difluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2278.	(+/-)-(1R,2S)-2-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2279.	(+/-)-(1R,2R)-2-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2280.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropanecarboxamide

Mol #	IUPAC name
2281.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}oxetane-3-carboxamide
2282.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}cyclobutanecarboxamide
2283.	(+/-)-methyl N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}carbamate
2284.	methyl 4-{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}benzoate
2285.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}-1-methylpiperidine-4-carboxamide
2286.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]pyridine-2-carboxamide
2287.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]pyridine-3-carboxamide
2288.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{5-[(methylamino)methyl]-1,3,4-thiadiazol-2-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2289.	(+/-)-benzyl N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}carbamate
2290.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-4-[(morpholin-4-yl)methyl]benzamide
2291.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-3-[(morpholin-4-yl)methyl]benzamide
2292.	N-{[5-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}cyclopropanecarboxamide
2293.	N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}cyclopropanecarboxamide
2294.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]pyridine-4-carboxamide
2295.	2-fluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2296.	3-fluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2297.	4-fluoro-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2298.	(+/-)-(1S,2S)-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-2-phenylcyclopropane-1-carboxamide
2299.	4-{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}benzoic acid
2300.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-indazole-5-carboxamide
2301.	3-methyl-1-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]urea

Mol #	IUPAC name
2302.	2-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]propanamide
2303.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]acetamide
2304.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-2-phenylacetamide
2305.	2-methoxy-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]acetamide
2306.	N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2307.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2308.	4-methoxy-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2309.	3-methoxy-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2310.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]butanamide
2311.	2-methoxy-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]benzamide
2312.	2-[5-(aminomethyl)-1,3,4-thiadiazol-2-yl]-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2313.	3,3-dimethyl-1-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]urea
2314.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-indazole-6-carboxamide
2315.	benzyl N-{[5-(4-{[(3S,4R)-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl]methyl}carbamate
2316.	1-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2317.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-pyrazole-4-carboxamide
2318.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-pyrazole-5-carboxamide
2319.	1-ethyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]cyclopropane-1-carboxamide
2320.	(+/-)-methyl (1R,2R)-2-{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}cyclopropane-1-carboxylate
2321.	(+/-)-(1R,2R)-2-{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}cyclopropane-1-carboxylic acid
2322.	1-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-pyrrole-3-carboxamide
2323.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-1H-pyrrole-3-carboxamide

Mol #	IUPAC name
2324.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]-2-(thiophen-2-yl)cyclopropane-1-carboxamide
2325.	N-(1-methylpiperidin-4-yl)-2-(5-{[(pyrrolidin-3-yl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2326.	(+/-)-(1R,2S)-2-{[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-thiadiazol-2-yl)methyl]carbamoyl}cyclopropane-1-carboxylic acid
2327.	N-(1-methylpiperidin-4-yl)-2-(5-{[(1H-pyrazol-4-yl)amino]methyl}-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2328.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)cyclopentanecarboxamide
2329.	N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2330.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)benzamide
2331.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-thiadiazol-2-yl)methyl)cyclopropanecarboxamide
2332.	2-(5-((dimethylamino)methyl)-1,3,4-thiadiazol-2-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2333.	N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2334.	N-{[2-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-4-yl]methyl}cyclopropanecarboxamide
2335.	N-{[2-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-4-yl]methyl}benzamide
2336.	(+/-)-N-{[2-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-5-yl]methyl}benzamide
2337.	N-[(2-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]benzamide
2338.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(1,3-thiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2339.	N-[(2-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3-thiazol-5-yl)methyl]cyclopropanecarboxamide
2340.	(+/-)-N-{[2-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3-thiazol-5-yl]methyl}cyclopropanecarboxamide
2341.	(+/-)-2-[5-(aminomethyl)-1,3-thiazol-2-yl]-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2342.	2-(4-(aminomethyl)thiazol-2-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2343.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-{5-[(phenylamino)methyl]-1,3-thiazol-2-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine

Mol #	IUPAC name
2344.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3-thiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2345.	2-(5-{[(4-methanesulfonylphenyl)amino]methyl}thiophen-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2346.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}thiophen-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2347.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)thiophen-2-yl]methyl}benzamide
2348.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)thiophen-2-yl]methyl}cyclopropanecarboxamide
2349.	N-(1-methylpiperidin-4-yl)-2-(5-(((4-(methylsulfonyl)phenyl)amino)methyl)thiophen-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2350.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)thiophen-2-yl)methyl)benzamide
2351.	N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)thiophen-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2352.	2-(5-(amino(cyclohexyl)methyl)-1,3,4-oxadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2353.	N-(1-methylpiperidin-4-yl)-2-{5-[(phenylamino)methyl]-1,3,4-oxadiazol-2-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2354.	2-(5-(amino(tetrahydro-2H-pyran-4-yl)methyl)-1,3,4-oxadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2355.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,3,4-oxadiazol-2-yl)methyl]cyclopropanecarboxamide
2356.	2-(5-{[(4-methanesulfonylphenyl)amino]methyl}-1,3,4-oxadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2357.	N-(1-methylpiperidin-4-yl)-2-(5-{[(1H-pyrazol-4-yl)amino]methyl}-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2358.	2-(5-(aminomethyl)-1,3,4-oxadiazol-2-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2359.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2360.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl]methyl}-2-methoxybenzamide
2361.	(+/-)-2-[5-(aminomethyl)-1,3,4-oxadiazol-2-yl]-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2362.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl]methyl}-4-methoxybenzamide
2363.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl]methyl}benzamide
2364.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl]methyl}-3-methoxybenzamide

Mol #	IUPAC name
2365.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl]methyl}thiophene-2-carboxamide
2366.	(+/-)-2-(5-{[(cyclopropylmethyl)amino]methyl}-1,3,4-oxadiazol-2-yl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2367.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(3-methanesulfonylphenyl)amino]methyl}-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2368.	(+/-)-N-[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2369.	(+/-)-2-(5-((bis(cyclopropylmethyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-N-((3R,4S)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2370.	(+/-)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((3-(methylsulfonyl)phenyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2371.	(+/-)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2372.	(+/-)-2-(5-(aminomethyl)-1,3,4-oxadiazol-2-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2373.	(+/-)-N-((3S,4S)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2374.	N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)benzamide
2375.	(+/-)-N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)thiophene-2-carboxamide
2376.	(+/-)-N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-2-methoxybenzamide
2377.	(+/-)-N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-methoxybenzamide
2378.	(+/-)-N-((5-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-methoxybenzamide
2379.	(+/-)-2-(5-(((cyclopropylmethyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-N-((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2380.	(+/-)-N-((3R,4R)-3-fluoro-1-methylpiperidin-4-yl)-2-(5-(((2-methoxy-4-(methylsulfonyl)phenyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2381.	2-(3-{[(4-methanesulfonylphenyl)amino]methyl}-1,2,4-oxadiazol-5-yl)-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2382.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]cyclopropanecarboxamide

Mol #	IUPAC name
2383.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]benzamide
2384.	N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]thiophene-2-carboxamide
2385.	1-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]-1H-pyrazole-4-carboxamide
2386.	1-methyl-N-[(5-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-3-yl)methyl]-1H-pyrazole-3-carboxamide
2387.	N-(1-methylpiperidin-4-yl)-2-{5-[(phenylamino)methyl]-1,2,4-oxadiazol-3-yl}-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2388.	N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]thiophene-2-carboxamide
2389.	N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]benzamide
2390.	(+/-)-(1S,2R)-2-fluoro-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropane-1-carboxamide
2391.	N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2392.	(+/-)-(1S,2S)-2-fluoro-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropane-1-carboxamide
2393.	4-chloro-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]benzamide
2394.	N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1,3-thiazole-2-carboxamide
2395.	4-fluoro-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]benzamide
2396.	4-cyano-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]benzamide
2397.	1-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1H-pyrrole-3-carboxamide
2398.	3-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1-phenylurea
2399.	1-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1H-pyrazole-4-carboxamide
2400.	1-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-1H-pyrazole-3-carboxamide
2401.	(+/-)-(1R,2R)-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]-2-phenylcyclopropane-1-carboxamide
2402.	(+/-)-(1R,2R)-2-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropane-1-carboxamide
2403.	(+/-)-(1R,2S)-2-methyl-N-[(3-{4-[(1-methylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropane-1-carboxamide
2404.	N-[(3-{4-[(oxan-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide

Mol #	IUPAC name
2405.	N-({3-[4-(benzylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl]-1,2,4-oxadiazol-5-yl}methyl)cyclopropanecarboxamide
2406.	N-[(3-{4-[(1-acetylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2407.	N-[(3-{4-[(1,1-dioxo-1λ⁶-thian-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2408.	N-[(3-{4-[(1-benzylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2409.	N-[(3-{4-[(1-cyclopropylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2410.	N-[(3-{4-[(cyclopropylmethyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2411.	N-[(3-{4-[(cyclobutylmethyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2412.	(+/-)-N-[(3-{4-[(pyrrolidin-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2413.	N-[(3-{4-[(1-ethylpiperidin-4-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2414.	(+/-)-N-[(3-{4-[(1-methylpyrrolidin-3-yl)amino]-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl}-1,2,4-oxadiazol-5-yl)methyl]cyclopropanecarboxamide
2415.	N-{[3-(4-{[(425zetidine-3-yl)methyl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropanecarboxamide
2416.	(+/-)-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropanecarboxamide
2417.	(+/-)-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}benzamide
2418.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropanecarboxamide
2419.	N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropanecarboxamide
2420.	(+/-)-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}thiophene-2-carboxamide
2421.	(+/-)-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}thiophene-3-carboxamide
2422.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonylphenyl)amino]methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2423.	(+/-)-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1,3-thiazole-5-carboxamide
2424.	(+/-)-1-ethyl-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrrole-3-carboxamide

Mol #	IUPAC name
2425.	(+/-)-(1R,2R)-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-phenylcyclopropane-1-carboxamide
2426.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-methyl-1H-pyrrole-3-carboxamide
2427.	N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-methyl-1H-pyrrole-3-carboxamide
2428.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2429.	(+/-)-1-tert-butyl-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrrole-3-carboxamide
2430.	(+/-)-(1R,2R)-N-{[3-(4-{[(3RS,4SR)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-phenylcyclopropane-1-carboxamide
2431.	1-ethyl-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrrole-3-carboxamide
2432.	1-ethyl-N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrrole-3-carboxamide
2433.	(+/-)-N-[(3R,4S)-3-fluoropiperidin-4-yl]-2-(5-{[(4-methanesulfonyl-2-methoxyphenyl)amino]methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2434.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}thiophene-3-carboxamide
2435.	N-{[3-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}thiophene-3-carboxamide
2436.	(+/-)-N-[(3R,4S)-3-fluoropiperidin-4-yl]-2-(5-{[methyl(1H-pyrazol-4-yl)amino]methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2437.	(+/-)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[methyl(1H-pyrazol-4-yl)amino]methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2438.	(1RS,2RS)-2-cyano-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropane-1-carboxamide
2439.	1-tert-butyl-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrrole-3-carboxamide
2440.	(1RS,2SR)-2-cyano-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropane-1-carboxamide

Mol #	IUPAC name
2441.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}indolizine-2-carboxamide
2442.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-phenyl-1H-imidazole-4-carboxamide
2443.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methoxyethyl)-1H-pyrrole-3-carboxamide
2444.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(propan-2-yl)-1H-pyrrole-3-carboxamide
2445.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}pyridine-4-carboxamide
2446.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}pyridine-2-carboxamide
2447.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}pyridine-3-carboxamide
2448.	N-[(3S,4R)-3-fluoropiperidin-4-yl]-2-(5-{[(1H-pyrazol-4-yl)amino]methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2449.	benzyl N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}carbamate
2450.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-fluoroethyl)-1H-pyrrole-3-carboxamide
2451.	(1S,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-phenylcyclopropane-1-carboxamide
2452.	(1R,2S)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-phenylcyclopropane-1-carboxamide
2453.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-5-methylthiophene-3-carboxamide
2454.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-4-methylthiophene-3-carboxamide
2455.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-(4-fluorophenyl)cyclopropane-1-carboxamide
2456.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-methylthiophene-3-carboxamide
2457.	(1s,3r)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-3-methylcyclobutane-1-carboxamide

Mol #	IUPAC name
2458.	5-chloro-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}thiophene-3-carboxamide
2459.	N-[(3S,4R)-3-fluoropiperidin-4-yl]-2-(5-{[(1H-pyrazol-5-yl)amino]methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2460.	2-chloro-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}thiophene-3-carboxamide
2461.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}pyrazolo[1,5-a]pyridine-2-carboxamide
2462.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}imidazo[1,2-a]pyridine-2-carboxamide
2463.	1-cyclopropyl-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrrole-3-carboxamide
2464.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1,5-dimethyl-1H-pyrrole-3-carboxamide
2465.	4-(dimethylamino)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}benzamide
2466.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}benzenesulfonamide
2467.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclobutanecarboxamide
2468.	(1r,3s)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-3-methylcyclobutane-1-carboxamide
2469.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-(2-fluorophenyl)cyclopropane-1-carboxamide
2470.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-(1-methyl-1H-pyrazol-4-yl)cyclopropane-1-carboxamide
2471.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-(pyridin-2-yl)cyclopropane-1-carboxamide
2472.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(1H-pyrazol-4-yl)amino]methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2473.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}acetamide
2474.	1-[2-(dimethylamino)ethyl]-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrrole-3-carboxamide

Mol #	IUPAC name
2475.	N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(5-{[(1H-pyrazol-5-yl)amino]methyl}-1,2,4-oxadiazol-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2476.	1-tert-butyl-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrazole-4-carboxamide
2477.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(propan-2-yl)-1H-imidazole-4-carboxamide
2478.	(1S)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2,2-dimethylcyclopropane-1-carboxamide
2479.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-[(4-methylpiperazin-1-yl)methyl]cyclopropane-1-carboxamide
2480.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-(3-fluorophenyl)cyclopropane-1-carboxamide
2481.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-methyl-1H-1,2,3-triazole-4-carboxamide
2482.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(1-hydroxypropan-2-yl)-1H-pyrrole-3-carboxamide
2483.	2-[3-({[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}carbamoyl)-1H-pyrrol-1-yl]acetic acid
2484.	(1R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2,2-dimethylcyclopropane-1-carboxamide
2485.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methylpropyl)-1H-pyrrole-3-carboxamide
2486.	1-(cyclopropylmethyl)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrrole-3-carboxamide
2487.	3-(dimethylamino)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}benzamide
2488.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-4-(pyrrolidin-1-yl)benzamide
2489.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-hydroxypropyl)-1H-pyrrole-3-carboxamide
2490.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-[(morpholin-4-yl)methyl]cyclopropane-1-carboxamide

Mol #	IUPAC name
2491.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-{[(propan-2-yl)amino]methyl}cyclopropane-1-carboxamide
2492.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-[(propylamino)methyl]cyclopropane-1-carboxamide
2493.	3-[3-({[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}carbamoyl)-1H-pyrrol-1-yl]propanoic acid
2494.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-hydroxyethyl)-1H-pyrrole-3-carboxamide
2495.	1-(2,2-difluoroethyl)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-pyrrole-3-carboxamide
2496.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methoxy-2-methylpropyl)-1H-pyrrole-3-carboxamide
2497.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-hydroxy-2-methylpropyl)-1H-pyrrole-3-carboxamide
2498.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methoxypropyl)-1H-pyrrole-3-carboxamide
2499.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-methyl-1H-indole-6-carboxamide
2500.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(propan-2-yl)-1H-pyrazole-4-carboxamide
2501.	4-(4,4-difluoropiperidin-1-yl)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}benzamide
2502.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(propan-2-yl)-1H-imidazole-5-carboxamide
2503.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indole-5-carboxamide
2504.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-methyl-1H-indole-5-carboxamide
2505.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-4-(morpholin-4-yl)benzamide
2506.	2-[5-(aminomethyl)-1,2,4-oxadiazol-3-yl]-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine
2507.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-3-(morpholin-4-yl)benzamide

Mol #	IUPAC name
2508.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-3-(pyrrolidin-1-yl)benzamide
2509.	(1R,2R)-2-[(dimethylamino)methyl]-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropane-1-carboxamide
2510.	(1R,2R)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-[(pyrrolidin-1-yl)methyl]cyclopropane-1-carboxamide
2511.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-3-methyl-1H-indole-5-carboxamide
2512.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl] amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-indole-6-carboxamide
2513.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methoxyethyl)-1H-imidazole-5-carboxamide
2514.	(1R,2R)-2-ethyl-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}cyclopropane-1-carboxamide
2515.	1-tert-butyl-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1H-imidazole-5-carboxamide
2516.	(1S,2S)-N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-2-{[(propan-2-yl)amino]methyl}cyclopropane-1-carboxamide
2517.	N-{[3-(4-{[(3S,4R)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methoxyethyl)-1H-pyrrole-3-carboxamide
2518.	N-{[3-(4-{[(3R,4S)-1-ethyl-3-fluoropiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-1-(2-methoxyethyl)-1H-pyrrole-3-carboxamide
2519.	N-{[3-(4-{[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl]methyl}-3-methyl-1H-indole-6-carboxamide
2520.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl]methyl}cyclopropanecarboxamide
2521.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl]methyl}benzamide
2522.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl]methyl}thiophene-2-carboxamide
2523.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl]methyl}thiophene-3-carboxamide
2524.	(+/-)-N-{[5-(4-{[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]amino}-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-3-yl]methyl}-1,3-thiazole-5-carboxamide

Mol #	IUPAC name
2525.	N-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1-(1-fluoropropan-2-yl)-1H-pyrrole-3-carboxamide
2526.	N-((3-(4-(((3S,4R)-1-ethyl-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1-(2-fluoroethyl)-1H-pyrrole-3-carboxamide
2527.	N-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)-1,2,4-oxadiazol-5-yl)methyl)-1-(1-methoxypropan-2-yl)-1H-pyrrole-3-carboxamide

EXAMPLE 2: *Combination of Compound 1 and MDM2 inhibitors in MTT cell assays*

[0581] One of the key functions of activated p53 within cells is to cause growth arrest and potentially cell death. This complex array of activities can be assessed by following cell numbers over a period of time. One well established method is the MTT assay. The MTT assay is a colorimetric assay for assessing cell metabolic activity. NAD(P)H-dependent cellular oxidoreductase enzymes may, under defined conditions, reflect the number of viable cells present. These enzymes can reduce the tetrazolium dye MTT 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to its insoluble formazan, which has a purple color. Tetrazolium dye assays can also be used to measure cytotoxicity (loss of viable cells) or cytostatic activity (shift from proliferation to quiescence) of potential medicinal agents and toxic materials. We used this assay to assess the combination activity of Compound 1 (4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide) with MDM2 inhibitors (Nutlin 3a, RG7112, RG7388) in two human tumor lines were used: NUGC3 (JCRB gastric adenocarcinoma) and T3M4 (RIKEN pancreatic adenocarcinoma) which have homozygous TP53 Y220C mutations. MTT was purchased from Sigma and dissolved in PBS (Sigma) at 5 mg/ml and stored at 4C. Compounds were dissolved in 100% dimethyl sulfoxide (DMSO) (Sigma) at concentration of 10 mM and stored at -20C. The combination activity of Compound 1 with MDM2 inhibitors (Nutlin 3a, RG7112, RG7388) was evaluated using the MTT assay in 96-well plate format. Cell viability was determined by measuring the reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) (MTT) to formazan. Briefly, cells were seeded at a density of 750 ~ 1500 cells per well (depending on the growth rate) in 96-well microtiter plates in a volume of 180 µL growth medium (NUGC3 Growth medium RPMI1640 + 10% FBS; Seeding density 1500; T3M4 Growth medium DMEM-F12 HAM + 10% FBS; Seeding density 750). 180 µL of cell free medium was added to wells for MTT background. Plates were incubated at 37oC with 5% CO2 for 24 hours before the addition of Compound 1 and MDM2 inhibitors (Nutlin 3a, RG7112, RG7388). For the human cell line treatment, Compound 1 with MDM2 inhibitors

(Nutlin 3a, RG7112, RG7388) was tested at 10 μM followed by 6 additional 2-fold serial dilutions in a combinatorial matrix. Compound 1 and MDM2 inhibitors (Nutlin 3a, RG7112, RG7388) was prepared at 20X the final assay concentration in growth medium containing 2% dimethyl sulfoxide (DMSO) on drug dilution plate, 10 μL of appropriate dilution for each of the two compounds in combination was added to cell culture plate in duplicates. 20 μL of medium contained 2% DMSO was added to the wells for control (CTRL) and MTT background (BK). Antiproliferative activity in combination was assessed 5 days later by the addition of MTT. Cells were incubated with 50 μL per well of MTT at 5 mg/ml for 2 hours at 37C with 5% CO2. Thereafter, gently aspirated medium, 50 μL of 100% ethanol was added to each well to dissolve the formazan crystals. The conversion of MTT into formazan by viable cells was measured by microplate reader for absorbance with the wavelength of 570 nm and reference wavelength of 650 nm. The results were presented as a percentage of the viability of untreated cells (control), which were regarded as 100% viable using the formula:

$$percent\ viability = \frac{Mean\ absorance\ of\ experimental\ wells}{Mean\ absorance\ of\ control\ wells} \times 100$$

[0582] The IC_{50} was determined from the regression of a plot of the Logarithm of concentration versus percent of viability by XLfit IDBS. Combinations of Compound 1 (4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide) and MDM2 inhibitors shows changes in percent viability (mm^3) in an MTT cell model of gastric cancer (NUGC3). When plotted using Compusyn software, the color blue indicates combinations with an additive/synergistic effect (**FIGS. 6A-6C**). Combinations of Compound 1 and MDM2 inhibitors shows changes in percent viability (mm^3) in an MTT cell model of pancreatic cancer (T3M4). When plotted using Compusyn software, the color blue indicates combinations with additive/synergistic effect (**FIGS. 7A-7C**).

EXAMPLE 3: *Combination of Compound 1 and MDM2 inhibitors in mouse gastric cancer model*

[0583] Compound 1 (4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide) is an indole compound substituted with a trifluoroethyl group at the 1-position; propynyl amino-methoxy-methylamido phenyl group at the 2-position; and a heterocycle-substituted amino group at the 4-position. When NUGC3 tumors reached ~200 mm^3, mice were administered Vehicle, Compound 1 at 50 mg/kg, or 100 mg/kg QD, Compound 1 at 50 mg/kg simultaneous with MDM2 inhibitors at 20 mg/kg, or 100 mg/kg QD simultaneous with MDM2 inhibitors at

20 mg/kg; Compound 1 at 50 mg/kg six hours separated from dosing with MDM2 inhibitors at 20 mg/kg, or 100 mg/kg QD six hours separated from dosing with MDM2 inhibitors at 20 mg/kg; and MDM2 inhibitors at 20 mg/kg. Tumors were not harvested at the end of the survival study.

[0584] FIG. 1 shows the changes in % survival in a mouse xenograft model of gastric cancer (NUGC3). An increase in Overall Survival was Observed with a combination of Compound 1 and RG7388. When the tumor volumes were measured in a mouse xenograft model of gastric cancer (NUGC3-71), evaluating combinations of Compound 1 and AMG232 (**FIG. 2A**), reduction of tumor volumes were seen. There was no significant change in body weights (**FIG. 2B**). Similar results were observed with combinations of Compound 1 and RAIN-32 (**FIGS. 3A-3B**). Longer evaluation of the combination of Compound 1 (100 mg/kg) and AMG232 identified an improved decrease in tumor volume reduction and an increase in % survival, especially when the two were dosed 6 hour apart (**FIGS. 4A-4C** and **FIGS. 5A-5C**).

EXAMPLE 4: *Combination of Compound 1 and kinase inhibitors in CTG cell assays*

[0585] The effect of a combination of Compound 1 and various kinase inhibitors on p53 mediated growth arrest and cell death was assessed by following cell count over a period of time via a CellTiter-Glo® Luminescent Cell Viability Assay (Promega). The CellTiter-Glo® Assay is a homogeneous method to determine the number of viable cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells. The CellTiter-Glo® Luminescent Cell Viability Assay was purchased from Promega and used according to manufacturer's instructions. Compounds were dissolved in 100% dimethyl sulfoxide (DMSO) (Sigma) at concentration of 10 mM and stored at -20 °C. Briefly, cells [NUGC3 (JCRB gastric adenocarcinoma), T3M4 (RIKEN pancreatic adenocarcinoma), HCC366 (DSMZ, lung adenosquamous carcinoma), HUH-7 (JCRB, hepato cellular carcinoma), MFE-296 (DSMZ, endometrial adenocarcinoma), KON (JCRB, oral squamous carcinoma), SNU-NCC19 (KCLB, intestinal adenocarcinoma), TE-8 (RIKEN, esophagus squamous cell carcinoma), BxPC3 (ATCC, pancreatic adenocarcinoma), COV362 (ECACC, oavarian epithelial-endometroid carcinoma), HCC2935 (ATCC, lung pleural effusion), HCC1419 (ATCC, breast ductal carcinoma)] were seeded at a density of 750 ~ 5000 cells per well (depending on the growth rate) in 96-well microtiter plates in a volume of 120 µL growth medium. (NUGC3 Growth medium: RPMI1640 + 10% FBS; Seeding density 1500; T3M4 Growth medium: DMEM-F12 HAM + 10% FBS; Seeding density 750). 120 µL of cell free medium was added to wells for CTG background. Plates were incubated at 37 °C with 5% CO2 for 24 hours before the addition of Compound 1 and PI3K and AKT inhibitors. For the human cell line treatment, Compound 1 was tested at 10 µM followed by 8 additional 2-fold serial dilutions in a combinatorial matrix.

PI3K inhibitors were tested at 10 μM followed by 7 additional 2-fold serial dilutions in a combinatorial matrix. AKT inhibitors were tested at 10 μM followed by 5 additional 3-fold serial dilutions in a combinatorial matrix. Antiproliferative activity in combination was assessed 5 days later by the addition of CTG. 50 μL CTG was added per well, cells incubated for 10 mins with gentle shaking at room temperature, and luminescence was then read at 1000 ms. The results were presented as a percentage of the viability of untreated cells (control), which were regarded as 100% viable.

[0586] Results were also analyzed by Combenefit software (Roell KR, Reif DM, Motsinger-Reif AA. An introduction to terminology and methodology of chemical synergy-perspectives from across disciplines. Front Pharmacol. 2017;8:158), which enables the visualization, analysis and quantification of drug combination effects such as synergy and antagonism using classical Synergy models (Loewe, Bliss, HSA). If the actual effect of a drug combination was greater than the additive effect, the synergy score was larger than zero. If the actual effect of a drug combination was less than the additive effect the synergy score was less than zero. Thus, higher synergy scores imply synergy and lower (negative) scores imply antagonism.

[0587] FIGS. 8A-8L show highest single agent (HSA) synergy scores between PI3K inhibitor alpelisib (0.078-10 mM) and Compound 1 (0.039-10 mM) as calculated by Combenefit software in HCC2935 cells (**FIG. 8A**), SNUNCC19 cells (**FIG. 8B**), COV362 cells (**FIG. 8C**), T3M4 cells (**FIG. 8D**), HCC366 cells (**FIG. 8E**), NUGC3 cells (**FIG. 8F**), MFE296 cells (**FIG. 8G**), HUH7 cells (**FIG. 8H**), KON cells (**FIG. 8I**), TE8 cells (**FIG. 8J**), HCC1416 cells (**FIG. 8K**), and BxPC3 cells (**FIG. 8L**). .

[0588] FIGS. 9A-9B show changes in percent viability (**FIG. 9A**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9B**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor alpelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0589] FIGS. 9C-9D show changes in percent viability (**FIG. 9C**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9D**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor inavolisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0590] FIGS. 9E-9F show changes in percent viability (**FIG. 9E**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9F**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor serabelisib (0.07810 mM) together with Compound 1 (0.039-10 mM).

[0591] FIGS. 9G-9H show changes in percent viability (**FIG. 9G**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9H**) in a CTG cell model of lung cancer (HCC2935)

treated with vehicle, or PI3K inhibitor GSK2636771 (GSK263) (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0592] FIGS. 9I-9J show changes in percent viability (**FIG. 9I**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9J**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor eganelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0593] FIGS. 9K-9L show changes in percent viability (**FIG. 9K**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9L**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor idelalisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0594] FIGS. 9M-9N show changes in percent viability (**FIG. 9M**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9N**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or PI3K inhibitor duvelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0595] FIGS. 9O-9P show changes in percent viability (**FIG. 9O**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9P**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or AKT inhibitor MK2206 (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0596] FIGS. 9Q-9R show changes in percent viability (**FIG. 9Q**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9R**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or AKT inhibitor ipataserib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0597] FIGS. 9S-9T show changes in percent viability (**FIG. 9S**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 9T**) in a CTG cell model of lung cancer (HCC2935) treated with vehicle, or AKT inhibitor capivasertib (0.03-10 mM) together with Compound 1 (0.039-10 mM).

[0598] FIGS. 9U-AC show percent viability in HCC2935 cells treated with Compound 1 (0.04-10 mM) in combination with alpelisib (**FIG. 9U**), inavolisib (**FIG. 9V**), serabelisib (**FIG. 9W**), GSK2636771 (GSK263) (**FIG. 9X**), eganelisib (**FIG. 9Y**), idelalisib (**FIG. 9Z**), duvelisib (**FIG. 9AA**), MK2206 (**FIG. 9AB**), and ipatasertib (**FIG. 9AC**).

[0599] FIGS. 10A-10B show changes in percent viability (**FIG. 10A**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10B**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor alpelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0600] FIGS. 10C-10D show changes in percent viability (**FIG. 10C**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10D**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor inavolisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0601] FIGS. 10E-10F show changes in percent viability (**FIG. 10E**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10F**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor serabelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0602] FIGS. 10G-10H show changes in percent viability (**FIG. 10G**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10H**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor GSK2636771 (GSK263) (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0603] FIGS. 10I-10J show changes in percent viability (**FIG. 10I**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10J**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor eganelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0604] FIGS. 10K-10L show changes in percent viability (**FIG. 10K**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10L**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor idelalisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0605] FIGS. 10M-10N show changes in percent viability (**FIG. 10M**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10N**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or PI3K inhibitor duvelisib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0606] FIGS. 10O-10P show changes in percent viability (**FIG. 10O**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10P**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or AKT inhibitor MK2206 (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0607] FIGS. 10Q-10R show changes in percent viability (**FIG. 10Q**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10R**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or AKT inhibitor ipataserib (0.078-10 mM) together with Compound 1 (0.039-10 mM).**FIGS. 10S-10T** show changes in percent viability (**FIG. 10S**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 10T**) in a CTG cell model of gastric cancer (SNUNCC19) treated with vehicle, or AKT inhibitor capivasertib (0.078-10 mM) together with Compound 1 (0.039-10 mM).

[0608] FIGS. 10U-Z show percent viability in SNUNCC19 cells treated with Compound 1 (0.04-10 mM) in combination with GSK2636771 (GSK263) (**FIG. 10U**), eganelisib (**FIG. 10V**), idelalisib (**FIG. 10W**), duvelisib (**FIG. 10X**), MK2206 (**FIG. 10Y**), and ipatasertib (**FIG. 10Z**).

[0609] FIGS. 11A-11B show changes in percent viability (**FIG. 11A**) and Loewe synergy scores as calculated by Combenefit software (**FIG. 11B**) in a CTG cell model of pancreatic cancer (T3M4) treated with vehicle, or AKT inhibitor capivasertib (0.03-10 mM) together with Compound 1 (0.039-10 mM).

[0610] FIG. 12 provides a list of PI3K and AKT inhibitors.

EXAMPLE 5: *Combination of Compound 1 and alpesilib in mouse gastric cancer model and pancreatic cancer model*

[0611] The effect of a combination of Compound 1 (4-((3-(4-(((3S,4R)-3-fluoro-1-methylpiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxy-N-methylbenzamide and alpesilib was assessed in a mouse NUGC-3 gastric cancer model and a T3M-4 pancreatic cancer model.

[0612] NUGC-3 model. When NUGC-3 tumors reached ~200 mm^3, mice were administered vehicle, alpelisib at 20 mg/kg, Compound 1 at 50 mg/kg, or 100 mg/kg QD Compound 1 at 50 mg/kg simultaneously with alpelisib at 20 mg/kg, or 100 mg/kg QD Compound 1 simultaneously with alpelisib at 20 mg/kg. Tumors were harvested 4 and 24 h post dose for analysis of downstream biomarkers.

[0613] FIGURE 13 shows the changes in tumor volume (mm^3) in the mouse xenograft NUGC-3 model model of gastric cancer. Tumors treated with combinations exhibited decreased volumes compared to tumors treated with single agents. There was no significant decrease in percent body weight change from baseline.

[0614] T3M-4 model. When T3M-4 tumors reached an average of ~150 mm^3, mice were administered vehicle, alpelisib at 20 mg/kg, Compound 1 at 50 mg/kg, or 100 mg/kg QD Compound 1 at 50 mg/kg simultaneously with alpelisib at 20 mg/kg, or 100 mg/kg QD Compound 1 simultaneously with alpelisib at 20 mg/kg. Tumors were harvested 4 and 24 h post dose for analysis of downstream biomarkers.

[0615] FIGURE 14 shows the changes in tumor volume (mm^3) in the mouse xenograft T3M-4 model of pancreatic cancer. Tumors treated with combinations exhibited decreased volumes compared to tumors treated with single agents. There was no significant decrease in percent body weight change from baseline.

[0616] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application

and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes. The details of one or more embodiments of the disclosure are set forth in the accompanying description above. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

CLAIMS

WHAT IS CLAIMED IS:

1. A method of treating a solid tumor in a subject in need thereof, the method comprising:
   (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-tumor activity of a mutant p53 protein in the subject; and
   (ii) administering to the subject a therapeutically-effective amount of an anti-cancer agent that functions through a MDM2 pathway.

2. The method of claim 1, wherein the compound binds to the mutant p53 protein and reconforms the mutant p53 protein to a conformation of p53 that exhibits anti-tumor activity.

3. The method of claim 1, wherein the compound increases a stability of the mutant p53 protein.

4. The method of claim 1, wherein the solid tumor expresses the mutant p53 protein.

5. The method of claim 1, wherein the mutant p53 protein has a mutation at amino acid 220.

6. The method of claim 1, wherein the mutant p53 protein is p53 Y220C.

7. The method of claim 1, wherein the compound selectively binds the mutant p53 protein as compared to a wild type p53.

8. The method of claim 1, wherein the solid tumor is selected from small cell lung cancer, pancreatic cancer, prostate cancer, breast cancer, endometrial cancer, and ovarian cancer.


9. The method of claim 1, wherein the therapeutically-effective amount of the compound is from about 500 mg to about 3000 mg.

10. The method of claim 1, wherein the subject is human.


11. The method of claim 1, wherein the anti-cancer agent that functions through the MDM2 pathway is an MDM2 inhibitor.

12. The method of claim 11, wherein the MDM2 inhibitor is a small molecule.


13. The method of claim 11 wherein the MDM2 inhibitor is a compound, or a pharmaceutically-acceptable salt thereof, selected from BI-907828,




(Nutlin-1)




(Nutlin-2)




(Nutlin-3)




(RG7112)




(Idasanutlin)




(AMG-232)




(APG-115),




(CGM097),




(siremadlin),




(SAR405838),



(MK-8242),



(milademetan), and




(BI-907828).

14. The method of claim 11, wherein the therapeutically-effective amount of the MDM2

inhibitor is from about 5 mg/kg to about 500 mg/kg.

15. The method of claim 1, wherein the compound that increases anti-tumor activity of the mutant p53 protein is of the formula:



, or a pharmaceutically-acceptable salt thereof,

wherein:

- J is a cyclic group that is substituted or unsubstituted;
- R^1 is alkyl or alkenyl, each of which is unsubstituted or substituted, or -$C(O)R^{16}$, -$C(O)OR^{16}$, or -$C(O)NR^{16}R^{17}$;
- R^{16} and R^{17} are each independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -$C(O)R^{21}$, -$C(O)OR^{21}$, -$C(O)NR^{21}R^{22}$, -OR^{21}, -SR^{21}, -$NR^{21}R^{22}$, -$NR^{21}C(O)R^{22}$, -$OC(O)R^{21}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
- R^2 is substituted or unsubstituted alkyl; and
- R^3 is H.

16. The method of claim 15, wherein R^2 is substituted ethyl.


17. The method of claim 16, wherein R^2 is trifluoroethyl.

18. The method of claim 15, wherein J is aryl, heteroaryl, or heterocyclyl, each of which is substituted or unsubstituted.

19. The method of claim 18, wherein J is substituted heterocyclyl.

20. The method of claim 15, wherein R^1 is alkyl substituted with $NR^{16}R^{17}$; and each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.

21. The method of claim 15, wherein the compound that increases anti-tumor activity of the mutant p53 protein is of the formula:



,

or a pharmaceutically-acceptable salt thereof.


22. The method of claim 21, wherein R^3 is H, J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted; and each of R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or H.

23. The method of claim 22, wherein R^{16} is hydrogen or alkyl.

24. The method of claim 22, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

25. The method of claim 24, wherein R^{17} is phenyl substituted with a sulfoxide group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, or heterocyclyl, each of which is independently substituted or unsubstituted, or halo or cyano.

26. The method of claim 1, wherein the compound that increases anti-tumor activity of the mutant p53 protein is




, or a pharmaceutically-acceptable salt thereof.

27. A combination of a compound that increases anti-tumor activity of a mutant p53 protein in the subject; and an MDM2 inhibitor.

28. The combination of claim 27, wherein the compound that increases anti-tumor activity of the mutant p53 protein is contained in a first unit dosage form, and the MDM2 inhibitor is contained in a second unit dosage form.

29. The combination of claim 27, wherein the mutant p53 protein is p53 Y220C.

30. The combination of claim 27, wherein the compound is of the formula:



wherein R^3 is H; J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted; and each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or H.

31. The combination of claim 30, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.


32. The combination of claim 30, wherein R^{16} is hydrogen or alkyl.

33. The combination of claim 30, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.


34. The combination of claim 30, wherein R^{17} is substituted aryl.

35. The combination of claim 30, wherein R^{17} is phenyl substituted with a sulfoxide group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, or heterocyclyl, each of which is independently substituted or unsubstituted, or halo or cyano.


36. The combination of claim 30, wherein the MDM2 inhibitor is selected from:




(Nutlin-1)




(Nutlin-2)




(Nutlin-3)




(RG7112)




(Idasanutlin)




(AMG-232)




(APG-115),




(CGM097),




(siremadlin),




(SAR405838),



(MK-8242),




(milademetan), and



(BI-907828),


or a pharmaceutically-acceptable salt thereof.

37. The combination of claim 27, wherein the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.

38. A method of treating a solid tumor in a subject in need thereof, the method comprising:
(i) administering to the subject a therapeutically-effective amount of a compound that increases anti-tumor activity of a mutant p53 protein in the subject, wherein the compound is of the formula:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each Z is independently $-Q^1-N(R^3)J$, $-Q^1-O-J$, or $-Q^1-J$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- A is a linking group;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a bond;
- m is 1, 2, 3, or 4;
- each J is independently a cyclic group;
- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is

independently substituted or unsubstituted, or -C(O)R^{16}, -C(O)OR^{16}, -C(O)N$R^{16}R^{17}$, -OR^{16}, -SR^{16}, -N$R^{16}R^{17}$, -NR^{16}C(O)R^{16}, -OC(O)R^{16}, C=O, C=S, -CN, -Si$R^{16}R^{17}R^{18}$, or hydrogen;

- each R^3 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R^{19}, -C(O)OR^{19}, -C(O)N$R^{19}R^{20}$, -SOR^{19}, -SO_2R^{19}, or hydrogen, or R^3 and J together with the nitrogen atom to which R^3 and J are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or -C(O)R^{21}, -C(O)OR^{21}, -C(O)N$R^{21}R^{22}$, -OR^{21}, -SR^{21}, -N$R^{21}R^{22}$, -NR^{21}C(O)R^{22}, -OC(O)R^{21}, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or C(O)R^{23}, -C(O)OR^{23}, -C(O)N$R^{23}R^{24}$, -OR^{23}, -SR^{23}, -N$R^{23}R^{24}$, -NR^{23}C(O)R^{24}, -OC(O)R^{23}, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof; and

(ii) administering to the subject a therapeutically-effective amount of a PI3K inhibitor.

39. The method of claim 38, wherein the PI3K inhibitor is alpelisib, or a pharmaceutically-acceptable salt thereof.

40. The method of claim 38, wherein the PI3K inhibitor is inavolisib, or a pharmaceutically-acceptable salt thereof.

41. The method of claim 38, wherein the PI3K inhibitor is serabelisib, or a pharmaceutically-acceptable salt thereof.


42. The method of claim 38, wherein the PI3K inhibitor is GSK2636771, or a pharmaceutically-acceptable salt thereof.

43. The method of claim 38, wherein the PI3K inhibitor is eganelisib, or a pharmaceutically-acceptable salt thereof.

44. The method of claim 38, wherein the PI3K inhibitor is idelalisib, or a pharmaceutically-acceptable salt thereof.

45. The method of claim 38, wherein the PI3K inhibitor is duvelisib, or a pharmaceutically-acceptable salt thereof.

46. The method of claim 38, wherein the compound that increases anti-tumor activity of a mutant p53 protein is of the formula:



wherein R^3 is H; J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted; and each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or H.

47. The method of claim 46, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.


48. The method of claim 46, wherein R^{16} is hydrogen or alkyl.

49. The method of claim 46, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

50. The method of claim 46, wherein R^{17} is substituted aryl.


51. The method of claim 46, wherein R^{17} is phenyl substituted with a sulfoxide group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, or heterocyclyl, each of which is independently substituted or unsubstituted, or halo or cyano.

52. The method of claim 38, wherein the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.

53. A method of treating a solid tumor in a subject in need thereof, the method comprising: (i) administering to the subject a therapeutically-effective amount of a compound that increases anti-tumor activity of a mutant p53 protein in the subject, wherein the compound is of the formula:



,

wherein:

- each ------- is independently a single bond or a double bond;
- X^1 is CR^5, CR^5R^6, N, NR^5, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^2 is CR^7, CR^7R^8, N, NR^7, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^3 is CR^9, CR^9R^{10}, N, NR^9, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^4 is CR^{11}, $CR^{11}R^{12}$, N, NR^{11}, O, S, C=O, C=S, or a carbon atom connected to Q^1;
- X^5 is CR^{13}, N, or NR^{13};
- each Z is independently $-Q^1-N(R^3)J$, $-Q^1-O-J$, or $-Q^1-J$;

wherein at least one of X^1, X^2, X^3, and X^4 is a carbon atom connected to Q^1;

- A is a linking group;
- each Q^1 is independently alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or C=O, C=S, $C=CR^{14}R^{15}$, $C=NR^{14}$, or a

bond;

- m is 1, 2, 3, or 4;
- each J is independently a cyclic group;
- R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{16}$, $-C(O)OR^{16}$, $-C(O)NR^{16}R^{17}$, $-OR^{16}$, $-SR^{16}$, $-NR^{16}R^{17}$, $-NR^{16}C(O)R^{16}$, $-OC(O)R^{16}$, C=O, C=S, -CN, $-SiR^{16}R^{17}R^{18}$, or hydrogen;
- each R^3 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{19}$, $-C(O)OR^{19}$, $-C(O)NR^{19}R^{20}$, $-SOR^{19}$, $-SO_2R^{19}$, or hydrogen, or R^3 and J together with the nitrogen atom to which R^3 and J are bound form a ring, wherein the ring is substituted or unsubstituted;
- each R^2, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, and R^{18} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $-C(O)R^{21}$, $-C(O)OR^{21}$, $-C(O)NR^{21}R^{22}$, $-OR^{21}$, $-SR^{21}$, $-NR^{21}R^{22}$, $-NR^{21}C(O)R^{22}$, $-OC(O)R^{21}$, hydrogen, or halogen;
- each R^{19} and R^{20} is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or $C(O)R^{23}$, $-C(O)OR^{23}$, $-C(O)NR^{23}R^{24}$, $-OR^{23}$, $-SR^{23}$, $-NR^{23}R^{24}$, $-NR^{23}C(O)R^{24}$, $-OC(O)R^{23}$, hydrogen, or halogen;
- each R^{21} and R^{22} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
- each R^{23} and R^{24} is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,

or a pharmaceutically-acceptable salt thereof; and


(ii) administering to the subject a therapeutically-effective amount of a AKT inhibitor selected from MK2206, ipatasertib, and capivasertib.

54. The method of claim 53, wherein the AKT inhibitor is MK2206, or a pharmaceutically-acceptable salt thereof.

55. The method of claim 53, wherein the AKT inhibitor is ipatasertib, or a pharmaceutically-acceptable salt thereof.

56. The method of claim 53, wherein the AKT inhibitor is capivasertib, or a pharmaceutically-acceptable salt thereof.

57. The method of claim 53, wherein the compound is of the formula:



wherein R^3 is H; J is piperidinyl, piperazinyl, tetahydropyranyl, morpholinyl, or pyrrolidinyl, each of which is independently substituted or unsubstituted; and each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted, or H.

58. The method of claim 57, wherein each R^{16} and R^{17} is independently alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, each of which is independently substituted or unsubstituted; or hydrogen.


59. The method of claim 57, wherein R^{16} is hydrogen or alkyl.

60. The method of claim 57, wherein R^{17} is aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted.

61. The method of claim 57, wherein R^{17} is substituted aryl.

62. The method of claim 57, wherein R^{17} is phenyl substituted 1, 2, 3, or 4 groups each independently selected from a sulfoxide group, carbamoyl group, sulfonyl group, carboxyl group, amide group, amino group, alkyl, alkoxy, hydroxy, and heterocyclyl, each of which is independently substituted or unsubstituted, or halo or cyano.

63. The method of claim 53, wherein the compound that increases anti-tumor activity of the mutant p53 protein is



(Compound 1), or a pharmaceutically-acceptable salt thereof.



Survival to 1000 mm3 Tumor Volume
a Vehicle Control
b RG7388 20 mg/kg QD
c Cpd 1 50 mg/kg QD
d Cpd 1 + RG7388 Combo
e Cpd 1 100 mg/kg QD
f Cpd 1 + RG7388 Combo
% Survival
100
50
0
0
20
40
60
80
100
Days

FIG. 1



Mean Tumor Volumes
Tumor Volume (mm³)
2000
1500
1000
500
-10
0
10
20
30
Days
Vehicle
AGM232 20 mg/kg (0% TGI)
Cpd 1 50 mg/kg (78% TGI)
Cpd 1 50 mg/kg + AMG232 20mg/kg - Simultaneously (85% TGI)
Cpd 1 50 mg/kg + AMG232 20mg/kg - 6h Apart (97% TGI)
Cpd 1 100 mg/kg (10% Reg)
Cpd 1 100 mg/kg + AMG232 20mg/kg - Simultaneously (77% Reg)
Cpd 1 100 mg/kg + AMG232 20mg/kg - 6h Apart (76% Reg)

FIG. 2



% Body Weight Change
Body Weight change (%)
20
15
10
5
0
-5
0
5
10
15
Days
Vehicle
RAIN-32 20mg/kg
Cpd 1 50mg/kg
Cpd 1 50mg/kg + RAIN-32 20mg/kg - Simultaneously
Cpd 1 50mg/kg + RAIN-32 20mg/kg - 6hr Apart
Cpd 1 100mg/kg
Cpd 1 100mg/kg + RAIN-32 20mg/kg - Simultaneously
Cpd 1 100mg/kg + RAIN-32 20mg/kg - 6hr Apart

FIG. 3A



Mean Tumor Volumes
Tumor Volume (mm3)
1000
500
0
0
5
10
15
Days
Vehicle
RAIN-32 20mg/kg
Cpd 1 50mg/kg
Cpd 1 50mg/kg + RAIN-32 20mg/kg - Simultaneously
Cpd 1 50mg/kg + RAIN-32 20mg/kg - 6hr Apart
Cpd 1 100mg/kg
Cpd 1 100mg/kg + RAIN-32 20mg/kg - Simultaneously
Cpd 1 100mg/kg + RAIN-32 20mg/kg - 6hr Apart

FIG. 3B




FIG. 4A




FIG. 4B




FIG. 4C



Mean Tumor Volumes
Tumor Volume (mm³)
2500
2000
1500
1000
500
0
50
Days
Vehicle
RAIN-32 20 mg/kg
Cpd 1 50 mg/kg
Cpd 1 50 mg/kg + RAIN-32 20mg/kg - Simultaneously
Cpd 1 50 mg/kg + RAIN-32 20mg/kg - 6h Apart
Cpd 1 100 mg/kg
Cpd 1 100 mg/kg + RAIN-32 20mg/kg - Simultaneously
Cpd 1 100 mg/kg + RAIN-32 20mg/kg - 6h Apart

FIG. 5A



Survival of NUGC3-70
% Survival
100
50
0
0
20
40
60
80
Days
Vehicle
RAIN-32 20 mg/kg
Cpd 1 50 mg/kg
Cpd 1 50 mg/kg + RAIN-32 20mg/kg Simultaneously
Cpd 1 50 mg/kg +RAIN-32 20mg/kg 6h Apart
Cpd 1 100mg/kg
Cpd 1 100 mg/kg + RAIN-32 20mg/kg Simultaneously
Cpd 1 100 mg/kg + RAIN-32 20mg/kg 6h Apart

FIG. 5B



Survival of NUGC3-70
% Survival
100
50
0
0
20
40
60
80
Days
Vehicle
RAIN-32 20 mg/kg
Cpd 1 50 mg/kg
Cpd 1 50 mg/kg + RAIN-32 20mg/kg Simultaneously
Cpd 1 50 mg/kg + RAIN-32 20mg/kg 6h Apart
Cpd 1 100mg/kg
Cpd 1 100 mg/kg + RAIN-32 20mg/kg Simultaneously
Cpd 1 100 mg/kg + RAIN-32 20mg/kg 6h Apart

FIG. 5C




FIG. 6A

Avg. Via(%)	0	0.015625	0.03125	0.0625	0.125	0.25	0.5	1	2.5	5	10
0.01	100.0	97.4	101.0	108.8	108.7	96.6	91.5	95.4			
0.15625	94.0	94.3	96.1	96.1	96.7	94.3	96.3	92.8			
0.3125	92.3	89.8	93.1	86.1	83.6	80.2	79.4	76.1			
0.625	47.7	40.8	37.1	31.4	27.7	24.9	25.9	25.3			
1.25	27.4	25.6	26.5	22.7	21.2	19.8	17.6	15.3			
2.5	22.8	23.2	22.1	20.4	18.2	14.6	12.5	10.3			
5	21.6	22.0	21.1	19.6	15.7	12.7	9.7	8.1			
10	25.3	23.4	22.9	18.9	15.6	13.8	8.7	7.8			

Cpd 1 (μM) ← Nutlin 3a (μM)

FIG. 6B


Avg. Via (%)	0	0.015625	0.03125	0.0625	0.125	0.25	0.5	1	2.5	5	10
0	100.0	105.2	106.8	106.7	110.3	111.7	114.7	109.7			
0.15625	101.2	104.5	104.1	103.7	105.4	106.5	109.7	113.4			
0.3125	89.9	92.1	91.8	86.5	88.5	92.5	93.1	99.4			
0.625	44.9	42.0	42.9	36.6	34.4	28.8	28.3	25.0			
1.25	26.5	25.4	27.4	22.9	23.2	21.0	18.3	16.1			
2.5	21.7	21.1	23.0	20.2	19.1	19.2	15.4	12.7			
5	21.1	19.3	21.3	19.6	16.8	16.5	13.4	9.6			
10	21.1	20.7	24.7	18.6	17.8	20.1	13.1	11.3			

Cpd 1 (μM) ← RG7112 (μM)

FIG. 6C

Avg. Via (%)	0	0.015625	0.03125	0.0625	0.125	0.25	0.5	1	2.5	5	10
0	100.0	100.4	98.8	97.4	97.8	91.5	87.1	81.3			
0.15625	97.7	98.6	95.8	97.2	92.1	89.8	85.0	78.1			
0.3125	92.5	91.2	86.3	83.6	80.1	78.3	70.4	62.7			
0.625	52.6	49.0	47.3	43.6	43.4	42.7	35.0	24.3			
1.25	28.3	19.4	19.0	17.4	16.2	15.7	15.2	15.9			
2.5	23.2	16.1	15.0	14.1	11.4	10.9	9.9	9.0			
5	21.8	15.8	13.6	11.4	9.4	8.6	7.5	6.6			
10	23.6	16.1	14.1	11.7	10.4	7.6	6.2	5.8			

Cpd 1 (μM) ← RG7338 (μM)


Cpd 1 + Nutlin 3a
Nutlin 3a (μM)
0.0000
0.1563
0.3125
0.6250
1.2500
2.5000
5.0000
10
% of Control
Cpd 1 (μM)
Cpd 1 + RG7112
RG7112 (μM)
0.0000
0.0156
0.0313
0.0625
0.1250
0.2500
0.5000
1
% of Control
Cpd 1 (uM)
Cpd 1 + RG7388
RG7388 (μM)
0.0000
0.0156
0.0313
0.0625
0.1250
0.2500
0.5000
1
% of Control
Cpd 1 (μM)
Avg. Via (%)
← Nutlin 3a (μM)
0 0.015625 0.03125 0.0625 0.125 0.25 0.5 1 2.5 5 10
0.01 100.0 98.9 101.3 102.4 102.5 99.0 97.5 72.7
0.15625 102.6 102.2 102.1 98.9 96.3 92.7 88.7 74.6
0.3125 103.4 105.4 103.3 96.9 98.8 96.1 87.4 70.8
0.625 93.3 90.1 87.9 78.3 71.2 74.8 62.7 45.6
1.25 59.9 50.5 44.1 33.8 26.7 20.5 19.4 15.8
2.5 33.9 25.7 26.8 16.2 12.8 9.9 9.2 7.4
5 20.2 15.4 14.5 11.5 9.3 7.8 6.4 5.1
10 15.1 13.8 13.8 10.8 10.0 8.4 6.8 5.3
Cpd 1 (μM)
FIG. 7A
Avg. Via (%)
← RG7112 (μM)
0 0.015625 0.03125 0.0625 0.125 0.25 0.5 1
0 100.0 108.0 102.8 107.8 110.0 108.3 106.5 99.8
0.15625 97.0 102.9 105.5 104.0 107.8 101.6 102.3 101.8
0.3125 108.7 107.2 105.8 108.2 108.5 110.0 105.4 108.3
0.625 83.2 85.4 87.8 81.0 76.5 69.2 76.7 71.6
1.25 56.2 51.3 47.4 42.3 35.5 28.9 24.1 19.9
2.5 33.6 30.6 29.1 31.2 28.1 14.5 11.8 11.0
5 23.1 17.1 19.4 15.2 13.1 12.4 8.1 7.9
10 16.9 13.8 17.6 12.6 12.1 11.5 9.1 8.8
Cpd 1 (μM)
FIG. 7B
Avg. Via (%)
← RG7338 (μM)
0 0.015625 0.03125 0.0625 0.125 0.25 0.5 1
0 100.0 103.7 105.9 108.1 116.3 108.1 107.6 104.8
0.15625 97.3 105.6 98.5 98.6 102.0 101.0 105.5 101.9
0.3125 109.3 105.3 110.5 109.9 110.0 114.6 107.7 110.2
0.625 96.9 88.8 91.3 86.9 89.3 93.3 92.8 83.8
1.25 63.4 29.4 29.6 24.4 24.0 25.4 25.3 25.6
2.5 36.3 13.7 13.4 9.5 8.1 8.4 8.0 7.4
5 22.8 10.7 9.3 7.6 5.8 5.7 4.6 4.7
10 15.1 9.5 8.0 5.8 4.6 4.1 4.2 3.3
Cpd 1 (μM)
FIG. 7C

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-4	-5	-1	2	3	3	3	4	4
0.156	1	1	5	5	5	7	7	8	8
0.312	2	3	10	13	12	12	14	12	14
0.625	7	7	20	21	19	20	21	19	21
1.25	0	4	21	24	21	23	21	21	24
2.5	-1	5	24	33	32	32	33	34	34
5	0	8	26	37	40	24	41	41	43
10	7	15	25	29	32	32	31	31	33

HSA synergy and antagonism HCC2935 – Cpd 1 + Alpelisib

FIG. 8A

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	0	2	8	14	13	11	9	7	11
0.156	1	6	16	20	18	17	15	14	19
0.312	4	8	29	32	25	23	23	20	19
0.625	1	6	26	37	31	30	28	26	24
1.25	2	9	25	33	35	35	35	34	34
2.5	4	9	20	23	25	25	26	25	26
5	4	8	15	16	17	17	17	17	19
10	4	6	10	11	12	12	12	12	16

HSA synergy and antagonism SNUNCC19 – Cpd 1 + Alpelisib

FIG. 8B

Cpd 1(μM)

Alpelisib (μM)	0.0015	0.0045	0.0137	0.0411	0.123	0.37	1.11	3.33	10
0.1	0	2	8	14	13	11	9	7	11
0.3	1	6	16	20	18	17	15	14	19
1	4	8	29	32	25	23	23	20	19
3	1	6	26	37	31	30	28	26	24
10	2	9	25	33	35	35	35	34	34

HSA synergy and antagonism COV362 – Cpd 1 + Alpelisib

FIG. 8C

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	10	11	11	7	13	9	11	9	5
0.156	1	-3	5	2	3	20	12	7	5
0.312	-2	-6	0	1	15	16	16	9	6
0.625	-2	-3	5	11	25	34	25	15	10
1.25	-8	-2	1	3	15	25	31	18	12
2.5	-3	-2	1	4	13	17	19	19	15
5	4	6	7	7	9	10	10	10	10
10	4	4	4	5	5	5	5	5	5

HSA synergy and antagonism T3M4 – Cpd 1 + Alpelisib

FIG. 8D

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-18	-13	-5	-18	-9	5	6	3	3
0.156	-7	-9	-13	-29	-10	4	6	-4	5
0.312	10	3	-6	-12	3	18	16	11	11
0.625	8	-2	-9	-7	5	20	21	15	21
1.25	8	1	-9	-12	1	19	28	21	30
2.5	1	-2	-2	-13	8	10	18	25	32
5	-6	-4	-11	-8	0	11	11	14	23
10	-4	-1	1	1	4	6	8	11	17

HSA synergy and antagonism HCC366 – Cpd 1 + Alpelisib

FIG. 8E

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.156	0	-9	-2	1	7	-3	0	0	7
0.312	-2	1	4	10	3	-3	-1	3	7
0.625	0	7	6	19	11	-1	1	3	9
1.25	3	1	4	18	9	2	4	5	10
2.5	2	-3	1	23	17	7	9	9	13
5	10	6	1	28	24	14	13	14	18
10	5	2	5	14	19	18	16	17	21

HSA synergy and antagonism NUGC3 – Cpd 1 + Alpelisib

FIG. 8F

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-5	-8	-4	-5	4	5	0	-1	5
0.156	-9	-9	-10	-5	1	8	0	-2	5
0.312	3	1	1	4	11	13	5	2	7
0.625	-2	-2	0	6	10	10	5	3	8
1.25	-5	-4	-4	6	13	17	10	7	10
2.5	5	4	2	13	28	27	15	12	12
5	-3	-2	-1	8	21	30	22	15	13
10	0	2	3	14	30	42	32	22	15

HSA synergy and antagonism MFE296 – Cpd 1 + Alpelisib

FIG. 8G

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-2	-10	-2	1	-2	-5	-5	-2	7
0.156	-3	-9	-3	4	-1	-5	-3	0	10
0.312	5	3	6	10	4	-1	-1	2	10
0.625	4	3	3	10	5	1	0	4	13
1.25	3	4	10	15	7	5	5	9	16
2.5	7	7	17	25	18	12	12	15	21
5	2	5	10	16	19	18	18	19	25
10	0	4	7	9	11	15	18	23	27

HSA synergy and antagonism HUH7 – Cpd 1 + Alpelisib

FIG. 8H

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	9	-4	-1	3	0	-6	-3	1	6
0.156	4	0	0	4	2	-6	-2	2	3
0.312	11	4	1	7	2	-3	-3	1	6
0.625	11	9	9	8	7	-2	-2	1	5
1.25	11	7	20	19	11	2	0	3	6
2.5	4	10	18	27	14	7	2	4	6
5	-1	1	13	22	20	10	5	5	6
10	4	4	9	13	15	13	8	7	7

HSA synergy and antagonism KON – Cpd 1 + Alpelisib

FIG. 8I

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-4	-3	-6	-5	-5	-5	1	3	5
0.156	-3	-6	-8	-4	-8	-6	-1	9	13
0.312	5	4	4	3	3	2	6	15	14
0.625	-2	1	-3	0	-2	-1	4	15	19
1.25	-2	-2	-4	-3	-4	-3	5	17	26
2.5	6	5	5	4	4	7	11	21	36
5	-1	-1	-1	-2	0	3	8	16	34
10	1	0	0	1	3	6	10	16	29

HSA synergy and antagonism TE8 – Cpd 1 + Alpelisib

FIG. 8J

Cpd 1 (μM)

Alpelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-9	-9	-10	-9	-9	-5	0	2	2
0.156	-2	-1	-2	0	0	0	3	-2	-11
0.312	2	1	1	4	5	6	8	6	-3
0.625	4	5	4	5	7	10	16	22	21
1.25	1	0	2	3	4	8	12	21	8
2.5	0	0	0	2	2	7	11	17	33
5	-1	-1	-2	5	4	2	12	17	25
10	4	3	5	6	10	9	10	14	22

HSA synergy and antagonism HCC1416 – Cpd 1 + Alpelisib

FIG. 8K

Cpd 1 (μM)

Alpelisib (μM)	0.0015	0.0045	0.0137	0.0411	0.123	0.37	1.11	3.33	10
0.1	2	6	5	2	2	-1	0	1	4
0.3	4	9	9	7	4	2	1	3	6
1	2	3	16	15	6	3	4	5	8
3	-1	0	4	18	8	5	5	6	10
10	2	4	10	19	17	12	12	13	15

HSA synergy and antagonism BxPC3 – Cpd 1 + Alpelisib

FIG. 8L




FIG. 9A

Cpd 1 (μM)

Alpelisib (μM)

	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-4	-3	5	6	5	1	1	4	10
0.156	-7	-9	9	5	6	5	4	9	14
0.312	-5	0	11	14	9	9	8	11	16
0.625	-3	3	14	17	13	15	15	16	22
1.25	-4	0	20	22	20	21	20	22	24
2.5	-5	4	17	22	22	22	22	24	27
5	0	5	18	23	27	25	25	29	32
10	9	15	23	28	30	3	32	34	36

Loewe synergy and antagonism HCC2935 – Cpd 1 + Alpelisib

FIG. 9B




FIG. 9C

Cpd 1 (μM)

Inavolisib (μM)

	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	0	3	14	13	9	8	7	13	16
0.156	4	11	22	22	15	14	15	7	20
0.312	-8	2	19	15	14	12	11	18	20
0.625	-8	7	21	21	19	18	16	20	25
1.25	2	11	23	26	24	23	23	25	28
2.5	7	14	25	29	28	24	28	28	32
5	0	11	23	26	28	28	31	31	35
10	3	12	20	24	25	28	29	30	32

Loewe synergy and antagonism HCC2935 – Cpd 1 + Inavolisib

FIG. 9D




FIG. 9E

Cpd 1 (μM)

Serabelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-17	-17	-4	-10	-13	-10	-6	-5	4
0.156	-6	-9	-3	-3	-10	-2	-6	-2	5
0.312	-25	-24	-7	-10	-12	-8	-8	-8	2
0.625	-29	-21	-11	-9	-8	-7	-7	-3	4
1.25	-10	-12	1	1	-1	1	3	9	13
2.5	-4	-2	9	8	9	13	12	13	17
5	-2	3	14	20	23	22	22	23	25
10	5	11	24	28	33	31	29	28	32

Loewe synergy and antagonism HCC2935 – Cpd 1 + Serabelisib

FIG. 9F




FIG. 9G

Cpd 1 (µM)

GSK2636771 (µM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-2	5	11	9	1	-1	2	6	10
0.156	-1	3	13	7	3	2	3	5	13
0.312	-2	4	14	8	3	1	3	4	10
0.625	-1	3	13	6	2	1	3	6	10
1.25	0	7	15	11	5	2	3	7	11
2.5	-2	3	13	7	3	1	1	5	10
5	-1	4	12	8	2	0	2	3	5
10	1	7	14	8	3	4	5	4	8

Loewe synergy and antagonism HCC2935 – Cpd 1 + GSK2636771

FIG. 9H




FIG. 9I

Cpd 1 (μM)

Eganelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-6	-4	8	4	-1	-5	-3	1	10
0.156	-4	0	12	8	3	-1	1	4	10
0.312	-2	-1	11	9	7	5	4	7	12
0.625	-6	1	16	13	10	8	8	9	16
1.25	-5	1	15	21	15	12	12	13	17
2.5	-1	6	18	21	20	18	18	17	21
5	1	4	15	19	21	20	19	20	24
10	2	4	15	21	22	23	23	24	26

Loewe synergy and antagonism HCC2935 – Cpd 1 + Eganelisib

FIG. 9J




FIG. 9K

Cpd 1 (µM)

Idelalisib (µM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-6	-7	7	3	2	-2	-2	2	7
0.156	0	2	11	6	1	1	2	5	10
0.312	-7	-2	8	9	5	2	4	5	11
0.625	-7	-3	8	8	5	5	3	5	11
1.25	-2	5	16	14	10	8	8	10	14
2.5	-3	3	15	17	14	8	12	13	17
5	0	1	17	17	12	12	12	14	19
10	1	4	17	23	18	17	16	18	21

Loewe synergy and antagonism HCC2935 – Cpd 1 + Idelalisib

FIG. 9L




FIG. 9M

Cpd 1 (µM)

Duvelisib (µM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	10
0.078	4	3	14	13	8	2	4	10
0.156	-21	-19	-11	-1	-13	-15	-3	7
0.312	-3	1	12	10	6	5	4	14
0.625	-6	2	15	11	7	8	7	15
1.25	1	11	20	19	14	13	14	20
2.5	1	9	16	17	16	15	14	23
5	0	5	15	19	18	19	20	26
10	0	10	18	22	24	26	27	32

Loewe synergy and antagonism HCC2935 – Cpd 1 + Duvelisib

FIG. 9N




FIG. 9O

Cpd 1 (μM)

MK2206 (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-2	-2	15	20	19	15	15	16	20
0.156	3	10	24	28	26	23	21	23	25
0.312	-3	5	19	25	23	21	21	21	25
0.625	-1	4	18	23	23	22	22	23	25
1.25	0	6	17	21	22	22	24	23	28
2.5	-3	5	13	20	22	23	25	27	29
5	0	6	14	17	20	21	22	24	27
10	9	12	18	20	22	22	23	26	29

Loewe synergy and antagonism HCC2935 – Cpd 1 + MK2206

FIG. 9P




FIG. 9Q

Cpd 1 (μM)

patasertib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-9	-2	9	8	4	3	3	4	9
0.156	-4	1	14	14	9	7	7	10	13
0.312	-3	5	16	18	15	13	11	14	17
0.625	-2	8	19	21	20	18	16	18	20
1.25	3	11	21	23	23	21	22	20	23
2.5	0	7	17	21	23	23	21	21	23
5	2	9	16	21	23	24	22	24	25
10	5	10	17	21	22	24	25	25	26

Loewe synergy and antagonism HCC2935 – Cpd 1 + patasertib

FIG. 9R




FIG. 9S

Cpd 1 (μM)

Capivasertib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.03	-5	-9	-11	2	-1	2	4	6	8
0.1	-4	-5	-1	9	13	13	12	13	15
0.3	0	2	2	17	21	20	21	23	26
1	-1	0	6	22	25	26	26	26	28
3	-1	-2	4	17	22	24	26	27	28
10	-1	1	6	15	20	21	23	24	26

Loewe synergy and antagonism HCC2935 – Cpd 1 + Capivasertib

FIG. 9T

HCC2935 (Lung)		Cpd 1 (μM)									
		0	0.039	0.078	0.156	0.313	0.625	1.25	2.5	5.0	10.0
Alpelisib (μM)	0	100.0	101.0	97.5	76.1	62.6	54.2	53.4	46.7	41.4	36.7
	0.312	86.9	90.8	83.1	64.2	49.2	43.2	37.7	36.0	32.6	26.8
	0.625	79.4	84.1	75.0	57.9	44.7	38.8	31.6	28.9	27.0	21.2
	1.25	74.3	77.8	71.4	46.9	36.9	30.4	25.0	23.5	20.8	19.0
	2.5	73.9	70.7	59.9	43.4	32.8	27.2	23.1	22.1	18.7	15.5
	5	60.1	55.3	49.8	34.3	26.1	19.7	18.8	18.0	14.3	11.3
	10	40.6	36.5	29.5	21.2	15.3	13.4	11.7	10.4	9.3	7.2

FIG. 9U

HCC2935 (Lung)		Cpd 1 (μM)									
		0	0.039	0.078	0.156	0.313	0.625	1.25	2.5	5.0	10.0
Inavolisib (μM)	0	100.0	100.6	97.9	78.3	67.0	58.6	50.4	49.6	46.1	42.1
	0.312	96.6	97.4	84.0	58.8	50.5	41.5	37.0	35.6	28.6	25.5
	0.625	91.4	92.1	74.2	52.6	42.8	34.8	30.9	30.7	26.0	21.5
	1.25	80.2	74.7	63.2	45.1	34.8	28.6	25.2	24.0	21.6	18.3
	2.5	65.7	59.6	50.3	35.8	26.4	22.4	20.4	18.3	17.8	13.6
	5	57.4	53.9	42.6	28.2	23.1	19.7	18.1	15.2	14.5	11.1
	10	40.6	38.2	28.7	21.6	16.7	16.0	13.0	12.2	11.4	9.0

FIG. 9V

HCC2935 (Lung)		Cpd 1 (μM)									
		0	0.039	0.078	0.156	0.313	0.625	1.25	2.5	5.0	10.0
Serabelisib (μM)	0	100.0	100.7	95.2	74.2	65.3	62.2	54.3	56.0	47.4	42.3
	0.312	119.1	119.8	112.9	86.4	76.8	70.3	60.0	58.1	57.4	46.7
	0.625	118.1	122.9	108.7	89.0	75.6	65.7	59.1	56.7	52.0	44.7
	1.25	109.0	102.0	97.4	74.4	64.3	58.8	51.6	47.3	39.9	35.4
	2.5	93.2	91.2	81.8	63.0	55.2	48.8	39.7	37.9	36.2	31.5
	5	81.1	76.0	67.3	51.9	41.4	35.3	31.0	27.9	25.7	23.5
	10	63.7	58.2	51.6	37.0	32.0	25.4	21.2	21.6	21.0	17.1

FIG. 9W

HCC2935 (Lung)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
GSK263 (μM)	0	100	101.9	99.1	73.4	62.0	54.4	51.4	46.2	42.7	35.4
	0.31	90.0	92.5	85.3	65.8	55.6	48.3	44.6	41.3	39.8	33.1
	0.62	91.3	90.5	86.7	66.4	57.2	49.6	45.2	41.2	37.5	33.1
	1.25	87.2	89.5	82.3	65.0	52.7	46.0	43.9	40.7	36.4	32.0
	2.5	90.4	91.0	86.6	67.1	56.2	48.5	44.3	43.4	38.0	33.6
	5	92.1	90.3	85.4	67.6	55.7	49.3	45.9	41.6	40.6	38.1
	10	87.0	88.1	82.2	66.0	55.6	48.6	42.3	39.1	39.8	35.6

FIG. 9X

HCC2935 (Lung)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
Eganelisib (μM)	0	100	104.6	102	79.0	69.8	58.7	54.2	49.7	44.7	36.9
	0.31	90.2	94.0	89.6	70.3	60.7	50.9	44.9	41.9	37.0	31.4
	0.62	92.9	93.8	83.9	62.3	55.6	47.5	41.5	37.6	35.4	27.6
	1.25	82.1	86.4	77.5	58.7	45.1	41.2	37.1	34.1	31.4	27.1
	2.5	75.9	74.0	65.8	49.9	40.5	34.5	30.6	28.0	27.1	22.5
	5	66.1	62.9	59.2	45.4	38.2	31.4	27.9	26.6	24.6	19.5
	10	55.3	53.3	50.2	38.0	29.9	26.4	23.8	22.2	20.0	17.8

FIG. 9Y

HCC2935 (Lung)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
Idelalisib (μM)	0	100	103.6	97.0	78.8	65.4	59.8	53.1	49.8	45.6	41.5
	0.31	94.1	99.3	91.4	73.9	59.7	51.7	48.3	43.8	41.3	35.7
	0.62	93.4	97.0	90.4	72.4	59.6	51.5	45.3	44.3	41.4	35.3
	1.25	87.6	89.6	80.1	62.6	53.5	45.8	42.4	39.4	36.1	32.0
	2.5	86.9	87.0	79.0	61.8	50.2	42.7	41.6	35.8	33.6	29.6
	5	84.7	79.7	77.2	57.6	49.2	43.9	37.9	35.4	33.0	27.3
	10	74.4	74.2	70.3	54.0	42.2	38.4	32.9	31.3	28.1	24.9

FIG. 9Z

HCC2935 (Lung)		Cpd 1 (μM)								
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	10.0
Duvelisib (μM)	0	100	106.6	103	81.2	71.8	60.4	56.1	51.2	43.3
	0.31	97.9	97.7	90.2	72.5	61.2	52.5	47.3	45.1	34.7
	0.62	95.6	97.6	86.7	66.6	58.7	51.1	44.1	43.0	33.9
	1.25	88.6	85.4	73.0	58.3	48.9	43.3	38.8	35.5	28.9
	2.5	81.7	78.6	67.7	56.3	46.6	39.5	35.8	34.9	26.0
	5	72.7	69.1	62.0	49.5	40.0	35.5	31.8	29.5	23.1
	10	57.9	57.3	46.6	37.3	31.1	26.1	23.5	22.2	17.0

FIG. 9AA

HCC2935 (Lung)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
MK2206 (μM)	0	100.0	103.4	100.9	79.7	69.0	61.3	54.3	49.6	46.2	41.5
	0.312	73.6	69.4	60.9	44.9	35.7	31.8	28.6	26.5	24.9	20.9
	0.625	64.6	61.0	55.7	40.4	33.1	29.7	27.2	25.5	22.9	20.5
	1.25	56.1	53.5	47.1	35.4	30.1	27.2	25.5	22.8	22.6	18.0
	2.5	48.6	50.0	42.4	33.8	26.2	23.7	23.4	21.0	18.9	16.6
	5	42.8	40.8	34.7	26.7	23.1	20.0	18.8	18.1	16.0	13.0
	10	27.0	25.3	21.3	15.5	13.3	12.3	11.5	10.5	7.9	4.5

FIG. 9AB

HCC2935 (Lung)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
Ipatasertib (μM)	0	100.0	101.0	90.5	70.2	60.1	53.8	48.1	44.2	38.9	33.6
	0.312	67.3	70.6	60.4	45.5	37.8	33.9	30.6	29.8	26.0	22.7
	0.625	61.8	61.9	50.3	37.2	31.2	27.7	25.7	25.4	22.2	19.4
	1.25	52.4	49.8	41.0	30.2	26.1	22.9	22.2	19.6	19.5	16.1
	2.5	50.5	47.9	40.1	29.9	24.8	22.0	19.9	19.9	18.4	16.2
	5	47.7	42.7	36.1	29.0	22.8	20.7	18.6	18.8	16.3	14.5
	10	39.6	38.4	33.2	25.6	22.0	20.1	17.5	16.2	14.4	13.4

FIG. 9AC




FIG. 10A

Cpd 1 (µM)

Alpelisib (µM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-24	-18	1	6	6	5	6	8	20
0.156	-11	-3	14	15	13	15	19	18	24
0.312	0	10	14	24	24	25	25	25	28
0.625	-6	-1	19	32	36	35	35	37	41
1.25	-1	6	30	38	40	40	39	38	40
2.5	3	14	31	36	37	37	36	35	39
5	6	14	23	28	28	28	28	28	29
10	6	11	18	20	21	21	21	22	23

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + Alpelisib

FIG. 10B




FIG. 10C

Cpd 1 (μM)

Inavolisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	0	1	19	28	2	627	28	25	30
0.156	5	9	27	35	37	36	36	35	36
0.312	6	14	25	29	30	30	30	30	31
0.625	3	9	18	19	20	20	20	20	21
1.25	3	7	11	13	14	14	14	14	15
2.5	4	6	9	10	10	10	11	11	11
5	3	5	7	8	8	8	8	8	9
10	3	5	6	7	7	7	7	7	8

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + Inavolisib

FIG. 10D




FIG. 10E

Cpd 1 (μM)

Serabelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-10	-5	0	4	-1	-1	-1	-1	9
0.156	-10	-7	-5	3	1	2	1	-1	9
0.312	0	-2	8	17	13	8	8	9	18
0.625	-9	-5	7	15	11	11	10	12	16
1.25	-3	-4	15	21	20	19	18	20	23
2.5	3	8	22	30	30	30	23	26	29
5	3	10	22	25	25	23	25	24	24
10	5	8	14	16	17	18	17	16	16

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + Serabelisib

FIG. 10F




FIG. 10G

Cpd 1 (µM)

GSK2636771 (µM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-5	-9	3	-2	-4	-4	-5	-2	6
0.156	-2	-6	2	-1	-3	-1	0	0	6
0.312	3	3	11	7	2	0	0	2	11
0.625	-5	-4	6	6	0	0	-1	2	8
1.25	-7	-4	9	5	1	1	0	3	10
2.5	3	6	19	16	10	10	10	10	17
5	-1	2	18	13	9	8	9	10	16
10	2	5	13	10	8	7	7	9	15

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + GSK2636771

FIG. 10H




FIG. 10I

Cpd 1 (μM)

Eganelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-7	-5	2	3	1	0	-3	0	7
0.156	-3	-2	8	3	4	4	5	4	12
0.312	-1	3	14	10	8	8	8	7	17
0.625	-4	-1	12	12	9	8	8	8	19
1.25	-5	-1	11	16	14	12	13	13	21
2.5	4	9	20	24	23	21	21	22	29
5	2	10	22	23	23	21	22	24	33
10	4	9	18	21	20	20	20	21	33

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + Eganelisib

FIG. 10J




FIG. 10K

Cpd 1 (µM)

Idelalisib uM	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-5	-6	2	0	-5	-4	-5	-2	8
0.156	-1	-2	2	-1	-2	-3	-2	1	10
0.312	-1	-2	3	5	1	0	-1	2	11
0.625	-8	-12	-2	2	1	-1	-1	1	7
1.25	-10	-10	-1	7	2	0	0	2	9
2.5	-3	0	12	20	12	9	10	11	17
5	-4	0	13	21	16	12	10	11	16
10	1	7	23	28	20	15	14	13	18

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + Idelalisib

FIG. 10L




FIG. 10M

Cpd 1 (μM)

Duvelisib (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	10
0.078	-5	-8	-3	-1	-3	-6	-1	7
0.156	-3	-8	-5	0	0	-1	-2	7
0.312	-4	-3	1	3	-1	-1	0	9
0.625	-10	-9	-2	4	1	1	0	8
1.25	-10	-7	2	9	7	6	3	13
2.5	3	3	12	19	19	17	16	18
5	-2	2	14	23	21	20	16	20
10	1	4	19	27	28	25	24	24

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + Duvelisib

FIG. 10N




FIG. 10O

Cpd 1 (μM)

MK2206 (μM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-3	-7	6	15	14	16	14	12	16
0.156	-2	-2	12	22	25	25	22	21	23
0.312	1	6	23	30	32	30	29	28	30
0.625	2	9	21	26	28	29	27	26	28
1.25	2	6	15	19	20	20	19	20	22
2.5	4	6	12	14	15	16	16	16	19
5	1	3	8	10	11	12	12	12	19
10	4	6	9	11	12	12	14	17	19

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + MK2206

FIG. 10P




FIG. 10Q

Cpd 1 (μM)

Ipatasertib (μM)

	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.078	-7	-5	4	0	-3	-1	-2	-1	9
0.156	-7	-8	-4	-2	-1	0	0	1	7
0.312	3	3	11	11	9	9	9	10	17
0.625	-1	-3	7	12	14	11	10	13	18
1.25	-8	-5	10	16	18	18	18	19	19
2.5	5	9	22	28	30	31	30	27	28
5	5	12	26	29	32	31	30	30	29
10	5	10	18	19	20	20	20	20	20

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + Ipatasertib

FIG. 10R




FIG. 10S

Cpd 1 (µM)

Capivasertib (µM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.03	-13	-12	-15	-6	-13	-18	-15	-10	4
0.1	-13	-13	-6	-4	-11	-15	-11	-4	9
0.3	-8	-7	-1	-3	0	-6	2	4	17
1	1	-5	4	11	9	7	4	8	16
3	-2	2	12	23	24	23	23	23	28
10	7	10	16	23	24	25	24	25	27

Loewe synergy and antagonism SNUNCC19 – Cpd 1 + Capivasertib

FIG. 10T

SNUNCC19 (Gastric)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
GSK263 (μM)	0	100.0	100.5	98.5	78.8	58.3	50.6	47.2	49.3	48.3	39.0
	0.312	90.5	89.3	85.5	67.6	50.8	46.3	46.7	46.0	44.0	35.1
	0.625	89.7	93.5	88.5	71.1	52.1	48.7	46.7	46.9	44.0	38.1
	1.25	89.8	90.9	85.3	67.5	52.6	47.7	45.9	46.8	43.1	36.5
	2.5	78.5	76.7	72.6	57.4	42.1	38.2	36.5	36.6	36.2	29.3
	5	79.7	78.2	75.1	58.2	44.7	39.7	38.4	37.7	36.2	30.2
	10	75.8	73.9	71.3	62.1	48.2	40.7	39.5	39.4	37.5	31.6

FIG. 10U

SNUNCC19 (Gastric)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
Eganelisib (μM)	0	100.0	103.1	101.5	76.6	59.0	54.5	52.7	54.3	50.0	39.1
	0.312	84.8	85.2	76.3	54.7	44.8	42.6	42.2	42.4	42.6	33.0
	0.625	81.1	79.9	73.7	52.3	41.8	42.0	42.0	42.6	42.3	31.2
	1.25	73.0	72.0	65.0	46.7	36.1	36.2	38.7	37.1	37.3	29.2
	2.5	54.9	52.8	46.0	32.1	26.8	27.5	28.8	29.4	28.5	21.3
	5	49.5	45.7	37.3	25.8	24.1	24.1	26.1	25.0	23.2	14.3
	10	36.8	33.0	27.7	19.6	16.5	17.4	17.4	17.0	15.7	4.5

FIG. 10V

SNUNCC19 (Gastric)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
Idelalisib (μM)	0	100.0	101.8	99.4	81.7	61.8	53.8	52.5	51.1	48.7	39.2
	0.312	95.4	96.9	92.4	75.9	57.6	50.8	49.0	49.0	46.0	36.6
	0.625	94.6	99.3	97.9	77.5	60.0	50.1	49.4	49.7	47.2	40.8
	1.25	90.3	93.1	89.0	73.1	55.0	49.8	49.0	47.8	46.2	38.9
	2.5	74.9	77.3	72.6	57.6	42.6	39.2	39.4	38.2	36.8	30.6
	5	70.8	73.7	69.0	54.8	41.4	35.8	36.9	38.1	37.5	32.3
	10	69.3	67.3	60.5	44.2	34.6	31.7	33.4	33.8	35.0	30.5

FIG. 10W

SNUNCC19 (Gastric)		Cpd 1 (μM)								
		0	0.039	0.078	0.156	0.313	0.625	1.25	2.5	10.0
Duvelisib (μM)	0	100.0	97.8	96.3	76.6	57.0	51.9	50.2	48.1	38.7
	0.312	88.4	92.7	87.4	71.9	54.4	49.4	47.4	46.2	37.3
	0.625	88.2	93.0	87.5	70.7	51.8	47.6	45.5	45.7	37.6
	1.25	83.9	85.5	78.6	62.4	45.8	41.3	40.4	43.0	33.5
	2.5	65.1	64.1	61.3	47.3	33.2	29.3	29.9	30.6	28.1
	5	60.6	59.6	54.4	39.8	27.0	25.9	26.2	29.8	26.5
	10	51.9	49.8	46.5	29.8	20.8	18.6	21.3	22.2	22.5

FIG. 10X

SNUNCC19 (Gastric)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
MK2206 (μM)	0	100.0	107.5	102.4	82.8	61.7	57.1	56.0	53.4	52.4	40.1
	0.078	81.9	80.5	80.7	60.2	41.6	38.5	35.6	37.2	39.5	35.3
	0.156	68.9	68.6	65.4	46.7	31.2	26.5	26.3	29.5	30.4	28.8
	0.312	54.9	54.0	47.4	29.1	21.1	19.6	21.0	22.4	23.7	20.9
	0.625	46.3	41.9	35.5	23.3	18.4	15.9	15.6	17.2	18.2	16.4
	1.25	33.7	31.8	27.6	18.7	14.7	13.9	13.5	14.6	14.2	12.0
	2.5	25.2	22.8	20.5	14.6	12.1	11.2	11.0	10.9	10.8	7.6

FIG. 10Y

SNUNCC19 (Gastric)		Cpd 1 (μM)									
		0	0.04	0.08	0.15	0.31	0.62	1.25	2.5	5.0	10.0
Ipatasertib (μM)	0	100.0	101.6	102.2	75.7	58.2	53.0	51.0	49.2	47.0	34.8
	0.312	84.4	85.4	80.2	59.8	43.5	39.4	38.2	37.1	36.7	29.9
	0.625	85.3	81.3	78.1	58.1	41.2	33.8	36.2	36.4	33.9	28.7
	1.25	78.0	77.6	70.0	47.7	34.8	29.5	28.7	28.1	27.9	27.2
	2.5	56.3	51.1	44.3	28.1	19.1	16.4	15.7	16.4	19.2	19.0
	5	42.3	37.8	30.6	16.3	13.6	10.9	11.6	12.1	12.6	13.3
	10	29.3	23.5	18.5	11.1	9.7	9.0	8.5	9.1	8.8	8.9

FIG. 10Z




FIG. 11A

Cpd 1 (µM)

Capivasertib (µM)	0.039	0.078	0.156	0.312	0.625	1.25	2.5	5	10
0.03	-6	-15	-5	-17	-3	0	1	-2	2
0.1	0	-12	-4	-5	2	6	4	0	6
0.3	-4	3	-1	0	-9	12	7	6	9
1	-3	2	2	2	3	16	13	10	10
3	1	-1	2	-1	8	9	13	12	13
10	0	-5	-1	-1	5	9	10	12	13

Loewe synergy and antagonism T3M4 – Cpd 1 + Capivasertib

FIG. 11B

Inhibitor	PI3Kα	PI3Kβ	PI3Kγ	PI3Kδ	Company
Alpelisib (PI3Kα)	5nM	1200nm	250nM	290nM	Novartis (Approved)
Inavolisib (PI3Kα)	0.038nM	>300-fold	>300-fold	>300-fold	Genentech
Serabelisib (PI3Kα)	15nM	4500nM	1900nM	13900nM	Takeda
GSK2636771(PI3Kβ)	>900-fold	5.2nM	>900-fold	>10-fold	GSK
Eganelisib (PI3Kγ)	3.2uM	3.5uM	16nM	8.4uM	Infinity Pharma
Idelalisib (PI3Kδ)	820nM	565nM	89nM	2.5nM	Gilead (Approved)
Duvelisib (PI3Kγ/δ)	1602nM	85nM	27nM	2.5nM	Secura Bio (Approved)
MK-2206 (AKT)	Akt1/2/3				Merck
Ipatasertib (AKT)	Akt1/2/3				Genentech

FIG. 12



NUGC3-74
Tumor Volume (mm3)
1200
1000
800
600
400
200
0
0
5
10
15
20
25
Days
Vehicle QDx21
alpelisib 20 mg/kg QDx21
Cpd 1 50 mg/kg QDx21
Cpd 1 50 mg/kg + alpelisib QDx21
Cpd 1 100 mg/kg QDx21
Cpd 1 100 mg/kg + alpelisib QDx21

FIG. 13



T3M4-019
Tumor Volume (mm3)
2500
2000
1500
1000
500
0
0
5
10
15
Days
Vehicle
alpelisib 20 mg/kg QDx13
Cpd 1 50 mg/kg QDx13
Cpd 1 50 mg/kg + alpelisib 20 mg/kg QDx13
Cpd 1 100 mg/kg QDx13
Cpd 1 100 mg/kg + alpelisib 20 mg/kg QDx13

FIG. 14